UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
2281,Clearstream,Twitter API,Twitter,@quatremer Clearstream  Euroclear...,nan,@quatremer Clearstream  Euroclear...,neutral,0.02,0.96,0.02,neutral,0.02,0.96,0.02,True,English,"['quatremer Clearstream', 'Euroclear', 'quatremer Clearstream', 'Euroclear']",2022-04-05,2022-04-11,Unknown
2351,Clearstream,Twitter API,Twitter,@ResGloStocks @hkuppy If Euroclear &amp; Clearstream truly open the lock  then GDR conversion should be possible for al‚Ä¶ https://t.co/m3JtzNwP3O,nan,@ResGloStocks @hkuppy If Euroclear &amp; Clearstream truly open the lock  then GDR conversion should be possible for al‚Ä¶ https://t.co/m3JtzNwP3O,neutral,0.03,0.95,0.02,neutral,0.03,0.95,0.02,True,English,"['GDR conversion', 'ResGloStocks', 'Euroclear', 'Clearstream', 'lock', 'm3JtzNwP3O', 'GDR conversion', 'ResGloStocks', 'Euroclear', 'Clearstream', 'lock', 'm3JtzNwP3O']",2022-04-06,2022-04-11,Unknown
2352,Clearstream,Twitter API,Twitter,MEDICAL EMERGENCY  CLEARSTREAM CT  BLACKHAWK (4/5/2022 11:14:02 PM),nan,MEDICAL EMERGENCY  CLEARSTREAM CT  BLACKHAWK (4/5/2022 11:14:02 PM),neutral,0.02,0.94,0.05,neutral,0.02,0.94,0.05,True,English,"['MEDICAL EMERGENCY', 'CLEARSTREAM CT', 'BLACKHAWK', '02', 'MEDICAL EMERGENCY', 'CLEARSTREAM CT', 'BLACKHAWK', '02']",2022-04-06,2022-04-11,Unknown
2436,Clearstream,Twitter API,Twitter,Cum-Ex: Deutsche Boerse‚Äôs Clearstream sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank‚Ä¶ https://t.co/AsYzHfmbaW,nan,Cum-Ex: Deutsche Boerse‚Äôs Clearstream sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank‚Ä¶ https://t.co/AsYzHfmbaW,negative,0.01,0.12,0.86,negative,0.01,0.12,0.86,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Cum-Ex', 'Clearstream', 'administrator', 'AsYzHfmbaW', 'defunct Maple Bank', 'Deutsche Boerse', 'Cum-Ex', 'Clearstream', 'administrator', 'AsYzHfmbaW']",2022-04-07,2022-04-11,Unknown
2437,Clearstream,Twitter API,Twitter,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/TUCWro8zFg,nan,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/TUCWro8zFg,negative,0.01,0.09,0.89,negative,0.01,0.09,0.89,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'TUCWro8zFg', 'defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'TUCWro8zFg']",2022-04-07,2022-04-11,Unknown
2438,Clearstream,Twitter API,Twitter,Deutsche Boerse AG‚Äôs Clearstream unit  the central settlement agent for trading in German shares  was sued for abou‚Ä¶ https://t.co/SY9qYuOv8w,nan,Deutsche Boerse AG‚Äôs Clearstream unit  the central settlement agent for trading in German shares  was sued for abou‚Ä¶ https://t.co/SY9qYuOv8w,negative,0.01,0.08,0.91,negative,0.01,0.08,0.91,True,English,"['Deutsche Boerse AG', 'central settlement agent', 'Clearstream unit', 'German shares', 'trading', 'SY9qYuOv8w', 'Deutsche Boerse AG', 'central settlement agent', 'Clearstream unit', 'German shares', 'trading', 'SY9qYuOv8w']",2022-04-07,2022-04-11,Unknown
2439,Clearstream,Twitter API,Twitter,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/xU8uxsTTsj,nan,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/xU8uxsTTsj,negative,0.01,0.09,0.89,negative,0.01,0.09,0.89,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'xU8uxsTTsj', 'defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'xU8uxsTTsj']",2022-04-07,2022-04-11,Unknown
2440,Clearstream,Twitter API,Twitter,JP Morgan  BNY notify Clearstream of option to cancel depositary receipts of Russian issuers https://t.co/4iIQ4d4GBq,nan,JP Morgan  BNY notify Clearstream of option to cancel depositary receipts of Russian issuers https://t.co/4iIQ4d4GBq,neutral,0.01,0.95,0.04,neutral,0.01,0.95,0.04,True,English,"['JP Morgan', 'depositary receipts', 'Russian issuers', 'BNY', 'Clearstream', 'option', 'iIQ4d4GBq', 'JP Morgan', 'depositary receipts', 'Russian issuers', 'BNY', 'Clearstream', 'option', 'iIQ4d4GBq']",2022-04-07,2022-04-11,Unknown
2449,Deutsche Boerse,Twitter API,Twitter,Cum-Ex: Deutsche Boerse‚Äôs Clearstream sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank‚Ä¶ https://t.co/AsYzHfmbaW,nan,Cum-Ex: Deutsche Boerse‚Äôs Clearstream sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank‚Ä¶ https://t.co/AsYzHfmbaW,negative,0.01,0.12,0.86,negative,0.01,0.12,0.86,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Cum-Ex', 'Clearstream', 'administrator', 'AsYzHfmbaW', 'defunct Maple Bank', 'Deutsche Boerse', 'Cum-Ex', 'Clearstream', 'administrator', 'AsYzHfmbaW']",2022-04-07,2022-04-11,Unknown
2450,Deutsche Boerse,Twitter API,Twitter,Deutsche B√∂rse‚Äôs derivatives-focused exchange  Eurex today said its total traded derivatives contracts grew by 26 p‚Ä¶ https://t.co/z94ZJs8mRF,nan,Deutsche B√∂rse‚Äôs derivatives-focused exchange  Eurex today said its total traded derivatives contracts grew by 26 p‚Ä¶ https://t.co/z94ZJs8mRF,neutral,0.02,0.95,0.03,neutral,0.02,0.95,0.03,True,English,"['Deutsche B√∂rse', 'derivatives-focused exchange', 'derivatives contracts', 'Eurex', 'total', 'z94ZJs8mRF', '26', 'Deutsche B√∂rse', 'derivatives-focused exchange', 'derivatives contracts', 'Eurex', 'total', 'z94ZJs8mRF', '26']",2022-04-07,2022-04-11,Unknown
2451,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/TUCWro8zFg,nan,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/TUCWro8zFg,negative,0.01,0.09,0.89,negative,0.01,0.09,0.89,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'TUCWro8zFg', 'defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'TUCWro8zFg']",2022-04-07,2022-04-11,Unknown
2452,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse AG‚Äôs Clearstream unit  the central settlement agent for trading in German shares  was sued for abou‚Ä¶ https://t.co/SY9qYuOv8w,nan,Deutsche Boerse AG‚Äôs Clearstream unit  the central settlement agent for trading in German shares  was sued for abou‚Ä¶ https://t.co/SY9qYuOv8w,negative,0.01,0.08,0.91,negative,0.01,0.08,0.91,True,English,"['Deutsche Boerse AG', 'central settlement agent', 'Clearstream unit', 'German shares', 'trading', 'SY9qYuOv8w', 'Deutsche Boerse AG', 'central settlement agent', 'Clearstream unit', 'German shares', 'trading', 'SY9qYuOv8w']",2022-04-07,2022-04-11,Unknown
2453,Deutsche Boerse,Twitter API,Twitter,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/xU8uxsTTsj,nan,Deutsche Boerse‚Äôs Clearstream unit is sued for ‚Ç¨27 million by the administrator of now-defunct Maple Bank in a laws‚Ä¶ https://t.co/xU8uxsTTsj,negative,0.01,0.09,0.89,negative,0.01,0.09,0.89,True,English,"['defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'xU8uxsTTsj', 'defunct Maple Bank', 'Deutsche Boerse', 'Clearstream unit', 'administrator', 'laws', 'xU8uxsTTsj']",2022-04-07,2022-04-11,Unknown
2514,Euroclear,Twitter API,Twitter,@EuroclearGroup Why did Euroclear block the securities of bank clients that were on the sanctions list?We have not‚Ä¶ https://t.co/F3sNdLCAJi,nan,@EuroclearGroup Why did Euroclear block the securities of bank clients that were on the sanctions list?We have not‚Ä¶ https://t.co/F3sNdLCAJi,negative,0.01,0.18,0.81,negative,0.01,0.18,0.81,True,English,"['bank clients', 'sanctions list', 'Euroclear', 'securities', 'F3sNdLCAJi', 'bank clients', 'sanctions list', 'Euroclear', 'securities', 'F3sNdLCAJi']",2022-04-08,2022-04-11,Unknown
2515,Euroclear,Twitter API,Twitter,@EuroclearGroup Hello   when will Euroclear unlock securities of private investors from Russia ?Why should private‚Ä¶ https://t.co/isbAZY4ojz,nan,@EuroclearGroup Hello   when will Euroclear unlock securities of private investors from Russia ?Why should private‚Ä¶ https://t.co/isbAZY4ojz,neutral,0.04,0.9,0.06,neutral,0.04,0.9,0.06,True,English,"['private investors', 'Euroclear', 'securities', 'Russia', 'isbAZY4ojz', 'private investors', 'Euroclear', 'securities', 'Russia', 'isbAZY4ojz']",2022-04-08,2022-04-11,Unknown
2516,Euroclear,Twitter API,Twitter,Credit unions‚Äô tax-subsidized bank purchases harm consumers #AAA Websites Euroclear Fintech https://t.co/9eOj0Ii8qO #regtech,nan,Credit unions‚Äô tax-subsidized bank purchases harm consumers #AAA Websites Euroclear Fintech https://t.co/9eOj0Ii8qO #regtech,negative,0.01,0.21,0.78,negative,0.01,0.21,0.78,True,English,"['Credit unions‚Äô tax-subsidized bank purchases', 'consumers', 'Fintech', '9eOj0Ii8qO', 'regtech', 'Credit unions‚Äô tax-subsidized bank purchases', 'consumers', 'Fintech', '9eOj0Ii8qO', 'regtech']",2022-04-08,2022-04-11,Unknown
2517,Euroclear,Twitter API,Twitter,inflation-indexed (UI) global bonds  which can both be held in Euroclear  as well as Central Bank notes (Letras) ‚Ä¶ https://t.co/Wo9IluuSfQ,nan,inflation-indexed (UI) global bonds  which can both be held in Euroclear  as well as Central Bank notes (Letras) ‚Ä¶ https://t.co/Wo9IluuSfQ,neutral,0.02,0.97,0.01,neutral,0.02,0.97,0.01,True,English,"['inflation-indexed (UI) global bonds', 'Central Bank notes', 'Euroclear', 'Letras', 'Wo9IluuSfQ', 'inflation-indexed (UI) global bonds', 'Central Bank notes', 'Euroclear', 'Letras', 'Wo9IluuSfQ']",2022-04-08,2022-04-11,Unknown
2529,Clearstream,Twitter API,Twitter,üìä #MonthlyResults Discover #Clearstream's March results here  containing all facts and figures.‚Ä¶ https://t.co/epYkFBmNvx,nan,üìä #MonthlyResults Discover #Clearstream's March results here  containing all facts and figures.‚Ä¶ https://t.co/epYkFBmNvx,neutral,0.04,0.94,0.02,neutral,0.04,0.94,0.02,True,English,"['March results', 'facts', 'figures', 'epYkFBmNvx', 'March results', 'facts', 'figures', 'epYkFBmNvx']",2022-04-08,2022-04-11,Unknown
2530,Clearstream,Twitter API,Twitter,@JoshuaLloyd1 Or free with Clearstream üòÇ,nan,@JoshuaLloyd1 Or free with Clearstream üòÇ,neutral,0.24,0.75,0.01,neutral,0.24,0.75,0.01,True,English,"['JoshuaLloyd1', 'Clearstream', 'JoshuaLloyd1', 'Clearstream']",2022-04-07,2022-04-11,Unknown
2534,Deutsche Boerse,Twitter API,Twitter,Brexit fallout: HQ location behind collapse of the LSE &amp; Deutsche Boerse merger - https://t.co/SkuJhmKsSu https://t.co/0X2kaZlSWR,nan,Brexit fallout: HQ location behind collapse of the LSE &amp; Deutsche Boerse merger - https://t.co/SkuJhmKsSu https://t.co/0X2kaZlSWR,negative,0.01,0.14,0.85,negative,0.01,0.14,0.85,True,English,"['Deutsche Boerse merger', 'Brexit fallout', 'HQ location', 'collapse', 'LSE', 'SkuJhmKsSu', '0X2kaZlSWR', 'Deutsche Boerse merger', 'Brexit fallout', 'HQ location', 'collapse', 'LSE', 'SkuJhmKsSu', '0X2kaZlSWR']",2022-04-08,2022-04-11,Unknown
2585,Euroclear,Twitter API,Twitter,@VXO150 @garyvee @686Prism its just the Euroclear MDMA pills I got from the Prism store m8 üò§,nan,@VXO150 @garyvee @686Prism its just the Euroclear MDMA pills I got from the Prism store m8 üò§,negative,0.08,0.33,0.58,negative,0.08,0.33,0.58,True,English,"['Euroclear MDMA pills', 'Prism store', 'VXO150', 'garyvee', '686Prism', 'Euroclear MDMA pills', 'Prism store', 'VXO150', 'garyvee', '686Prism']",2022-04-09,2022-04-11,Unknown
2586,Euroclear,Twitter API,Twitter,New York City shuns Wells Fargo over discrimination claims #AAA Websites Euroclear Fintech https://t.co/tOBO6YECZn #regtech,nan,New York City shuns Wells Fargo over discrimination claims #AAA Websites Euroclear Fintech https://t.co/tOBO6YECZn #regtech,neutral,0.02,0.78,0.2,neutral,0.02,0.78,0.2,True,English,"['New York City', 'Wells Fargo', 'discrimination claims', 'Fintech', 'tOBO6YECZn', 'regtech', 'New York City', 'Wells Fargo', 'discrimination claims', 'Fintech', 'tOBO6YECZn', 'regtech']",2022-04-09,2022-04-11,Unknown
2587,Euroclear,Twitter API,Twitter,Fannie Mae chair Sheila Bair leads trio of departures from the GSE's board #AAA Websites Euroclear Fintech https://t.co/w5YpCPxqem #regtech,nan,Fannie Mae chair Sheila Bair leads trio of departures from the GSE's board #AAA Websites Euroclear Fintech https://t.co/w5YpCPxqem #regtech,neutral,0.01,0.98,0.01,neutral,0.01,0.98,0.01,True,English,"['Fannie Mae chair', 'Sheila Bair', 'trio', 'departures', 'GSE', 'board', 'Fintech', 'w5YpCPxqem', 'regtech', 'Fannie Mae chair', 'Sheila Bair', 'trio', 'departures', 'GSE', 'board', 'Fintech', 'w5YpCPxqem', 'regtech']",2022-04-09,2022-04-11,Unknown
2588,Euroclear,Twitter API,Twitter,Fintechs create tech that lets banks offer tax prep help #AAA Websites Euroclear Fintech https://t.co/9IhGst7JOX #regtech,nan,Fintechs create tech that lets banks offer tax prep help #AAA Websites Euroclear Fintech https://t.co/9IhGst7JOX #regtech,neutral,0.04,0.93,0.03,neutral,0.04,0.93,0.03,True,English,"['tax prep', 'Fintechs', 'banks', '9IhGst7JOX', 'regtech', 'tax prep', 'Fintechs', 'banks', '9IhGst7JOX', 'regtech']",2022-04-08,2022-04-11,Unknown
2603,EuroNext,Twitter API,Twitter,@Pangubright @cz_binance @news_of_bsc Fist will bring More players around the world to Fist and FSTSwap by hosting Binance and EURonext,nan,@Pangubright @cz_binance @news_of_bsc Fist will bring More players around the world to Fist and FSTSwap by hosting Binance and EURonext,neutral,0.06,0.93,0.01,neutral,0.06,0.93,0.01,True,English,"['More players', 'Pangubright', 'news', 'world', 'Fist', 'FSTSwap', 'Binance', 'EURonext', 'More players', 'Pangubright', 'news', 'world', 'Fist', 'FSTSwap', 'Binance', 'EURonext']",2022-04-09,2022-04-11,Unknown
2608,Clearstream,Google API,https://elinformadorqr.com/student-rfid-tracking-systems-market-growth-rate-analysis-2022-2026-child-safety-datalogic-spa-clearstream-coresonant-systems-pvt-ltd-dominaterifd-and-card-tec/,Student RFID Tracking Systems Market Growth Rate Analysis 2022 ‚Äì 2026 ‚Äì Child Safety  Datalogic SpA  Clearstream  Coresonant Systems Pvt. Ltd.  DominateRIFD and Card Tec ‚Äì Elinformadorqr.com,1 day ago,A research report on the Student RFID Tracking Systems market gives a comprehensive description of the scale of the market  the market share  and the market segmentation. The analysis also identifies the most recent disruption in the Student RFID Tracking Systems field and presents a comprehensive business intelligence survey. In addition  the Student RFID Tracking Systems report provides in-depth business predictions  future high-growth applications  technical insight  and other market vital indicators that are helpful for strategic market strategy decisions. The annual Student RFID Tracking Systems business study helps clients to understand future growth patterns  innovative strategies  and global industry sales information. The Student RFID Tracking Systems industry study examines the sector‚Äôs latest technical advancements and discoveries. The Student RFID Tracking Systems market analysis includes rigorous methods to obtain and combine critical data narratives and points from datasets  detailed expert interviews  and proprietary models to bring consumers up to speed with the rapidly expanding market.Request a sample report : https://www.orbisresearch.com/contacts/request-sample/5803791The main players in the global Student RFID Tracking Systems market areCard TecClearstreamChild SafetyDatalogic SpADominateRIFDCoresonant Systems Pvt. Ltd.Pulse SeventeenGAO RFID and Inc.Magnasoft Consulting India Pvt. Limited ‚Äì NorthstarS√É vantData System LLC and Inc.Seon DesignThe product type divides the Student RFID Tracking Systems market intoTagsReadersMiddlewareThe product application divides the Student RFID Tracking Systems market intoK-12Higher EducationIn addition  the Student RFID Tracking Systems report offers a major overview of the status of the company  market growth  trends  development  market share  and cost structure of the sector. This research contains comprehensive Student RFID Tracking Systems industry capacity estimates  historical evidence  and prediction interpretation. The Student RFID Tracking Systems business report also offers an aggregated and thorough description of the market  including all growth aspects that influence market growth. The Student RFID Tracking Systems study is a detailed qualitative and quantitative analysis of the global demand for keywords  including information to develop new strategies for business competitiveness and growth.Similarly  the Student RFID Tracking Systems sector report provides a basic market overview for the firm  including classifications  descriptions  and the structure of the supply and demand chain. The Student RFID Tracking Systems market study provides information on global economies  competitive environment studies  growth trends  and significant development status statistics. The market study Student RFID Tracking Systems extensively examines business expansion strategies and activities  as well as cost knowledge and development procedures. The study also includes detailed data on the Student RFID Tracking Systems industry‚Äôs import and export use  pricing  sales  supply and demand numbers  and gross margins.Do Inquiry before Accessing Report at: https://www.orbisresearch.com/contacts/enquiry-before-buying/5803791Key Reasons to Purchase this Student RFID Tracking Systems Industry Report:‚Ä¢ To get accurate insights of the Student RFID Tracking Systems market study with a detailed overview of market segmentation based on product type  application  and geographic regions.‚Ä¢ The Student RFID Tracking Systems market research sample also included in the report provides top vendors and customers.‚Ä¢ The Student RFID Tracking Systems report also focuses on the potential of goods  value  manufacturing  consumption  growth opportunities in major regions and offers quantitative information on the world‚Äôs leading markets.‚Ä¢ To know key analysis such as product logo  company profiles  product specifications  contact information  and other specifics are generated by a global Student RFID Tracking Systems market report.Key Points Covered in the Student RFID Tracking Systems Market Report:‚Ä¢ This research report includes the viability of new business ventures  as well as tables and figures to help assess the worldwide Student RFID Tracking Systems market.‚Ä¢ A global Student RFID Tracking Systems market analysis report offers important figures and forecasts and is a valuable source of guidance and recommendations for investors who are interested in investing in this market.‚Ä¢ The research includes a SWOT analysis of each of the important players listed  as well as a corporate profile  with the use of Porter‚Äôs five forces tool mechanism to supplement the same.‚Ä¢ This study comprises thorough research of upstream raw materials  as well as Student RFID Tracking Systems marketing networks  instrumentation  and downstream demand assessments.About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.Contact Us:Hector CostelloSenior Manager ‚Äì Client Engagements4144N Central Expressway Suite 600  Dallas Texas ‚Äì 75204  U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [email protected]Buy Complete Report at: https://www.orbisresearch.com/contact/purchase-single-user/5803791,neutral,0.01,0.99,0.0,neutral,0.05,0.92,0.03,True,English,"['Student RFID Tracking Systems Market Growth Rate Analysis', 'Coresonant Systems Pvt. Ltd', 'Child Safety', 'Datalogic SpA', 'Card Tec', 'Clearstream', 'DominateRIFD', 'Elinformadorqr', 'comprehensive Student RFID Tracking Systems industry capacity estimates', 'The Student RFID Tracking Systems industry study', 'The Student RFID Tracking Systems market research sample', 'global Student RFID Tracking Systems market analysis report', 'annual Student RFID Tracking Systems business study', 'The Student RFID Tracking Systems business report', 'The Student RFID Tracking Systems market study', 'The Student RFID Tracking Systems market analysis', 'global Student RFID Tracking Systems market report', 'Student RFID Tracking Systems marketing networks', 'The Student RFID Tracking Systems study', 'The Student RFID Tracking Systems report', 'Student RFID Tracking Systems Industry Report', 'worldwide Student RFID Tracking Systems market', 'Student RFID Tracking Systems sector report', 'Student RFID Tracking Systems field', 'Magnasoft Consulting India Pvt. Limited', 'comprehensive business intelligence survey', 'S√É vantData System LLC', 'five forces tool mechanism', 'strategic market strategy decisions', 'global industry sales information', 'other market vital indicators', 'Coresonant Systems Pvt.', 'significant development status statistics', 'depth business predictions', 'new business ventures', 'business expansion strategies', 'market research requirements', 'basic market overview', 'future high-growth applications', 'Datalogic SpA DominateRIFD', 'competitive environment studies', 'upstream raw materials', 'single point aid', 'latest technical advancements', 'critical data narratives', 'detailed expert interviews', 'downstream demand assessments', 'sample report', 'future growth patterns', 'GAO RFID', 'research report', 'global demand', 'global economies', 'comprehensive description', 'business competitiveness', 'market share', 'market segmentation', 'expanding market', 'market growth', 'quantitative analysis', 'key analysis', 'SWOT analysis', 'other specifics', 'new strategies', 'detailed data', 'thorough research', 'Orbis Research', 'detailed overview', 'technical insight', 'innovative strategies', 'major overview', 'development procedures', 'detailed qualitative', 'demand chain', 'demand numbers', 'recent disruption', 'rigorous methods', 'proprietary models', 'main players', 'Card Tec', 'Child Safety', 'Seon Design', 'product type', 'Higher Education', 'historical evidence', 'prediction interpretation', 'thorough description', 'growth aspects', 'cost knowledge', 'gross margins', 'Key Reasons', 'accurate insights', 'geographic regions', 'top vendors', 'growth opportunities', 'major regions', 'quantitative information', 'leading markets', 'product logo', 'product specifications', 'contact information', 'valuable source', 'important players', 'corporate profile', 'vast database', 'leading publishers', 'product application', 'cost structure', 'growth trends', 'company profiles', 'Key Points', 'important figures', 'scale', 'addition', 'clients', 'discoveries', 'datasets', 'consumers', 'speed', 'orbisresearch', 'contacts', 'request', 'Clearstream', 'Pulse', 'Inc.', 'Northstar', 'Tags', 'Readers', 'Middleware', 'K-12', 'aggregated', 'keywords', 'firm', 'classifications', 'descriptions', 'supply', 'activities', 'export', 'use', 'pricing', 'Inquiry', 'customers', 'potential', 'goods', 'value', 'manufacturing', 'consumption', 'viability', 'tables', 'forecasts', 'guidance', 'recommendations', 'investors', 'Porter', 'same', 'instrumentation', 'reports', 'authors']",2022-04-11,2022-04-11,elinformadorqr.com
2610,Clearstream,Twitter API,Twitter,@DarkRiketz @Nasmog @supermegadrivin @JeanMassiet L'affaire Clearstream ?,nan,@DarkRiketz @Nasmog @supermegadrivin @JeanMassiet L'affaire Clearstream ?,neutral,0.08,0.51,0.41,neutral,0.08,0.51,0.41,True,English,"['affaire Clearstream', 'DarkRiketz', 'Nasmog', 'supermegadrivin', 'JeanMassiet', 'affaire Clearstream', 'DarkRiketz', 'Nasmog', 'supermegadrivin', 'JeanMassiet']",2022-04-10,2022-04-11,Unknown
2614,EuroNext,NewsApi.org,https://finance.yahoo.com/news/tetragon-financial-group-limited-announcement-193000846.html,Tetragon Financial Group Limited Announcement of Final Results of Tender Offer to Purchase Tetragon Non-Voting Shares,"Tetragon announces the final results of the ""modified Dutch auction"" tender offer to purchase a portion of the outstanding non-voting shares of Tetragon for ...","LONDON  10 April 2022 /PRNewswire/ -- Tetragon announces the final results of the ""modified Dutch auction"" tender offer to purchase a portion of the outstanding non-voting shares of Tetragon for a maximum aggregate payment of $50 000 000 in cash. The tender offer expired at 11:59 p.m. (ET) on 7 April 2022.J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) acted as dealer manager for the tender offer and Computershare Investor Services PLC acted as tender agent for the tender offer. As dealer manager  J.P. Morgan determined the final purchase price at which Tetragon will purchase shares in the tender offer. As tender agent  Computershare determined the final proration factor.In accordance with the terms of the tender offer  Tetragon has accepted for purchase 4 291 157 non‚Äëvoting shares at a purchase price of $9.75 per share. The aggregate cost of this purchase is $41 838 780.75  excluding fees and expenses relating to the tender offer. A total of 4 291 157 Tetragon non-voting shares were properly tendered and not properly withdrawn at or below the purchase price of $9.75 per share.Tetragon will promptly make payment for the shares validly tendered and accepted for purchase  which is expected to occur on or about 14 April 2022.About Tetragon:Tetragon is a closed-ended investment company that invests in a broad range of assets  including public and private equities and credit (including distressed securities and structured credit)  convertible bonds  real estate  venture capital  infrastructure  bank loans and TFG Asset Management  a diversified alternative asset management business. Where appropriate  through TFG Asset Management  Tetragon seeks to own all  or a portion  of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit  equity  interest rate  inflation and real estate cycles. The company's non-voting shares are traded on Euronext in Amsterdam  a regulated market of Euronext Amsterdam N.V.  and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at www.tetragoninv.com .Story continuesTetragon: Yuko Thomas Investor Relations ir@tetragoninv.com Press Inquiries: Prosek Partners Pro-tetragon@prosek.com United States Ryan FitzGibbon Remy Marin +1 646 818 9298 +1 646 818 9234 United Kingdom Henrietta Dehn Alexa Bethell +44 7717 281 665 +44 7940 166 251This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU) (""EU MAR"") and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933  as amended  and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition  Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940  as amended  and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.J.P. Morgan Securities plc  which is authorised by the UK Prudential Regulation Authority and regulated by the UK Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom  is acting exclusively for Tetragon and for no one else in connection with the tender offer and will not be responsible to anyone (whether or not recipient of the tender offer) other than Tetragon for providing the protections afforded to the clients of J.P. Morgan Securities plc or for providing advice in relation to the tender offer.CisionView original content:https://www.prnewswire.com/news-releases/tetragon-financial-group-limited-announcement-of-final-results-of-tender-offer-to-purchase-tetragon-non-voting-shares-301522405.htmlSOURCE Tetragon Financial Group Limited",neutral,0.02,0.95,0.04,mixed,0.2,0.27,0.53,True,English,"['Tetragon Financial Group Limited Announcement', 'Tetragon Non-Voting Shares', 'Final Results', 'Tender Offer', 'United States Ryan FitzGibbon Remy Marin', 'Dutch Financial Markets Supervision Act', 'J.P. Morgan Securities plc', 'diversified alternative asset management business', 'SOURCE Tetragon Financial Group Limited', 'modified Dutch auction"" tender offer', 'U.S. Investment Company Act', 'J.P. Morgan Cazenove', 'Henrietta Dehn Alexa Bethell', 'UK investment banking business', 'UK Financial Conduct Authority', 'Computershare Investor Services PLC', 'U.S. Securities Act', 'UK Prudential Regulation Authority', 'Euronext Amsterdam N.V.', 'EU Market Abuse Regulation', 'U.S. persons', 'alternative investment fund', 'TFG Asset Management', 'asset management companies', 'Specialist Fund Segment', 'closed-ended investment company', 'final proration factor', 'outstanding non-voting shares', 'real estate cycles', 'London Stock Exchange', 'maximum aggregate payment', '4,291,157 non‚Äëvoting shares', 'final purchase price', '4,291,157 Tetragon non-voting shares', 'investment objective', 'Withdrawal) Act', 'Netherlands Authority', 'UK version', 'UK law', 'Investor Relations', 'distressed securities', 'final results', 'regulated market', 'main market', 'United Kingdom', 'aggregate cost', 'tender agent', 'dealer manager', 'broad range', 'private equities', 'convertible bonds', 'bank loans', 'distributable income', 'interest rate', 'Yuko Thomas', 'Press Inquiries', 'European Union', 'other jurisdiction', 'applicable law', 'original content', 'structured credit', 'venture capital', 'capital appreciation', 'various credit', 'public offer', 'public register', 'stable returns', 'Prosek Partners', '10 April', 'portion', 'cash', '7 April', 'accordance', 'terms', 'fees', 'expenses', 'total', '14 April', 'assets', 'infrastructure', 'order', 'investors', 'equity', 'inflation', 'information', 'website', 'tetragoninv', 'Story', 'release', 'inside', 'meaning', 'Article', 'virtue', 'solicitation', 'registration', 'addition', 'benefits', 'Section', 'connection', 'recipient', 'protections', 'clients', 'advice', 'Cision', 'prnewswire', 'financial-group-limited-announcement', 'final-results', '11:59']",2022-04-10,2022-04-11,finance.yahoo.com
2615,EuroNext,NewsApi.org,https://www.kold.com/prnewswire/2022/04/10/tetragon-financial-group-limited-announcement-final-results-tender-offer-purchase-tetragon-non-voting-shares/,Tetragon Financial Group Limited Announcement of Final Results of Tender Offer to Purchase Tetragon Non-Voting Shares,,"LONDON  10 April 2022 /PRNewswire/ -- Tetragon announces the final results of the ""modified Dutch auction"" tender offer to purchase a portion of the outstanding non-voting shares of Tetragon for a maximum aggregate payment of $50 000 000 in cash. The tender offer expired at 11:59 p.m. (ET) on 7 April 2022.J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) acted as dealer manager for the tender offer and Computershare Investor Services PLC acted as tender agent for the tender offer. As dealer manager  J.P. Morgan determined the final purchase price at which Tetragon will purchase shares in the tender offer. As tender agent  Computershare determined the final proration factor.In accordance with the terms of the tender offer  Tetragon has accepted for purchase 4 291 157 non‚Äëvoting shares at a purchase price of $9.75 per share. The aggregate cost of this purchase is $41 838 780.75  excluding fees and expenses relating to the tender offer. A total of 4 291 157 Tetragon non-voting shares were properly tendered and not properly withdrawn at or below the purchase price of $9.75 per share.Tetragon will promptly make payment for the shares validly tendered and accepted for purchase  which is expected to occur on or about 14 April 2022.About Tetragon:Tetragon is a closed-ended investment company that invests in a broad range of assets  including public and private equities and credit (including distressed securities and structured credit)  convertible bonds  real estate  venture capital  infrastructure  bank loans and TFG Asset Management  a diversified alternative asset management business. Where appropriate  through TFG Asset Management  Tetragon seeks to own all  or a portion  of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit  equity  interest rate  inflation and real estate cycles. The company's non-voting shares are traded on Euronext in Amsterdam  a regulated market of Euronext Amsterdam N.V.  and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at www.tetragoninv.com .Tetragon: Yuko Thomas Investor Relations ir@tetragoninv.com Press Inquiries: Prosek Partners Pro-tetragon@prosek.com United States Ryan FitzGibbon Remy Marin +1 646 818 9298 +1 646 818 9234 United Kingdom Henrietta Dehn Alexa Bethell +44 7717 281 665 +44 7940 166 251This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU) (""EU MAR"") and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933  as amended  and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition  Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940  as amended  and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.J.P. Morgan Securities plc  which is authorised by the UK Prudential Regulation Authority and regulated by the UK Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom  is acting exclusively for Tetragon and for no one else in connection with the tender offer and will not be responsible to anyone (whether or not recipient of the tender offer) other than Tetragon for providing the protections afforded to the clients of J.P. Morgan Securities plc or for providing advice in relation to the tender offer.View original content:SOURCE Tetragon Financial Group Limited",neutral,0.02,0.95,0.04,negative,0.02,0.22,0.76,True,English,"['Tetragon Financial Group Limited Announcement', 'Tetragon Non-Voting Shares', 'Final Results', 'Tender Offer', 'United Kingdom Henrietta Dehn Alexa Bethell', 'United States Ryan FitzGibbon Remy Marin', 'J.P. Morgan Securities plc', 'Dutch Financial Markets Supervision Act', 'diversified alternative asset management business', 'SOURCE Tetragon Financial Group Limited', 'modified Dutch auction"" tender offer', 'J.P. Morgan Cazenove', 'U.S. Investment Company Act', 'UK investment banking business', 'UK Financial Conduct Authority', 'Computershare Investor Services PLC', 'U.S. Securities Act', 'UK Prudential Regulation Authority', 'Euronext Amsterdam N.V.', 'EU Market Abuse Regulation', 'U.S. persons', 'alternative investment fund', 'TFG Asset Management', 'asset management companies', 'Specialist Fund Segment', 'closed-ended investment company', 'final proration factor', 'outstanding non-voting shares', 'real estate cycles', 'London Stock Exchange', '4,291,157 non‚Äëvoting shares', 'maximum aggregate payment', 'final purchase price', '4,291,157 Tetragon non-voting shares', 'investment objective', 'Netherlands Authority', 'UK version', 'UK law', 'Investor Relations', 'distressed securities', 'final results', 'regulated market', 'main market', 'aggregate cost', 'tender agent', 'dealer manager', 'broad range', 'private equities', 'convertible bonds', 'bank loans', 'distributable income', 'interest rate', 'Yuko Thomas', 'Press Inquiries', 'European Union', 'other jurisdiction', 'applicable law', 'original content', 'public offer', 'structured credit', 'venture capital', 'capital appreciation', 'various credit', 'public register', 'stable returns', 'Prosek Partners', '10 April', 'portion', 'cash', '7 April', 'accordance', 'terms', 'fees', 'expenses', 'total', '14 April', 'assets', 'infrastructure', 'order', 'investors', 'equity', 'inflation', 'information', 'website', 'tetragoninv', 'release', 'inside', 'meaning', 'Article', 'virtue', 'Withdrawal', 'solicitation', 'registration', 'addition', 'benefits', 'Section', 'connection', 'recipient', 'protections', 'clients', 'advice', '11:59']",2022-04-10,2022-04-11,kold.com
2624,EuroNext,Twitter API,Twitter,@RedDavidFR77 Euronext,nan,@RedDavidFR77 Euronext,neutral,0.02,0.96,0.02,neutral,0.02,0.96,0.02,True,English,[],2022-04-10,2022-04-11,Unknown
2625,Euroclear,NewsApi.org,https://www.moneycontrol.com/news/india/how-indias-much-hyped-global-bond-index-inclusion-unraveled-8341921.html,How India√¢¬Ä¬ôs much-hyped global bond index inclusion unraveled,The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the n‚Ä¶,For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping international wealth.The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn‚Äôt make any mention of it in her February budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt markets saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn‚Äôt likely for at least a year. Officials say a path forward isn‚Äôt possible until Group of 20 nations reach a consensus on a country‚Äôs right to tax capital gains  another pressure point for India.‚ÄúFrom India‚Äôs perspective  we are losing an opportunity to tap a pool of liquidity and an investor base ‚Äù said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors‚Äô perspective  India is one of the largest EM bond markets that is yet to be included in major bond indexes.‚ÄùWith inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits ‚Äù he said.The challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the Feb. 1 budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn‚Äôt reply to multiple requests for comment. A spokesperson for India‚Äôs finance ministry didn‚Äôt respond to an email seeking clarification.In hindsight  officials said India‚Äôs reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi‚Äôs party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party‚Äôs traditional vote bank. Every year  they hold informal discussions with the government ahead of the budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors ‚Äù Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February budget speech.For now  index inclusion appears all but impossible in the short term.In a recent interview with Bloomberg  Ajay Seth  the secretary of India‚Äôs economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India‚Äôs bond market. In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That‚Äôs a concern for the government as it plans to borrow a record amount from the markets to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal‚Äôs borrowing commences in April ‚Äù said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody‚Äôs Investors Service. ‚ÄúIf there are concrete steps toward bond index inclusion during the year  it could help to cap yields.‚ÄùDownload your money calendar for 2022-23 here and keep your dates with your moneybox  investments  taxes,neutral,0.06,0.67,0.27,negative,0.01,0.13,0.86,True,English,"['global bond index inclusion', 'India√¢', 'Senior Asia Rates Strategist', 'largest EM bond markets', 'Prime Minister Narendra Modi', 'Finance Minister Nirmala Sitharaman', 'Powerful Hindu nationalist groups', 'dollar-denominated sovereign bond', 'eleventh hour concerns', 'Standard Chartered Plc', 'traditional vote bank', 'Swadeshi Jagran Manch', 'international clearing platforms', 'key tax exemptions', 'new financial year', 'contentious tax negotiations', 'risk diversification benefits', 'Local debt markets', 'Feb. 1 budget talk', 'global minimum rate', 'tax avoidance issues', 'public OECD forums', 'international fiscal policy', 'international bond transactions', 'crucial step change', 'February budget speech', 'major bond indexes', 'senior government officials', 'finance ministry official', 'foreign investors‚Äô perspective', 'India long bonds', 'senior official', 'international wealth', 'Indian debt', 'a year', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'global indexes', 'Global investors', 'local investors', 'local businesses', 'remarkable milestone', 'Citigroup Inc.', 'Policy makers', 'sudden silence', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'increasing clout', 'top bureaucrat', 'Ashwani Mahajan', 'Indian officials', 'securities transactions', 'Paris-based group', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'informal discussions', 'index inclusion', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal', 'transfer', 'reason', 'advantages', 'leaders', 'Bloomberg']",2022-04-11,2022-04-11,moneycontrol.com
2626,Euroclear,NewsApi.org,https://finance.yahoo.com/news/notice-attend-annual-general-meeting-165000357.html,Notice To Attend The Annual General Meeting Of Shareholders,GOTHENBURG  SWEDEN / ACCESSWIRE / April 11  2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)The shareholders of IRLAB Therapeutics AB  company registration...,"GOTHENBURG  SWEDEN / ACCESSWIRE / April 11  2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)The shareholders of IRLAB Therapeutics AB  company registration no. 556931-4692 (""IRLAB"" or the ""Company"")  are hereby given notice to attend the Annual General Meeting to be held on Wednesday 11 May 2022 at 5.00 PM at the Wallenberg Conference Center  Medicinaregatan 20 A  Gothenburg. Registration for the Annual General Meeting will start at 3.30 PM.The board of IRLAB has in accordance with the temporary rules decided to allow shareholders who do not wish to be physically present at the Annual General Meeting to instead vote by advance voting (Sw. postr√∂stning).Right to participate and notice of intention to participateIn order to have the right to participate at the Annual General Meeting a shareholder must:be entered in the share register maintained by Euroclear Sweden AB as per 3 May 2022  andgive notice of its intention to participate by mail to Computershare AB  ""IRLAB Therapeutics AB √Örsst√§mma""  P.O. Box 5267  102 46 Stockholm  or by telephone +46 771 24 64 00  or by e-mail to proxy@computershare.se or at the Company's website (www.irlab.se)  no later than 5 May 2022.The notice of intention to participate shall state the complete name  personal identity number or corporate registration number  number of shares held  daytime telephone number as well as information of the number of advisors accompanying the shareholder (maximum two advisors).Notice for a legal entity shall be made in accordance with the instructions above.How advance voting worksA specific form is used for advance voting.Shareholders must use the form and follow the instructions which will be available on the Company's website  www.irlab.se  and at the Company's premises at Arvid Wallgrens backe 20  413 46 Gothenburg. The completed and signed form for advance voting must be sent by mail to Computershare AB  ""Irlab √•rsst√§mma""  P.O. Box 5267  102 46 Stockholm. The completed form must be received by Computershare AB no later than 5 May 2022. The completed and signed form may also be submitted electronically and must then be sent to proxy@computershare.se. Shareholders can also cast a postal vote electronically with BankID via the Company's website  www.irlab.se. If shareholders cast advance votes through a proxy  a power of attorney must be attached to the form. If the shareholder is a legal entity  a registration certificate or other authorization document must be attached to the power of attorney. Anyone wishing to revoke advance voting and instead exercise their right to vote by attending the meeting physically or by proxy must notify the secretariat of the meeting before the meeting opens.Story continuesComplete instructions for shareholders who wish to exercise their voting by advance voting can be found in form for advance voting.Nominee registered sharesTo be entitled to participate at the Annual General Meeting  shareholders who have had their shares registered with a nominee  must request that they be temporarily re-registered in their own name. Shareholders who wish to carry out such re-registration  so called registration for voting rights (Sw. r√∂str√§ttsregistrering)  should notify the nominee in due time before 3 May 2022. The re-registration must be executed with Euroclear Sweden AB no later than 5 May 2022.ProxyIf shareholder is to be represented by a proxy  the proxy must have a written  dated  and signed by the shareholder power of attorney to the Annual General Meeting. The power of attorney may not be older than one year  unless a longer period of validity (however  a maximum of five years) has been stated in the power of attorney. If the power of the attorney has been issued by a legal entity  the proxy must also have relevant certificate of registration or equivalent authorization document for the legal entity. To facilitate the registration at the Annual General Meeting  a copy of the power of attorney and other authorization documents should be attached to the notification to the Annul General Meeting. Power of attorney forms are available on the Company's website (www.irlab.se) and are sent by mail to shareholders who contact the Company and state their address.BusinessProposed agenda1) Opening of the meeting;2) Election of chairman of the meeting;3) Preparation and approval of the voting register;4) Resolution to allow broadcast of the Annual General Meeting over the internet;5) Election of one or two persons to verify the minutes;6) Determination of whether the Annual General Meeting has been duly convened;7) Approval of the agenda;8) Presentation of the annual report and the auditor's report for the Company and the group;9) Resolution regarding adoption of the income statement and balance sheet for the Company and the group;10) Resolution regarding allocation of the Company's results according to the adopted balance sheet;11) Resolution regarding discharge from liability for the directors and the CEO;i) Gunnar Olssonii) Carole Lemneiii) Lars Adlerssoniv) Rein Piirv) Martin Nicklassonvi) Lena Torleg√•rdvii) Nicholas Waters12) Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditors;13) Resolution regarding determination of the fees payable to the directors and the auditors;14) Election of the Board of Directors;The nominations committee's proposal:i) Gunnar Olssonii) Carole Lemneiii) Rein Piiriv) An van Es-Johanssonv) Catharina Gustafsson Wallich15) Election of auditor and deputy auditors  if any;16) Resolution regarding principles for the nomination committee;17) Resolution regarding presentation and approval of the Board of Directors' report of paid and outstanding remuneration to senior management (remuneration report);18) Resolution regarding salary and other compensation to senior management:19) Resolution regarding adoption of new articles of association;20) Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;21) Resolution regarding adjustment authorization;22) Closing of the meeting.Nomination committeeIn accordance with the Annual General Meeting's principles adopted last year  the nomination committee is composed of one representative each from the three largest shareholders as per the last banking day of August 2021  as well as the chairman of the Company's Board of Directors. The nomination committee consists of Daniel Johnsson (appointed by one of the shareholders group representing approximately 21 percent of shares and votes)  Bo Rydlinger (appointed by one of the shareholder groups representing approximately 15 percent of shares and votes)  Clas Sonesson (appointed by one of the shareholder groups representing approximately 10 percent of shares and votes) and Gunnar Olsson  the chairman of the Board of Directors. Daniel Johnsson has served as the chairman of the nomination committee.Proposed resolutions by the nomination committee2. Election of chairman of the meetingThe nomination committee proposes advokat Dag Fredlund or  in the event of an impediment  the person appointed by the nomination committee  to be elected as the chairman of the Annual General Meeting.12. Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditorsThe nomination committee proposes that the number of directors for the period until the next Annual General Meeting shall be five and that one auditor and no deputy auditor shall be appointed for the same period.13. Resolution regarding determination of the fees payable to the directors and the auditorsThe nomination committee proposes that the fee per director elected by the Annual General Meeting shall be distributed as follows (last year's figures in brackets): chairman of the Board of Directors SEK 500 000 (400 000) and director not employed by the Company SEK 250 000 (200 000).It is proposed that the fee for work in the audit committee be SEK 75 000 (75 000) to the chairman and SEK 50 000 (50 000) to each of the other members.It is proposed that the fee for work in the remuneration committee be SEK 50 000 (50 000) to the chairman and SEK 30 000 (30 000) to each of the other members.If the meeting resolves according to the nomination committee's proposal as regards the composition of the Board of Directors  the total fee will amount to SEK 1 785 000 (1 685 000).It is proposed that the auditor shall be remunerated according to invoices approved by the Company.14. Election of the Board of DirectorsThe nomination committee proposes the following Board of Directors: re-election of Gunnar Olsson. Carola Lemne  and Rein Piir  as well as new election of An van Es-Johansson and Catharina Gustafsson Wallich.Gunnar Olsson is proposed to be re-elected as the chairperson of the Board of Directors and Carola Lemne is proposed to be re-elected as the deputy chairperson.Lena Torleg√•rd and Lars Aldersson have declined to be re-elected.Further information about the proposed directors can be found on www.irlab.se.The proposed composition of the Board of Directors of the Company complies with the rules of the Code of Corporate Governance regarding independence. All directors are independent in relation to the Company and its executive management and are independent in relation to the Company's major shareholders.15. Election of auditorThe nomination committee proposes re-election of √ñhrlings PricewaterhouseCoopers AB (PwC) as auditor of the Company for the period until the end of the next Annual General Meeting. PwC has informed that in the event it is re-elected  Johan Rippe will continue in his capacity as principal auditor.16. Resolution regarding instruction to the nomination committeeThe nomination committee proposes the following instruction to the nomination committee (which materially corresponds to the instructions adopted at the 2021 Annual General Meeting).1. Appointment of the nomination committee etc.1.1 The nomination committee shall consist of four members - one representative for each one of the three largest shareholders or groups of owners in accordance with clause 1.2. below  which wish to appoint a member to the nomination committee as well as the chairman of the Board of Directors.1.2 The identification of those  who have the right to appoint members to the nomination committee  shall be based on ownership statistics from Euroclear Sweden AB per the last banking day in August. For the purpose of assessing the size of the shareholders  a group of shareholders shall be deemed one shareholder if they are grouped as owners in Euroclear Sweden AB's register.1.3 The chairman of the Board of Directors shall  without undue delay  after receipt by the Company of ownership statistics from Euroclear Sweden AB as per the last banking day in August  contact the three largest shareholders to ascertain if they wish to appoint members to the nomination committee. If one or more of the three largest shareholders refrains from appointing a member to the nomination committee  the chairman of the Board of Directors shall offer other major shareholders to appoint a member to the nomination committee. If such offer is made  it shall be made in due order to the largest shareholders (i.e. first to the fourth largest shareholder  thereafter to the fifth largest shareholder  etc.). The procedure shall continue until such time as the nomination committee consists of four members  including the chairman of the Board of Directors.1.4 Board members may be members of the nomination committee  but shall not constitute a majority of its members.1.5 At its first meeting  the nomination committee shall elect a chairman from among its members. The chairman of the board or  where applicable  another board member shall not be the chairman of the nomination committee.1.6 As soon as the nomination committee has been constituted  the Company shall  on its website  disclose the names of the members of the nomination committee  and provide information regarding how shareholders may submit proposals to the nomination committee.1.7 The nomination committee's mandate period shall continue until a new nomination committee has been appointed.1.8 If there is a change to the Company's ownership structure after the last banking day in August  but prior to the date which falls two months prior to the upcoming Annual General Meeting  and if a shareholder  which has not previously had the right to appoint a member to the nomination committee thereby becomes a larger shareholder than one or any of those who have appointed a member to the nomination committee (""new major shareholder"")  the nomination committee shall  if the new major owner requests to appoint a member to the nomination committee  decide that the member of the nomination committee who represents the smallest shareholder after the change shall be dismissed and replaced by the member who is appointed by the new major owner. If a new major owner wishes to appoint a member to the nomination committee  they must notify the chairman of the nomination committee. The application must contain the name of the person appointed by the new major owner as a member of the nomination committee.1.9 A shareholder  which has appointed a member to the nomination committee  has the right to dismiss the member and appoint a new member. If such change takes place  the shareholder shall immediately notify the chairman of the nomination committee (or  if it is the chairman of the nomination committee who shall be replaced  to the chairman of the Board of Directors). The application must contain the name of the dismissed member and the person who shall replace him/her as member of the nomination committee.2. Duties2.1 The nomination committee shall submit proposals for:a) chairman of the Annual General Meeting b) number of board members c) election of board members and election of the chairman of the board d) remuneration to each of the board members elected by the Annual General Meeting e) number of auditors and deputy auditors f) auditor and  where applicable  deputy auditors g) remuneration to auditors  andh) where applicable  amendment of instructions for the nomination committee.2.2 The members of the nomination committee shall serve the interests of all the shareholders.2.3 The nomination committee shall provide the Board of Directors with its proposals for resolution in due time prior to the latest day for the summons to the Annual General meeting or  where applicable  the extraordinary General Meeting.3. Meeting3.1 The nomination committee shall meet as often as is required in order for the nomination committee to be able to fulfil its duties. The chairman of the board shall convene its first meeting. Summons to other meetings shall be issued by the chairman of the nomination committee. If a member requests that the nomination committee be convened  the request must be complied with.3.2 The nomination committee is quorate if more than half of the members are present. Decisions in matters may  however  not be made unless all the members have been offered the opportunity to take part in the processing of the matter.3.3 Upon election of chairman of the nomination committee the person who receives the most votes is considered elected. In the event of an equal number of votes  the election shall be decided by drawing of lots.3.4 The nomination committee's decision is the opinion that more than half of the members present vote for or  if there are an equal amount of votes  the opinion that is supported by the chairman of the nomination committee.3.5 Minutes shall be taken at the nomination committee's meetings  which shall be signed and adjusted by the chairman of the nomination committee and the member appointed by the nomination committee. The minutes shall be taken and kept in accordance with what is applicable for board minutes.4. Confidentiality4.1 A member of the nomination committee is subject to a duty of confidentiality regarding the Company's affairs and this obligation shall  at the Company's request  be confirmed by the member by signing a special confidentiality agreement between the member and the Company.5. Fee and reimbursement of costs5.1 Fees shall not be paid to members of the nomination committee.The Company shall be responsible for reasonable costs attributable to the nomination committee's work.Proposed resolutions by the Board of Directors3. Preparation and approval of the voting registerThe voting register  which is proposed for approval under clause 3 of the agenda is the voting register that has been prepared by the chairman  based on the annual general meeting share register and advance votes received  and which have been verified by the adjusters.5. Election of one or two adjustorsThe Board of Directors proposes that the minutes shall be adjusted by Stefan Andersson and Daniel Johnsson or  in the event of an impediment for one or both of them  the person or persons indicated by the Board of Directors. The adjustors' tasks also include checking the voting list and that advance votes received are correctly stated in the minutes of the Annual General Meeting.10. Resolution on allocation of the Company's results according to the adopted balance sheetThe Board of Directors proposes that the Annual General Meeting resolves that the Company's profit or loss is allocated according to the Board of Directors' proposal in the annual report. The Board of Directors further proposes that no dividend be paid for the financial year 2021.17. Resolution regarding presentation and approval of the Board of Directors report on paid and outstanding compensation to senior management (remuneration report).The Board of Directors proposes that the Annual General Meeting approves the report presented by the Board of Directors on compensation paid and outstanding to senior management  prepared in accordance with Chapter 8  Section 53a of the Swedish Companies Act.18. Resolution regarding guidelines for salary and other compensation to senior managementThe Board of Directors proposes the following guidelines for the determination of salaries and other compensation to senior management.These guidelines include board members  the CEO and members of IRLAB's company management (Management Group). The guidelines shall be applicable to compensation that is agreed and amendments made to previously agreed compensation  subsequent to the adoption of the guidelines at the Annual General Meeting 2022. The guidelines do not include compensation resolved by the Annual General Meeting.The guidelines' promotion of the Company's business strategy  long-term interest and sustainabilityThe Company's business strategy is to discover new drug candidates with the help of ISP (Integrative Screening Process) and develop them into a so-called clinical ""Proof of Concept"" when clear indications of efficacy  tolerability and safety are achieved and thereafter seek partnership with international pharmaceutical companies for further development  registration and marketing.For further detailed information about the Company's business strategy please refer to the Company's annual reports and the website.The work with drug development takes a long time which means that continuity as well as low employee turnover are important. Successful implementation of the Company's business strategy and safeguarding of the Company's long-term interest  including concern for the sustainability of the business  therefore assumes that the Company is able to recruit and retain qualified employees. To achieve this  it is necessary that the Company can offer good working conditions with competitive levels of compensation. These guidelines enables the Company's executives to be offered a competitive total compensation.Forms of compensation etc.In the Company  the market compensation consists of fixed cash salary  pension benefits and other benefits. In addition and independently of these guidelines  the Annual General Meeting may resolve on  for example  share and share price-related compensation.Cash variable compensation can be paid in extraordinary circumstances  provided that such extraordinary arrangements are limited in time and only made at the individual level as compensation for extraordinary work effort in addition to the person's ordinary duties. Such compensation may not be paid more than twice a year and per individual and may not exceed an amount in total corresponding to 25 percent of the fixed annual cash salary. Decision on such compensation shall be made by the board of directors on the proposal of the remuneration committee.The pension premiums for defined contribution pensions for the CEO and management group in the company vary greatly depending on  among other things  age  previous salary and employment conditions.For the CEO  pension benefits  including health insurance  must be defined-contribution. Any variable cash compensation shall not be pension-based. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.For other senior executives  pension benefits  including health insurance  shall be defined-contribution unless the executive is covered by a defined-benefit pension in accordance with mandatory collective agreement provisions. Variable cash compensation shall be pension-based to the extent it follows from mandatory collective agreement provisions that are applicable to the executive. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.Other benefits may include  among other things  life insurance  health insurance and car benefit. Such benefits may amount in total to a maximum of 10 percent of the fixed annual cash salary.Termination of employmentUpon termination of employment  the notice period may not exceed twelve months. Fixed cash salary during the notice period and severance pay may not exceed an amount in total corresponding to the fixed cash salary for two years. In the event of termination on the part of the executive  the termination period may be not exceed 18 months for the CEO and no longer than six months for the other senior executives.In addition  compensation may be paid for any undertaking to restrict competition. Such compensation shall compensate for any loss of income and shall only be paid to the extent that the previous executive is not entitled to severance pay. The compensation shall be based on the fixed cash salary at the time of termination and shall be paid during the period the undertaking regarding restriction of competition applies  which shall be no longer than six months after the termination of employment.Salary and terms of employment for employeesIn preparation of the Board of Directors' proposal for these compensation guidelines  salary and terms of employment for the Company's employees have been taken into consideration through information about employees' total compensation  compensation components and the increase and rate of increase over time has formed part of the remuneration committee's and Board of Directors' basis for decision in the evaluation of the equity of the guidelines and the restrictions that follow as a result of these. The development of the gap between compensation for senior executives and compensation for other employees will be detailed in the remuneration report.The decision-making process to establish  review and implement the guidelinesThe Board of Directors has established a remuneration committee. The committee's duties include preparing the Board of Director's decision on proposed guidelines for compensation to senior executives. The Board of Directors shall prepare proposals for new guidelines at least every four years and submit the proposal for resolution at the Annual General Meeting. The guidelines shall apply until new guidelines have been adopted by the Annual General Meeting. The remuneration committee shall also monitor and evaluate the application of guidelines for compensation to senior executives as well as current compensation structures and levels in the Company. The members of the remuneration committee are independent in relation to the Company and the company management. During consideration of and decisions on compensation-related issues by the Board of Directors  neither the CEO nor other persons in the company management shall attend  insofar as they are affected by the issues.Deviation from the guidelinesThe Board of Directors may decide to temporarily deviate from the guidelines in whole or in part  if in an individual case if there are special reasons to do so and a deviation is necessary to meet the Company's long-term interests  including its sustainability  or to ensure the Company's economic viability. As stated above  it is part of the remuneration committee's duties to prepare Board of Directors' decisions in compensation issues  which include decisions regarding deviations from the guidelines.Description of important changes to the guidelines and how the shareholders' views have been taken into account.These guidelines correspond to the guidelines adopted at the 2020 Annual General Meeting19. Resolution on adoption of new Articles of AssociationThe Board of Directors proposes that a new ¬ß 12 is added to the Articles of Association in order to give the Board of Directors the right to collect powers of attorney  and to allow advance voting (Sw. postr√∂stning) for future general meetings. The numbering of the subsequent parts of the Articles of Association will change as a consequence.Current wording Proposed wording Not applicable ¬ß 12 Collection of powers of attorney and advance votingThe Board of Directors may collect powers of attorney in the manner stipulated in Chapter 7 Section 4  second paragraph of the Swedish Companies Act (2005:551). The board may before a general meeting resolve to allow shareholders to exercise their voting rights in advance of the general meeting in accordance with what is stipulated in Chapter 7  Section 4a of the Swedish Companies Act (2005:551).The approval by the Annual General Meeting of this proposal in accordance with the above is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.20. Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to resolve  on one or several occasions  on issue of shares of series A and/or convertibles entitling to conversion to shares of series A during the time until the next Annual General Meeting for payment in cash and/or with terms regarding set-off or issue in kind or otherwise with terms and thereby deviate from the preferential right of the shareholders.The issues shall be done to a marketable issue price determined by the Board of Directors in consultation with the Company's financial advisers  if any  taking into consideration any marketable issue-discount  where applicable.The Board of Directors proposes that 5 166 630 shares of series A could be issued with or without the preferential right of the shareholders corresponding to a reduced shareholding for non-participating shareholders (dilution) amounting to just under 9.1 percent or an increase of the existing number of outstanding shares with just under 10 percent.The purpose of the authorization and the reason to deviate from the preferential right of the shareholders is that issues shall be possible for financing the Company's business  commercialisation and development of the Company's products and markets and/or acquisition of businesses  companies or parts of companies and/or enable a broadening of the owner base of the Company.The approval by the Annual General Meeting of this proposal is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.21. Resolution regarding adjustment authorizationThe Board of Directors or the person appointed by the Board of Directors shall be authorized to make such minor amendments and clarifications of the resolution by the Annual General Meeting that may prove necessary in connection with registration of the resolutions.Number of shares and votesAt the time of this notice  the total number of shares in the Company amounts to 51 748 406  whereof 51 668 630 series A and 79 776 series B. The total number of votes amounts to 51 748 406. The Company holds no treasury shares.InformationWhere so requested by any shareholder and the Board of Directors deems that it can take place without serious harm to the Company  the Board of Directors and the CEO shall provide information regarding circumstances which may have an impact on the assessment of an item on the agenda and any circumstances which may have an impact on the assessment of the financial position of the Company. The obligation to provide information also refers to the Company's relationship to other Group companies and consolidated accounts as well as such relationships regarding Group companies as referred to above.Annual report and other documentsAccounting documents  auditors' report and other documents to be considered at the Annual General Meeting will be available at the Company's office at Arvid Wallgrens backe 20  413 46 G√∂teborg and on the Company's website  www.irlab.se  no later than three weeks prior to the Annual General Meeting. The documents are also be forwarded free of charge to the shareholders who request it and provide their address.Processing of personal dataFor information on how your personal data is processed  see https://www.euroclear.com/dam/ESwithLegal/Integritetspolicy-bolagsstammor-svenska.pdf.G√∂teborg in April 2022IRLAB Therapeutics ABThe Board of DirectorsFor more informationNicholas Waters  CEOPhone: +46 730 75 77 01E-mail: nicholas.waters@irlab.seViktor Siewertz  CFOPhone: +46 727 10 70 70E-mail: viktor.siewertz@irlab.seAbout IRLABIRLAB discovers and develops novel treatments of Parkinson's disease and other disorders of the brain. The company's most advanced drug candidates  mesdopetam (IRL790) and pirepemat (IRL752)  are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's disease. In 2021  IRLAB entered an exclusive and worldwide license with Ipsen for the development and marketing of mesdopetam.Through ISP  its proprietary research platform  IRLAB has discovered and developed all its experimental drug candidates and continues to discover innovative drug candidates for the treatment of disorders of the brain. In addition to IRLAB's strong clinical pipeline  IRLAB runs several preclinical programs with IRL942 and IRL757 currently in development towards Phase I. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.AttachmentsIRLAB AGM Notice 2022 English TranslationSOURCE: IRLAB TherapeuticsView source version on accesswire.com:https://www.accesswire.com/696932/Notice-To-Attend-The-Annual-General-Meeting-Of-Shareholders",neutral,0.03,0.9,0.07,mixed,0.3,0.31,0.39,True,English,"['Annual General Meeting', 'Notice', 'The', 'Shareholders', 'IRLAB Therapeutics AB √Örsst√§mma', 'Irlab √•rsst√§mma', 'Wallenberg Conference Center', 'P.O. Box', 'Arvid Wallgrens backe', 'other authorization document', 'equivalent authorization document', 'Annul General Meeting', 'Annual General Meeting', 'personal identity number', 'Euroclear Sweden AB', 'daytime telephone number', 'corporate registration number', 'maximum two advisors', 'Nominee registered shares', 'two persons', 'Computershare AB', 'annual report', 'Medicinaregatan 20 A', 'temporary rules', 'share register', 'legal entity', 'postal vote', 'due time', 'longer period', 'five years', 'relevant certificate', 'income statement', 'balance sheet', 'Gunnar Olsson', 'Carole Lemne', 'Lars Adlersson', 'Rein Piir', 'voting rights', 'voting register', 'advance voting', 'complete name', 'registration certificate', 'one year', 'Complete instructions', 'specific form', 'completed form', 'Wednesday 11 May', 'attorney forms', 'company registration', 'shareholder power', '3 May', '5 May', 'GOTHENBURG', 'ACCESSWIRE', 'April', 'IRLAB-A', 'FRA', '6IRA', 'shareholders', 'notice', '3.30 PM', 'board', 'accordance', 'intention', 'order', 'mail', 'Stockholm', 'proxy', 'se', 'website', 'information', 'BankID', 'votes', 'Anyone', 'Story', 're-registration', 'validity', 'copy', 'notification', 'address', 'Business', 'agenda', 'Opening', 'Election', 'chairman', 'Preparation', 'approval', 'Resolution', 'broadcast', 'internet', 'minutes', 'Determination', 'auditor', 'group', 'adoption', 'allocation', 'results', 'discharge', 'liability', 'directors', 'CEO', 'Mar', '5.00', '102']",2022-04-11,2022-04-11,finance.yahoo.com
2627,Euroclear,NewsApi.org,https://finance.yahoo.com/news/notice-annual-general-meeting-spago-072000905.html,Notice to Annual General Meeting of Spago Nanomedical AB (publ),LUND  SWEDEN / ACCESSWIRE / April 11  2022 / Spago Nanomedical (STO:SPAGO.F)The shareholders of Spago Nanomedical AB (publ)  corporate registration number...,"LUND  SWEDEN / ACCESSWIRE / April 11  2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)The shareholders of Spago Nanomedical AB (publ)  corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Wednesday May 18  2022  at 4.00 p.m. CEST in the premises of Advokatfirman Cederquist at Hovslagargatan 3 in Stockholm.Right to attendShareholders wishing to attend the Annual General Meeting shall:be registered in the share register kept by Euroclear Sweden AB on Tuesday May 10  2022 and give notice of their intention to attend the Annual General Meeting of Spago Nanomedical no later than Thursday May 12  2022. Notice of attendance may be given:by e-mail to ursula.sorqvist@cederquist.se by mail to Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB  AGM 2022"")  or by phone +46 (0)8 522 065 34 between 9.00 a.m. and 4.00 p.m CEST.When giving notice of attendance  the shareholders shall state their name  address  daytime telephone number  personal identification number or company registration number and any assistants who shall participate (but not more than two).Nominee-registered sharesShareholders whose shares are nominee-registered must  to be entitled to exercise their voting rights and attend the Annual General Meeting  temporarily register such shares in their own names in the share register kept by Euroclear Sweden (so called voting right registration). The shareholders' register as of the record date  Tuesday May 10  2022  will consider voting right registrations made no later than the second banking day after May 10  2022. This means that shareholders should notify their nominee in this matter well in advance of this date.Proxy etc.Shareholders who wish to participate through a proxy representative should send power of attorneys  certificates of incorporation and other authorisation documents to Spago Nanomedical to the above address well in advance of the Annual General Meeting. Such original power of attorney shall be brought to the Annual General Meeting. A proxy form is available on the company¬¥s website  www.spagonanomedical.se.Story continuesPersonal data processingIn connection with the notice of attendance the company will process the personal data regarding shareholders that has been requested in accordance with the above. The personal data collected from the share register  notice of attendance at the Annual General Meeting and information on proxies and assistants will be used for registration  preparation of the voting list and  where applicable  minutes of the Annual General Meeting. The personal data will only be used for the Annual General Meeting. For further information on how your personal data is processed by the company and your rights  please see the company¬¥s website  www.spagonanomedical.se.Proposed agendaOpening of the Annual General Meeting. Election of chairman of the Annual General Meeting. Preparation and approval of the voting list. Election of one or two persons to verify the minutes. Approval of the agenda. Determination of whether the meeting has been duly convened. Presentation of the annual report and the auditor's report. Presentation by the CEO. Resolutions on adoption of the income statement and balance sheet. dispositions regarding the company¬¥s earnings in accordance with the adopted balance sheet. discharge from liability for the directors of the board and the CEO for the financial year 2021. Determination of the number of directors and deputy directors of the board. Determination of remuneration to the directors of the board and the auditors. Election of directors and chairman of the board of directors. Election of auditor. Resolution on adopting instructions to the nomination committee. Resolution on amendments to the articles of association. Resolution on authorisation for the board of directors to resolve to issue new shares. Closing of the Annual General Meeting.Proposed resolutionsItem 2. Election of chairman of the Annual General MeetingThe nomination committee proposes that Tone Myhre-Jensen  member of the Swedish Bar Association  is elected chairman of the Annual General Meeting  or  if she should be unable to attend the meeting  the person appointed by the nomination committee.Item 9. b) Resolution on dispositions regarding the company¬¥s earnings in accordance with the adopted balance sheetThe board of directors proposes that accumulated funds of KSEK 59 211  of which KSEK -39 071 are the results for the year  be transferred to new accounts.Item 10. Determination of the number of directors and deputy directors of the boardThe nomination committee proposes that the board of directors  for the period until the end of the next Annual General Meeting  shall consist of five directors with no deputies.Item 11. Determination of remuneration to the directors of the board and the auditorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that remuneration of SEK 200 000 (unchanged) shall be paid to the chairman of the board of directors and SEK 95 000 (unchanged) shall be paid to each of the other directors of the board.The nomination committee proposes that remuneration to the auditor shall be paid in accordance with approved invoices.Item 12. Election of directors and chairman of the board of directorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that Peter Leander  Sten Nilsson  Kari Gr√∏n√•s  Eugen Steiner and Nicklas Westerholm shall be re-elected as directors of the board.The nomination committee proposes that Eugen Steiner shall be re-elected as chairman of the board of directors.Further information about the proposed directors is available on the company¬¥s website  www.spagonanomedical.se.Item 13. Election of auditorThe nomination committee proposes that the registered accounting firm BDO M√§lardalen AB is re-elected as auditor for the period until the end of the next Annual General Meeting. BDO M√§lardalen AB has informed the nomination committee that if re-elected  J√∂rgen L√∂vgren  authorised public accountant  will continue to be the auditor in charge.Item 14. Resolution on adopting instructions to the nomination committeeThe nomination committee proposes that the Annual General Meeting resolves to adopt the following instructions for the nomination committee  to apply until the General Meeting decides otherwise.The nomination committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for resolutions:proposal for chairman of the meeting proposal for number of directors and deputy directors of the board proposal for directors and any deputy directors of the board proposal for chairman of the board of directors proposal for remuneration and other fees for board assignments to each of the board members and remuneration for committee work proposal for auditor (if applicable) proposal for fees for the auditor of the company  and proposal for instructions for the nomination committee¬¥s work and compositionThe nomination committee shall consist of at least three members and be formed in consultation with the largest shareholders of the company as per September 30th and who wish to appoint a member. It is the responsibility of the chairman of the board of directors to convene the nomination committee for its first meeting and to be available  when necessary  in the nomination committee¬¥s work. The chairman of the board of directors shall not be a member of the nomination committee. The nomination committee shall appoint a chairman for the nomination committee at its first meeting.The nomination committee is appointed for a period from the time it is formed until the next nomination committee is formed. If a member leaves its assignment prematurely  the nomination committee may appoint a new member. Provided that the shareholder who appointed the resigned member is still one of the largest shareholders in the company  the shareholder shall be asked to appoint a new member. If this shareholder refrains from appointing a new member  the nomination committee may ask the next shareholder in order of size of shareholding who has not previously appointed a member of the nomination committee. The chairman of the nomination committee shall  however  continue to contact shareholders next in turn if necessary for the nomination committee to consist of three members. If the ownership structure of the company changes  the nomination committee may choose to change its composition so that the nomination committee reflects the ownership structure of the company in an appropriate manner. However  the total number of members may never exceed five. Even if there are changes in the company's ownership structure  no changes need to be made in the composition of the nomination committee in the event of minor changes or if a change occurs less than three months before the Annual General Meeting  unless it is motivated due to special circumstances.Remuneration shall only be paid for costs attributable to contracting recruitment consultants in connection with the nomination committee's work and other potential direct costs that are necessary for the nomination committee to be able to fulfil its work. No remuneration shall be paid to the members of the nomination committee.The nomination committee shall annually evaluate these instructions and  if necessary  propose changes to the Annual General Meeting. These instructions shall apply until the Annual General Meeting decides otherwise.Item 15. Resolution on amendments to the articles of associationThe board of directors proposes that the Annual General Meeting resolves to change the articles of association's (i) ¬ß 4 so that the limits for the company's share capital are adjusted  and (ii) ¬ß 5 so that the limits for the number of shares are adjusted. ¬ß¬ß 4 and 5 of the articles of association will then have the following wordings:¬ß 4 Share capitalThe share capital shall amount to a minimum of SEK 40 000 000 and a maximum of SEK 160 000 000.¬ß 5 Number of sharesThe number of shares may not be fewer than 40 000 000 and not exceed 160 000 000.Item 16. Resolution on authorisation for the board of directors to resolve to issue new sharesThe board of directors proposes that the General Meeting resolves on authorisation for the board of directors to resolve to issue new shares in accordance with the following.The board of directors is authorised to  on one or several occasions before the next Annual General Meeting  resolve to issue new shares. Such issues of new shares may be made with or without deviation from the shareholders' preferential rights. By resolutions based on the authorisation to issue new shares  issues of shares without deviation from the shareholders' preferential rights may be made up to  in total  as many shares as falls within the limits of the articles of association at the time of exercise of the authorisation. By resolutions based on the authorisation to issue new shares  issues of shares with deviation from the shareholders' preferential rights may be made up to  in total  the number of shares corresponding to twenty (20) percent of the total number of outstanding shares in the company at the time of exercise of the authorisation the first time. The authorisation shall include the right to resolve on issues where payment is made in cash  by contribution in kind or by way of set-off. A cash issue or issue by way of set-off that is made with deviation from the shareholders' preferential rights shall be in line with market terms.The purpose of the authorisation and the reasons for potential deviations from the shareholders' preferential rights are that issues shall be able to be made in order to enable capital raisings if market conditions would be deemed appropriate and/or to broaden the ownership base of Spago Nanomedical by offering financial and industrial investors to invest in the company.Other informationMajority requirementsThe resolutions of the Annual General Meeting pursuant to items 15 and 16 above require that the resolutions are supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.Number of sharesSpago Nanomedical has a total of 41 182 287 shares with one vote each  thus a total of 41 182 287 votes.Shareholders' right to receive informationShareholders have the right to  if the board of directors believes that it can be done without significant damage to the company  receive information from the board of directors and the CEO regarding circumstances that may affect the assessment of a matter on the agenda or the company's financial situation. Shareholders who wish to submit questions in advance of the Annual General Meeting can do so in writing to Spago Nanomedical AB (publ)  c/o Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB (publ)  AGM 2022"") or by sending an e-mail to ursula.sorqvist@cederquist.se (state ""Spago Nanomedical AB (publ)  AGM 2022"" as the subject).DocumentsProxy forms  information regarding proposed board members  proposed new articles of association  accounting documents and auditor's report are available at Spago Nanomedical no later than from April 27  2022  and on the company's website www.spagonanomedical.se  and will also be sent free of charge to shareholders who so requests and states their postal or e-mail address. The documents are available at the Annual General Meeting.________________Lund  April 2022Spago Nanomedical AB (publ)The board of directorsFor further information  please contact Mats Hansen  CEO Spago Nanomedical AB  +46 46 811 88  mats.hansen@spagonanomedical.seSpago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company¬¥s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical¬¥s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information  see www.spagonanomedical.se.FNCA Sweden AB is the Certified Adviser of the company  +46 8 528 00 399  info@fnca.se.AttachmentsNotice to Annual General Meeting of Spago Nanomedical AB (publ)SOURCE: Spago NanomedicalView source version on accesswire.com:https://www.accesswire.com/696848/Notice-to-Annual-General-Meeting-of-Spago-Nanomedical-AB-publ",neutral,0.02,0.96,0.02,mixed,0.31,0.37,0.32,True,English,"['Annual General Meeting', 'Spago Nanomedical AB', 'Notice', 'next Annual General Meeting', 'P.O. Box', 'second banking day', 'daytime telephone number', 'Ursula S√∂rqvist', 'other authorisation documents', 'Such original power', 'Swedish Bar Association', 'Spago Nanomedical AB', 'personal identification number', 'Personal data processing', 'Euroclear Sweden AB', 'voting right registrations', 'company registration number', 'annual report', 'voting list', 'corporate registration', 'share register', 'two persons', 'income statement', 'balance sheet', 'nomination committee', 'Tone Myhre-Jensen', 'new accounts', 'voting rights', 'Advokatfirman Cederquist', 'proxy representative', 'proxy form', 'Wednesday May', 'Thursday May', 'Nominee-registered shares', 'record date', 'financial year', 'new shares', 'deputy directors', 'five directors', ""shareholders' register"", 'LUND', 'ACCESSWIRE', 'April', 'FRA', '7UX', 'publ', 'premises', 'Hovslagargatan', 'Stockholm', 'Tuesday', 'notice', 'intention', 'attendance', 'mail', 'sorqvist', 'envelope', 'AGM', '9.00 a', 'CEST', 'name', 'address', 'assistants', 'matter', 'advance', 'attorneys', 'certificates', 'incorporation', 'website', 'spagonanomedical', 'Story', 'connection', 'accordance', 'above', 'information', 'proxies', 'preparation', 'minutes', 'agenda', 'Opening', 'Election', 'chairman', 'approval', 'Determination', 'Presentation', 'auditor', 'CEO', 'Resolutions', 'adoption', 'dispositions', 'earnings', 'discharge', 'liability', 'board', 'remuneration', 'instructions', 'amendments', 'articles', 'Closing', 'Item', 'member', 'funds', 'KSEK', 'results', 'period', 'deputies', '4.00']",2022-04-11,2022-04-11,finance.yahoo.com
2628,Euroclear,NewsApi.org,https://www.business-standard.com/article/markets/how-india-s-much-anticipated-global-bond-index-inclusion-unraveled-122041100134_1.html,How India's much-anticipated global bond index inclusion unraveled,Inclusion was perceived as a crucial step change for the $1 trillion market.,For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping international wealth.The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn‚Äôt make any mention of it in her February budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn‚Äôt likely for at least a year. Officials say a path forward isn‚Äôt possible until Group of 20 nations reach a consensus on a country‚Äôs right to tax capital gains  another pressure point for India.‚ÄúFrom India‚Äôs perspective  we are losing an opportunity to tap a pool of liquidity and an investor base ‚Äù said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors‚Äô perspective  India is one of the largest EM bond that is yet to be included in major bond indexes.‚ÄùWith inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits ‚Äù he said.An About-FaceThe challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the Feb. 1 budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn‚Äôt reply to multiple requests for comment. A spokesperson for India‚Äôs finance ministry didn‚Äôt respond to an email seeking clarification.What Went WrongIn hindsight  officials said India‚Äôs reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi‚Äôs party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party‚Äôs traditional vote bank. Every year  they hold informal discussions with the government ahead of the budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors ‚Äù Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February budget speech.Looking AheadFor now  index inclusion appears all but impossible in the short term.In a recent interview with Bloomberg  Ajay Seth  the secretary of India‚Äôs economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India‚Äôs bond market. In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That‚Äôs a concern for the government as it plans to borrow a record amount from the to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal‚Äôs borrowing commences in April ‚Äù said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody‚Äôs Investors Service. ‚ÄúIf there are concrete steps toward inclusion during the year  it could help to cap yields.‚Äù,neutral,0.06,0.82,0.12,negative,0.01,0.12,0.86,True,English,"['global bond index inclusion', 'India', 'Senior Asia Rates Strategist', 'Prime Minister Narendra Modi', 'Finance Minister Nirmala Sitharaman', 'Powerful Hindu nationalist groups', 'eleventh hour concerns', 'Standard Chartered Plc', 'largest EM bond', 'traditional vote bank', 'dollar-denominated sovereign bond', 'Swadeshi Jagran Manch', 'international clearing platforms', 'key tax exemptions', 'new financial year', 'contentious tax negotiations', 'risk diversification benefits', 'Feb. 1 budget talk', 'global minimum rate', 'tax avoidance issues', 'public OECD forums', 'international fiscal policy', 'crucial step change', 'international bond transactions', 'February budget speech', 'major bond indexes', 'senior government officials', 'finance ministry official', 'foreign investors‚Äô perspective', 'India long bonds', 'senior official', 'international wealth', 'a year', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'global indexes', 'Global investors', 'remarkable milestone', 'Citigroup Inc.', 'Indian debt', 'Policy makers', 'sudden silence', 'Local debt', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'local investors', 'increasing clout', 'local businesses', 'top bureaucrat', 'Ashwani Mahajan', 'Indian officials', 'securities transactions', 'Paris-based group', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'informal discussions', 'index inclusion', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'Face', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal', 'transfer', 'reason', 'advantages', 'leaders']",2022-04-11,2022-04-11,business-standard.com
2629,Euroclear,Google API,https://www.deccanherald.com/business/how-india-s-much-hyped-global-bond-index-inclusion-unravelled-1099617.html,How India‚Äôs much-hyped global bond index inclusion unravelled,16 hours ago,By Vrishti BeniwalFor months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping international wealth.The timeline seemed so final that Citigroup Inc advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn‚Äôt make any mention of it in her February Budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt markets saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn‚Äôt likely for at least a year. Officials say a path forward isn‚Äôt possible until Group of 20 nations reach a consensus on a country‚Äôs right to tax capital gains  another pressure point for India.‚ÄúFrom India‚Äôs perspective  we are losing an opportunity to tap a pool of liquidity and an investor base ‚Äù said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors‚Äô perspective  India is one of the largest EM bond markets that is yet to be included in major bond indexes.‚ÄùWith inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits ‚Äù he said.An about-faceThe challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the February 1 Budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn‚Äôt reply to multiple requests for comment. A spokesperson for India‚Äôs finance ministry didn‚Äôt respond to an email seeking clarification.Bloomberg LP is the parent company of Bloomberg Index Services Limited (BISL)  which administers indexes that compete with indexes from other providers.What went wrongIn hindsight  officials said India‚Äôs reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi‚Äôs party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party‚Äôs traditional vote bank. Every year  they hold informal discussions with the government ahead of the Budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors ‚Äù Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February Budget speech.Looking aheadFor now  index inclusion appears all but impossible in the short term.In a recent interview with Bloomberg  Ajay Seth  the secretary of India‚Äôs economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India‚Äôs bond market. In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That‚Äôs a concern for the government as it plans to borrow a record amount from the markets to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal‚Äôs borrowing commences in April ‚Äù said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody‚Äôs Investors Service. ‚ÄúIf there are concrete steps toward bond index inclusion during the year  it could help to cap yields.‚ÄùWatch the latest DH Videos here:,neutral,0.06,0.72,0.22,negative,0.01,0.12,0.87,True,English,"['global bond index inclusion', 'India', 'Senior Asia Rates Strategist', 'largest EM bond markets', 'Prime Minister Narendra Modi', 'Bloomberg Index Services Limited', 'Powerful Hindu nationalist groups', 'Finance Minister Nirmala Sitharaman', 'dollar-denominated sovereign bond', 'eleventh hour concerns', 'Standard Chartered Plc', 'traditional vote bank', 'international clearing platforms', 'key tax exemptions', 'new financial year', 'contentious tax negotiations', 'risk diversification benefits', 'Local debt markets', 'February 1 Budget talk', 'global minimum rate', 'tax avoidance issues', 'public OECD forums', 'international fiscal policy', 'international bond transactions', 'crucial step change', 'February Budget speech', 'foreign investors‚Äô perspective', 'major bond indexes', 'senior government officials', 'finance ministry official', 'India long bonds', 'senior official', 'Bloomberg LP', 'international wealth', 'Indian debt', 'a year', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'Global investors', 'local investors', 'local businesses', 'index inclusion', 'Vrishti Beniwal', 'remarkable milestone', 'Citigroup Inc', 'Policy makers', 'sudden silence', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'parent company', 'other providers', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'increasing clout', 'top bureaucrat', 'global indexes', 'Indian officials', 'securities transactions', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'Paris-based group', 'informal discussions', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'face', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'BISL', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal', 'transfer']",2022-04-11,2022-04-11,deccanherald.com
2630,Euroclear,Google API,https://finance.yahoo.com/news/notice-annual-general-meeting-eolus-111500441.html,Notice of Annual General Meeting in Eolus Vind AB (publ),9 hours ago,"Eolus Vind ABH√§ssleholm  Sweden  April 11th  2022The shareholders of Eolus Vind AB (publ) Reg. No. 556389-3956 are hereby invited to attend the Annual General Meeting (‚ÄúAGM‚Äù) to be held on May 19  2022 at 2 p.m. CEST in Kulturhuset in H√§ssleholm  Vattugatan 18. Registration for the AGM begins at 1.30 p.m. CEST.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the regulations in Eolus‚Äô Articles of Association.Right to participateParticipation in the meeting roomA) Anyone wishing to attend the meeting room in person or through a representative must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB  made as of May 11  2022  and no later than May 13  2022 preferably before 4 p.m. CEST  notify the company of their intention to participate in the AGM.Registration to attend the AGM should primarily be made via the company‚Äôs website https://www.eolusvind.com/en/investors/corporate-governance/general-meeting/Registration to attend can also be made in writing under the address Eolus Vind AB ‚ÄùAnnual General Meeting‚Äù  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden or by phone  08-402 90 41. When registering  the shareholder must state name  social security- or company registration number  address  telephone number and the number of possible assistants (maximum two).If shareholders are represented by a proxy  a written and dated power of attorney signed by the shareholder must be issued to the proxy. Proxy form is available on the company‚Äôs website www.eolusvind.com . A power of attorney is valid one year from its issue date or such longer time period as set out in the power of attorney  however not more than five years. If the shareholder is a legal person  a registration certificate or other authorization document must be attached to the form  listing the authorized signatories. In order to facilitate the registration process at the AGM  a proxy together with registration certificate and any other authorization documents shall be received by the company at the above address at 4 p.m. CEST on May 13  2022  at the latest. If a proxy and other authorization documents have not been submitted in advance of the AGM  a proxy and other authorization documents shall be presented at the AGM.Story continuesParticipation by postal votingB) Anyone wishing to attend the meeting by postal voting must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB  made as of May 11  2022  and no later than May 13  2022 notify the company by casting their postal vote in accordance with the instructions below  so that the postal vote is received by Euroclear Sweden AB no later than that day.Anyone who wishes to attend the meeting room in person or through a representative  must give notice in accordance with the instructions stated under A) above. Hence  a notice through postal voting only is not sufficient for those who wishes to attend the meeting room.A special form must be used for postal voting. The form is available on the company‚Äôs website www.eolusvind.com . The completed and signed form may be sent by mail to Eolus Vind AB  ""Annual General Meeting""  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden or by email to GeneralMeetingService@euroclear.com . The completed form must be received by Euroclear Sweden AB no later than May 13  2022. Shareholders may also cast their votes electronically by verifying with BankID via Euroclear Sweden AB‚Äôs website https://anmalan.vpc.se/EuroclearProxy/ .Shareholders may not provide special instructions or conditions to the postal vote. If so  the entire postal vote is invalid. Further instructions and conditions can be found in the postal voting form.If the shareholder submits its postal vote by proxy  a written and dated power of attorney signed by the shareholder must be attached to the postal voting form. Proxy form is available on the company‚Äôs website www.eolusvind.com . A power of attorney is valid one year from its issue date or such longer time period as set out in the power of attorney  however not more than five years. If the shareholder is a legal person  a registration certificate or other authorization document must be attached to the form  listing the authorized signatories.Nominee-registered sharesIn order to be entitled to participate in the AGM  a shareholder whose shares are registered in the name of a nominee must  in addition to giving notice of participation in the AGM  register its shares in its own name so that the shareholder is listed in the presentation of the share register as of May 11  2022. Such registration may be temporary (so-called voting rights registration)  and request for such voting rights registration shall be made to the nominee  in accordance with the nominee‚Äôs routines  at such a time in advance as decided by the nominee. Voting rights registrations that have been made by the nominee no later than May 13  2022 will be taken into account in the presentation of the share register.Proposed agendaOpening of the meeting Election of chairman of the meeting Election of two persons to check the minutes Preparation and approval of the voting list Approval of the agenda Determination of compliance with the rules of convocation Presentation ofthe annual report and the auditor‚Äôs report and the consolidated financial statements and the auditor‚Äôs report for the Group the statement by the auditor on the compliance of the guidelines for remuneration to senior executives the Board of Directors‚Äô proposal on appropriation of the company‚Äôs profit and reasoned statement thereonResolutions regardingadoption of the statement of income and the balance sheet and the consolidated statement of income and the consolidated balance sheet appropriation of the company‚Äôs profit according to the adopted balance sheet discharge of the Board of Directors and the CEO from liability for the financial year 2021Determination of the number of Board members  deputy Board members  auditors and deputy auditors Determination of fees to Board members and auditor Election of Board members and Chairman of the BoardThe Nomination Committee‚Äôs proposal:Sigrun Hjelmquist Hans Johansson Jan Johansson Hans Linnarson Bodil Rosvall J√∂nsson Hans-G√∂ran Stennert Hans-G√∂ran Stennert  as Chairman of the BoardElection of auditor Resolution on approval of remuneration report Resolution on the implementation of a long-term share savings program Closing of the meetingProposed resolutionsElection of chairman of the meeting (item 2)The Nomination Committee for the AGM 2022 has consisted of the chairman Hans Gydell (appointed by Hans-G√∂ran Stennert)  Ingvar Svantesson (appointed by Domne√•ns Kraftaktiebolag)  Hans Johansson (appointed by √Öke Johansson) and the Chairman of the Board  Hans-G√∂ran Stennert.The Nomination Committe has proposed that Eolus‚Äô General Counsel  Karl Olsson  shall be elected chairman of the AGM 2022.Dividend (item 8b)The Board of Directors proposes that a dividend of SEK 1.50 per share is declared for the financial year 2021. As record date for the dividend  the Board of Directors proposes May 23  2022. If the AGM resolves in accordance with the proposal  the dividend is expected to be distributed by Euroclear Sweden AB starting May 27  2022.Election of Board members  Chairman of the Board and auditor  and determination of fees(items 9-12)The Nomination Committee proposes that the AGM resolves as follows:that the Board of Directors shall consist of six members  with no deputy members;that one Auditor shall be appointed  with no deputy Auditor;that  fees to the Board members shall be SEK 450 000 to the Chairman of the Board and SEK 225 000 each to other Board members who are not employed by the company  fees for work in the Audit Committee shall be paid in the amount of SEK 60 000 to the Chairman of the Audit Committee and in the amount of SEK 30 000 to other members who are not employed by the company  and fees for work in the Remuneration Committee shall be paid in the amount of SEK 15 000 to members who are not employed by the company;that the Auditor‚Äôs fee is to be paid according to agreement;that Board members Sigrun Hjelmquist  Hans Johansson  Jan Johansson  Hans Linnarson  Bodil Rosvall J√∂nsson and Hans-G√∂ran Stennert are re-elected;that Hans-G√∂ran Stennert is re-elected as Chairman of the Board;that   in accordance with the recommendation of the Audit Committee  the accounting firm PricewaterhouseCoopers AB is elected as auditor; PricewaterhouseCoopers AB has informed that the authorized public accountant Vicky Johansson will be appointed as auditor in charge should the AGM resolve in accordance with the Nomination Committee‚Äôs proposal.Resolution on approval of remuneration report (item 13)The Board of Directors proposes that the AGM resolves to approve the Board of Directors‚Äô report regarding compensation pursuant to Chapter 8  Section 53 a of the Swedish Companies Act.Resolution on the implementation of a long-term share savings program (item 14)The Board of Directors of Eolus Vind AB (publ) proposes that the AGM 2022 resolves on a long-term share savings program for the company‚Äôs employees (the ‚ÄúShare Savings Program 2022‚Äù).The Share Savings Program 2022 entails that all employees within Eolus can choose to use an amount corresponding to a maximum of one month‚Äôs salary of their potential variable cash remuneration relating to the financial year 2022 to acquire shares in Eolus (‚ÄùSavings Shares‚Äù). Acquisition of Savings Shares shall be made through the company on Nasdaq Stockholm within twenty trading days from when the outcome of the variable cash remuneration program has been established and the participants have informed Eolus whether they want to participate in the Share Savings Program.Provided that the participant still holds all of the Savings Shares and is still employed within the Eolus group three years after the acquisition of Savings Shares  Eolus will remunerate the participant with an amount corresponding to the cost for acquiring the number of Eolus shares corresponding to half of the number of Savings Shares (‚ÄúMatching Shares‚Äù). Acquisition of Matching Shares shall be made through the company on Nasdaq Stockholm within twenty trading days from the date falling three years after the acquisition of Savings Shares.In order to ensure that the participant‚Äôs financial situation as far as possible shall remain unchanged  the number of Matching Shares shall be subject to customary recalculation should the company‚Äôs share capital increase or decrease  convertible debt instruments or options be issued or the company be liquidated or merged  or any similar changes to the company occur.Should the participant be prohibited from acquiring Savings Shares due to possession of inside information  the Board of Directors may in individual cases prolong or postpone the above mentioned investment period  although not beyond the next AGM. The Board of Directors shall be responsible for the detailed conditions and the administration of the Share Savings Program 2022 within the terms and conditions set forth above  and may also make such minor adjustments and applications as may be appropriate for legal or administrative reasons.Based on the assumptions of maximum outcome in the variable cash remuneration program  full investments by the entitled participants and an unchanged share price at the time of delivery of the Matching Shares  Eolus‚Äô costs relating to the Share Savings Program 2022 are estimated to amount to a maximum of SEK 2 2 million. Assuming a 25 per cent increase in Eolus‚Äô share price at the time of delivery of Matching Shares  Eolus‚Äô costs relating to the Share Savings Program 2022  including employer contributions  are estimated to amount to a maximum of SEK 2 8 million and assuming a 50 per cent increase in the share price at such time  the costs are estimated to amount to a maximum of SEK 3 3 million  including employer contributions. The Share Savings Program 2022 does not result in any dilution of the holdings of the company‚Äôs shareholders and is not deemed to affect any performance measure important for Eolus. No measures have been taken to hedge Eolus‚Äô costs against its own share price in connection with the purchase of Matching shares.The proposal on Share Savings Program 2022 has been prepared by the Board of Directors and the Remuneration Committee. In the company  similar share savings programs for the financial years 2021  2019/2020 and 2018/2019 relating to the variable cash remuneration have previously been adopted. By requiring  as described above  that the participants make an own investment in Eolus shares and thereby reconciling the employees‚Äô and the shareholders‚Äô interests of a long-term increase of the company‚Äôs value  the Share Savings Program 2022 is expected to enhance Eolus‚Äô possibilities to recruit and retain competent employees while at the same time promoting Eolus‚Äô business strategy  long-term interests and sustainability.The proposal must be supported by shareholders representing more than half of the votes cast at the general meeting.Available documentationThe following documentation will be held available at the company and on the company‚Äôs website at least three weeks ahead of the AGM. The documentation will also be sent  without any cost for the recipients  to shareholders who so request and provide their address or e-mail address: (i) the accounting material and the auditor‚Äôs report  (ii)  the statement by the auditor on the compliance of the resolved guidelines for remuneration to senior executives  (iii) remuneration report  (iv) the complete proposal of the Board of Directors with respect to appropriation of profit and the Board of Directors‚Äô motivated statement thereon  and (v) the complete proposal of the Board of Directors with respect to the long-term share savings program.Number of shares and votes in the companyAt the time of issue of this convening notice  the total number of shares in the company amounts to 24 907 000  of which 1 285 625 shares are Class A shares and 23 621 375 shares are Class B shares. The total number of votes in the company amounts to 3 647 762.5.Information at the AGMThe Board of Directors and the CEO shall  if any shareholder so request and if the Board of Directors considers that this can be done without significant harm for the company or its subsidiaries  give information on circumstances that can affect the assessment of an item on the agenda  circumstances that can affect the assessment of the financial situation of the company or its subsidiaries and the company‚Äôs relationship with another group company (including the consolidated financial statements).Processing of personal dataFor information about the processing of your personal data  see https://www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdf .H√§ssleholm in April 2022Eolus Vind AB (publ)The Board of DirectorsFor further information contact:Per Witalisson  CEO  +46 70-265 16 15Johan Hammarqvist  Head of Communications  +46 720 50 59 11About Eolus:Eolus Vind AB is one of the leading wind power developers in the Nordics. Eolus is active in the whole value chain from development of green field projects to construction and operation of wind farms. Eolus offers attractive and competitive investments in the Nordic and Baltic countries  Poland as well as the United States to both local and international investors. Founded in 1990  Eolus has constructed 666 wind turbines with a capacity of 1 414 MW. Eolus has signed contracts for about 1 320 MW of asset management services of which 914 MW are in operation and the rest under construction.Eolus Vind AB has 34 500 shareholders. Eolus shares are listed at Nasdaq Stockholm.For more information about Eolus  please visit www.eolusvind.comAttachment",neutral,0.02,0.96,0.02,mixed,0.19,0.15,0.66,True,English,"['Annual General Meeting', 'Eolus Vind AB', 'Notice', 'P.O. Box', 'other authorization document', 'Eolus Vind AB', 'Euroclear Sweden AB', 'longer time period', 'Voting rights registrations', 'Annual General Meeting', 'entire postal vote', 'postal voting form', 'company registration number', 'Eolus‚Äô Articles', 'meeting room', 'H√§ssleholm', 'April 11th', 'share register', 'telephone number', 'possible assistants', 'issue date', 'five years', 'authorized signatories', 'registration certificate', 'registration process', 'special form', 'completed form', 'legal person', 'special instructions', 'Further instructions', 'state name', 'dated power', 'above address', 'Nominee-registered shares', 'Proxy form', 'shareholders', 'No.', 'AGM', 'May', 'CEST', 'Kulturhuset', 'Vattugatan', 'Board', 'Directors', 'accordance', 'regulations', 'Association', 'Participation', 'Anyone', 'representative', 'intention', 'website', 'eolusvind', 'investors', 'corporate-governance', 'writing', 'SE-101', 'Stockholm', 'written', 'attorney', 'order', 'advance', 'Story', 'day', 'notice', 'mail', 'GeneralMeetingService', 'votes', 'BankID', 'anmalan', 'vpc', 'EuroclearProxy', 'conditions', 'addition', 'presentation', 'request', 'routines', 'account', '2', '1.30', '4']",2022-04-11,2022-04-11,finance.yahoo.com
2631,Euroclear,Google API,https://economictimes.indiatimes.com/markets/stocks/news/how-indias-much-hyped-global-bond-index-inclusion-unraveled/articleshow/90768809.cms,How India‚Äôs much-hyped global bond index inclusion unraveled,19 hours ago,For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping international wealth.The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn‚Äôt make any mention of it in her February budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt markets saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn‚Äôt likely for at least a year. Officials say a path forward isn‚Äôt possible until Group of 20 nations reach a consensus on a country‚Äôs right to tax capital gains  another pressure point for India.‚ÄúFrom India‚Äôs perspective  we are losing an opportunity to tap a pool of liquidity and an investor base ‚Äù said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors‚Äô perspective  India is one of the largest EM bond markets that is yet to be included in major bond indexes.‚ÄùWith inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits ‚Äù he said.The challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the Feb. 1 budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn‚Äôt reply to multiple requests for comment. A spokesperson for India‚Äôs finance ministry didn‚Äôt respond to an email seeking clarification.In hindsight  officials said India‚Äôs reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi‚Äôs party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party‚Äôs traditional vote bank. Every year  they hold informal discussions with the government ahead of the budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors ‚Äù Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February budget speech.For now  index inclusion appears all but impossible in the short term.In a recent interview with Bloomberg  Ajay Seth  the secretary of India‚Äôs economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India‚Äôs bond market . In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That‚Äôs a concern for the government as it plans to borrow a record amount from the markets to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal‚Äôs borrowing commences in April ‚Äù said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody‚Äôs Investors Service. ‚ÄúIf there are concrete steps toward bond index inclusion during the year  it could help to cap yields.‚Äù,neutral,0.07,0.72,0.21,negative,0.02,0.13,0.86,True,English,"['global bond index inclusion', 'India', 'Senior Asia Rates Strategist', 'largest EM bond markets', 'Prime Minister Narendra Modi', 'Finance Minister Nirmala Sitharaman', 'Powerful Hindu nationalist groups', 'dollar-denominated sovereign bond', 'eleventh hour concerns', 'Standard Chartered Plc', 'traditional vote bank', 'Swadeshi Jagran Manch', 'international clearing platforms', 'key tax exemptions', 'new financial year', 'contentious tax negotiations', 'risk diversification benefits', 'Feb. 1 budget talk', 'Local debt markets', 'global minimum rate', 'tax avoidance issues', 'public OECD forums', 'February budget speech', 'international fiscal policy', 'international bond transactions', 'crucial step change', 'major bond indexes', 'senior government officials', 'finance ministry official', 'foreign investors‚Äô perspective', 'India long bonds', 'senior official', 'international wealth', 'Indian debt', 'a year', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'global indexes', 'Global investors', 'local investors', 'local businesses', 'remarkable milestone', 'Citigroup Inc.', 'Policy makers', 'sudden silence', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'increasing clout', 'top bureaucrat', 'Ashwani Mahajan', 'Indian officials', 'securities transactions', 'Paris-based group', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'informal discussions', 'index inclusion', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal', 'transfer', 'reason', 'advantages', 'leaders', 'Bloomberg']",2022-04-11,2022-04-11,economictimes.indiatimes.com
2632,Euroclear,Google API,https://www.streetinsider.com/SEC+Filings/Form+424B2+ROYAL+BANK+OF+CANADA/19900506.html,Form 424B2 ROYAL BANK OF CANADA,1 hour ago,"Royal Bank of Canada Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-259205Pricing Supplement Dated April 7  2022 To the Prospectus Dated September 14  2021 andProspectus Supplement Dated September 14  2021 $400 000 000Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaThe notes (the ‚ÄúNotes‚Äù) are senior unsecured floating rate notes. Interest and the amount payable upon maturity of the Notes will be paid in cash as described in this pricing supplement.The Notes will be bail-inable notes (as defined in the accompanying prospectus supplement dated September 14  2021 ) and subject to conversion in whole or in part ‚Äì by means of a transaction or series of transactions and in one or more steps ‚Äì into common shares of the Bank or any of its affiliates under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act (the ‚ÄúCDIC Act‚Äù) and to variation or extinguishment in consequence  and subject to the application of the laws of the Province of Ontario and the federal laws of Canada applicable therein in respect of the operation of the CDIC Act with respect to the Notes.We may not redeem the Notes prior to their maturity. There is no sinking fund for the Notes. All payments on the Notes are subject to our credit risk.The CUSIP number for the Notes is 78016EZ91.The Notes will not be listed on any securities exchange.Investing in the Notes involves a number of risks. See ‚ÄúRisk Factors‚Äù on page P-5 of this pricing supplement and beginning on page S-2 of the prospectus supplement dated September 14  2021.The Notes are unsecured and are not savings accounts or insured deposits of a bank. The Notes are not insured or guaranteed by the Canada Deposit Insurance Corporation  the U.S. Federal Deposit Insurance Corporation or any other governmental agency or instrumentality of Canada or the United States.Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.Per Note Total Price to public 100.000% $ 400 000 000 Underwriting discount 0.150% $ 600 000 Proceeds to Royal Bank of Canada 99.850% $ 399 400 000We will deliver the Notes in book-entry only form through the facilities of The Depository Trust Company (‚ÄúDTC‚Äù) (including through its indirect participants Euroclear  Clearstream and CDS Clearing and Depository Services Inc. (‚ÄúCDS‚Äù)) on or about April 14  2022  against payment in immediately available funds.Lead Managers and Joint Book RunnersRBC Capital Markets Citigroup Goldman Sachs & Co. LLC J.P. MorganKeyBanc Capital Markets US Bancorp Westpac Banking CorporationSenior Floating Rate Notes Due April 14  2025Royal Bank of CanadaTERMS OF THE NOTESWe describe the basic features of the Notes in the sections of the prospectus dated September 14  2021 called ‚ÄúDescription of Debt Securities‚Äù and prospectus supplement dated September 14  2021 called ‚ÄúDescription of the Notes We May Offer ‚Äù subject to and as modified by the provisions described below.Issuer: Royal Bank of Canada (the ‚ÄúBank‚Äù) Issue: Senior Global Medium-Term Notes  Series I Title of Series: Senior Floating Rate Notes  due April 14  2025 Principal Amount: US $400 000 000 Ranking: Senior Currency: U.S. Dollars Interest Rate: The interest rate for each period will be equal to the Base Rate plus the Spread. Base Rate: USD Compounded SOFR Index Rate Spread: 0.840% Minimum Denominations: $2 000 and integral multiples of $1 000 in excess thereof Pricing Date: April 7  2022 Issue Date: April 14  2022 Maturity Date: April 14  2025 CUSIP / ISIN / CommonCode: 78016EZ91 / US78016EZ911 / 246980349 Interest Payment Dates: Quarterly on the 14th of each January  April  July  and October  beginning July 14  2022  subject to the modified following business day convention described below under ‚ÄúPayment Convention.‚Äù Interest Period: Each quarterly period from  and including  an Interest Payment Date (or  in the case of the first Interest Period  April 14  2022) to  but excluding  the next Interest Payment Date (or  in the case of the final Interest Period  the Maturity Date)  subject to the modified following business day convention described below under ‚ÄúPayment Convention.‚Äù Record Dates for InterestPayments: The day immediately preceding each Interest Payment Date (or  if the Notes are held in definitive form  the fifteenth calendar day preceding each Interest Payment Date  whether or not a Business Day).P- 2Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaInterest PaymentDetermination Date: The date two U.S. Government Securities Business Days before each Interest Payment Date. Observation Period: In respect of each Interest Period  the period from  and including  the date two U.S. Government Securities Business Days preceding the first date in such Interest Period to  but excluding  the date two U.S. Government Securities Business Days preceding the Interest Payment Date (or in the final Interest Period  preceding the Maturity Date). Payment Convention: If any Interest Payment Date would otherwise fall on a day that is not a business day  then the interest payment date will be the next day that is a business day. However  if the next business day falls in the next calendar month  then the Interest Payment Date will be advanced to the next preceding day that is a business day. If the Maturity Date falls on a day that is not a business day  we will make the required payment of principal  premium  if any  and interest on the next succeeding business day  and no additional interest will accrue in respect of the payment made on that next succeeding business day. Business Day: Any weekday that is a U.S. Government Securities Business Day and is not a legal holiday in New York or Toronto and is not a date on which banking institutions in those cities are authorized or required by law or regulation to be closed. U.S. GovernmentSecurities Business Day: Any day except for a Saturday  a Sunday or a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S. government securities. Day Count Convention: Actual / 360 Redemption at our Option: Not applicable. Canadian Bail-in PowersAcknowledgment: The Notes are bail-inable notes. See ‚ÄúSpecific Terms of the Notes‚ÄîAgreement with Respect to the Exercise of Canadian Bail-in Powers‚Äù. Repayment at Option ofHolder: Not applicable. Lead Managers and JointBook Runners: RBC Capital Markets  LLC  Citigroup Global Markets Inc.  Goldman Sachs & Co. LLC  J.P. Morgan Securities LLC  KeyBanc Capital Markets Inc.  U.S. Bancorp Investments  Inc. and Westpac Banking Corporation Calculation Agent: RBC Capital Markets  LLC Public Offering Price: 100.000% Underwriting Discount: 0.150% Clearance and Settlement: DTC (including through its indirect participants Euroclear  Clearstream and CDS  as described under ‚ÄúOwnership and Book-Entry Issuance‚Äù in the prospectus dated September 14  2021).P- 3Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaListing: The Notes will not be listed on any securities exchange or quotation system. Terms Incorporated in theMaster Note: All of the terms appearing above on pages P-2 and P-3 and P-4 under the caption ‚ÄúTerms of the Notes‚Äù of this pricing supplement and the terms appearing under the caption ‚ÄúSpecific Terms of the Notes‚Äù below. The Notes are part of a series of senior debt securities of the Bank entitled ‚ÄúSenior Global Medium-Term Notes  Series I.‚Äù The Notes will have the CUSIP No. 78016EZ91  the ISIN No. US78016EZ911 and the Common Code No. 246980349.P- 4Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaRISK FACTORSAn investment in the Notes is subject to the risks described below  as well as the risks described under ‚ÄúRisk Factors‚Äù in the accompanying prospectus  dated September 14  2021  and the accompanying prospectus supplement  dated September 14  2021. The Notes are not secured debt. You should carefully consider whether the Notes are suited to your particular circumstances. This pricing supplement should be read together with the accompanying prospectus  dated September 14  2021  and the accompanying prospectus supplement  dated September 14  2021. The information in the accompanying prospectus and the accompanying prospectus supplement is supplemented by  and to the extent inconsistent therewith replaced and superseded by  the information in this pricing supplement. This section describes certain significant risks relating to an investment in the Notes. We urge you to read the following information about these risks  together with the other information in this pricing supplement and the accompanying prospectus and accompanying prospectus supplement  before investing in the Notes.Investors Are Subject to Our Credit Risk  and Market Perceptions About Our Creditworthiness May Adversely Affect the Market Value of the Notes.Investors are dependent on our ability to pay all amounts due on the Notes on the interest payment dates and at maturity  and  therefore  investors are subject to our credit risk and to changes in the market‚Äôs view of our creditworthiness. Any decrease in the market‚Äôs view on or confidence in our creditworthiness is likely to adversely affect the market value of the Notes.The Market Value of the Notes May Be Influenced by Unpredictable Factors.The market value of your Notes may fluctuate between the date you purchase them and the Maturity Date. Several factors  many of which are beyond our control  will influence the market value of the Notes. Factors that may influence the market value of the Notes include:¬∑ supply and demand for the Notes  including inventory positions with the underwriters or any other market-maker;¬∑ interest rates in the market and expectations about future interest rates;¬∑ the creditworthiness of the Bank;¬∑ the time remaining to the maturity of the Notes; and¬∑ economic  financial  political  regulatory or judicial events that affect financial markets generally.The Notes Will Not Be Listed on Any Securities Exchange and Secondary Trading May Be Limited.The Notes will not be listed on any securities exchange. Therefore  there may be little or no secondary market for the Notes. The underwriters may  but are not obligated to  make a market in the Notes. Even if there is a secondary market  it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because we do not expect that other broker-dealers will participate significantly in the secondary market for the Notes  the price at which you may be able to trade your Notes is likely to depend on the price  if any  at which the underwriters are willing to transact. If at any time the underwriters were not to make a market in the Notes  it is likely that there would be no secondary market for the Notes. Accordingly  you should be willing to hold your Notes to maturity.P- 5Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaWe or Our Designee Will Make Determinations with respect to the Notes.We or our designee will make certain determinations with respect to the Notes as further described under the caption ‚ÄúSpecific Terms of the Notes.‚Äù In addition  if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred  we or our designee will make certain determinations with respect to the Notes in our or our designee‚Äôs sole discretion as further described under the section ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021. Any of these determinations may adversely affect the value of the Notes  the return on the Notes and the price at which you can sell such Notes. Moreover  certain determinations may require the exercise of discretion and the making of subjective judgments  such as with respect to Compounded SOFR Index or the occurrence or non-occurrence of a Benchmark Transition Event and any Benchmark Replacement Conforming Changes. These potentially subjective determinations may adversely affect the value of the Notes  the return on the Notes and the price at which you can sell such Notes. For further information regarding these types of determinations  see ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021.P- 6Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSPECIFIC TERMS OF THE NOTESPlease note that in this section entitled ‚ÄúSpecific Terms of the Notes ‚Äù references to ‚Äúholders‚Äù mean those who own Notes registered in their own names  on the books that we or the trustee maintain for this purpose  and not those who own beneficial interests in Notes registered in street name or in Notes issued in book-entry form through DTC or another depositary. Owners of beneficial interests in the Notes should read the section entitled ‚ÄúDescription of the Notes We May Offer‚ÄîLegal Ownership‚Äù in the accompanying prospectus supplement  dated September 14  2021  and ‚ÄúOwnership and Book-Entry Issuance‚Äù in the accompanying prospectus  dated September 14  2021.The Notes are part of a series of senior debt securities entitled ‚ÄúSenior Global Medium-Term Notes  Series I ‚Äù that we may issue under our senior indenture  dated as of October 23  2003  between the Bank and The Bank of New York Mellon  as successor to the corporate trust business of JPMorgan Chase Bank  N.A.  as trustee  as supplemented by a first supplemental indenture  dated as of July 21  2006  by a second supplemental indenture  dated as of February 28  2007  and by a third supplemental indenture  dated as of September 7  2018 and as further amended  from time to time (the ‚Äúindenture‚Äù). The Notes are described in the accompanying prospectus supplement. This pricing supplement summarizes financial and other terms that apply to the Notes. We describe terms that apply generally to all Series I Medium-Term Notes in ‚ÄúDescription of the Notes We May Offer‚Äù in the accompanying prospectus supplement. The terms described in this pricing supplement  and should be read in conjunction with  those described in the accompanying prospectus and accompanying prospectus supplement and  if the terms described here are inconsistent with those described there  the terms described here are controlling.Please note that the information about the price to the public and the net proceeds to the Bank on the front cover of this pricing supplement relates only to the initial sale of the Notes. If you have purchased the Notes in a market-making transaction after the initial sale  information about the price and date of sale to you will be provided in a separate confirmation of sale.In addition to the terms described on the front and inside cover of this pricing supplement  the following specific terms will apply to the Notes:InterestThe interest rate on the Notes for each period will be equal to USD Compounded SOFR Index (as defined in the accompanying prospectus supplement dated September 14  2021) plus a margin of 84.0 basis points. Interest will be payable quarterly in arrears on January 14  April 14  July 14 and October 14 of each year  beginning on July 14  2022 (each  an ‚ÄúInterest Payment Date‚Äù) and ending on the Maturity Date  subject to the modified following business day convention as described under the section ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîInterest Payment Dates‚Äù in the accompanying prospectus supplement dated September 14  2021. The interest rate on the Notes will be calculated as described for SOFR Index Notes in the section ‚Äú Description of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021.DefeasanceThere shall be no defeasance  full or covenant  applicable to the Notes.Payment at MaturityAt maturity you will receive an amount equal to the principal of your Notes plus any accrued and unpaid interest.P- 7Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaManner of Payment and DeliveryAny payment on the Notes at maturity will be made to accounts designated by you and approved by us  or at the office of the trustee in New York City  but only when the Notes are surrendered to the trustee at that office. We also may make any payment in accordance with the applicable procedures of the depositary.Calculation AgentPlease note that RBC Capital Markets  LLC is currently serving as the calculation agent for the Notes. We may change the calculation agent for the Notes at any time without notice and RBC Capital Markets  LLC may resign as calculation agent at any time upon sixty (60) days‚Äô written notice to the Bank.Agreement with Respect to the Exercise of Canadian Bail-in PowersBy its acquisition of an interest in any Note  each holder or beneficial owner of that Note is deemed to (i) agree to be bound  in respect of that Note  by the CDIC Act  including the conversion of that Note  in whole or in part ‚Äì by means of a transaction or series of transactions and in one or more steps ‚Äì into common shares of the Bank or any of its affiliates under subsection 39.2(2.3) of the CDIC Act and the variation or extinguishment of that Note in consequence  and by the application of the laws of the Province of Ontario and the federal laws of Canada applicable therein in respect of the operation of the CDIC Act with respect to that Note; (ii) attorn and submit to the jurisdiction of the courts in the Province of Ontario with respect to the CDIC Act and those laws; (iii) have represented and warranted to the Bank that the Bank has not directly or indirectly provided financing to the holder for the express purpose of investing in the Note; and (iv) acknowledge and agree that the terms referred to in paragraphs (i) and (ii)  above  are binding on that holder or beneficial owner despite any provisions in the indenture or that Note  any other law that governs that Note and any other agreement  arrangement or understanding between that holder or beneficial owner and the Bank with respect to that Note.Holders and beneficial owners of any Note will have no further rights in respect of that Note to the extent that Note is converted in a bail-in conversion  other than those provided under the bail-in regime  and by its acquisition of an interest in any Note  each holder or beneficial owner of that Note is deemed to irrevocably consent to the converted portion of the principal amount of that Note and any accrued and unpaid interest thereon being deemed paid in full by the Bank by the issuance of common shares of the Bank (or  if applicable  any of its affiliates) upon the occurrence of a bail-in conversion  which bail-in conversion will occur without any further action on the part of that holder or beneficial owner or the trustee; provided that  for the avoidance of doubt  this consent will not limit or otherwise affect any rights that holders or beneficial owners may have under the bail-in regime.See ‚ÄúDescription of Notes We May Offer‚ÄïSpecial Provisions Related to Bail-inable Notes‚Äù in the accompanying prospectus supplement dated September 14  2021 for a description of provisions applicable to the Notes as a result of Canadian bail-in powers.P- 8Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaADDITIONAL AMOUNTSWe will pay any amounts to be paid by us on the Notes without deduction or withholding for  or on account of  any and all present or future income  stamp and other taxes  levies  imposts  duties  charges  fees  deductions or withholdings (‚Äútaxes‚Äù) now or hereafter imposed  levied  collected  withheld or assessed by or on behalf of Canada or any Canadian political subdivision or authority that has the power to tax  unless the deduction or withholding is required by law or by the interpretation or administration thereof by the relevant governmental authority. At any time a Canadian taxing jurisdiction requires us to deduct or withhold for or on account of taxes from any payment made under or in respect of the Notes  we will pay such additional amounts (‚ÄúAdditional Amounts‚Äù) as may be necessary so that the net amounts received by each holder (including Additional Amounts)  after such deduction or withholding  shall not be less than the amount the holder would have received had no such deduction or withholding been required.However  no Additional Amounts will be payable with respect to a payment made to a holder of a Note  or of a right to receive payment in respect thereto (a ‚ÄúPayment Recipient‚Äù)  which we refer to as an ‚ÄúExcluded Holder ‚Äù in respect of any taxes imposed because the beneficial owner or Payment Recipient:(i) is someone with whom we do not deal at arm‚Äôs length (within the meaning of the Income Tax Act (Canada)) at the time of making such payment;(ii) is subject to such taxes by reason of its being connected presently or formerly with Canada or any province or territory thereof other than by reason of the holder‚Äôs activity in connection with purchasing such Note  the holding of such Note or the receipt of payments thereunder;(iii) is  or does not deal at arm‚Äôs length with a person who is  a ‚Äúspecified shareholder‚Äù (as defined in subsection 18(5) of the Income Tax Act (Canada)) of the Bank;(iv) presents such Note for payment (where presentation is required) more than 30 days after the relevant date (except to the extent that the holder thereof would have been entitled to such Additional Amounts on presenting a Note for payment on the last day of such 30 day period); for this purpose  the ‚Äúrelevant date‚Äù in relation to any payments on any Note means:(a) the due date for payment thereof  or(b) if the full amount of the monies payable on such date has not been received by the trustee on or prior to such due date  the date on which the full amount of such monies has been received and notice to that effect is given to holders of the Notes in accordance with the indenture;(v) could lawfully avoid (but has not so avoided) such withholding or deduction by complying  or requiring that any agent comply with  any statutory requirements necessary to establish qualification for an exemption from withholding or by making  or requiring that any agent make  a declaration of non-residence or other similar claim for exemption to any relevant tax authority; or(vi) is subject to deduction or withholding on account of any tax  assessment  or other governmental charge that is imposed or withheld by reason of the application of Sections 1471 through 1474 of the United States Internal Revenue Code of 1986 (or any successor provisions) (the ‚ÄúInternal Revenue Code‚Äù)  any regulation  pronouncement  or agreement thereunder  official interpretations thereof  or any law implementing an intergovernmental approach thereto  whether currently in effect or as published and amended from time to time.P- 9Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaFor the avoidance of doubt  we will not have any obligation to pay any holders Additional Amounts on any tax which is payable otherwise than by deduction or withholding from payments made under or in respect of the Notes.We will also make such withholding or deduction and remit the full amount deducted or withheld to the relevant authority in accordance with applicable law. We will furnish to the trustee  within 30 days after the date the payment of any taxes is due pursuant to applicable law  certified copies of tax receipts evidencing that such payment has been made or other evidence of such payment satisfactory to the trustee. We will indemnify and hold harmless each holder of Notes (other than an Excluded Holder) and upon written request reimburse each such holder for the amount of (x) any taxes so levied or imposed and paid by such holder as a result of payments made under or with respect to the Notes  and (y) any taxes levied or imposed and paid by such holder with respect to any reimbursement under (x) above  but excluding any such taxes on such holder‚Äôs net income or capital.U.S. FEDERAL INCOME TAX CONSIDERATIONSThe discussion below supplements the discussion under ‚ÄúTax Consequences‚ÄîUnited States Taxation‚Äù in the accompanying prospectus  dated September 14  2021  and is subject to the limitations and exceptions set forth therein. This discussion is only applicable to you if you are a U.S. holder (as defined in the accompanying prospectus). If you are not a U.S. holder  please consult your own tax advisor.In the opinion of our counsel  Sullivan & Cromwell LLP  your Notes should be treated as variable rate debt instruments for United States federal income tax purposes. Under this characterization  you should include the interest payments on the Notes in ordinary income at the time you receive or accrue such payments  depending on your method of accounting for tax purposes  and recognize capital gain or loss on the sale or retirement of your Notes equal to the difference between the amount you realize on the sale or retirement  excluding any amounts attributable to accrued but unpaid interest (which should be treated as interest payments)  and your tax basis in your Notes.For a further discussion of the variable rate debt instrument rules  please see the discussion under the heading ‚ÄúTax Consequences‚ÄîUnited States Taxation‚ÄîOriginal Issue Discount‚ÄîVariable Rate Debt Securities‚Äù in the accompanying prospectus.P- 10Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaCANADIAN FEDERAL INCOME TAX CONSIDERATIONSFor a discussion of the Canadian federal income tax consequences of owning the Notes  please see the section ‚ÄúTax Consequences‚Äî Canadian Taxation‚Äù in the accompanying prospectus  dated September 14  2021 and the section ‚ÄúCertain Income Tax Consequences‚ÄîCanadian Taxation‚Äù in the accompanying prospectus supplement  dated September 14  2021.BENEFIT PLAN INVESTOR CONSIDERATIONSA fiduciary of a pension  profit-sharing or other employee benefit plan (a ‚Äúplan‚Äù) subject to the Employee Retirement Income Security Act of 1974  as amended (‚ÄúERISA‚Äù)  should consider the fiduciary standards of ERISA in the context of the plan‚Äôs particular circumstances before authorizing an investment in the debt securities.Any purchaser or holder of debt securities or any interest therein will be deemed to have represented (both on behalf of itself and any plan) by its purchase and holding of the debt securities that either (1) it is not a plan and is not purchasing those debt securities on behalf of or with ‚Äúplan assets‚Äù of any plan or (2) the purchase and holding of the debt securities will not constitute a non-exempt prohibited transaction under ERISA or the Internal Revenue Code. In addition  any purchaser or holder of debt securities or any interest therein which is a non-ERISA arrangement will be deemed to have represented by its purchase or holding or  if applicable  exchange of the debt securities that its purchase and holding will not violate the provisions of any similar law.For a further discussion of benefit plan investor considerations  please see the discussion under the heading ‚ÄúBenefit Plan Investor Considerations‚Äù in the accompanying prospectus  dated September 14  2021.CLEARANCE AND SETTLEMENTThe Notes will settle through DTC  and its indirect participants Euroclear  Clearstream and CDS. For a description of DTC  Euroclear  Clearstream and CDS  see ‚ÄúOwnership and Book-Entry Issuance‚Äù in the accompanying prospectus  dated September 14  2021.P- 11Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)We have entered into a terms agreement  dated April 7  2022  with the underwriters pursuant to the Distribution Agreement  dated September 14  2021  among us and the agents party thereto for the purchase and sale of the Notes. We have agreed to sell to each of the underwriters  and each of the underwriters has agreed to purchase from us  the principal amount of the Notes shown opposite its name at the public offering price set forth above.Name Principal Amount of Notes RBC Capital Markets  LLC $ 72 000 000 Citigroup Global Markets Inc. $ 72 000 000 Goldman Sachs & Co. LLC $ 72 000 000 J.P. Morgan Securities LLC $ 72 000 000 KeyBanc Capital Markets Inc. $ 20 000 000 U.S. Bancorp Investments  Inc. $ 20 000 000 Westpac Banking Corporation $ 20 000 000 BNY Mellon Capital Markets  LLC $ 4 000 000 Capital One Securities  Inc. $ 4 000 000 Desjardins Securities Inc. $ 4 000 000 Fifth Third Securities  Inc. $ 4 000 000 Huntington Securities  Inc. $ 4 000 000 MUFG Securities Americas Inc. $ 4 000 000 National Bank of Canada Financial Inc. $ 4 000 000 Regions Securities LLC $ 4 000 000 Scotia Capital (USA) Inc. $ 4 000 000 Swedbank AB (publ) $ 4 000 000 Truist Securities  Inc. $ 4 000 000 Academy Securities  Inc. $ 4 000 000 R. Seelaus & Co.  LLC $ 2 000 000 Samuel A. Ramirez & Company  Inc. $ 2 000 000 Total $ 400 000 000Each of Westpac Banking Corporation  Desjardins Securities Inc. and Swedbank AB (publ) is not a U.S. registered broker-dealer and will not effect any offers or sales of any Notes in the United States unless it is through one or more U.S. registered broker-dealers as permitted by the regulations of the Financial Industry Regulatory Authority  Inc. (‚ÄúFINRA‚Äù).The underwriters may sell the Notes to certain dealers at the public offering price  less a concession that will not exceed 0.100% of their principal amount. The underwriters and those dealers may resell the Notes to other dealers at a reallowance discount that will not exceed 0.050% of their principal amount. After the initial offering of the Notes  the concession and reallowance discounts on the Notes may change. The offering of the Notes by the underwriters is subject to receipt and acceptance and subject to the underwriters‚Äô right to reject any order in whole or in part.We estimate that the total offering expenses for the Notes  excluding underwriting discounts and commissions  will be approximately $41 603.P- 12Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSubject to the terms and conditions of the terms agreement  the underwriters have agreed to purchase the Notes as principal  for their own account at a purchase price equal to the issue price specified on the front cover of this pricing supplement  less an underwriting discount of 0.150%. To the extent the underwriters resell Notes to a broker or dealer less a concession equal to the entire underwriting discount  such broker or dealer may be deemed to be an ‚Äúunderwriter‚Äù of the Notes as such term is defined in the Securities Act of 1933  as amended. The underwriters have advised us that  if they are unable to sell all the Notes at the public offering price  the underwriters propose to offer the Notes from time to time for sale in negotiated transactions or otherwise  at prices to be determined at the time of sale.In the future  the underwriters may repurchase and resell the Notes in market-making transactions. For more information about the plan of distribution  the Distribution Agreement (of which the terms agreement forms a part) and possible market-making activities; see ‚ÄúSupplemental Plan of Distribution‚Äù in the accompanying prospectus supplement dated September 14  2021.We expect that delivery of the Notes will be made against payment therefor on April 14  2022  which is the fifth scheduled business day following the trade date. Under Rule 15c6-1 of the Securities Exchange Act of 1934  trades in the secondary market generally are required to settle no later than two business days after the trade date  unless the parties to any such trade expressly agree otherwise at the time of the trade. Accordingly  purchasers who wish to trade Notes on any date more than two business days prior to delivery of the Notes hereunder will be required  by virtue of the fact that the Notes will initially settle in five business days (T + 5) to specify alternative settlement arrangements to prevent a failed settlement.Conflicts of InterestRBC Capital Markets  LLC is our affiliate  and is deemed to have a conflict of interest under FINRA Rule 5121. Accordingly  the offering of the Notes will conform to the requirements of FINRA Rule 5121. The underwriters  with the exception of Westpac Banking Corporation  Desjardins Securities Inc. and Swedbank AB (publ)  are members of FINRA. RBC Capital Markets  LLC is not permitted to sell the Notes to an account over which it exercises discretionary authority without the prior specific written approval of the account holder.The underwriters and their respective affiliates are full service financial institutions engaged in various activities  which may include securities trading  commercial and investment banking  financial advisory  investment management  investment research  principal investment  hedging  financing and brokerage activities. Certain of the underwriters and their respective affiliates have  from time to time  performed  and may in the future perform  various financial advisory and investment banking services for the Bank  for which they received or will receive customary fees and expenses.In the ordinary course of their various business activities  the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers  and such investment and securities activities may involve securities and/or instruments of the Bank. The underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold  or recommend to clients that they acquire  long and/or short positions in such securities and instruments.P- 13Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSelling RestrictionsEuropean Economic Area. PROHIBITION OF SALES TO EEA RETAIL INVESTORS. The Notes are not intended to be offered  sold or otherwise made available to  and should not be offered  sold or otherwise made available to  any retail investor in the European Economic Area (‚ÄúEEA‚Äù). For these purposes  the expression ‚Äúoffer"" includes the communication in any form and by any means of sufficient information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe the Notes  and a ‚Äúretail investor‚Äù means a person who is one (or more) of: (a) a retail client  as defined in point (11) of Article 4(1) of Directive 2014/65/EU  as amended (‚ÄúMiFID II‚Äù)Õæ or (b) a customer  within the meaning of Insurance Distribution Directive 2016/97/EU  as amended  where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID IIÕæ or (c) not a qualified investor as defined in Regulation (EU) 2017/1129 (the ‚ÄúProspectus Regulation‚Äù). Consequently  no key information document required by Regulation (EU) No 1286/2014  as amended (the ‚ÄúPRIIPs Regulation‚Äù) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared  and therefore  offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. This pricing supplement has been prepared on the basis that any offer of Notes in any Member State of the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of Notes. This pricing supplement is not a prospectus for the purposes of the Prospectus Regulation.United Kingdom. PROHIBITION OF SALES TO UK RETAIL INVESTORS.The Notes are not intended to be offered  sold or otherwise made available to  and should not be offered  sold or otherwise made available to  any retail investor in the United Kingdom (‚ÄúUK‚Äù). For these purposes  a retail investor means a person who is one (or more) of: (i) a retail client  as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the ‚ÄúEUWA‚Äù); or (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (the ‚ÄúFSMA‚Äù) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97  where that customer would not qualify as a professional client  as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA (the ‚ÄúUK Prospectus Regulation‚Äù). Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the ‚ÄúUK PRIIPs Regulation‚Äù) for offering or selling the Notes or otherwise making them available to retail investors in the United Kingdom has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the United Kingdom may be unlawful under the UK PRIIPs Regulation. This pricing supplement has been prepared on the basis that any offer of Notes in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of Notes. This pricing supplement is not a prospectus for the purposes of the UK Prospectus Regulation.This pricing supplement and any other material in relation to the Notes are only being distributed to  and are only directed at  persons in the UK that are qualified investors within the meaning of Article 2(1)(e) of the UK Prospectus Regulation that also (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005  as amended (the ‚ÄúOrder‚Äù)  (ii) who fall within Article 49(2)(a) to (d) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as ‚Äúrelevant persons‚Äù). The Notes are only available to  and any invitation  offer or agreement to purchase or otherwise acquire such Notes will be engaged in only with  relevant persons. This pricing supplement and its contents should not be distributed  published or reproduced (in whole or in part) or disclosed by recipients to any other person in the UK. Any person in the UK that is not a relevant person should not act or rely on this pricing supplement or any of its contents.P- 14Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaHong Kong. The Notes may not be offered or sold in Hong Kong by means of any document other than (a) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (‚ÄúCompanies (Winding Up and Miscellaneous Provisions) Ordinance‚Äù) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (‚ÄúSecurities and Futures Ordinance‚Äù)  or (b) to ‚Äúprofessional investors‚Äù as defined in the Securities and Futures Ordinance and any rules made thereunder  or (c) in other circumstances which do not result in the document being a ‚Äúprospectus‚Äù as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance  and no advertisement  invitation or document relating to the Notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere)  which is directed at  or the contents of which are likely to be accessed or read by  the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Notes which are or are intended to be disposed of only to persons outside Hong Kong or only to ‚Äúprofessional investors‚Äù in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.Singapore. This pricing supplement and the accompanying prospectus and prospectus supplement have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly  this pricing supplement  the accompanying prospectus and prospectus supplement and any other document or material in connection with the offer or sale  or invitation for subscription or purchase  of the Notes may not be circulated or distributed  nor may the Notes be offered or sold  or be made the subject of an invitation for subscription or purchase  whether directly or indirectly  to persons in Singapore other than (a) to an institutional investor (as defined in Section 4A of the Securities and Futures Act  Chapter 289 of Singapore (the ‚ÄúSFA‚Äù)) under Section 274 of the SFA  (b) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA  or any person pursuant to Section 275(1A) of the SFA  and in accordance with the conditions specified in Section 275 of the SFA or (c) otherwise pursuant to  and in accordance with the conditions of  any other applicable provision of the SFA  in each case subject to conditions set forth in the SFA.Where the Notes are subscribed or purchased under Section 275 of the SFA by a relevant person which is (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals  each of whom is an accredited investor  or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor  the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for six months after that corporation has acquired the Notes under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA)  (2) where such transfer arises from an offer in that corporation‚Äôs securities pursuant to Section 275(1A) or Section 276(4)(i)(B) of the SFA  (3) where no consideration is or will be given for the transfer  (4) where the transfer is by operation of law  (5) as specified in Section 276(7) of the SFA  or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.Notification under Section 309B(1)(c) of the SFA. The Bank has determined that the Notes are (a) prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and (b) Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).P- 15Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSwitzerland. The Notes are not offered  sold or advertised  directly or indirectly  in  into or from Switzerland on the basis of a public offering and will not be listed on the SIX Swiss Exchange or any other offering or regulated trading facility in Switzerland. Accordingly  neither this pricing supplement  the accompanying prospectus and prospectus supplement nor other marketing material constitute a prospectus as defined in article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus as defined in article 32 of the Listing Rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland. Any resales of the Notes may only be undertaken on a private basis to selected individual investors in compliance with Swiss law. This pricing supplement  the accompanying prospectus or prospectus supplement may not be copied  reproduced  distributed or passed on to others or otherwise made available in Switzerland without our prior written consent. By accepting this pricing supplement  the accompanying prospectus or prospectus supplement or by subscribing to the notes  investors are deemed to have acknowledged and agreed to abide by these restrictions.Japan. The Notes have not been and will not be registered pursuant to Article 4  Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly  none of the Notes nor any interest therein may be offered or sold  directly or indirectly  in Japan or to  or for the benefit of  any ‚Äúresident‚Äù of Japan (which term as used herein means any person resident in Japan  including any corporation or other entity organized under the laws of Japan)  or to others for re-offering or resale  directly or indirectly  in Japan or to or for the benefit of a resident of Japan  except pursuant to an exemption from the registration requirements of  and otherwise in compliance with  the Financial Instruments and Exchange Act and any other applicable laws  regulations and ministerial guidelines of Japan in effect at the relevant time.Canada. Sales into Canada are permitted.P- 16Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaVALIDITY OF NOTESThe validity of the Notes will be passed upon for us by Sullivan & Cromwell LLP  New York  New York  as to matters of New York law  and by Norton Rose Fulbright Canada LLP  Toronto  Ontario  as to matters of Canadian law and applicable matters of Ontario law. Certain legal matters will be passed upon for the underwriters by Davis Polk & Wardwell LLP  New York  New York.WHERE YOU CAN FIND ADDITIONAL INFORMATIONYou should read this pricing supplement  together with the documents listed below  which together contain the terms of the Notes and supersede all prior or contemporaneous oral statements as well as any other written materials. You may access the following documents on the SEC Website at www.sec.gov as follows (or if such address has changed  by reviewing our filings for the relevant date on the SEC Website):¬∑ Series I MTN prospectus supplement dated September 14  2021:https://www.sec.gov/Archives/edgar/data/1000275/000121465921009472/rbcsupp911210424b3.htm¬∑ Prospectus dated September 14  2021:https://www.sec.gov/Archives/edgar/data/1000275/000121465921009470/rbc911212424b3.htmOur Central Index Key  or CIK  on the SEC Website is 1000275.P-17Exhibit 107.1The pricing supplement to which this Exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of the offering is $400 000 000.",neutral,0.01,0.99,0.01,negative,0.03,0.09,0.88,True,English,"['Form 424B2 ROYAL BANK', 'CANADA', 'US Bancorp Westpac Banking Corporation Senior Floating Rate Notes', 'two U.S. Government Securities Business Days', 'RBC Capital Markets Citigroup Goldman Sachs', 'U.S. Federal Deposit Insurance Corporation', 'U.S. Dollars Interest Rate', 'senior unsecured floating rate notes', 'Canada Deposit Insurance Corporation Act', 'Per Note Total Price', 'Senior Global Medium-Term Notes', 'SOFR Index Rate Spread', 'The Depository Trust Company', 'next Interest Payment Date', 'Interest Payment Determination Date', 'KeyBanc Capital Markets', 'Depository Services Inc', 'business day convention', 'other governmental agency', 'state securities commission', 'Joint Book Runners', 'J.P. Morgan', 'fifteenth calendar day', '246980349 Interest Payment Dates', 'final Interest Period', 'first Interest Period', 'accompanying prospectus supplement', 'page S', 'Senior Currency', 'Base Rate', 'federal laws', 'securities exchange', 'Debt Securities', 'Payment Convention', 'CDIC Act', 'first date', 'Exchange Commission', 'Record Dates', 'Pricing Date', 'Issue Date', 'Interest Payments', 'Pricing Supplement', 'The Notes', 'bail-inable notes', 'Registration Statement', 'common shares', 'sinking fund', 'credit risk', 'Risk Factors', 'savings accounts', 'insured deposits', 'United States', 'criminal offense', '400,000,000 Underwriting discount', 'indirect participants', 'available funds', 'Lead Managers', 'Co. LLC', 'basic features', 'Principal Amount', 'Minimum Denominations', 'integral multiples', 'Common Code', 'quarterly period', 'Observation Period', 'Maturity Date', 'Royal Bank', 'Bank‚Äù) Issue', 'CDS Clearing', 'definitive form', 'Series I', 'CUSIP number', 'Rule', 'September', 'cash', 'conversion', 'means', 'transaction', 'one', 'steps', 'affiliates', 'subsection', 'variation', 'extinguishment', 'consequence', 'application', 'Province', 'Ontario', 'respect', 'operation', 'risks', 'instrumentality', 'representation', 'contrary', 'public', 'Proceeds', 'book-entry', 'facilities', 'DTC', 'Euroclear', 'Clearstream', 'April', 'TERMS', 'sections', 'Description', 'provisions', 'Issuer', 'Title', 'excess', 'ISIN', 'US78016EZ911', '14th', 'January', 'July', 'October', 'following', 'case', '0.']",1990-05-06,2022-04-11,streetinsider.com
2633,Euroclear,Google API,https://www.natlawreview.com/article/russian-sanctions-how-will-they-impact-credit-default-swaps,Russian Sanctions and Global Financial Impact of Sovereign Debt,5 hours ago,Monday  April 11  2022Economic sanctions against Russia as a result of the invasion of Ukraine have had a broad impact on the global economy and have raised the question of whether Russia will be able to meet its obligations on foreign denominated bonds. If Russia defaults on its bonds  credit default swaps meant to protect investors from a Russian default may not work as planned because of these sanctions.At the end of last year  Russia had $40 billion in foreign currency sovereign debt  half of which is owed to foreign investors. While U.S. sanctions allow for Russia to continue to make debt payments at least through the end of May 2022  Russian restrictions on allowing foreign exchange transactions could force a default on bonds that do not allow for payment in Rubles. On Monday  April 4  2022  the U.S. Treasury restricted U.S. banks from processing payments on Russian bonds  increasing the risk of a default.Credit default swaps are meant to help investors receive near full recovery in the event of a default on the underlying debt. Payments under credit default swaps are owed to the purchaser of the credit default swap when a ‚ÄúCredit Event‚Äù has occurred. Credit Events include: a failure to make a payment under the debt (following any applicable grace period)  insolvency of the issuer  debt restructuring and repudiation of the debt. There are approximately $4.5 billion in credit default swaps tied to Russian government debt and another $1.5 billion in derivative indices  according to JPMorgan.Escalating western sanctions against Russia have raised questions about whether Russia will be able to meet its obligations under its sovereign debt  whether credit default swaps will be triggered if Russia does not meet the terms of its obligations and whether sanctions will interfere with the settlement of credit default swaps if a Credit Event is triggered.Will credit default swaps be triggered if Russia does not meet the terms of its obligations?Russia‚Äôs decision in March to pay some of its foreign debtors in Rubles could have triggered a Credit Event. ISDA‚Äôs Credit Derivatives Determinations Committee (the ‚ÄúDC‚Äù) applies the terms of market-standard credit derivatives to specific cases  and makes a factual determination as to whether a Credit Event or other events under a credit default swap have occurred and other issues. The DC determined that payment of obligations in Rubles  when not the original currency of denomination of the debt  would not constitute a Credit Event where the underlying debt allows for payment in Rubles. However  certain of Russia‚Äôs bonds do not provide for payment in Rubles. A failure by Russia to make a payment under the terms of the bonds (whether by failing to make a payment entirely  or by making a payment in Rubles when not permitted under the terms of the debt) would most likely constitute a Credit Event  triggering credit default swaps referencing Russian debt.For the time being  Russia has avoided defaulting on its foreign currency debt  making $732 million in coupon payments on US Dollar denominated bonds in the month of March 2022. Russia owed approximately $2 billion on a bond that came due on Monday  April 4  2022  and owes another $84 million in interest payments on a second bond. The recent U.S. Treasury restrictions on U.S. banks processing Russian government debt effectively blocked the payment on both bonds. A failure by the Russian government to find another way to make the payments within the thirty day grace period provided for in the bonds would likely constitute a default under the bonds and trigger a Credit Event under credit default swaps referencing Russian sovereign debt.What debt will be ‚Äúdeliverable‚Äù under credit default swaps?The settlement of a credit default swap requires the delivery (for physical settlement) or pricing (for cash settlement) of debt that meets certain characteristics  including Not Domestic Currency (i.e.  payable in a currency other than the Ruble)  Not Domestic Law (i.e.  governed by non-Russian law) and Not Domestic Issuance (i.e.  not issued primarily in the Russian market). Additionally  the obligation must be payable in a G-7 currency and transferable to institutional investors without contractual or regulatory restrictions. The DC has determined that non-Ruble denominated debt that allows for payment in Rubles will not meet the Not Domestic Currency test and therefore will not be ‚Äúdeliverable‚Äù for settlement under credit default swaps. Similarly  if the Russian government decides to make a payment in Rubles under G-7 denominated debt  such debt may no longer be considered ‚Äúdeliverable‚Äù. Additionally  on March 25  2022  ISDA published ‚ÄúAdditional Provisions for Certain Russian Entities: Excluded Obligations and Excluded Deliverable Obligations‚Äù (the ‚ÄúProtocol‚Äù) which contains new terms that can be added to existing or new credit derivatives transactions. The new terms in the Protocol provide that a default under certain Russian sovereign debt (‚ÄúRestricted Debt‚Äù) will not trigger a Credit Event under credit default swap transactions and exclude such debt from the definition of ‚Äúdeliverable‚Äù obligations. In an FAQ released in conjunction with the publication of the Protocol  ISDA noted that it would be impractical to hold a settlement auction referencing Restricted Debt.Will sanctions interfere with the settlement of credit default swaps?Sanctions could prevent certain bonds from being delivered in the event a credit default swap is triggered and/or misalign the pricing mechanism for settlement of credit default swaps. The expected recovery under credit default swaps is usually determined using an auction process based on bonds that are ‚Äúdeliverable‚Äù under the terms of the credit default swaps. The auction process relies on the existence of a secondary trading market for the debt. Russia has blocked offshore settlement of bonds through Euroclear which would make certain bonds  which by their terms are to settle in Russia  untradeable. Further sanctions could also impact whether other Russian bonds are tradeable and eligible to be delivered under credit default swap contracts. If fewer bonds are deemed ‚Äúdeliverable‚Äù under the terms of the credit default swap  the auction price is likely to be higher (as more parties bid on fewer bonds)  leading to a lower recovery for credit default swap buyers and a possible loss on the bonds that the purchase of the credit default swaps was meant to avert. One solution would be to circumvent the auction process entirely  leaving parties to the credit default swaps to agree to a cash price to close out the swap. This could potentially result in different recoveries for different market participants.Credit default swap buyers should carefully review the terms of their contracts to determine whether they will be required to physically deliver the underlying debt to receive the expected payout under the terms of their credit default swap contracts and determine whether they will be able to deliver the debt.,neutral,0.04,0.48,0.48,negative,0.01,0.17,0.82,True,English,"['Global Financial Impact', 'Russian Sanctions', 'Sovereign Debt', 'recent U.S. Treasury restrictions', 'thirty day grace period', 'Credit Derivatives Determinations Committee', 'US Dollar denominated bonds', 'new credit derivatives transactions', 'credit default swap transactions', 'foreign currency sovereign debt', 'applicable grace period', 'U.S. banks', 'foreign exchange transactions', 'market-standard credit derivatives', 'U.S. sanctions', 'Certain Russian Entities', 'credit default swaps', 'Domestic Currency test', 'Escalating western sanctions', 'G-7 denominated debt', 'foreign denominated bonds', 'foreign currency debt', 'Russian sovereign debt', 'Ruble denominated debt', 'Russian government debt', 'Excluded Deliverable Obligations', 'Not Domestic Currency', 'Russian restrictions', 'G-7 currency', 'regulatory restrictions', 'Russian default', 'foreign debtors', 'Credit Events', 'original currency', 'Domestic Law', 'Domestic Issuance', 'Russian debt', 'Russian law', 'Russian market', 'foreign investors', 'underlying debt', 'debt restructuring', 'Restricted Debt', 'Economic sanctions', 'broad impact', 'global economy', 'last year', 'full recovery', 'derivative indices', 'specific cases', 'factual determination', 'other events', 'other issues', 'Additional Provisions', 'Russian bonds', 'new terms', 'Excluded Obligations', 'The DC', 'debt payments', 'coupon payments', 'interest payments', 'second bond', 'institutional investors', 'physical settlement', 'cash settlement', 'Monday', 'April', 'result', 'invasion', 'Ukraine', 'question', 'end', 'half', 'May', 'Rubles', 'processing', 'risk', 'purchaser', 'failure', 'insolvency', 'issuer', 'repudiation', 'JPMorgan', 'decision', 'March', 'ISDA', 'denomination', 'time', 'month', 'way', 'delivery', 'pricing', 'characteristics', 'contractual', 'Protocol', 'existing']",2022-04-11,2022-04-11,natlawreview.com
2634,Euroclear,Google API,https://www.marketscreener.com/quote/stock/STORSKOGEN-GROUP-AB-PUBL-127708983/news/Notice-to-the-Annual-General-Meeting-in-Storskogen-Group-AB-publ-40020367/,Notice to the Annual General Meeting in Storskogen Group AB (publ),11 hours ago,"Homepage Equities Sweden Nasdaq Stockholm Storskogen Group AB (publ) News Summary STOR B SE0016797732 STORSKOGEN GROUP AB (PUBL) (STOR B) Add to my list Report Report Delayed Nasdaq Stockholm - 04/11 11:29:49 am EDT 23.36 SEK +3.82% 04/08 Storskogen Buys Swedish Kitchen Supplies Distributor Dafra MT 04/08 Storskogen's subsidiary Vikingsun acquires Dafra AQ 04/08 Storskogen Unit Buys Swedish Industrial Equipment Group DETAB Ecomat Automation MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Summary Most relevant All News Other languages Press Releases Official Publications Sector news Notice to the Annual General Meeting in Storskogen Group AB (publ) 04/11/2022 | 05:38am EDT Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields The shareholders of Storskogen Group AB (publ)   reg. no. 559223-8694  are hereby summoned to the annual general meeting on Tuesday  17 May 2022   at 14:00 (CEST) at Moderna Museet  Exercisplan 4  SE-111 49 Stockholm. Entry and registration begins at 13:30 (CEST). The board of directors has  pursuant to Chapter 7  Section 4 a of the Swedish Companies Act and the company's articles of association  decided that shareholders shall have the right to exercise their voting rights by post prior to the annual general meeting. Accordingly  shareholders may choose to participate at the annual general meeting in person  by proxy or through postal voting. EXERCISE OF VOTING RIGHTS AT THE ANNUAL GENERAL MEETING Shareholders who wish to exercise their voting rights at the annual general meeting must: be entered in the share register kept by Euroclear Sweden AB ("" Euroclear "") on Monday  9 May 2022 or  if the shares are registered in the name of a nominee  request that the nominee registers the shares in the shareholder's own name for voting purposes in such time that the registration is completed on Wednesday  11 May 2022 ; and("" "") on Monday  or  if the shares are registered in the name of a nominee  request that the nominee registers the shares in the shareholder's own name for voting purposes in such time that the registration is completed on Wednesday  ; and give notice of attendance in accordance with the instructions set out under the heading ""Notification of attendance in person or by proxy"" not later than on Wednesday  11 May 2022 or submit a postal vote in accordance with the instructions set out under the heading ""Instructions for postal voting"" not later than on Monday  16 May 2022 . Notification of attendance in person or by proxy Shareholders who wish to attend the annual general meeting in person or by proxy shall give notice to the company of this not later than on Wednesday  11 May 2022 either: electronically on the company's website (www.storskogen.com);by post to Storskogen Group AB (publ)   ""Annual General Meeting""  c/o Euroclear Sweden AB   Box 191  SE-101 23 Stockholm; or  ""Annual General Meeting""  c/o   Box 191  SE-101 23 Stockholm; or by telephone on +46 (0)8-402 90 40 on weekdays between 09:00 and 16:00 (CEST). The notification shall state the shareholder's name or company name  personal identification number or corporate identification number  address  phone number and  where applicable  the number of accompanying assistants (not more than two). Shareholders who do not wish to participate in person or exercise their voting rights by postal voting may exercise their voting rights at the annual general meeting through a proxy with a written  signed and dated power of attorney. If the power of attorney is issued by a legal entity  a copy of the certificate of registration or an equivalent authorisation document for the legal entity must be enclosed. In order to facilitate the registration at the annual general meeting  powers of attorney  certificates of registration and other authorisation documents should be received by the company at the address Storskogen Group AB (publ)   ""Annual General Meeting""  c/o Euroclear Sweden AB   Box 191  SE-101 23 Stockholm not later than on Wednesday  11 May 2022 . Please note that a notification of attendance at the annual general meeting must be made even if the shareholder wishes to exercise its voting rights at the annual general meeting through a proxy. A submitted power of attorney is not considered as a notification of attendance at the annual general meeting. A form of power of attorney in Swedish and in English is available on the company's website (www.storskogen.com). Instructions for postal voting Shareholders who wish to exercise their voting rights through postal voting must use the postal voting form and follow the instructions that are available on the company's website (www.storskogen.com). The postal voting form must be received by the company not later than on Monday  16 May 2022 . The postal voting form must either: be sent by e-mail to GeneralMeetingService@euroclear.com;be submitted electronically in accordance with the instructions on the company's website (www.storskogen.com); orbe sent by post to Storskogen Group AB (publ)   ""Annual General Meeting""  c/o Euroclear Sweden AB   Box 191  SE-101 23 Stockholm. Personal data Personal data obtained from the share register  notifications of attendance at the annual general meeting and information regarding proxies will be used for registration  preparation of the voting list for the annual general meeting and  where applicable  the minutes of the annual general meeting. For more information on how personal data is processed in connection with the annual general meeting  please refer to Euroclear's privacy notice that is available on Euroclear's website (www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdf). PROPOSED AGENDA Election of a chairman of the annual general meeting Preparation and approval of the voting list Election of one or two persons to verify the minutes Determination of whether the annual general meeting has been duly convened Approval of the agenda Submission of the annual report and the auditor's report  the consolidated financial statements and the auditor's report for the group as well as the remuneration report and the auditor's statement on compliance with the remuneration guidelines Resolution on: adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet allocation of the company's profit according to the adopted balance sheet discharge of liability for the members of the board of directors and the CEO approval of the remuneration report Determination of the number of members of the board of directors Determination of: the fees to be paid to the board of directors the fees to be paid to the auditor Election of the members of the board of directors and the auditor Alexander Murad Bj√§rg√•rd  board member (re-election) Bengt Braun   board member (re-election) Annette Brodin Rampe   board member (new election) Louise Hedberg   board member (re-election) Johan Thorell   board member (re-election) Annette Brodin Rampe   chair of the board of directors (new election) Ernst & Young Aktiebolag  auditor (re-election) Resolution on implementation of an employee stock option plan etc. Resolution on implementation of a share savings programme etc. Resolution on: a reduction of the share capital with redemption of 16 848 061 shares of series B a bonus issue Resolution on an authorisation for the board of directors to resolve on issuances of shares of series B  warrants that may be exercised for subscription of shares of series B and/or convertibles that may be converted to shares of series B Resolution on an authorisation for the board of directors to resolve on acquisitions and transfers of treasury shares of series B Resolution on guidelines for remuneration to senior executives Closing of the annual general meeting PROPOSED RESOLUTIONS Election of a chairman of the annual general meeting  item 1 The nomination committee proposes that Carl Westerberg   member of the Swedish Bar Association   shall be appointed as chairman of the annual general meeting or  in his absence  the person appointed by a representative of the nomination committee. Election of one or two persons to verify the minutes  item 3 The board of directors proposes that Dick Bergqvist   who represents AMF  or if he is absent  the person or persons appointed by the board of directors  is appointed to verify the minutes of the annual general meeting. Resolution on allocation of the company's profit according to the adopted balance sheet  item 7(b) The board of directors proposes a dividend for the financial year 2021 of SEK 0.07 per share (the previously communicated amount of SEK 0.065 has been rounded due to technical reasons for the purpose of enabling payment of the dividends through Euroclear ). The board of directors proposes 19 May 2022 as the record date for the dividend. If the annual general meeting resolves in accordance with the board of directors' proposal  payment of the dividend is expected to be made through Euroclear on 24 May 2022 . Determination of the number of members of the board of directors  the fees to be paid to the board of directors and the auditor as well as election of the members of the board of directors and the auditor  items 8-10 The nomination committee proposes: That the board of directors shall comprise five (5) directors (item 8).That fees to the board of directors of SEK 2 145 000 in total shall be paid and allocated in accordance with the following: SEK 900 000 shall be paid to the chair of the board of directors and SEK 415 000 shall be paid to each of the other members of the board of directors. However  a member of the board of directors who receives remuneration from the company due to employment shall not receive any fees (item 9).in total shall be paid and allocated in accordance with the following: shall be paid to the chair of the board of directors and shall be paid to each of the other members of the board of directors. However  a member of the board of directors who receives remuneration from the company due to employment shall not receive any fees (item 9). That the members of the board of directors who are members of the board of directors' audit committee shall receive additional fees of SEK 100 000 per member ( SEK 200 000 for the chair of the audit committee) and that the members of the board of directors who are members of the board of directors' remuneration committee shall receive additional fees of SEK 50 000 per member ( SEK 75 000 for the chair of the remuneration committee) (item 9).per member ( for the chair of the audit committee) and that the members of the board of directors who are members of the board of directors' remuneration committee shall receive additional fees of per member ( for the chair of the remuneration committee) (item 9). That fees to the auditor shall be paid in accordance with approved invoice (item 9).Re-election of the board members Alexander Murad Bj√§rg√•rd  Bengt Braun   Louise Hedberg and Johan Thorell as well as new election of Annette Brodin Rampe (as chair of the board of directors) for the period until the close of the annual general meeting 2023 (item 10).  and as well as new election of (as chair of the board of directors) for the period until the close of the annual general meeting 2023 (item 10). Re-election of the company's auditor Ernst & Young Aktiebolag for the period until the close of the annual general meeting 2023 (item 10). Elisabeth Thand Ringqvist (current chair of the board of directors) has informed the nomination committee that she is not available for re-election as a member of the board of directors at the annual general meeting 2022. The nomination committee's complete proposals  including a presentation of the proposed members of the board of directors and an assessment of their independence in relation to the company  the executive management and the company's major shareholders  are available on the company's website (www.storskogen.com). Resolution on implementation of an employee stock option plan etc.  item 11 The board of directors proposes that the annual general meeting resolves to establish an employee stock option plan  also known as Employee Stock Option Plan 2022 (""ESOP 2022"") directed to senior executives and other key employees of the group. The purpose of the ESOP 2022 is to ensure that the company has the appropriate tools to attract and retain the right talent to the group  to increase the motivation amongst the ESOP-participants (as defined below)  increase their loyalty to the company and align their interests with that of the company's shareholders as well as to promote an individual shareholding in the company and thereby promote shareholder value and the long-term value growth of the company. The board of directors proposes that ESOP 2022 is established in accordance with the following principal terms and conditions. The board of directors shall be responsible for the details and management of ESOP 2022 within the framework of its proposal. Approval for admission to participate in ESOP 2022 is at the sole discretion of the board of directors (primarily acting through its remuneration committee). ESOP 2022 is directed to up to 137 full-time employed senior executives and other key employees of the group (the ""ESOP-participants""). The maximum number of shares of series B (""B-shares"") in the company available under the programme shall be 16 891 002. Subject to the terms and conditions of ESOP 2022  the company will grant options (the ""Options"")  free of charge  to the ESOP-participants in a number allocated by the board of directors pursuant to the principles described below. The date of grant of Options for each participant is referred to as the ""Date of Grant"". The intention is to launch ESOP 2022 and grant the Options to ESOP-participants in a first tranche not later than 10 June 2022 and in a second tranche not later than 30 November 2022 . The Options will  subject to the terms and conditions of ESOP 2022  vest on the third anniversary of the Date of Grant (the ""Vesting Date"") in a number dependant on  e.g.  the level of fulfilment of the performance criterion as set out below. The period from and including the Date of Grant to the Vesting Date is referred to as the ""Vesting Period"". Vested Options will be available for an exercise period of three months after determination by the board of directors of the number of vested Options (if any). Any vested Options not exercised by an ESOP-participant will automatically terminate and be forfeited. Employees in the categories below are eligible for participation in ESOP 2022. The maximum number of Options that an ESOP-participant will be entitled to be allotted depends on which category such person belongs to: Employee (category) Total # of Options per category (maximum) # of Options per ESOP-participant (maximum) # of ESOP-participants (maximum) CEO 558 270 558 270 1 Members of the group management 1 825 206 406 740 6 Senior key employees of the group 3 668 000 326 987 14 Other senior key employees of the group 4 747 986 167 481 38 Mid key employees of the group 2 267 800 76 750 50 Base key employees of the group 781 144 47 201 28 Total (maximum) 13 848 406 N/A 137 The price payable per B-share upon exercise of an Option (the ""Exercise Price"") shall (prior to any re-calculations) correspond to the volume weighted average price for the company's B-share on Nasdaq Stockholm during the trading days falling within a period of ten (10) banking days immediately prior to the Date of Grant. The number of B-shares in the company which can be delivered following exercise of the Options  and the Exercise Price  may be re-calculated by the board of directors in the event of share issues  share splits  reversed share splits  dividends in-kind or similar events. Following the Vesting Period  each Option entitles the ESOP-participant to exercise one (1) Option in order to acquire one (1) B-share in the company against payment of the Exercise Price subject to the terms of ESOP 2022. These terms include: Performance criterion: The number of Options available for exercise depends on the level of fulfilment of the stipulated performance criterion. If the ESOP-participant is offered to participate in ESOP 2022 in May 2022   the performance criterion is based on the increase in adjusted EBITA for the last twelve months as stated in the financial report for the period 1 January- 31 March 2025 in comparison with the adjusted EBITA for the last twelve months stated in the financial report for the period 1 January- 31 March 2022 . If the ESOP-participant is offered to participate in ESOP 2022 in November 2022   the performance criterion is based on the increase in adjusted EBITA for the last twelve months as stated in the financial report for the period 1 January- 30 September 2025 in comparison with the adjusted EBITA for the last twelve months stated in the financial report for the period 1 January- 30 September 2022 . If the adjusted EBITA from 2022 to 2025 during the relevant period has: decreased or increased by 50 per cent or less  no Options shall have vested for ESOP-participants; increased by 100 per cent or more than 100 per cent  the maximum number of Options will have vested for the ESOP-participants; and increased by more than 50 per cent  but the increase is less than 100 per cent  the vesting of Options of the ESOP-participants will be linear in relation to the vesting set out in (i) and (ii). Any Options that are not vested will immediately be deemed forfeited without consideration. Continued employment: The terms of ESOP 2022 include a condition of the ESOP-participant's continued employment within the group during the Vesting Period (under certain conditions  the ESOP-participant may have a right to some of the Options even if the employment has been terminated before the end of the Vesting Period and the board of directors shall furthermore be authorised to waive the employment condition under extraordinary circumstances  for example  if the ESOP-participant's employment is terminated as a result of long-term illness). The profit (before tax) of the value of the B-shares in the company  which can be delivered upon exercise of Options to ESOP-participants  less the Exercise Price for these Options may not exceed the following levels. Employee (category) Maximum profit (before tax) of the value of B-shares by the end of the Vesting Period  less the Exercise Price  as a percentage of fixed yearly remuneration when the ESOP-participant received the offer to participate in ESOP 2022 CEO  members of the group management and senior key employees of the group 200% Other senior key employees of the group 150% Mid key employees of the group and base key employees of the group 100% Subject to the above principal conditions  the company shall  following payment by the ESOP-participant of the Exercise Price  procure that B-shares corresponding to the number of exercised Options (if any) are delivered to the ESOP-participants not later than 60 days after expiry of the exercise period (the exercise period is three months following the Vesting Date). The board of directors shall be entitled to postpone such date if  among other things  the ESOP-participant is not permitted to acquire shares during this period. An ESOP-participant's participation in ESOP 2022 requires that it is legally possible and appropriate in the jurisdiction in which such ESOP-participant is resident and that such participation  in the board of director's opinion  is deemed possible with reasonable administrative and financial costs. If significant changes occur in the company or in the market  or in the event the costs for ESOP 2022 significantly exceed the estimated costs  and this  in the opinion of the board of directors  results in a situation where the conditions for allotment of B-shares based upon exercised Options become unreasonable  the board of directors is entitled to make adjustments to ESOP 2022  including  among other things  to resolve on a reduced allotment of B-shares  or to not allot any B-shares at all. In the event that delivery of B-shares to an ESOP-participant cannot take place under applicable law or at reasonable cost or with reasonable administrative effort  the board of directors of the company may pay a part of or the entire allotment to such ESOP-participant in cash instead of with B-shares. The board of directors of the company may also retain allotted B-shares and settle a part of the allotment in cash in order to facilitate the payment of the ESOP-participants' tax liabilities. Issue and transfer of warrants The board of directors proposes  for the purposes of (1) securing delivery of B-shares to the ESOP-participants 2022 when exercising their Options  and (2) securing and covering costs that may be triggered by ESOP 2022 (e.g.  social security charges and taxes)  that the annual general meeting resolves on (i) a directed issue of warrants in accordance with the below terms  and (ii) transfer of warrants to ESOP-participants (or a third party) or to cover social security costs and taxes under ESOP 2022 in accordance with the below terms and conditions. Issue of warrants The board of directors proposes that the annual general meeting resolves to issue warrants in accordance with the below: Warrants shall be issued in series 2022/2026  comprising a maximum of 16 891 002 warrants for ESOP 2022 (in total  a maximum of 20 031 166 warrants of series 2022/2026 shall be issued which also includes warrants for LTIP 2022 (as defined below))  of which each warrant entitles to subscription for one (1) B-share in the company. Entitled to subscribe for the warrants is - with deviation from the shareholders' preferential right - the company itself. The reason for deviating from the shareholders' preferential right is to secure delivery of B-shares to the participants of ESOP 2022 (and of LTIP 2022)  and secure and cover costs that may be triggered by ESOP 2022 (and by LTIP 2022) for the purposes of enabling the company to establish and implement and ESOP 2022 (and LTIP 2022). The warrants shall be issued without consideration. Subscription for the warrants shall be made on a separate subscription list on 30 June 2022 at the latest. The board of directors may prolong the subscription period. There may be no over-subscription. The subscription price for each B-share upon subscription of B-shares by exercise of the warrants shall be equal to the quota value of the B-share at the time of subscription of the B-share. The share capital may following exercise of warrants be increased with a maximum of SEK 8 445.501 (based on the number of warrants of series 2022/2026 which are being issued for ESOP 2022). Subscription for B-shares by exercise of warrants can be made during the subscription period from and including 1 January 2023 up to and including 30 June 2026 . The complete terms and conditions for the warrants are set out in ""Terms and conditions for warrants of series 2022/2026 regarding subscription for B-shares in Storskogen Group AB (publ) "". Shares which are issued after subscription will entitle to dividends for the first time at the record date for dividends occurring immediately thereafter. A transcript of the company's articles of association is held available at the company's office. Transfer of warrants The board of directors proposes that the annual general meeting approves: The transfer of not more than 13 848 406 warrants to participants in ESOP 2022 (or a designated third party) in connection with the delivery of B-shares to participants in ESOP 2022. Transfers of not more than 3 042 596 warrants to cover social security costs and taxes under ESOP 2022. Estimated costs for ESOP 2022 The costs for ESOP 2022 are based on the IFRS 2 reporting standards and will be amortised over the period during which the Options are earned. The board of directors has made a preliminary cost calculation for ESOP 2022  which is based on an Exercise Price of SEK 25.00   that the maximum number of Options is vested following the Vesting Period and that each ESOP-participant exercises a maximum number of Options. On the basis of the above assumptions  the preliminary value of each Option has  using the Black and Scholes method  been set at SEK 5.02 . The value of the Options has been calculated on the basis of a share price of SEK 25.00 at the establishment of ESOP 2022 and an estimate of the future volatility of the company's B-share of 30 per cent. Based on the assumptions set forth above  the total costs for ESOP 2022 are estimated amount to approximately SEK 69 million   excluding costs for social security charges. The costs for social security charges on the basis of an annual total shareholder return of the company's B-share of 26 per cent until the time for allocation (which corresponds to a total shareholder return of approximately 100 per cent during the Vesting period) is approximately SEK 76 million . Based on the same assumptions as above  but provided that 50 per cent of the number of Options are vested following the Vesting Period and that each ESOP-participant exercises the maximum number of vested Options  the expected costs for ESOP 2022 amount to approximately SEK 35 million   excluding costs for social security charges. The costs for social security charges are estimated to approximately SEK 29 million   based on an annual total shareholder return of Storskogen's B-share of approximately 21 per cent (which corresponds to a total shareholder return of 75 per cent during the Vesting Period). Effects on key ratios The group's operating profit for the financial year 2021 amounted to approximately SEK 1 406 million (approximately SEK 774 million for the financial year 2020). The estimated costs for ESOP 2022 of approximately SEK 145 million in accordance with the above  correspond to approximately 10 per cent of the group's operating profit for the financial year 2021. The group's equity as of 31 December 2021 amounted to approximately SEK 16 588 million . The cost for ESOP 2022 of approximately SEK 145 million correspond to approximately 0.9 per cent of the equity. The estimated costs for ESOP 2022 of approximately SEK 63 million   at 50 per cent of the number of Options vested according to the above  correspond to approximately 4 per cent of the group's operating profit for the financial year 2021. The estimated costs for ESOP 2022 of approximately SEK 63 million correspond to approximately 0.4 per cent of the equity  according to the above. Dilution effect For the purpose of ensuring delivery of B-shares upon exercise of the options and hedging social security costs under ESOP 2022  the company will issue not more than 16 891 002 warrants without consideration to the company itself. At the end of the Exercise Period  some of the warrants will be converted into B-shares and transferred to ESOP-participants that have exercised their Options. Assuming full vesting  the increase in the company's share capital will not amount to more than SEK 8 445.501 . If all Options are exercised  the total number of B-shares under ESOP 2022 will amount to not more than 16 891 002. If all Options are exercised  there will consequently be a dilution effect for the company's current shareholders of approximately 1.0 per cent of the total number of shares and approximately 0.6 per cent of the total number of votes in the company. Full allotment under both LTIP 2022 and ESOP 2022  would mean that the total number of B-shares under both programmes amount to not more than 20 031 166. In the event of full allotment under both programmes  there will consequently be a dilution effect for the company's current shareholders of approximately 1.2 per cent of the total number of shares and approximately 0.7 per cent of the total number of votes in the company. Preparation of the proposal The proposal on ESOP 2022 has been prepared by the board of directors' remuneration committee and has been resolved by the board of directors of the company. Alexander Murad Bj√§rg√•rd is an employee of the company and it is proposed that he be offered to participate in ESOP 2022 in his role as a management person. Alexander Murad Bj√§rg√•rd has not participated in the preparation of the proposal or in the board of directors' resolution regarding the proposal. Majority requirement A resolution to approve this proposal under item 11 is valid only where supported by shareholders holding not less than nine-tenths of both the shares voted for and of the shares represented at the meeting. Outstanding share related incentive programmes For information about other share related incentive programmes in the company  please refer to the company's annual report for 2021 under ""Principles for remuneration to the board and group management - Incentive programme"". Principal terms of the programmes are also available on the company's website (www.storskogen.com). Other than as described therein  there are no other share related incentive programmes in the company. Authorisation The board of directors  or a person appointed by the board of directors  is authorised to undertake such minor adjustments in the resolution that may be required for the registration with the Swedish Companies Registration Office and Euroclear and shall have the right to undertake such minor adjustments to the resolution that are required pursuant to applicable foreign rules and laws. Resolution on implementation of a share savings programme etc.  item 12 The board of directors proposes that the annual general meeting resolves to establish a share savings program  also known as Long Term Incentive Programme 2022 (""LTIP 2022"") directed to certain employees of the group. The purpose of LTIP 2022 is to encourage a broad shareholding amongst the group's employees  maintain competent employees  facilitate recruitment  increase the alignment of interest between the employees and the company's shareholders  encourage the company's long-term growth and increase motivation to reach or exceed the company's financial targets. The board of directors proposes that LTIP 2022 is established in accordance with the following principal terms and conditions. LTIP 2022 is directed to up to 176 full-time employed key employees of the group (the ""LTIP-participants""). Participation in LTIP 2022 requires the LTIP-participants to either (i) make own investments in the company's shares of series B (""B-shares"") at market price at Nasdaq Stockholm  or (ii) allocate B-shares already held by the LTIP-participant to LTIP 2022 that have not previously been allocated as savings shares under LTIP 2021 (""Savings Shares""). Each LTIP-participant can  as a maximum  allocate such number of Savings Shares as set out in this proposal. The board of directors may  however  set the limit to a lower number than as set out below for certain LTIP-participants. Acquisitions of Savings Shares must be made not later than on 15 July 2022 if the LTIP-participant is offered to participate in LTIP 2022 in May 2022 and not later than 15 December 2022 if the LTIP-participant is offered to participate in LTIP 2022 in November 2022 . If applicable insider rules and regulations prevent an LTIP-participant from acquiring Savings Shares in the company during the period  the board of directors has the right to postpone the last day of investment for such LTIP-participant. If the LTIP-participant chooses to allocate already held B-shares as Savings Shares  this must be done not later than the date of acquisition stated above. Subject to: the LTIP-participant (i) not disposing of its Saving Shares during the period commencing on 10 June 2022 if the LTIP-participant is offered to participate in LTIP 2022 in May 2022   alternatively not disposing of its Saving Shares during the period commencing on 30 November 2022 if the LTIP-participant is offered to participate in LTIP 2022 in November 2022   and ending on the date which occurs three (3) years thereafter (the ""Retention Period"") and (ii) not later than 15 July 2022 have proven that it holds the correct number of Savings Shares if the LTIP-participant was offered to participate in LTIP 2022 in May 2022   alternatively ; not later than 15 December 2022 have proven that it holds the correct number of Savings Shares if the LTIP-participant was offered to participate in LTIP 2022 in November 2022   the LTIP-participant's continued employment within the group during the Retention Period (under certain conditions  the LTIP-participant may have a right to some of the Performance Shares (as defined below) even if the employment has been terminated before the end of the Vesting Period and the board of directors shall furthermore be authorised to waive the employment condition under extraordinary circumstances  for example  if the LTIP-participant's employment is terminated as a result of long-term illness); and subject to the performance criteria set out below are satisfied  each Saving Share will entitle the LTIP-participant to an additional two to three B-shares in the company (""Performance Shares"")  in each case free of charge. The Performance Shares are subject to the following two performance criteria during the Retention Period  of which each performance criterion can result in a maximum allocation of 50 per cent of the total number of Performance Shares: The first performance criterion is based on the total shareholder return in the company (that is  the sum of the price change and reinvested dividends for the B-share) during the period commencing on 31 May 2022 if the LTIP-participant is offered to participate in LTIP 2022 in May 2022 and the period commencing on 18 November 2022 if the LTIP-participant is offered to participate in LTIP 2022 in November 2022 and ending on the last day of each respective Vesting Period (the ""TSR Period""). If the total shareholder return in the company during the TSR Period is: 50 per cent or less  the LTIP-participants will not be entitled to any Performance Shares; 100 per cent or higher  50 per cent of the maximum number of Performance Shares will be allocated to the LTIP-participants; and higher than 50 per cent but lower than 100 per cent  the allocation of Performance Shares to the LTIP-participants will be linear in relation to the allocation set out in (i) and (ii) above. If the LTIP-participant is offered to participate in LTIP 2022 in May 2022   the second performance criterion is based on the increase in adjusted EBITA for the last twelve months as stated in the financial report for the period 1 January- 31 March 2025 in comparison with the adjusted EBITA for the last twelve months stated in the financial report for the period 1 January- 31 March 2022 . If the LTIP-participant is offered to participate in LTIP 2022 in November 2022   the second performance criterion is based on the increase in adjusted EBITA for the last twelve months as stated in the financial report for the period 1 January- 30 September 2025 in comparison with the adjusted EBITA for the last twelve months stated in the financial report for the period 1 January- 30 September 2022 . If the adjusted EBITA from 2022 to 2025 for the relevant period has: decreased or increased by 50 per cent or less  the LTIP-participants will not be entitled to any Performance Shares; increased by 100 per cent or more than 100 per cent  50 per cent of the maximum number of Performance Shares will be allocated to the LTIP-participants; and increased by more than 50 per cent  but the increase is less than 100 per cent  the allocation of Performance Shares to the LTIP-participants will be linear in relation to the allocation set out in (i) and (ii) above. In aggregate  a maximum of 2 433 904 Performance Shares may be allotted to the LTIP-participants. The maximum number of Performance Shares that an LTIP-participant will be entitled to receive for each Saving Share and the possible investment in Savings Shares depends on which category such LTIP-participant belongs to: Category Maximum # LTIP-participants in each category Maximum # of Performance Shares per Savings Share Maximum # of Savings Shares per LTIP-participant in each category CEO and other key employees in business units/subsidiaries with an EBITA of SEK 20 million or more during 2021 88 3 11 520 CEO and other key employees in business units/subsidiaries with an EBITA of less than SEK 20 million during 2021 88 2 9 536 The number of Performance Shares to be allotted (if any) may be re-calculated by the board of directors in the event of share issues  share splits  reversed share splits  dividends in-kind or similar events. If significant changes occur in the company or in the market  or in the event the costs for LTIP 2022 significantly exceed the estimated costs  and this  in the opinion of the board of directors  results in a situation where the conditions for allotment of Performance Shares become unreasonable  the board of directors is entitled to make adjustments to LTIP 2022  including  among other things  to resolve on a reduced allotment of Performance Shares  or to not allot any Performance Shares at all. Participation in LTIP 2022 requires that it is permitted and appropriate with regard to applicable laws and regulations in the jurisdiction in which the relevant LTIP-participant is resident and that the board of directors deems it feasible at reasonable administrative and financial costs. In the event delivery of Performance Shares to an LTIP-participant cannot take place under applicable law or at reasonable cost or with reasonable administrative effort  the company may pay a part of or the entire allotment to such LTIP-participant in cash instead of with B-shares. The company may also retain allotted Performance Shares and settle a part of the allotment in cash in order to facilitate the payment of the LTIP-participants' tax liabilities. The board of directors is responsible for the detailed design and implementation of LTIP 2022. Accordingly  the board of directors is to prepare and execute any necessary agreements and otherwise manage and administer LTIP 2022. Issue and transfer of warrants The board of directors proposes  for the purposes of (1) securing delivery of B-shares to the participants of LTIP 2022 at exercise of the Performance Share rights  and (2) securing and covering costs that may be triggered by LTIP 2022 (e.g.  social security charges and taxes)  that the annual general meeting resolves on (x) a directed issue of warrants in accordance with the below terms  and (y) transfer of warrants to LTIP-participants (or a third party) or to cover social security costs and taxes under LTIP 2022 in accordance with the below terms and conditions. Issue of warrants The board of directors proposes that the annual general meeting resolves to issue warrants in accordance with the below: Warrants shall be issued in series 2022/2026  comprising a maximum of 3 140 164 warrants for LTIP 2022 (in total  a maximum of 20 031 166 warrants of series 2022/2026 shall be issued which also includes warrants for ESOP 2022)  of which each warrant entitles to subscription for one (1) B-share in the company. Entitled to subscribe for the warrants is - with deviation from the shareholders' preferential right - the company itself. The reason for deviating from the shareholders' preferential right is to secure delivery of shares to the participants of LTIP 2022 (and of ESOP 2022)  and secure and cover costs that may be triggered by the LTIP 2022 (and by ESOP 2022) for the purposes of enabling the company to establish and implement LTIP 2022 (and ESOP 2022). The warrants shall be issued without consideration. Subscription for the warrants shall be made on a separate subscription list on 30 June 2022 at the latest. The board of directors may prolong the subscription period. There may be no over-subscription. The subscription price for each B-share upon subscription of B-shares by exercise of the warrants shall be equal to the quota value of the B-share at the time of subscription of the B-shares. The share capital may following subscription of B-shares by exercise of warrants be increased with a maximum of SEK 1 570.082 (based on the number of warrants of series 2022/2026 which are being issued for LTIP 2022). Subscription for B-shares by exercise of warrants can be made during the subscription period from and including 1 January 2023 up to and including 30 June 2026 . The complete terms and conditions for the warrants are set out in ""Terms and conditions for warrants of series 2022/2026 regarding subscription for B-shares in Storskogen Group AB (publ) "". Shares which are issued after subscription will entitle to dividends for the first time at the record date for dividends occurring immediately thereafter. A transcript of the company's articles of association is held available at the company's office. Transfer of warrants The board of directors proposes that the annual general meeting approves: The transfer of not more than 2 433 904 warrants to participants in the LTIP 2022 (or a designated third party) in connection with the delivery of Performance Shares to participants in LTIP 2022. Transfers of not more than 706 260 warrants to cover social security costs and taxes under LTIP 2022. Estimated costs for LTIP 2022 The cost for LTIP 2022 will be accounted for in accordance with IFRS 2 and will be amortised over the period during which the Performance Shares are earned  and the company's total cost for LTIP 2022 is not expected to exceed approximately SEK 72 million   assuming that 100 per cent of the maximum number of Performance Shares is allotted to the LTIP-participants and that the share price increase with a maximum of 100 per cent. Of these total costs  outgoing social security charges are estimated to amount to approximately SEK 35 million assuming a share price increase of 100 per cent during the vesting period of LTIP 2022 and approximately 29 per cent estimated average social security costs. Based on the same assumptions as above  but instead that 50 per cent of the maximum number of Performance Shares are allotted to LTIP-participants and that the share price increases with a maximum of 75 per cent  Storskogen's total cost for LTIP 2022 is not expected to exceed approximately SEK 37 million . Of these total costs  social security charges are estimated to amount to approximately SEK 15 million . Effects on key ratios The group's operating profit for the financial year 2021 amounted to approximately SEK 1 406 million (approximately SEK 774 million for the financial year 2020). The estimated costs for LTIP 2022 of approximately SEK 72 million in accordance with the first example above  correspond to approximately 5 per cent of the group's operating profit for the financial year 2021. The estimated costs for the share savings programme of SEK 37 million in accordance with the second example above  correspond to approximately 3 per cent of the operating profit for the financial year 2021. The group's equity as of 31 December 2021 amounted to approximately SEK 16 588 million . The estimated costs of LTIP 2022 of SEK 72 and 37 million  respectively  correspond to approximately 0.4 and 0.2 per cent of the equity  respectively. Dilution effect For the purpose of ensuring delivery of Performance Shares and hedging social security costs under LTIP 2022  the company will issue not more than 3 140 164 warrants without consideration to the company itself. At the end of the Retention Period  some of the warrants will be converted into B-shares and transferred to LTIP-participants that have been granted allotment. Assuming full allotment  the increase in the company's share capital will not amount to more than SEK 1 570.082 . Full allotment of Performance Shares would mean that the total number of shares under the programme will amount to not more than 3 140 164 B-shares. In the event of full allotment  there consequently will be a dilution effect for the company's current shareholders of approximately 0.2 per cent of the total number of shares and approximately 0.1 per cent of the total number of votes in the company. Full allotment under both LTIP 2022 and ESOP 2022 would mean that the total number of B-shares under both programmes amount to not more than 20 031 166. In the event of full allotment under both programmes  there will consequently be a dilution effect for the company's current shareholders of approximately 1.2 per cent of the total number of shares and approximately 0.7 per cent of the total number of votes in the company. Preparation of the proposal The proposal on LTIP 2022 has been prepared by the board of directors' remuneration committee and has been resolved by the board of directors of the company. Majority requirement A resolution to approve this proposal under item 12 is valid only where supported by shareholders holding not less than nine-tenths of both the shares voted for and of the shares represented at the meeting. Outstanding share related incentive programmes For information about other share related incentive programmes in the company  please refer to the company's annual report for 2021 under ""Principles for remuneration to the board and group management - Incentive programme"". Principal terms of the programmes are also available on the company's website (www.storskogen.com). Other than as described therein  there are no other share related incentive programmes in the company. Authorisation The board of directors  or a person appointed by the board of directors  is authorised to undertake such minor adjustments in the resolution that may be required for the registration with the Swedish Companies Registration Office and Euroclear and shall have the right to undertake such minor adjustments to the resolution that are required pursuant to applicable foreign rules and laws. Resolution on (a) a reduction of the share capital with redemption of 16 848 061 shares of series B and (b) a bonus issue  items 13(a)-(b) Background of the board of directors' proposal In connection with the admission to trading of the company's shares of series B on Nasdaq Stockholm  the company granted a so-called overallotment option to Carnegie Investment Bank AB (publ) (""Carnegie"")  J.P. Morgan Securities plc and Goldman Sachs Bank Europe SE (together  the ""Managers"")  which entitled the Managers  not later than 30 days from the first day of trading in the company's shares of series B on Nasdaq Stockholm  to acquire up to 52 205 241 shares of series B in the company to cover any overallotments or short positions in connection with the admission to trading of the company's shares of series B on Nasdaq Stockholm. In order to facilitate the overallotment option  the company issued 52 205 241 shares of series B to Carnegie  of which 35 357 180 shares of series B were exercised by the Managers under the overallotment option and the remaining 16 848 061 shares of series B were transferred back to the company by Carnegie without consideration. The board of directors now proposes that these 16 848 061 shares of series B shall be redeemed. Resolution on a reduction of the share capital with redemption of 16 848 061 shares of series B  item 13(a) The board of directors proposes that the annual general meeting resolves on a reduction of the share capital with redemption of shares on the following terms and conditions. The share capital is to be reduced by not more than SEK 8 424.0305 . The reduction of the share capital is to be effected with redemption of the 16 848 061 shares of series B that are held by the company. The purpose of the reduction is allocation to unrestricted shareholders' equity. The company may implement the resolution to reduce the share capital without authorisation from the Swedish Companies Registration Office since the company simultaneously carries out a bonus issue that increases the company's restricted shareholders' equity and share capital by SEK 16 600.734330 (see item 13(b) of the agenda). Combined  the actions under this item 13(a) and the bonus issue under item 13(b) of the agenda entail that neither the company's restricted shareholders' equity nor its share capital is reduced. Resolution on a bonus issue  item 13(b) The board of directors proposes that the annual general meeting resolves on a bonus issue on the following terms and conditions. The share capital is to be increased by SEK 16 600.734330 . No new shares are to be issued in connection with the increase of the share capital. The amount by which the share capital is to be increased shall be transferred to the share capital from unrestricted shareholders' equity. The purpose of the bonus issue is to restore the company's restricted equity and share capital after the proposed reduction of the share capital pursuant to item 13(a) of the agenda as well as to  in connection therewith  achieve a quotient value of the shares with a limited number of decimals. Majority requirements etc. The board of directors proposes that the annual general meeting's resolutions pursuant to items 13(a)-(b) on the agenda shall be adopted as a joint resolution. Accordingly  the resolution is only valid where supported by shareholders holding not less than two-thirds of the votes cast and the shares represented at the annual general meeting. Resolution on an authorisation for the board of directors to resolve on issuances of shares of series B  warrants that may be exercised for subscription of shares of series B and/or convertibles that may be converted to shares of series B  item 14 The board of directors proposes that the annual general meeting authorises the board of directors to  at one or several occasions during the period up until the next annual general meeting  resolve upon the issuance of shares of series B  convertibles that can be converted to shares of series B and/or warrants that can be exercised for subscription of shares of series B. Subscribed shares  convertibles or warrants shall be paid for in cash  by set-off or in-kind. The authorisation shall be limited so that the board of directors may not resolve upon issues of shares  convertibles of warrants that entail that the total number of shares that are issued  issued through conversion of convertibles or issued through exercise of warrants exceeds 10 per cent of the total number of shares of series B in the company at the time the board of directors exercises the authorisation for the first time. If the board of directors resolves on the issuance of shares  convertibles and/or warrants with deviation from the shareholders' preferential rights  the reason for the deviation shall be to use shares as consideration (including earn-out consideration) in connection with  or as financing of  acquisitions of companies or businesses or for the company's operations in general. Majority requirements etc. A resolution pursuant to this item 14 is only valid where supported by shareholders holding not less than two-thirds of the votes cast and the shares represented at the annual general meeting. Resolution on an authorisation for the board of directors to resolve on acquisitions and transfers of treasury shares of series B  item 15 The board of directors proposes that the annual general meeting authorises the board of directors to  at one or several occasions during the period up until the next annual general meeting  resolve upon acquisitions and transfers of shares of series B in the company on the following terms. Acquisitions may be made of a maximum of so many shares that the company's holding of treasury shares  following the acquisition  does not exceed ten per cent of all shares in the company. Acquisitions of treasury shares shall be made on Nasdaq Stockholm. Acquisitions of treasury shares shall be made at a price per share within the at each time prevailing price interval for the shares of series B on Nasdaq Stockholm. Payment for acquired treasury shares shall be made in cash. Transfers may be made of treasury shares held by the company at the time of the board of directors' resolution to transfer shares. Transfers of treasury shares may be made by other means than on Nasdaq Stockholm. Transfers of treasury shares shall be made at market terms. Payment for treasury shares that are transferred may be made in cash  in-kind or by set-off. Transfers of treasury shares may be made with deviation from the shareholders' preferential rights. The reason for an acquisition or a transfer of treasury shares  and the reason for any transfer with deviation from the shareholders' preferential rights  shall be to: (a) optimise the company's capital structure or (b) use shares as consideration (including earn-out consideration) in connection with  or as financing of  acquisitions of companies or businesses. Majority requirements etc. A resolution pursuant to this item 15 is only valid where supported by shareholders holding not less than two-thirds of the votes cast and the shares represented at the annual general meeting. Resolution on guidelines for remuneration to senior executives  item 16 The board of directors proposes that the following guidelines for remuneration to senior executives shall be applied to remunerations agreed upon by the company after the annual general meeting 2022. Introduction The following guidelines encompass the company's CEO and the other members of the company's executive management. Executive management refers to  in addition to the company's CEO  Heads of Business Areas  CFO  Head of M&A and Head of DACH as well as members of the board of directors of the company who have entered into an employment agreement or a consulting agreement with the company or another group company. After the guidelines have been adopted by the general meeting  the guidelines shall be applied to remunerations agreed upon as well as to amendments of remunerations already agreed upon. The guidelines do not apply to any remuneration resolved upon by the general meeting. The guidelines' promoting of the company's business strategy  long-term interests and sustainability Storskogen strives towards being the best owner for small and medium-sized enterprises. Focus lies on long-term ownership  good profitability  stable cash flows and supporting the companies in maintaining and developing a strong position within their niches. A prerequisite for a successful implementation of the company's strategy is that the company is able to recruit and retain qualified senior executives  which is enabled by these guidelines. Remunerations that are subject to these guidelines shall aim to promote the company's business strategy  sustainability and long-term interests. Remuneration components as well as other terms and conditions The total remuneration shall be in line with market conditions and may consist of the following components: fixed cash remuneration  short-term variable cash remuneration  long-term variable cash remuneration and other benefits as well as pension benefits. In addition to what is determined in the guidelines  the general meeting may resolve on  inter alia  share or share price related remunerations. The performance criteria measurement period for payment of variable cash remuneration shall be measurable during a period of one or several years. The total variable cash remuneration may not amount to more than 50 per cent of the fixed cash remuneration during the measurement period of the objectives for variable cash remuneration. The executive management's pension benefits shall be in line with market conditions in relation to the common practice for comparable executives on the market on which the respective senior executive operates and should be based on defined contribution pension plans or be in line with general pension plans (in Sweden   the ITP plan). Subject to applicable law or mandatory collective agreement provisions  pension benefits may not amount to more than 30 per cent of the fixed cash remuneration and variable cash remuneration shall not be pensionable. Other benefits may consist of  inter alia  company health care and company car benefits. Premiums and other expenses relating to these benefits may not exceed ten per cent of the fixed cash remuneration. Termination of employment The notice period for a member of the executive management shall be not more than twelve months. Fixed cash remuneration and potential severance pay  including compensation for any competition restrictions  combined during the notice period may not exceed an amount corresponding to the fixed cash remuneration for two years for a member of the executive management. Objectives for awarding variable cash remuneration The variable component shall award the fulfilment of clear objectives and key figures that promotes the company's business strategy and long-term interests  including the sustainability agenda. When the performance criteria measurement period for payment of variable cash remuneration has ended  an evaluation of the outcome shall be made. The remuneration committee is responsible for such evaluation of the CEO's outcome  while the CEO is responsible for the evaluation of the other senior executives' outcomes. Salary and terms of employment for employees In connection with the preparation of the board of directors' proposal on these remuneration guidelines  salaries and employment terms for the company's employees have been considered by way of assessing information on the total remuneration to employees  the remuneration's components as well as the remuneration's growth and growth rate over time. The information has formed a part of the board of directors' basis for decision-making when evaluating the reasonableness of the guidelines and the limitations set out in the guidelines. The decision-making process to determine  review and implement the guidelines The remuneration committee of the board of directors shall prepare the board of directors' resolution to propose guidelines for remunerations to senior executives. The board of directors shall prepare a proposal for new guidelines at least every four years and submit the proposal to the annual general meeting. The guidelines shall apply until new guidelines are adopted by the general meeting. The remuneration committee shall also monitor and evaluate programmes for variable remunerations to the company's executive management and the application of the guidelines in relation to current remuneration levels and structures. Members of the executive management do not participate in the board of directors' preparations of and decisions regarding remuneration-related matters if they are affected by such matters. Deviations from the guidelines The board of directors may temporarily resolve to deviate from the guidelines  in whole or in part  if there in an individual case are special reasons for a deviation and it is necessary to serve the company's long-term interests  including its sustainability  or to ensure the company's financial viability. As set out above  the remuneration committee's assignments include preparing the board of directors' resolutions in remuneration-related matters  which includes any resolution to deviate from the guidelines. NUMBER OF SHARES AND VOTES As of the date of this notice  the total number of shares in the company amounts to 1 676 921 494 (of which 148 001 374 shares of series A with ten votes each and 1 528 920 120 shares of series B with one vote each) and the total number of votes in the company amounts to 3 008 933 860 (including 4 158 306 shares of series B that  as of the date of the announcement of this notice  have been issued but not yet registered with the Swedish Companies Registration Office). The company holds 16 848 061 treasury shares of series B as of the date of this notice. SHAREHOLDERS' RIGHT TO REQUEST INFORMATION The board of directors and the CEO shall  if any shareholder so requests and the board of directors believes that it can be done without significant harm to the company  provide information in respect of any circumstances which may affect the assessment of a matter on the agenda and any circumstances that may affect the assessment of the company's financial position. The duty to provide information shall also apply to the company's relationship with another group company  the consolidated accounts and such circumstances regarding subsidiaries that are referred to in the preceding sentence. AVAILABLE DOCUMENTS Complete proposals and other documentation that shall be kept available before the annual general meeting according to the Swedish Companies Act and the Swedish Corporate Governance Code will be kept available at the company at address Hovslagargatan 3  SE-111 48 Stockholm  and on the company's website (www.storskogen.com) not later than three weeks before the annual general meeting. The documents will also be sent to the shareholders who request it and state their postal address. Such a request may be sent to Storskogen Group AB (publ)   ""Annual General Meeting""  Hovslagargatan 3  SE-111 48 Stockholm  or by e-mail to ir@storskogen.com. * * * Stockholm in April 2022 Storskogen Group AB (publ) The board of directors https://news.cision.com/storskogen-group-ab/r/notice-to-the-annual-general-meeting-in-storskogen-group-ab--publ- c3543921 https://mb.cision.com/Main/20705/3543921/1562750.pdf (c) 2022 Cision. All rights reserved.  source Press Releases - English All news about STORSKOGEN GROUP AB (PUBL) 04/08 Storskogen Buys Swedish Kitchen Supplies Distributor Dafra MT 04/08 Storskogen's subsidiary Vikingsun acquires Dafra AQ 04/08 Storskogen Unit Buys Swedish Industrial Equipment Group DETAB Ecomat Automation MT 04/08 Storskogen's subsidiary PV Systems acquires DETAB AQ 04/06 Storskogen publishes Annual Report for 2021 AQ 04/05 Certain B Shares of Storskogen Group AB are subject to a Lock-Up Agreement Ending on 5-.. CI 04/01 Storskogen resolves on a directed share issue to the sellers of Swedwise AQ 03/29 Stroskogen Purchases German Advertising Firm Dimabay to Boost Customer Acquisition MT 03/29 Storskogen acquires Dimabay AQ 03/29 Storskogen enters into bank facility agreement AQ Financials SEK USD Sales 2022 29 818 M 3 158 M 3 158 M Net income 2022 1 671 M 177 M 177 M Net Debt 2022 8 805 M 933 M 933 M P/E ratio 2022 22 4x Yield 2022 0 50% Capitalization 37 731 M 3 996 M 3 996 M EV / Sales 2022 1 56x EV / Sales 2023 1 35x Nbr of Employees 8 719 Free-Float 79 0% Chart STORSKOGEN GROUP AB (PUBL) Duration : Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max. Period : Day Week Technical analysis trends STORSKOGEN GROUP AB (PUBL) Short Term Mid-Term Long Term Trends Neutral Bearish Neutral Income Statement Evolution Please enable JavaScript in your browser's settings to use dynamic charts. Consensus Sell Buy Mean consensus OUTPERFORM Number of Analysts 8 Last Close Price 22 50 SEK Average target price 37 81 SEK Spread / Average Target 68 1% EPS Revisions Please enable JavaScript in your browser's settings to use dynamic charts. Managers and Directors Daniel Samuel Kaplan Chief Executive Officer Lena Krauss Chief Financial Officer Lena Paulina Glader Chief Financial Officer Elisabeth Kristin Thand Ringqvist Chairman Lars Johan Thorell Director Sector and Competitors 1st jan. Capi. (M$) STORSKOGEN GROUP AB (PUBL) -63.08% 3 996 INVESTOR AB (PUBL) -5.07% 70 317 CK HUTCHISON HOLDINGS LIMITED 12.33% 27 637 GROUPE BRUXELLES LAMBERT SA -4.73% 14 875 HAL TRUST -4.66% 13 108 AB INDUSTRIV√ÑRDEN (PUBL) -8.74% 11 942",neutral,0.01,0.96,0.02,neutral,0.02,0.95,0.04,True,English,"['Annual General Meeting', 'Storskogen Group AB', 'Notice', 'DETAB Ecomat Automation MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Summary', 'Other languages Press Releases Official Publications Sector news Notice', 'Homepage Equities Sweden Nasdaq Stockholm Storskogen Group AB', 'News Summary', 'Swedish Kitchen Supplies Distributor', 'Swedish Industrial Equipment Group', 'other authorisation documents', 'Euroclear Sweden AB', 'Dafra MT', 'list Report Report', 'Annual General Meeting', 'multiple email addresses', 'Swedish Companies Act', 'equivalent authorisation document', 'personal identification number', 'corporate identification number', 'postal voting form', 'postal voting Shareholders', 'postal vote', 'Storskogen Unit', 'phone number', 'voting rights', 'voting purposes', 'STOR B', 'Dafra AQ', 'Moderna Museet', 'share register', 'accompanying assistants', 'legal entity', 'company name', 'First name', 'dated power', 'proxy Shareholders', '49 Stockholm', 'EDT', 'SEK', 'subsidiary', 'Vikingsun', 'commas', 'Message', 'fields', 'reg.', 'Tuesday', 'May', 'Exercisplan', 'Entry', 'registration', 'board', 'directors', 'Chapter', 'Section', 'articles', 'association', 'EXERCISE', 'Monday', 'shares', 'nominee', 'time', 'Wednesday', 'attendance', 'instructions', 'heading', 'Notification', 'accordance', 'website', 'Box', 'c/o', 'telephone', 'weekdays', 'written', 'signed', 'attorney', 'copy', 'certificate', 'order', 'powers', 'submitted', 'English', 'GeneralMeetingService', '14:00', '11', '101']",2022-04-11,2022-04-11,marketscreener.com
2635,Euroclear,Google API,https://www.marketscreener.com/quote/stock/AZELIO-AB-PUBL-61747217/news/Notice-to-annual-general-meeting-in-Azelio-AB-publ-40023139/,Notice to annual general meeting in Azelio AB (publ),7 hours ago,"Notice to annual general meeting in Azelio AB (publ) 04/11/2022 | 09:21am EDT Send by mail :Name : First name : From * : To * : (You can enter multiple email addresses separated by commas) Message : * Required fields The shareholders in Azelio AB (publ)  reg.no. 556714-7607  with its registered office in Gothenburg   are hereby summoned to an annual general meeting to be held on 12 May 2022 . On the basis of temporary statutory rules  the board of directors has decided that the annual general meeting will be conducted by advance voting only  without physical presence of shareholders  proxies and third parties. Azelio welcomes all shareholders to exercise their voting rights at this annual general meeting through advance voting  according to the procedure set out below. Information on the resolutions passed at the annual general meeting will be published on 12 May 2022   as soon as the result of the voting has been finally confirmed. In the advance voting form  the shareholders may request that a resolution on one or several of the matters on the proposed agenda below should be deferred to a so-called continued general meeting  which cannot be conducted solely by way of advance voting. Such continued general meeting shall take place if the annual general meeting so resolves or if shareholders with at least one tenth of all shares in the company so request. The shareholders are reminded of their right to request information according to Chapter 7  Section 32 of the Swedish Companies Act. A request for such information shall be made in writing to Azelio AB   Forsbrogatan 4  SE-662 34 √Öm√•l  Sweden   or via e-mail to info@azelio.com  no later than on 2 May 2022 . The information will be made available at Azelio AB   Forsbrogatan 4  SE-662 34 √Öm√•l  Sweden and on www.azelio.com  on 7 May 2022 at the latest. The information will also be sent  within the same period of time  to the shareholder who has requested it and stated its address. Notification  etc. Shareholders who wish to participate  through advance voting  in the annual general meeting must: firstly be included in the shareholders' register maintained by Euroclear Sweden AB as of 4 May 2022 ; and secondly notify the company of their participation in the annual general meeting by casting their advance vote in accordance with the instructions under the heading ""Advance voting"" below  so that the advance voting form is received by Azelio no later than on 11 May 2022 . Shareholders whose shares are registered in the name of a nominee through a bank or a securities institution must re-register their shares in their own names to be entitled to participate in the annual general meeting. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee's procedures and such time in advance as the nominee determines. Voting right registration completed not later than the second banking day after 4 May 2022 are taken into account when preparing the shareholders' register. Advance voting The shareholders may only exercise their voting rights at the annual general meeting by voting in advance  so-called postal voting in accordance with section 22 of the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations. A special form shall be used for advance voting. The form is available on Azelio's website  www.azelio.com. The advance voting form is considered as the notification of participation. The completed voting form must be received by Azelio AB no later than Wednesday 11 May 2022 . The form may be submitted via e-mail to info@azelio.com or by post to Azelio AB   ""Annual general meeting""  Forsbrogatan 4  SE-662 34 √Öm√•l  Sweden . If the shareholder votes in advance by proxy  a power of attorney shall be enclosed to the form. If the shareholder is a legal entity  a certificate of incorporation or a corresponding document shall be enclosed to the form. The shareholder may not provide special instructions or conditions in the voting form. If so  the vote (i.e. the advance vote in its entirety) is invalid. Further instructions and conditions are included in the form for advance voting. For questions regarding the annual general meeting or to have the advance voting form sent by post  please contact Azelio AB on info@azelio.com. Number of shares and votes There is a total of 115 877 180 shares  with one vote per share at the annual general meeting  in the company as of the date of this notice. Proposed agenda Election of a chairman at the meeting; Election of one or two persons who shall approve the minutes of the meeting; Preparation and approval of the voting list; Approval of the agenda; Determination of whether the meeting was duly convened; Submission of the annual report and the auditors' report and  when applicable  the consolidated financial statements and the auditors' report for the group; Resolutions regarding the adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet; Resolutions regarding allocation of the company's profits or losses in accordance with the adopted balance sheet; Resolutions regarding discharge of the members of the board of directors and the managing director from liability; Determination of the number of members and deputy members of the board of directors and the number of auditors and deputy auditors; Determination of fees for members of the board of directors and auditors; Election of the members of the board of directors; 12a. Bo Dankis (re-election) 12b. Bertil Villard (re-election) 12c. Kent Jan√©r (re-election) 12d. P√§r Nuder (re-election) 12e. Hicham Bouzekri (re-election) 12f. Elaine Weidman-Grunewald (re-election) 12g. Hans Ola Meyer (re-election) Election of the chairman of the board of directors; Bo Dankis (re-election) Election of auditors and deputy auditors; The nomination committee's proposal on principles for appointment of a nomination committee; The board of directors' proposal on authorisation for the board of directors to resolve to issue shares and/or warrants and/or convertibles without deviation from the shareholders' preferential rights; The board of directors' proposal on authorisation for the board of directors to resolve upon issue of shares with or without deviation from the shareholders' preferential rights; The board of directors' proposal on amendments to the articles of association; The board of directors' proposal to resolve on a long-term incentive program for the executive management in the form of warrants; The principal shareholders' proposal to resolve on a long-term incentive program for the board of directors in the form of warrants. The nomination committee's resolution proposals Proposal regarding the chairman of the general meeting  the number of members of the board of directors  the number of auditors and deputy auditors  fees to the board of directors and auditors  and election of members of the board of directors and chairman of the board of directors  as well as election of auditors and deputy auditors (items 1 and 10-14) The company's nomination committee has submitted the following proposals: that Bo Dankis   or the person proposed by the nomination committee if he has an impediment to attend  is elected chairman of the annual general meeting (item 1).  or the person proposed by the nomination committee if he has an impediment to attend  is elected chairman of the annual general meeting (item 1). that the board of directors shall consist of seven board members  as appointed by the general meeting  with no deputy members and that the company shall have one auditor  with no deputy auditors (item 10).that the chairman of the board shall receive SEK 650 000 and the other board members not employed by the company shall receive SEK 250 000 each in board fees  that the members of the finance committee not employed by the company shall receive SEK 50 000 each and that the members of the remuneration committee not employed by the company shall receive SEK 50 000 each  for the period until the end of the next annual general meeting. If the chairman of the board is part of the finance committee or remuneration committee  the chairman of the board shall not receive any fees in excess of customary board fees. The principal owner Kent Jan√©r has informed that he will decline remuneration for his work as a board and committee member. Thus  the proposed board fees amount to a maximum of SEK 2 000 000 . It is proposed that auditor fees shall be paid against approved accounts (item 11).and the other board members not employed by the company shall receive each in board fees  that the members of the finance committee not employed by the company shall receive each and that the members of the remuneration committee not employed by the company shall receive each  for the period until the end of the next annual general meeting. If the chairman of the board is part of the finance committee or remuneration committee  the chairman of the board shall not receive any fees in excess of customary board fees. The principal owner Kent Jan√©r has informed that he will decline remuneration for his work as a board and committee member. Thus  the proposed board fees amount to a maximum of . It is proposed that auditor fees shall be paid against approved accounts (item 11). that Bo Dankis   Bertil Villard   Kent Jan√©r  P√§r Nuder  Hicham Bouzekri   Elaine Weidman-Grunewald and Hans Ola Meyer are re-elected as members of the board of directors  for the period up until the end of the next annual general meeting (item 12). It was noted that Carol M. Browner declined re-election as a board member.    Kent Jan√©r  P√§r Nuder    and are re-elected as members of the board of directors  for the period up until the end of the next annual general meeting (item 12). It was noted that declined re-election as a board member. that Bo Dankis is re-elected as chairman of the board  for the period up until the end of the next annual general meeting (item 13).is re-elected as chairman of the board  for the period up until the end of the next annual general meeting (item 13). that the registered accounting firm KPMG AB is re-elected as auditor for the time until the end of the next annual general meeting. In the event that KPMG is re-elected  it is noted that KPMG has announced that the authorized accountant Fredrik Waern will be appointed auditor in charge and that the authorized accountant Johan Kratz will be appointed auditor (item 14). The nomination committee's proposal on principles for appointment of a nomination committee (item 15) The nomination committee proposes that the annual general meeting shall resolve on principles for appointment of a nomination committee for the annual general meeting 2023 in accordance with the below. The nomination committee shall be composed of the chairman of the board of directors together with one representative of each of the three largest shareholders  based on ownership in the company as of the expiry of the third quarter of the financial year. Should any of the three largest shareholders renounce its right to appoint one representative to the nomination committee  such right shall transfer to the shareholder who then in turn  after these three  is the largest shareholder in the company. The chairman of the board of directors shall convene the nomination committee. The member representing the largest shareholder shall be appointed chairman of the nomination committee  unless the nomination committee unanimously appoints someone else. Should a shareholder having appointed a representative to the nomination committee no longer be among the three largest shareholders  three months before the annual general meeting at the latest  the representative appointed by such shareholder shall resign and the shareholder who is then among the three largest shareholders shall have the right to appoint one representative to the nomination committee. However  unless there are special reasons otherwise  the already established composition of the nomination committee shall remain unchanged in case such change in the ownership is only marginal or occurs during the three-month period prior to the annual general meeting. Where a shareholder has become one of the three largest shareholders due to a material change in the ownership at a point in time falling later than three months before the annual general meeting  such shareholder shall in any event have the right to take part of the work of the nomination committee and participate in its meetings. Should a member resign from the nomination committee before his or her work is completed  the shareholder who has appointed such member shall appoint a new member  unless that shareholder is no longer one of the three largest shareholders  in which case the largest shareholder in turn shall appoint the substitute member. A shareholder who has appointed a representative to the nomination committee shall have the right to discharge such representative and appoint a new representative. Changes to the composition of the nomination committee shall be announced immediately. The term of office for the nomination committee ends when the next nomination committee has been appointed. On the nomination committee's meetings  it shall carry out the nomination committee's duties as set out in the Swedish Code of Corporate Governance. The board of directors' resolution proposals Election of one or two persons who shall approve the minutes of the meeting (item 2) Bertil Villard   or the person appointed by the board of directors if he has an impediment to attend  is proposed to be elected to approve the minutes together with the chairman. The task of approving the minutes also includes verifying the voting list and that the advance votes received are correctly stated in the minutes of the annual general meeting. Preparation and approval of the voting list (item 3) The voting list proposed for approval under item 3 of the agenda is the voting list drawn up by the company  based on the general meeting's share register and advance votes received  as verified and recommended by the person approving the minutes. Proposal regarding allocation of the company's profits or losses in accordance with the adopted balance sheet (item 8) The board of directors proposes that no dividends shall be paid for the financial year 2021 and that the company's results shall be carried forward. The board of directors' proposal on authorisation for the board of directors to resolve to issue shares and/or warrants and/or convertibles without deviation from the shareholders' preferential rights (item 16) The board of directors proposes that the annual general meeting authorises the board of directors to resolve to issue new shares and/or warrants and/or convertibles on one or several occasions until the next annual general meeting  without preferential rights for the shareholders  against cash payment or against payment through set-off or in kind  or otherwise on special conditions. The number of shares that may be issued and the number of shares that shall be possible to subscribe/convert may amount to the number of shares allowed by the articles of association  as amended from time to time. The purpose of the authorisation is to increase the financial flexibility of the company and the acting scope of the board of directors. The board of directors or the CEO shall have the right to make such minor adjustments in this resolution that may be necessary in connection with the registration of the authorisation with the Swedish Companies Registration Office. The board of directors' proposal on authorisation for the board of directors to resolve upon issue of shares with or without deviation from the shareholders' preferential rights (item 17) The board of directors proposes that the annual general meeting authorises the board to resolve - at one or several occasions and for the time period until the next annual general meeting - to increase the company's share capital by new share issues  to the extent that it corresponds to a dilution of not more than 20 percent of the number of shares outstanding at the time of the notice of the annual general meeting  after full exercise of the hereby proposed authorisation. New share issues may be made with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind  set-off or other conditions. Pursuant to Chapter 16 of the Swedish Companies Act  the board of directors may not by virtue of this authorisation resolve on issues to board members in group companies  employees  etc. The purpose of the authorisation is to increase the financial flexibility of the company and the acting scope of the board. Should the board of directors resolve on an issue with deviation from the shareholder's preferential rights  the reason shall be to enable the company to finance the operations in a fast and efficient way  acquire companies  businesses or parts thereof and to enable a broadening of the ownership of the company. Upon such deviation from the shareholders' preferential rights  the new issue shall be made at market terms and conditions. The board of directors or the CEO shall have the right to make such minor adjustments in this resolution that may be necessary in connection with the registration of the authorisation with the Swedish Companies Registration Office. The board of directors' proposal on amendments to the articles of association (item 18) The board of directors proposes that the annual general meeting resolve on the adaption of new articles of association. The proposed amendments are as follows: 4 ¬ß Share capital Current wording: The share capital shall be not less than SEK 20 000 000 and not more than SEK 80 000 000 . Proposed wording: The share capital shall be not less than SEK 55 000 000 and not more than SEK 220 000 000 . 5 ¬ß Number of shares Current wording: The number of shares shall be not less than 40 000 000 and not more than 160 000 000. Proposed wording: The number of shares shall be not less than 110 000 000 and not more than 440 000 000 The board of directors' proposal to resolve on a long-term incentive program for the executive management in the form of warrants (item 19) The board of directors proposes that the annual general meeting resolves to issue not more than 750 000 warrants within the scope of a long-term incentive program to the CEO and the other members of the executive management in Azelio  in total six persons. The incentive program entails that the CEO is offered to subscribe for not more than 250 000 warrants  and the other participants are each offered to subscribe for not more than 100 000 warrants  at market value calculated according to the Black & Scholes valuation formula. Subscription of the warrants shall be made within four weeks from the date of the resolution to issue warrants. Payment for the subscribed warrants shall be made within four weeks after subscription. The board of directors is entitled to extend the subscription period and time of payment. Each warrant entitles the holder to subscribe for one new ordinary share in Azelio for an exercise price of SEK 50 . Subscription of shares can be done during two periods  both during two weeks from the day of publication of the interim report for the period 1 January - 31 March 2025 as well as during two weeks from the day of publication of the interim report for the period 1 January - 30 June 2025 . The price per warrant upon transfer to the participants shall be established by the company  or by an independent appraiser or auditor firm retained by the company  and correspond to the market value of the warrant calculated in accordance with the Black & Scholes valuation formula. The complete terms and conditions for the warrants have been resolved by the board of directors and are available to the shareholders in accordance with the below. Scope and costs for the program  including subsidy by the company and effect on important key ratios and dilution Azelio shall partly subsidize the option premium to be paid by the participants for the subscription of warrants  in order to facilitate and promote a personal long-term interest in Azelio for senior executives. The subsidy shall  for the majority of participants  correspond to 50 percent of the option premium  post tax in the form of an additional cash payment. For two participants  the CEO and one other member of the executive management  the subsidy correspond to 75 percent of the option premium  post tax in the form of an additional cash payment. The company's cost for the subsidy (including social security contributions in relation hereto) is estimated to amount to approximately SEK 650 000   in total  based on a price of the company's shares of SEK 12 . Other than the above  the costs for the program include certain limited costs for administration of the program. The total cost  including the cost for the subsidy  for Azelio for the warrant program is estimated to amount to approximately SEK 750 000 during the term of the incentive program. According to a preliminary valuation  the market value of the warrants will correspond to approximately SEK 0.47 per warrant (assuming a price of the company's shares of SEK 12 per share) based on the Black & Scholes valuation formulae. In addition to this  the costs for the program have been estimated on the basis that all participants subscribe for their maximum allotment as set out above. The costs are expected to have a limited effect on Azelio's key ratios. Upon maximum allotment of warrants  not more than 750 000 shares will be allotted to participants under the incentive program  meaning a dilution effect of approximately 0.7 percent of the number of shares and votes in the company (based on the total number of shares in the company at the date of this notice). The board of directors considers the positive effects expected to result from the incentive program to outweigh the costs attributable to the program. The rationale for the incentive program The rationale for the incentive program is to retain a competent executive management team in the company by offering the members a long-term ownership commitment in the company and thereby the opportunity to participate in and promote a positive value development of the company's shares and to increase the member's sense of association with the company and its other shareholders. The board of directors considers that the implementation of the incentive program as described above is in the favour of the group and the shareholders in the company. Preparation of the proposal The incentive program has been prepared by the board of directors together with advisors. Other incentive programs For a description of Azelio's other share-related incentive programs  reference is made to the annual report 2021  note 25. The shareholders' resolution proposal The principal shareholder's proposal to resolve on a long-term incentive program for the board of directors in the form of warrants (item 20) The principal shareholder  Blue Marlin AB (the ""Principal Shareholder"")  proposes that the annual general meeting resolves to issue not more than 350 000 warrants within the scope of a long-term incentive program to all members of the board of directors in Azelio  save for Kent Jan√©r  in total a maximum of six persons. The incentive program entails that the chairman of the board of directors is offered to subscribe for not more than 100 000 warrants and the five other participating members of the board of directors are each offered to subscribe for not more than 50 000 warrants  at market value calculated according to the Black & Scholes valuation formula. Subscription of the warrants shall be made within four weeks from the date of the resolution to issue warrants. Payment for the subscribed warrants shall be made within four weeks after subscription. Each warrant entitles the holder to subscribe for one new ordinary share in Azelio for an exercise price of SEK 70 . Subscription of shares can be done during two periods  both during two weeks from the day of publication of the interim report for the period 1 January - 31 March 2026 as well as during two weeks from the day of publication of the interim report for the period 1 January - 30 June 2026 . The price per warrant upon transfer to the participants shall be established by the Principal Shareholder  or by an independent appraiser or auditor firm retained by the Principal Shareholder  and correspond to the market value of the warrant calculated in accordance with the Black & Scholes valuation formula. The complete terms and conditions for the warrants are available to the shareholders in accordance with the below. Scope and costs for the program  including subsidy by the company and effect on important key ratios and dilution As the offering of warrants to the members of the board of directors is based on market value the costs for the program are limited to costs for administration of the program. The total cost for Azelio for the warrant program is estimated not to exceed SEK 50 000 during the term of the incentive program. The costs are expected to have a limited effect on Azelio's key ratios. Upon maximum allotment of warrants  not more than 350 000 shares will be allotted to participants under the incentive program  meaning a dilution effect of approximately 0.3 percent of the number of shares and votes in the company (based on the total number of shares in the company at the date of this notice). The Principal Shareholder considers the positive effects expected to result from the incentive program to outweigh the costs attributable to the program. The rationale for the incentive program The rationale for the incentive program is to retain a competent board of directors in the company by offering the board members a long-term ownership commitment in the company and thereby the opportunity to participate in and promote a positive value development of the company's shares and to increase the board members' sense of association with the company. The Principal Shareholder considers that the implementation of the incentive program as described above is in the favour of the group and the shareholders in the company. Preparation of the proposal The incentive program has been prepared by the Principal Shareholder. Other incentive programs For a description of Azelio's other share-related incentive programs  reference is made to the annual report 2021  note 25. Majority requirements Resolution in accordance with item 17 and 18 above require approval of at least two thirds (2/3) of the shares represented and votes cast at the annual general meeting. Resolution in accordance with item 19 and 20 above requires approval of at least nine tenths (9/10) of the shares represented and votes cast at the annual general meeting. Miscellaneous The annual report and the auditor's report as well as documents related to the annual general meeting will be available at the address of the company and on the company webpage www.azelio.com  no later than three weeks prior to the general meeting. Copies of the documents will be sent to the shareholders who so request and who inform the company of their postal address. _____________ For information on how your personal data is processed  see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdf. _____________ Gothenburg in April 2022 Azelio AB (publ) The board of directors https://news.cision.com/azelio/r/notice-to-annual-general-meeting-in-azelio-ab--publ- c3543991 https://mb.cision.com/Main/16031/3543991/1562886.pdf (c) 2022 Cision. All rights reserved.  source Press Releases - English All news about AZELIO AB (PUBL) 09:21a Notice to annual general meeting in Azelio AB (publ) AQ 03/30 Swedish Renewable Energy Firm Azelio Appoints New CEO MT 03/30 Jonas Wallmander appointed as new CEO of Azelio AQ 03/30 Azelio AB Announces CEO Changes CI 03/28 Azelio to install U.S. certification project for its Long-Duration Energy Storage Produ.. AQ 03/28 Azelio AB to Install U.S. Certification Project for its Long-Duration Energy Storage Pr.. CI 02/25 AZELIO : Year-end report 2021 AQ 02/25 Azelio AB Reports Earnings Results for the Fourth Quarter Ended December 31  2021 CI 02/25 Azelio AB Reports Earnings Results for the Full Year Ended December 31  2021 CI 2021 Azelio's Energy Storage System TES.POD is Validated by DNV CI",neutral,0.01,0.97,0.02,negative,0.01,0.03,0.96,True,English,"['annual general meeting', 'Azelio AB', 'Notice', 'multiple email addresses', 'second banking day', 'consolidated financial statements', 'temporary statutory rules', 'continued general meeting', 'annual general meeting', 'consolidated income statement', 'consolidated balance sheet', 'voting right registration', 'Swedish Companies Act', 'Euroclear Sweden AB', 'advance voting form', 'annual report', 'general meetings', 'Such registration', 'temporary exceptions', 'voting rights', 'postal voting', 'voting list', 'physical presence', 'third parties', '34 √Öm√•l', 'same period', 'securities institution', 'other associations', 'legal entity', 'corresponding document', 'two persons', ""auditors' report"", 'special form', 'advance vote', 'one tenth', 'special instructions', 'Further instructions', 'Azelio AB', 'one vote', 'First name', ""shareholders' register"", 'Wednesday 11 May', 'agenda Election', '12 May', '7 May', '4 May', 'Notice', 'commas', 'Message', 'fields', 'publ', 'registered', 'office', 'Gothenburg', 'basis', 'board', 'directors', 'proxies', 'procedure', 'Information', 'resolutions', 'result', 'matters', 'way', 'place', 'shares', 'company', 'Chapter', 'Section', 'request', 'writing', 'Forsbrogatan', 'time', 'Notification', 'participation', 'accordance', 'heading', 'nominee', 'names', 'account', 'execution', 'website', 'proxy', 'power', 'attorney', 'certificate', 'incorporation', 'conditions', 'entirety', 'questions', 'Number', 'votes', 'total', 'chairman', 'minutes', 'Preparation', 'approval', 'Determination', 'Submission', 'group', 'adoption']",2022-04-11,2022-04-11,marketscreener.com
2636,Euroclear,Bing API,https://menafn.com/1103992214/Notice-of-Annual-General-Meeting-in-Eolus-Vind-AB-publ,Notice of Annual General Meeting in Eolus Vind AB (publ),A) Anyone wishing to attend the meeting room in person or through a representative must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB  made as of May 11 ...,(MENAFN- GlobeNewsWire - Nasdaq) English SwedishH√§ssleholm  Sweden  April 11th  2022The shareholders of Eolus Vind AB (publ) Reg. No. 556389-3956 are hereby invited to attend the Annual General Meeting (‚Äú AGM ‚Äù) to be held on May 19  2022 at 2 p.m. CEST in Kulturhuset in H√§ssleholm  Vattugatan 18. Registration for the AGM begins at 1.30 p.m. CEST.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the regulations in Eolus' Articles of Association.Right to participateParticipation in the meeting roomA) Anyone wishing to attend the meeting room in person or through a representative must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB  made as of May 11  2022  and no later than May 13  2022 preferably before 4 p.m. CEST  notify the company of their intention to participate in the AGM.Registration to attend the AGM should primarily be made via the company's websiteRegistration to attend can also be made in writing under the address Eolus Vind AB‚ÄùAnnual General Meeting‚Äù  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden or by phone  08-402 90 41. When registering  the shareholder must state name  social security- or company registration number  address  telephone number and the number of possible assistants (maximum two).If shareholders are represented by a proxy  a written and dated power of attorney signed by the shareholder must be issued to the proxy. Proxy form is available on the company's website . A power of attorney is valid one year from its issue date or such longer time period as set out in the power of attorney  however not more than five years. If the shareholder is a legal person  a registration certificate or other authorization document must be attached to the form  listing the authorized signatories. In order to facilitate the registration process at the AGM  a proxy together with registration certificate and any other authorization documents shall be received by the company at the above address at 4 p.m. CEST on May 13  2022  at the latest. If a proxy and other authorization documents have not been submitted in advance of the AGM  a proxy and other authorization documents shall be presented at the AGM.Participation by postal votingB) Anyone wishing to attend the meeting by postal voting must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB  made as of May 11  2022  and no later than May 13  2022 notify the company by casting their postal vote in accordance with the instructions below  so that the postal vote is received by Euroclear Sweden AB no later than that day.Anyone who wishes to attend the meeting room in person or through a representative  must give notice in accordance with the instructions stated under A) above. Hence  a notice through postal voting only is not sufficient for those who wishes to attend the meeting room.A special form must be used for postal voting. The form is available on the company's website . The completed and signed form may be sent by mail to Eolus Vind AB  'Annual General Meeting'  c/o Euroclear Sweden AB  P.O. Box 191  SE-101 23 Stockholm  Sweden or by email to . The completed form must be received by Euroclear Sweden AB no later than May 13  2022. Shareholders may also cast their votes electronically by verifying with BankID via Euroclear Sweden AB's website .Shareholders may not provide special instructions or conditions to the postal vote. If so  the entire postal vote is invalid. Further instructions and conditions can be found in the postal voting form.If the shareholder submits its postal vote by proxy  a written and dated power of attorney signed by the shareholder must be attached to the postal voting form. Proxy form is available on the company's website . A power of attorney is valid one year from its issue date or such longer time period as set out in the power of attorney  however not more than five years. If the shareholder is a legal person  a registration certificate or other authorization document must be attached to the form  listing the authorized signatories.Nominee-registered sharesIn order to be entitled to participate in the AGM  a shareholder whose shares are registered in the name of a nominee must  in addition to giving notice of participation in the AGM  register its shares in its own name so that the shareholder is listed in the presentation of the share register as of May 11  2022. Such registration may be temporary (so-called voting rights registration)  and request for such voting rights registration shall be made to the nominee  in accordance with the nominee's routines  at such a time in advance as decided by the nominee. Voting rights registrations that have been made by the nominee no later than May 13  2022 will be taken into account in the presentation of the share register.Proposed agendaOpening of the meetingElection of chairman of the meetingElection of two persons to check the minutesPreparation and approval of the voting listApproval of the agendaDetermination of compliance with the rules of convocationPresentation ofthe annual report and the auditor's report and the consolidated financial statements and the auditor's report for the Groupthe statement by the auditor on the compliance of the guidelines for remuneration to senior executivesthe Board of Directors' proposal on appropriation of the company's profit and reasoned statement thereonResolutions regardingadoption of the statement of income and the balance sheet and the consolidated statement of income and the consolidated balance sheetappropriation of the company's profit according to the adopted balance sheetdischarge of the Board of Directors and the CEO from liability for the financial year 2021Determination of the number of Board members  deputy Board members  auditors and deputy auditorsDetermination of fees to Board members and auditorElection of Board members and Chairman of the BoardThe Nomination Committee's proposal:Sigrun HjelmquistHans JohanssonJan JohanssonHans LinnarsonBodil Rosvall J√∂nssonHans-G√∂ran StennertHans-G√∂ran Stennert  as Chairman of the BoardElection of auditorResolution on approval of remuneration reportResolution on the implementation of a long-term share savings programClosing of the meetingProposed resolutionsElection of chairman of the meeting (item 2)The Nomination Committee for the AGM 2022 has consisted of the chairman Hans Gydell (appointed by Hans-G√∂ran Stennert)  Ingvar Svantesson (appointed by Domne√•ns Kraftaktiebolag)  Hans Johansson (appointed by √Öke Johansson) and the Chairman of the Board  Hans-G√∂ran Stennert.The Nomination Committe has proposed that Eolus' General Counsel  Karl Olsson  shall be elected chairman of the AGM 2022.Dividend (item 8b)The Board of Directors proposes that a dividend of SEK 1.50 per share is declared for the financial year 2021. As record date for the dividend  the Board of Directors proposes May 23  2022. If the AGM resolves in accordance with the proposal  the dividend is expected to be distributed by Euroclear Sweden AB starting May 27  2022.Election of Board members  Chairman of the Board and auditor  and determination of fees(items 9-12)The Nomination Committee proposes that the AGM resolves as follows:that the Board of Directors shall consist of six members  with no deputy members;that one Auditor shall be appointed  with no deputy Auditor;that  fees to the Board members shall be SEK 450 000 to the Chairman of the Board and SEK 225 000 each to other Board members who are not employed by the company  fees for work in the Audit Committee shall be paid in the amount of SEK 60 000 to the Chairman of the Audit Committee and in the amount of SEK 30 000 to other members who are not employed by the company  and fees for work in the Remuneration Committee shall be paid in the amount of SEK 15 000 to members who are not employed by the company;that the Auditor's fee is to be paid according to agreement;that Board members Sigrun Hjelmquist  Hans Johansson  Jan Johansson  Hans Linnarson  Bodil Rosvall J√∂nsson and Hans-G√∂ran Stennert are re-elected;that Hans-G√∂ran Stennert is re-elected as Chairman of the Board;that  in accordance with the recommendation of the Audit Committee  the accounting firm PricewaterhouseCoopers AB is elected as auditor; PricewaterhouseCoopers AB has informed that the authorized public accountant Vicky Johansson will be appointed as auditor in charge should the AGM resolve in accordance with the Nomination Committee's proposal.Resolution on approval of remuneration report (item 13)The Board of Directors proposes that the AGM resolves to approve the Board of Directors' report regarding compensation pursuant to Chapter 8  Section 53 a of the Swedish Companies Act.Resolution on the implementation of a long-term share savings program (item 14)The Board of Directors of Eolus Vind AB (publ) proposes that the AGM 2022 resolves on a long-term share savings program for the company's employees (the‚Äú Share Savings Program 2022 ‚Äù).The Share Savings Program 2022 entails that all employees within Eolus can choose to use an amount corresponding to a maximum of one month's salary of their potential variable cash remuneration relating to the financial year 2022 to acquire shares in Eolus (‚Äù Savings Shares ‚Äù). Acquisition of Savings Shares shall be made through the company on Nasdaq Stockholm within twenty trading days from when the outcome of the variable cash remuneration program has been established and the participants have informed Eolus whether they want to participate in the Share Savings Program.Provided that the participant still holds all of the Savings Shares and is still employed within the Eolus group three years after the acquisition of Savings Shares  Eolus will remunerate the participant with an amount corresponding to the cost for acquiring the number of Eolus shares corresponding to half of the number of Savings Shares (‚Äú Matching Shares ‚Äù). Acquisition of Matching Shares shall be made through the company on Nasdaq Stockholm within twenty trading days from the date falling three years after the acquisition of Savings Shares.In order to ensure that the participant's financial situation as far as possible shall remain unchanged  the number of Matching Shares shall be subject to customary recalculation should the company's share capital increase or decrease  convertible debt instruments or options be issued or the company be liquidated or merged  or any similar changes to the company occur.Should the participant be prohibited from acquiring Savings Shares due to possession of inside information  the Board of Directors may in individual cases prolong or postpone the above mentioned investment period  although not beyond the next AGM. The Board of Directors shall be responsible for the detailed conditions and the administration of the Share Savings Program 2022 within the terms and conditions set forth above  and may also make such minor adjustments and applications as may be appropriate for legal or administrative reasons.Based on the assumptions of maximum outcome in the variable cash remuneration program  full investments by the entitled participants and an unchanged share price at the time of delivery of the Matching Shares  Eolus' costs relating to the Share Savings Program 2022 are estimated to amount to a maximum of SEK 2 2 million. Assuming a 25 per cent increase in Eolus' share price at the time of delivery of Matching Shares  Eolus' costs relating to the Share Savings Program 2022  including employer contributions  are estimated to amount to a maximum of SEK 2 8 million and assuming a 50 per cent increase in the share price at such time  the costs are estimated to amount to a maximum of SEK 3 3 million  including employer contributions. The Share Savings Program 2022 does not result in any dilution of the holdings of the company's shareholders and is not deemed to affect any performance measure important for Eolus. No measures have been taken to hedge Eolus' costs against its own share price in connection with the purchase of Matching shares.The proposal on Share Savings Program 2022 has been prepared by the Board of Directors and the Remuneration Committee. In the company  similar share savings programs for the financial years 2021  2019/2020 and 2018/2019 relating to the variable cash remuneration have previously been adopted. By requiring  as described above  that the participants make an own investment in Eolus shares and thereby reconciling the employees' and the shareholders' interests of a long-term increase of the company's value  the Share Savings Program 2022 is expected to enhance Eolus' possibilities to recruit and retain competent employees while at the same time promoting Eolus' business strategy  long-term interests and sustainability.The proposal must be supported by shareholders representing more than half of the votes cast at the general meeting.Available documentationThe following documentation will be held available at the company and on the company's website at least three weeks ahead of the AGM. The documentation will also be sent  without any cost for the recipients  to shareholders who so request and provide their address or e-mail address: (i) the accounting material and the auditor's report  (ii)  the statement by the auditor on the compliance of the resolved guidelines for remuneration to senior executives  (iii) remuneration report  (iv) the complete proposal of the Board of Directors with respect to appropriation of profit and the Board of Directors' motivated statement thereon  and (v) the complete proposal of the Board of Directors with respect to the long-term share savings program.Number of shares and votes in the companyAt the time of issue of this convening notice  the total number of shares in the company amounts to 24 907 000  of which 1 285 625 shares are Class A shares and 23 621 375 shares are Class B shares. The total number of votes in the company amounts to 3 647 762.5.Information at the AGMThe Board of Directors and the CEO shall  if any shareholder so request and if the Board of Directors considers that this can be done without significant harm for the company or its subsidiaries  give information on circumstances that can affect the assessment of an item on the agenda  circumstances that can affect the assessment of the financial situation of the company or its subsidiaries and the company's relationship with another group company (including the consolidated financial statements).Processing of personal dataFor information about the processing of your personal data  see .H√§ssleholm in April 2022Eolus Vind AB (publ)The Board of DirectorsFor further information contact:Per Witalisson  CEO  +46 70-265 16 15Johan Hammarqvist  Head of Communications  +46 720 50 59 11About Eolus:Eolus Vind AB is one of the leading wind power developers in the Nordics. Eolus is active in the whole value chain from development of green field projects to construction and operation of wind farms. Eolus offers attractive and competitive investments in the Nordic and Baltic countries  Poland as well as the United States to both local and international investors. Founded in 1990  Eolus has constructed 666 wind turbines with a capacity of 1 414 MW. Eolus has signed contracts for about 1 320 MW of asset management services of which 914 MW are in operation and the rest under construction.Eolus Vind AB has 34 500 shareholders. Eolus shares are listed at Nasdaq Stockholm.For more information about Eolus  please visitAttachment220411 Press release Notice of Annual General Meeting in Eolus Vind AB (publ)Tags eolus annual general meeting renewables wind power energy storage solar power Eolus √•rsst√§mma f√∂rnybart Vindkraft energilagring solkraft Attachments 220411 Press release Notice of Annual General Meeting in Eolus Vind AB (publ)...,neutral,0.02,0.96,0.02,negative,0.0,0.05,0.95,True,English,"['Annual General Meeting', 'Eolus Vind AB', 'Notice', 'P.O. Box', 'other authorization document', 'Eolus Vind AB', 'Euroclear Sweden AB', 'longer time period', 'Voting rights registrations', 'Annual General Meeting', 'entire postal vote', 'postal voting form', 'company registration number', ""Eolus' Articles"", 'MENAFN- GlobeNewsWire', 'English Swedish', 'H√§ssleholm', 'Reg. No.', 'meeting room', 'share register', 'telephone number', 'possible assistants', 'issue date', 'five years', 'authorized signatories', 'two persons', 'registration certificate', 'registration process', 'special form', 'completed form', 'legal person', 'special instructions', 'Further instructions', 'state name', 'dated power', 'above address', 'Nominee-registered shares', 'Proxy form', 'Nasdaq', 'April', 'shareholders', 'AGM', 'May', 'CEST', 'Kulturhuset', 'Vattugatan', 'Board', 'Directors', 'accordance', 'regulations', 'Association', 'Participation', 'Anyone', 'representative', 'intention', 'website', 'writing', 'Stockholm', 'written', 'attorney', 'order', 'advance', 'day', 'notice', 'mail', 'votes', 'BankID', 'conditions', 'addition', 'presentation', 'request', 'routines', 'account', 'agenda', 'Opening', 'Election', 'chairman', 'minutes', 'Preparation', 'approva', '2', '1.30', '4', '101']",2022-04-11,2022-04-11,menafn.com
2637,Euroclear,Bing API,https://www.natlawreview.com/article/russian-sanctions-how-will-they-impact-credit-default-swaps,Russian Sanctions: How Will They Impact Credit Default Swaps?,Economic sanctions against Russia as a result of the invasion of Ukraine have had a broad impact on the global economy and have raised the question of whether Russia will be able to meet its obligatio,Monday  April 11  2022Economic sanctions against Russia as a result of the invasion of Ukraine have had a broad impact on the global economy and have raised the question of whether Russia will be able to meet its obligations on foreign denominated bonds. If Russia defaults on its bonds  credit default swaps meant to protect investors from a Russian default may not work as planned because of these sanctions.At the end of last year  Russia had $40 billion in foreign currency sovereign debt  half of which is owed to foreign investors. While U.S. sanctions allow for Russia to continue to make debt payments at least through the end of May 2022  Russian restrictions on allowing foreign exchange transactions could force a default on bonds that do not allow for payment in Rubles. On Monday  April 4  2022  the U.S. Treasury restricted U.S. banks from processing payments on Russian bonds  increasing the risk of a default.Credit default swaps are meant to help investors receive near full recovery in the event of a default on the underlying debt. Payments under credit default swaps are owed to the purchaser of the credit default swap when a ‚ÄúCredit Event‚Äù has occurred. Credit Events include: a failure to make a payment under the debt (following any applicable grace period)  insolvency of the issuer  debt restructuring and repudiation of the debt. There are approximately $4.5 billion in credit default swaps tied to Russian government debt and another $1.5 billion in derivative indices  according to JPMorgan.Escalating western sanctions against Russia have raised questions about whether Russia will be able to meet its obligations under its sovereign debt  whether credit default swaps will be triggered if Russia does not meet the terms of its obligations and whether sanctions will interfere with the settlement of credit default swaps if a Credit Event is triggered.Will credit default swaps be triggered if Russia does not meet the terms of its obligations?Russia‚Äôs decision in March to pay some of its foreign debtors in Rubles could have triggered a Credit Event. ISDA‚Äôs Credit Derivatives Determinations Committee (the ‚ÄúDC‚Äù) applies the terms of market-standard credit derivatives to specific cases  and makes a factual determination as to whether a Credit Event or other events under a credit default swap have occurred and other issues. The DC determined that payment of obligations in Rubles  when not the original currency of denomination of the debt  would not constitute a Credit Event where the underlying debt allows for payment in Rubles. However  certain of Russia‚Äôs bonds do not provide for payment in Rubles. A failure by Russia to make a payment under the terms of the bonds (whether by failing to make a payment entirely  or by making a payment in Rubles when not permitted under the terms of the debt) would most likely constitute a Credit Event  triggering credit default swaps referencing Russian debt.For the time being  Russia has avoided defaulting on its foreign currency debt  making $732 million in coupon payments on US Dollar denominated bonds in the month of March 2022. Russia owed approximately $2 billion on a bond that came due on Monday  April 4  2022  and owes another $84 million in interest payments on a second bond. The recent U.S. Treasury restrictions on U.S. banks processing Russian government debt effectively blocked the payment on both bonds. A failure by the Russian government to find another way to make the payments within the thirty day grace period provided for in the bonds would likely constitute a default under the bonds and trigger a Credit Event under credit default swaps referencing Russian sovereign debt.What debt will be ‚Äúdeliverable‚Äù under credit default swaps?The settlement of a credit default swap requires the delivery (for physical settlement) or pricing (for cash settlement) of debt that meets certain characteristics  including Not Domestic Currency (i.e.  payable in a currency other than the Ruble)  Not Domestic Law (i.e.  governed by non-Russian law) and Not Domestic Issuance (i.e.  not issued primarily in the Russian market). Additionally  the obligation must be payable in a G-7 currency and transferable to institutional investors without contractual or regulatory restrictions. The DC has determined that non-Ruble denominated debt that allows for payment in Rubles will not meet the Not Domestic Currency test and therefore will not be ‚Äúdeliverable‚Äù for settlement under credit default swaps. Similarly  if the Russian government decides to make a payment in Rubles under G-7 denominated debt  such debt may no longer be considered ‚Äúdeliverable‚Äù. Additionally  on March 25  2022  ISDA published ‚ÄúAdditional Provisions for Certain Russian Entities: Excluded Obligations and Excluded Deliverable Obligations‚Äù (the ‚ÄúProtocol‚Äù) which contains new terms that can be added to existing or new credit derivatives transactions. The new terms in the Protocol provide that a default under certain Russian sovereign debt (‚ÄúRestricted Debt‚Äù) will not trigger a Credit Event under credit default swap transactions and exclude such debt from the definition of ‚Äúdeliverable‚Äù obligations. In an FAQ released in conjunction with the publication of the Protocol  ISDA noted that it would be impractical to hold a settlement auction referencing Restricted Debt.Will sanctions interfere with the settlement of credit default swaps?Sanctions could prevent certain bonds from being delivered in the event a credit default swap is triggered and/or misalign the pricing mechanism for settlement of credit default swaps. The expected recovery under credit default swaps is usually determined using an auction process based on bonds that are ‚Äúdeliverable‚Äù under the terms of the credit default swaps. The auction process relies on the existence of a secondary trading market for the debt. Russia has blocked offshore settlement of bonds through Euroclear which would make certain bonds  which by their terms are to settle in Russia  untradeable. Further sanctions could also impact whether other Russian bonds are tradeable and eligible to be delivered under credit default swap contracts. If fewer bonds are deemed ‚Äúdeliverable‚Äù under the terms of the credit default swap  the auction price is likely to be higher (as more parties bid on fewer bonds)  leading to a lower recovery for credit default swap buyers and a possible loss on the bonds that the purchase of the credit default swaps was meant to avert. One solution would be to circumvent the auction process entirely  leaving parties to the credit default swaps to agree to a cash price to close out the swap. This could potentially result in different recoveries for different market participants.Credit default swap buyers should carefully review the terms of their contracts to determine whether they will be required to physically deliver the underlying debt to receive the expected payout under the terms of their credit default swap contracts and determine whether they will be able to deliver the debt.,negative,0.02,0.45,0.54,negative,0.01,0.17,0.82,True,English,"['Credit Default Swaps', 'Russian Sanctions', 'recent U.S. Treasury restrictions', 'thirty day grace period', 'Credit Derivatives Determinations Committee', 'US Dollar denominated bonds', 'new credit derivatives transactions', 'credit default swap transactions', 'foreign currency sovereign debt', 'applicable grace period', 'U.S. banks', 'foreign exchange transactions', 'market-standard credit derivatives', 'U.S. sanctions', 'Certain Russian Entities', 'credit default swaps', 'Domestic Currency test', 'Escalating western sanctions', 'G-7 denominated debt', 'foreign denominated bonds', 'foreign currency debt', 'Russian sovereign debt', 'Ruble denominated debt', 'Russian government debt', 'Excluded Deliverable Obligations', 'Not Domestic Currency', 'Russian restrictions', 'G-7 currency', 'regulatory restrictions', 'Russian default', 'foreign debtors', 'Credit Events', 'original currency', 'Domestic Law', 'Domestic Issuance', 'Russian debt', 'Russian law', 'Russian market', 'foreign investors', 'underlying debt', 'debt restructuring', 'Restricted Debt', 'Economic sanctions', 'broad impact', 'global economy', 'last year', 'full recovery', 'derivative indices', 'specific cases', 'factual determination', 'other events', 'other issues', 'Additional Provisions', 'Russian bonds', 'new terms', 'Excluded Obligations', 'The DC', 'debt payments', 'coupon payments', 'interest payments', 'second bond', 'institutional investors', 'physical settlement', 'cash settlement', 'Monday', 'April', 'result', 'invasion', 'Ukraine', 'question', 'end', 'half', 'May', 'Rubles', 'processing', 'risk', 'purchaser', 'failure', 'insolvency', 'issuer', 'repudiation', 'JPMorgan', 'decision', 'March', 'ISDA', 'denomination', 'time', 'month', 'way', 'delivery', 'pricing', 'characteristics', 'contractual', 'Protocol', 'existing']",2022-04-11,2022-04-11,natlawreview.com
2638,Euroclear,Bing API,https://www.finanznachrichten.de/nachrichten-2022-04/55752382-irlab-therapeutics-notice-to-attend-the-annual-general-meeting-of-shareholders-200.htm,IRLAB Therapeutics: Notice To Attend The Annual General Meeting Of Shareholders,"GOTHENBURG  SWEDEN / ACCESSWIRE / April 11  2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)The shareholders of IRLAB Therapeutics AB  company registration no. 556931-4692 (""IRLAB"" or the ""Company"")","GOTHENBURG  SWEDEN / ACCESSWIRE / April 11  2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)The shareholders of IRLAB Therapeutics AB  company registration no. 556931-4692 (""IRLAB"" or the ""Company"")  are hereby given notice to attend the Annual General Meeting to be held on Wednesday 11 May 2022 at 5.00 PM at the Wallenberg Conference Center  Medicinaregatan 20 A  Gothenburg. Registration for the Annual General Meeting will start at 3.30 PM.The board of IRLAB has in accordance with the temporary rules decided to allow shareholders who do not wish to be physically present at the Annual General Meeting to instead vote by advance voting (Sw. postr√∂stning).Right to participate and notice of intention to participateIn order to have the right to participate at the Annual General Meeting a shareholder must:be entered in the share register maintained by Euroclear Sweden AB as per 3 May 2022  andgive notice of its intention to participate by mail to Computershare AB  ""IRLAB Therapeutics AB √Örsst√§mma""  P.O. Box 5267  102 46 Stockholm  or by telephone +46 771 24 64 00  or by e-mail to proxy@computershare.se or at the Company's website (www.irlab.se)  no later than 5 May 2022.The notice of intention to participate shall state the complete name  personal identity number or corporate registration number  number of shares held  daytime telephone number as well as information of the number of advisors accompanying the shareholder (maximum two advisors).Notice for a legal entity shall be made in accordance with the instructions above.How advance voting worksA specific form is used for advance voting.Shareholders must use the form and follow the instructions which will be available on the Company's website  www.irlab.se  and at the Company's premises at Arvid Wallgrens backe 20  413 46 Gothenburg. The completed and signed form for advance voting must be sent by mail to Computershare AB  ""Irlab √•rsst√§mma""  P.O. Box 5267  102 46 Stockholm. The completed form must be received by Computershare AB no later than 5 May 2022. The completed and signed form may also be submitted electronically and must then be sent to proxy@computershare.se. Shareholders can also cast a postal vote electronically with BankID via the Company's website  www.irlab.se. If shareholders cast advance votes through a proxy  a power of attorney must be attached to the form. If the shareholder is a legal entity  a registration certificate or other authorization document must be attached to the power of attorney. Anyone wishing to revoke advance voting and instead exercise their right to vote by attending the meeting physically or by proxy must notify the secretariat of the meeting before the meeting opens.Complete instructions for shareholders who wish to exercise their voting by advance voting can be found in form for advance voting.Nominee registered sharesTo be entitled to participate at the Annual General Meeting  shareholders who have had their shares registered with a nominee  must request that they be temporarily re-registered in their own name. Shareholders who wish to carry out such re-registration  so called registration for voting rights (Sw. r√∂str√§ttsregistrering)  should notify the nominee in due time before 3 May 2022. The re-registration must be executed with Euroclear Sweden AB no later than 5 May 2022.ProxyIf shareholder is to be represented by a proxy  the proxy must have a written  dated  and signed by the shareholder power of attorney to the Annual General Meeting. The power of attorney may not be older than one year  unless a longer period of validity (however  a maximum of five years) has been stated in the power of attorney. If the power of the attorney has been issued by a legal entity  the proxy must also have relevant certificate of registration or equivalent authorization document for the legal entity. To facilitate the registration at the Annual General Meeting  a copy of the power of attorney and other authorization documents should be attached to the notification to the Annul General Meeting. Power of attorney forms are available on the Company's website (www.irlab.se) and are sent by mail to shareholders who contact the Company and state their address.BusinessProposed agenda1) Opening of the meeting;2) Election of chairman of the meeting;3) Preparation and approval of the voting register;4) Resolution to allow broadcast of the Annual General Meeting over the internet;5) Election of one or two persons to verify the minutes;6) Determination of whether the Annual General Meeting has been duly convened;7) Approval of the agenda;8) Presentation of the annual report and the auditor's report for the Company and the group;9) Resolution regarding adoption of the income statement and balance sheet for the Company and the group;10) Resolution regarding allocation of the Company's results according to the adopted balance sheet;11) Resolution regarding discharge from liability for the directors and the CEO;i) Gunnar Olssonii) Carole Lemneiii) Lars Adlerssoniv) Rein Piirv) Martin Nicklassonvi) Lena Torleg√•rdvii) Nicholas Waters12) Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditors;13) Resolution regarding determination of the fees payable to the directors and the auditors;14) Election of the Board of Directors;The nominations committee's proposal:i) Gunnar Olssonii) Carole Lemneiii) Rein Piiriv) An van Es-Johanssonv) Catharina Gustafsson Wallich15) Election of auditor and deputy auditors  if any;16) Resolution regarding principles for the nomination committee;17) Resolution regarding presentation and approval of the Board of Directors' report of paid and outstanding remuneration to senior management (remuneration report);18) Resolution regarding salary and other compensation to senior management:19) Resolution regarding adoption of new articles of association;20) Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;21) Resolution regarding adjustment authorization;22) Closing of the meeting.Nomination committeeIn accordance with the Annual General Meeting's principles adopted last year  the nomination committee is composed of one representative each from the three largest shareholders as per the last banking day of August 2021  as well as the chairman of the Company's Board of Directors. The nomination committee consists of Daniel Johnsson (appointed by one of the shareholders group representing approximately 21 percent of shares and votes)  Bo Rydlinger (appointed by one of the shareholder groups representing approximately 15 percent of shares and votes)  Clas Sonesson (appointed by one of the shareholder groups representing approximately 10 percent of shares and votes) and Gunnar Olsson  the chairman of the Board of Directors. Daniel Johnsson has served as the chairman of the nomination committee.Proposed resolutions by the nomination committee2. Election of chairman of the meetingThe nomination committee proposes advokat Dag Fredlund or  in the event of an impediment  the person appointed by the nomination committee  to be elected as the chairman of the Annual General Meeting.12. Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditorsThe nomination committee proposes that the number of directors for the period until the next Annual General Meeting shall be five and that one auditor and no deputy auditor shall be appointed for the same period.13. Resolution regarding determination of the fees payable to the directors and the auditorsThe nomination committee proposes that the fee per director elected by the Annual General Meeting shall be distributed as follows (last year's figures in brackets): chairman of the Board of Directors SEK 500 000 (400 000) and director not employed by the Company SEK 250 000 (200 000).It is proposed that the fee for work in the audit committee be SEK 75 000 (75 000) to the chairman and SEK 50 000 (50 000) to each of the other members.It is proposed that the fee for work in the remuneration committee be SEK 50 000 (50 000) to the chairman and SEK 30 000 (30 000) to each of the other members.If the meeting resolves according to the nomination committee's proposal as regards the composition of the Board of Directors  the total fee will amount to SEK 1 785 000 (1 685 000).It is proposed that the auditor shall be remunerated according to invoices approved by the Company.14. Election of the Board of DirectorsThe nomination committee proposes the following Board of Directors: re-election of Gunnar Olsson. Carola Lemne  and Rein Piir  as well as new election of An van Es-Johansson and Catharina Gustafsson Wallich.Gunnar Olsson is proposed to be re-elected as the chairperson of the Board of Directors and Carola Lemne is proposed to be re-elected as the deputy chairperson.Lena Torleg√•rd and Lars Aldersson have declined to be re-elected.Further information about the proposed directors can be found on www.irlab.se.The proposed composition of the Board of Directors of the Company complies with the rules of the Code of Corporate Governance regarding independence. All directors are independent in relation to the Company and its executive management and are independent in relation to the Company's major shareholders.15. Election of auditorThe nomination committee proposes re-election of √ñhrlings PricewaterhouseCoopers AB (PwC) as auditor of the Company for the period until the end of the next Annual General Meeting. PwC has informed that in the event it is re-elected  Johan Rippe will continue in his capacity as principal auditor.16. Resolution regarding instruction to the nomination committeeThe nomination committee proposes the following instruction to the nomination committee (which materially corresponds to the instructions adopted at the 2021 Annual General Meeting).1. Appointment of the nomination committee etc.1.1 The nomination committee shall consist of four members - one representative for each one of the three largest shareholders or groups of owners in accordance with clause 1.2. below  which wish to appoint a member to the nomination committee as well as the chairman of the Board of Directors.1.2 The identification of those  who have the right to appoint members to the nomination committee  shall be based on ownership statistics from Euroclear Sweden AB per the last banking day in August. For the purpose of assessing the size of the shareholders  a group of shareholders shall be deemed one shareholder if they are grouped as owners in Euroclear Sweden AB's register.1.3 The chairman of the Board of Directors shall  without undue delay  after receipt by the Company of ownership statistics from Euroclear Sweden AB as per the last banking day in August  contact the three largest shareholders to ascertain if they wish to appoint members to the nomination committee. If one or more of the three largest shareholders refrains from appointing a member to the nomination committee  the chairman of the Board of Directors shall offer other major shareholders to appoint a member to the nomination committee. If such offer is made  it shall be made in due order to the largest shareholders (i.e. first to the fourth largest shareholder  thereafter to the fifth largest shareholder  etc.). The procedure shall continue until such time as the nomination committee consists of four members  including the chairman of the Board of Directors.1.4 Board members may be members of the nomination committee  but shall not constitute a majority of its members.1.5 At its first meeting  the nomination committee shall elect a chairman from among its members. The chairman of the board or  where applicable  another board member shall not be the chairman of the nomination committee.1.6 As soon as the nomination committee has been constituted  the Company shall  on its website  disclose the names of the members of the nomination committee  and provide information regarding how shareholders may submit proposals to the nomination committee.1.7 The nomination committee's mandate period shall continue until a new nomination committee has been appointed.1.8 If there is a change to the Company's ownership structure after the last banking day in August  but prior to the date which falls two months prior to the upcoming Annual General Meeting  and if a shareholder  which has not previously had the right to appoint a member to the nomination committee thereby becomes a larger shareholder than one or any of those who have appointed a member to the nomination committee (""new major shareholder"")  the nomination committee shall  if the new major owner requests to appoint a member to the nomination committee  decide that the member of the nomination committee who represents the smallest shareholder after the change shall be dismissed and replaced by the member who is appointed by the new major owner. If a new major owner wishes to appoint a member to the nomination committee  they must notify the chairman of the nomination committee. The application must contain the name of the person appointed by the new major owner as a member of the nomination committee.1.9 A shareholder  which has appointed a member to the nomination committee  has the right to dismiss the member and appoint a new member. If such change takes place  the shareholder shall immediately notify the chairman of the nomination committee (or  if it is the chairman of the nomination committee who shall be replaced  to the chairman of the Board of Directors). The application must contain the name of the dismissed member and the person who shall replace him/her as member of the nomination committee.2. Duties2.1 The nomination committee shall submit proposals for:a) chairman of the Annual General Meeting b) number of board members c) election of board members and election of the chairman of the board d) remuneration to each of the board members elected by the Annual General Meeting e) number of auditors and deputy auditors f) auditor and  where applicable  deputy auditors g) remuneration to auditors  andh) where applicable  amendment of instructions for the nomination committee.2.2 The members of the nomination committee shall serve the interests of all the shareholders.2.3 The nomination committee shall provide the Board of Directors with its proposals for resolution in due time prior to the latest day for the summons to the Annual General meeting or  where applicable  the extraordinary General Meeting.3. Meeting3.1 The nomination committee shall meet as often as is required in order for the nomination committee to be able to fulfil its duties. The chairman of the board shall convene its first meeting. Summons to other meetings shall be issued by the chairman of the nomination committee. If a member requests that the nomination committee be convened  the request must be complied with.3.2 The nomination committee is quorate if more than half of the members are present. Decisions in matters may  however  not be made unless all the members have been offered the opportunity to take part in the processing of the matter.3.3 Upon election of chairman of the nomination committee the person who receives the most votes is considered elected. In the event of an equal number of votes  the election shall be decided by drawing of lots.3.4 The nomination committee's decision is the opinion that more than half of the members present vote for or  if there are an equal amount of votes  the opinion that is supported by the chairman of the nomination committee.3.5 Minutes shall be taken at the nomination committee's meetings  which shall be signed and adjusted by the chairman of the nomination committee and the member appointed by the nomination committee. The minutes shall be taken and kept in accordance with what is applicable for board minutes.4. Confidentiality4.1 A member of the nomination committee is subject to a duty of confidentiality regarding the Company's affairs and this obligation shall  at the Company's request  be confirmed by the member by signing a special confidentiality agreement between the member and the Company.5. Fee and reimbursement of costs5.1 Fees shall not be paid to members of the nomination committee.The Company shall be responsible for reasonable costs attributable to the nomination committee's work.Proposed resolutions by the Board of Directors3. Preparation and approval of the voting registerThe voting register  which is proposed for approval under clause 3 of the agenda is the voting register that has been prepared by the chairman  based on the annual general meeting share register and advance votes received  and which have been verified by the adjusters.5. Election of one or two adjustorsThe Board of Directors proposes that the minutes shall be adjusted by Stefan Andersson and Daniel Johnsson or  in the event of an impediment for one or both of them  the person or persons indicated by the Board of Directors. The adjustors' tasks also include checking the voting list and that advance votes received are correctly stated in the minutes of the Annual General Meeting.10. Resolution on allocation of the Company's results according to the adopted balance sheetThe Board of Directors proposes that the Annual General Meeting resolves that the Company's profit or loss is allocated according to the Board of Directors' proposal in the annual report. The Board of Directors further proposes that no dividend be paid for the financial year 2021.17. Resolution regarding presentation and approval of the Board of Directors report on paid and outstanding compensation to senior management (remuneration report).The Board of Directors proposes that the Annual General Meeting approves the report presented by the Board of Directors on compensation paid and outstanding to senior management  prepared in accordance with Chapter 8  Section 53a of the Swedish Companies Act.18. Resolution regarding guidelines for salary and other compensation to senior managementThe Board of Directors proposes the following guidelines for the determination of salaries and other compensation to senior management.These guidelines include board members  the CEO and members of IRLAB's company management (Management Group). The guidelines shall be applicable to compensation that is agreed and amendments made to previously agreed compensation  subsequent to the adoption of the guidelines at the Annual General Meeting 2022. The guidelines do not include compensation resolved by the Annual General Meeting.The guidelines' promotion of the Company's business strategy  long-term interest and sustainabilityThe Company's business strategy is to discover new drug candidates with the help of ISP (Integrative Screening Process) and develop them into a so-called clinical ""Proof of Concept"" when clear indications of efficacy  tolerability and safety are achieved and thereafter seek partnership with international pharmaceutical companies for further development  registration and marketing.For further detailed information about the Company's business strategy please refer to the Company's annual reports and the website.The work with drug development takes a long time which means that continuity as well as low employee turnover are important. Successful implementation of the Company's business strategy and safeguarding of the Company's long-term interest  including concern for the sustainability of the business  therefore assumes that the Company is able to recruit and retain qualified employees. To achieve this  it is necessary that the Company can offer good working conditions with competitive levels of compensation. These guidelines enables the Company's executives to be offered a competitive total compensation.Forms of compensation etc.In the Company  the market compensation consists of fixed cash salary  pension benefits and other benefits. In addition and independently of these guidelines  the Annual General Meeting may resolve on  for example  share and share price-related compensation.Cash variable compensation can be paid in extraordinary circumstances  provided that such extraordinary arrangements are limited in time and only made at the individual level as compensation for extraordinary work effort in addition to the person's ordinary duties. Such compensation may not be paid more than twice a year and per individual and may not exceed an amount in total corresponding to 25 percent of the fixed annual cash salary. Decision on such compensation shall be made by the board of directors on the proposal of the remuneration committee.The pension premiums for defined contribution pensions for the CEO and management group in the company vary greatly depending on  among other things  age  previous salary and employment conditions.For the CEO  pension benefits  including health insurance  must be defined-contribution. Any variable cash compensation shall not be pension-based. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.For other senior executives  pension benefits  including health insurance  shall be defined-contribution unless the executive is covered by a defined-benefit pension in accordance with mandatory collective agreement provisions. Variable cash compensation shall be pension-based to the extent it follows from mandatory collective agreement provisions that are applicable to the executive. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.Other benefits may include  among other things  life insurance  health insurance and car benefit. Such benefits may amount in total to a maximum of 10 percent of the fixed annual cash salary.Termination of employmentUpon termination of employment  the notice period may not exceed twelve months. Fixed cash salary during the notice period and severance pay may not exceed an amount in total corresponding to the fixed cash salary for two years. In the event of termination on the part of the executive  the termination period may be not exceed 18 months for the CEO and no longer than six months for the other senior executives.In addition  compensation may be paid for any undertaking to restrict competition. Such compensation shall compensate for any loss of income and shall only be paid to the extent that the previous executive is not entitled to severance pay. The compensation shall be based on the fixed cash salary at the time of termination and shall be paid during the period the undertaking regarding restriction of competition applies  which shall be no longer than six months after the termination of employment.Salary and terms of employment for employeesIn preparation of the Board of Directors' proposal for these compensation guidelines  salary and terms of employment for the Company's employees have been taken into consideration through information about employees' total compensation  compensation components and the increase and rate of increase over time has formed part of the remuneration committee's and Board of Directors' basis for decision in the evaluation of the equity of the guidelines and the restrictions that follow as a result of these. The development of the gap between compensation for senior executives and compensation for other employees will be detailed in the remuneration report.The decision-making process to establish  review and implement the guidelinesThe Board of Directors has established a remuneration committee. The committee's duties include preparing the Board of Director's decision on proposed guidelines for compensation to senior executives. The Board of Directors shall prepare proposals for new guidelines at least every four years and submit the proposal for resolution at the Annual General Meeting. The guidelines shall apply until new guidelines have been adopted by the Annual General Meeting. The remuneration committee shall also monitor and evaluate the application of guidelines for compensation to senior executives as well as current compensation structures and levels in the Company. The members of the remuneration committee are independent in relation to the Company and the company management. During consideration of and decisions on compensation-related issues by the Board of Directors  neither the CEO nor other persons in the company management shall attend  insofar as they are affected by the issues.Deviation from the guidelinesThe Board of Directors may decide to temporarily deviate from the guidelines in whole or in part  if in an individual case if there are special reasons to do so and a deviation is necessary to meet the Company's long-term interests  including its sustainability  or to ensure the Company's economic viability. As stated above  it is part of the remuneration committee's duties to prepare Board of Directors' decisions in compensation issues  which include decisions regarding deviations from the guidelines.Description of important changes to the guidelines and how the shareholders' views have been taken into account.These guidelines correspond to the guidelines adopted at the 2020 Annual General Meeting19. Resolution on adoption of new Articles of AssociationThe Board of Directors proposes that a new ¬ß 12 is added to the Articles of Association in order to give the Board of Directors the right to collect powers of attorney  and to allow advance voting (Sw. postr√∂stning) for future general meetings. The numbering of the subsequent parts of the Articles of Association will change as a consequence.Current wording Proposed wording Not applicable ¬ß 12 Collection of powers of attorney and advance votingThe Board of Directors may collect powers of attorney in the manner stipulated in Chapter 7 Section 4  second paragraph of the Swedish Companies Act (2005:551). The board may before a general meeting resolve to allow shareholders to exercise their voting rights in advance of the general meeting in accordance with what is stipulated in Chapter 7  Section 4a of the Swedish Companies Act (2005:551).The approval by the Annual General Meeting of this proposal in accordance with the above is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.20. Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to resolve  on one or several occasions  on issue of shares of series A and/or convertibles entitling to conversion to shares of series A during the time until the next Annual General Meeting for payment in cash and/or with terms regarding set-off or issue in kind or otherwise with terms and thereby deviate from the preferential right of the shareholders.The issues shall be done to a marketable issue price determined by the Board of Directors in consultation with the Company's financial advisers  if any  taking into consideration any marketable issue-discount  where applicable.The Board of Directors proposes that 5 166 630 shares of series A could be issued with or without the preferential right of the shareholders corresponding to a reduced shareholding for non-participating shareholders (dilution) amounting to just under 9.1 percent or an increase of the existing number of outstanding shares with just under 10 percent.The purpose of the authorization and the reason to deviate from the preferential right of the shareholders is that issues shall be possible for financing the Company's business  commercialisation and development of the Company's products and markets and/or acquisition of businesses  companies or parts of companies and/or enable a broadening of the owner base of the Company.The approval by the Annual General Meeting of this proposal is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.21. Resolution regarding adjustment authorizationThe Board of Directors or the person appointed by the Board of Directors shall be authorized to make such minor amendments and clarifications of the resolution by the Annual General Meeting that may prove necessary in connection with registration of the resolutions.Number of shares and votesAt the time of this notice  the total number of shares in the Company amounts to 51 748 406  whereof 51 668 630 series A and 79 776 series B. The total number of votes amounts to 51 748 406. The Company holds no treasury shares.InformationWhere so requested by any shareholder and the Board of Directors deems that it can take place without serious harm to the Company  the Board of Directors and the CEO shall provide information regarding circumstances which may have an impact on the assessment of an item on the agenda and any circumstances which may have an impact on the assessment of the financial position of the Company. The obligation to provide information also refers to the Company's relationship to other Group companies and consolidated accounts as well as such relationships regarding Group companies as referred to above.Annual report and other documentsAccounting documents  auditors' report and other documents to be considered at the Annual General Meeting will be available at the Company's office at Arvid Wallgrens backe 20  413 46 G√∂teborg and on the Company's website  www.irlab.se  no later than three weeks prior to the Annual General Meeting. The documents are also be forwarded free of charge to the shareholders who request it and provide their address.Processing of personal dataFor information on how your personal data is processed  see https://www.euroclear.com/dam/ESwithLegal/Integritetspolicy-bolagsstammor-svenska.pdf.G√∂teborg in April 2022IRLAB Therapeutics ABThe Board of DirectorsFor more informationNicholas Waters  CEOPhone: +46 730 75 77 01E-mail: nicholas.waters@irlab.seViktor Siewertz  CFOPhone: +46 727 10 70 70E-mail: viktor.siewertz@irlab.seAbout IRLABIRLAB discovers and develops novel treatments of Parkinson's disease and other disorders of the brain. The company's most advanced drug candidates  mesdopetam (IRL790) and pirepemat (IRL752)  are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's disease. In 2021  IRLAB entered an exclusive and worldwide license with Ipsen for the development and marketing of mesdopetam.Through ISP  its proprietary research platform  IRLAB has discovered and developed all its experimental drug candidates and continues to discover innovative drug candidates for the treatment of disorders of the brain. In addition to IRLAB's strong clinical pipeline  IRLAB runs several preclinical programs with IRL942 and IRL757 currently in development towards Phase I. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.AttachmentsIRLAB AGM Notice 2022 English TranslationSOURCE: IRLAB TherapeuticsView source version on accesswire.com:https://www.accesswire.com/696932/Notice-To-Attend-The-Annual-General-Meeting-Of-Shareholders",neutral,0.02,0.9,0.08,negative,0.04,0.26,0.7,True,English,"['Annual General Meeting', 'IRLAB Therapeutics', 'Notice', 'Shareholders', 'IRLAB Therapeutics AB √Örsst√§mma', 'Irlab √•rsst√§mma', 'Wallenberg Conference Center', 'P.O. Box', 'Arvid Wallgrens backe', 'other authorization document', 'equivalent authorization document', 'Annul General Meeting', 'Annual General Meeting', 'personal identity number', 'Euroclear Sweden AB', 'daytime telephone number', 'corporate registration number', 'maximum two advisors', 'Nominee registered shares', 'two persons', 'Computershare AB', 'annual report', 'Medicinaregatan 20 A', 'temporary rules', 'share register', 'legal entity', 'postal vote', 'due time', 'longer period', 'five years', 'relevant certificate', 'income statement', 'balance sheet', 'Gunnar Olsson', 'Carole Lemne', 'Lars Adlersson', 'Rein Piir', 'Martin Nicklasson', 'voting rights', 'voting register', 'advance voting', 'complete name', 'registration certificate', 'one year', 'Complete instructions', 'specific form', 'completed form', 'Wednesday 11 May', 'attorney forms', 'company registration', 'shareholder power', '3 May', '5 May', 'GOTHENBURG', 'ACCESSWIRE', 'April', 'IRLAB-A', 'FRA', '6IRA', 'shareholders', 'notice', '3.30 PM', 'board', 'accordance', 'intention', 'order', 'mail', 'Stockholm', 'proxy', 'se', 'website', 'information', 'BankID', 'votes', 'Anyone', 're-registration', 'validity', 'copy', 'notification', 'address', 'Business', 'agenda', 'Opening', 'Election', 'chairman', 'Preparation', 'approval', 'Resolution', 'broadcast', 'internet', 'minutes', 'Determination', 'auditor', 'group', 'adoption', 'allocation', 'results', 'discharge', 'liability', 'directors', 'CEO', '5.00', '102']",2022-04-05,2022-04-11,finanznachrichten.de
2639,Euroclear,Bing API,https://www.morningstar.com/news/accesswire/696932msn/notice-to-attend-the-annual-general-meeting-of-shareholders,Notice To Attend The Annual General Meeting Of Shareholders,"The shareholders of IRLAB Therapeutics AB  company registration no. 556931-4692 (""IRLAB"" or the ""Company"")  are hereby given notice to attend the Annual General Meeting to be held on Wednesday 11 May 2022 at 5.","GOTHENBURG  SWEDEN / ACCESSWIRE / April 11  2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)The shareholders of IRLAB Therapeutics AB  company registration no. 556931-4692 (""IRLAB"" or the ""Company"")  are hereby given notice to attend the Annual General Meeting to be held on Wednesday 11 May 2022 at 5.00 PM at the Wallenberg Conference Center  Medicinaregatan 20 A  Gothenburg. Registration for the Annual General Meeting will start at 3.30 PM.The board of IRLAB has in accordance with the temporary rules decided to allow shareholders who do not wish to be physically present at the Annual General Meeting to instead vote by advance voting (Sw. postr√∂stning).Right to participate and notice of intention to participateIn order to have the right to participate at the Annual General Meeting a shareholder must:be entered in the share register maintained by Euroclear Sweden AB as per 3 May 2022  andgive notice of its intention to participate by mail to Computershare AB  ""IRLAB Therapeutics AB √Örsst√§mma""  P.O. Box 5267  102 46 Stockholm  or by telephone +46 771 24 64 00  or by e-mail to proxy@computershare.se or at the Company's website (www.irlab.se)  no later than 5 May 2022.The notice of intention to participate shall state the complete name  personal identity number or corporate registration number  number of shares held  daytime telephone number as well as information of the number of advisors accompanying the shareholder (maximum two advisors).Notice for a legal entity shall be made in accordance with the instructions above.How advance voting worksA specific form is used for advance voting.Shareholders must use the form and follow the instructions which will be available on the Company's website  www.irlab.se  and at the Company's premises at Arvid Wallgrens backe 20  413 46 Gothenburg. The completed and signed form for advance voting must be sent by mail to Computershare AB  ""Irlab √•rsst√§mma""  P.O. Box 5267  102 46 Stockholm. The completed form must be received by Computershare AB no later than 5 May 2022. The completed and signed form may also be submitted electronically and must then be sent to proxy@computershare.se. Shareholders can also cast a postal vote electronically with BankID via the Company's website  www.irlab.se. If shareholders cast advance votes through a proxy  a power of attorney must be attached to the form. If the shareholder is a legal entity  a registration certificate or other authorization document must be attached to the power of attorney. Anyone wishing to revoke advance voting and instead exercise their right to vote by attending the meeting physically or by proxy must notify the secretariat of the meeting before the meeting opens.Complete instructions for shareholders who wish to exercise their voting by advance voting can be found in form for advance voting.Nominee registered sharesTo be entitled to participate at the Annual General Meeting  shareholders who have had their shares registered with a nominee  must request that they be temporarily re-registered in their own name. Shareholders who wish to carry out such re-registration  so called registration for voting rights (Sw. r√∂str√§ttsregistrering)  should notify the nominee in due time before 3 May 2022. The re-registration must be executed with Euroclear Sweden AB no later than 5 May 2022.ProxyIf shareholder is to be represented by a proxy  the proxy must have a written  dated  and signed by the shareholder power of attorney to the Annual General Meeting. The power of attorney may not be older than one year  unless a longer period of validity (however  a maximum of five years) has been stated in the power of attorney. If the power of the attorney has been issued by a legal entity  the proxy must also have relevant certificate of registration or equivalent authorization document for the legal entity. To facilitate the registration at the Annual General Meeting  a copy of the power of attorney and other authorization documents should be attached to the notification to the Annul General Meeting. Power of attorney forms are available on the Company's website (www.irlab.se) and are sent by mail to shareholders who contact the Company and state their address.BusinessProposed agenda1) Opening of the meeting;2) Election of chairman of the meeting;3) Preparation and approval of the voting register;4) Resolution to allow broadcast of the Annual General Meeting over the internet;5) Election of one or two persons to verify the minutes;6) Determination of whether the Annual General Meeting has been duly convened;7) Approval of the agenda;8) Presentation of the annual report and the auditor's report for the Company and the group;9) Resolution regarding adoption of the income statement and balance sheet for the Company and the group;10) Resolution regarding allocation of the Company's results according to the adopted balance sheet;11) Resolution regarding discharge from liability for the directors and the CEO;i) Gunnar Olssonii) Carole Lemneiii) Lars Adlerssoniv) Rein Piirv) Martin Nicklassonvi) Lena Torleg√•rdvii) Nicholas Waters12) Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditors;13) Resolution regarding determination of the fees payable to the directors and the auditors;14) Election of the Board of Directors;The nominations committee's proposal:i) Gunnar Olssonii) Carole Lemneiii) Rein Piiriv) An van Es-Johanssonv) Catharina Gustafsson Wallich15) Election of auditor and deputy auditors  if any;16) Resolution regarding principles for the nomination committee;17) Resolution regarding presentation and approval of the Board of Directors' report of paid and outstanding remuneration to senior management (remuneration report);18) Resolution regarding salary and other compensation to senior management:19) Resolution regarding adoption of new articles of association;20) Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;21) Resolution regarding adjustment authorization;22) Closing of the meeting.Nomination committeeIn accordance with the Annual General Meeting's principles adopted last year  the nomination committee is composed of one representative each from the three largest shareholders as per the last banking day of August 2021  as well as the chairman of the Company's Board of Directors. The nomination committee consists of Daniel Johnsson (appointed by one of the shareholders group representing approximately 21 percent of shares and votes)  Bo Rydlinger (appointed by one of the shareholder groups representing approximately 15 percent of shares and votes)  Clas Sonesson (appointed by one of the shareholder groups representing approximately 10 percent of shares and votes) and Gunnar Olsson  the chairman of the Board of Directors. Daniel Johnsson has served as the chairman of the nomination committee.Proposed resolutions by the nomination committee2. Election of chairman of the meetingThe nomination committee proposes advokat Dag Fredlund or  in the event of an impediment  the person appointed by the nomination committee  to be elected as the chairman of the Annual General Meeting.12. Resolution regarding determination of the number of directors as well as the number of auditors and deputy auditorsThe nomination committee proposes that the number of directors for the period until the next Annual General Meeting shall be five and that one auditor and no deputy auditor shall be appointed for the same period.13. Resolution regarding determination of the fees payable to the directors and the auditorsThe nomination committee proposes that the fee per director elected by the Annual General Meeting shall be distributed as follows (last year's figures in brackets): chairman of the Board of Directors SEK 500 000 (400 000) and director not employed by the Company SEK 250 000 (200 000).It is proposed that the fee for work in the audit committee be SEK 75 000 (75 000) to the chairman and SEK 50 000 (50 000) to each of the other members.It is proposed that the fee for work in the remuneration committee be SEK 50 000 (50 000) to the chairman and SEK 30 000 (30 000) to each of the other members.If the meeting resolves according to the nomination committee's proposal as regards the composition of the Board of Directors  the total fee will amount to SEK 1 785 000 (1 685 000).It is proposed that the auditor shall be remunerated according to invoices approved by the Company.14. Election of the Board of DirectorsThe nomination committee proposes the following Board of Directors: re-election of Gunnar Olsson. Carola Lemne  and Rein Piir  as well as new election of An van Es-Johansson and Catharina Gustafsson Wallich.Gunnar Olsson is proposed to be re-elected as the chairperson of the Board of Directors and Carola Lemne is proposed to be re-elected as the deputy chairperson.Lena Torleg√•rd and Lars Aldersson have declined to be re-elected.Further information about the proposed directors can be found on www.irlab.se.The proposed composition of the Board of Directors of the Company complies with the rules of the Code of Corporate Governance regarding independence. All directors are independent in relation to the Company and its executive management and are independent in relation to the Company's major shareholders.15. Election of auditorThe nomination committee proposes re-election of √ñhrlings PricewaterhouseCoopers AB (PwC) as auditor of the Company for the period until the end of the next Annual General Meeting. PwC has informed that in the event it is re-elected  Johan Rippe will continue in his capacity as principal auditor.16. Resolution regarding instruction to the nomination committeeThe nomination committee proposes the following instruction to the nomination committee (which materially corresponds to the instructions adopted at the 2021 Annual General Meeting).1. Appointment of the nomination committee etc.1.1 The nomination committee shall consist of four members - one representative for each one of the three largest shareholders or groups of owners in accordance with clause 1.2. below  which wish to appoint a member to the nomination committee as well as the chairman of the Board of Directors.1.2 The identification of those  who have the right to appoint members to the nomination committee  shall be based on ownership statistics from Euroclear Sweden AB per the last banking day in August. For the purpose of assessing the size of the shareholders  a group of shareholders shall be deemed one shareholder if they are grouped as owners in Euroclear Sweden AB's register.1.3 The chairman of the Board of Directors shall  without undue delay  after receipt by the Company of ownership statistics from Euroclear Sweden AB as per the last banking day in August  contact the three largest shareholders to ascertain if they wish to appoint members to the nomination committee. If one or more of the three largest shareholders refrains from appointing a member to the nomination committee  the chairman of the Board of Directors shall offer other major shareholders to appoint a member to the nomination committee. If such offer is made  it shall be made in due order to the largest shareholders (i.e. first to the fourth largest shareholder  thereafter to the fifth largest shareholder  etc.). The procedure shall continue until such time as the nomination committee consists of four members  including the chairman of the Board of Directors.1.4 Board members may be members of the nomination committee  but shall not constitute a majority of its members.1.5 At its first meeting  the nomination committee shall elect a chairman from among its members. The chairman of the board or  where applicable  another board member shall not be the chairman of the nomination committee.1.6 As soon as the nomination committee has been constituted  the Company shall  on its website  disclose the names of the members of the nomination committee  and provide information regarding how shareholders may submit proposals to the nomination committee.1.7 The nomination committee's mandate period shall continue until a new nomination committee has been appointed.1.8 If there is a change to the Company's ownership structure after the last banking day in August  but prior to the date which falls two months prior to the upcoming Annual General Meeting  and if a shareholder  which has not previously had the right to appoint a member to the nomination committee thereby becomes a larger shareholder than one or any of those who have appointed a member to the nomination committee (""new major shareholder"")  the nomination committee shall  if the new major owner requests to appoint a member to the nomination committee  decide that the member of the nomination committee who represents the smallest shareholder after the change shall be dismissed and replaced by the member who is appointed by the new major owner. If a new major owner wishes to appoint a member to the nomination committee  they must notify the chairman of the nomination committee. The application must contain the name of the person appointed by the new major owner as a member of the nomination committee.1.9 A shareholder  which has appointed a member to the nomination committee  has the right to dismiss the member and appoint a new member. If such change takes place  the shareholder shall immediately notify the chairman of the nomination committee (or  if it is the chairman of the nomination committee who shall be replaced  to the chairman of the Board of Directors). The application must contain the name of the dismissed member and the person who shall replace him/her as member of the nomination committee.2. Duties2.1 The nomination committee shall submit proposals for:a) chairman of the Annual General Meeting b) number of board members c) election of board members and election of the chairman of the board d) remuneration to each of the board members elected by the Annual General Meeting e) number of auditors and deputy auditors f) auditor and  where applicable  deputy auditors g) remuneration to auditors  andh) where applicable  amendment of instructions for the nomination committee.2.2 The members of the nomination committee shall serve the interests of all the shareholders.2.3 The nomination committee shall provide the Board of Directors with its proposals for resolution in due time prior to the latest day for the summons to the Annual General meeting or  where applicable  the extraordinary General Meeting.3. Meeting3.1 The nomination committee shall meet as often as is required in order for the nomination committee to be able to fulfil its duties. The chairman of the board shall convene its first meeting. Summons to other meetings shall be issued by the chairman of the nomination committee. If a member requests that the nomination committee be convened  the request must be complied with.3.2 The nomination committee is quorate if more than half of the members are present. Decisions in matters may  however  not be made unless all the members have been offered the opportunity to take part in the processing of the matter.3.3 Upon election of chairman of the nomination committee the person who receives the most votes is considered elected. In the event of an equal number of votes  the election shall be decided by drawing of lots.3.4 The nomination committee's decision is the opinion that more than half of the members present vote for or  if there are an equal amount of votes  the opinion that is supported by the chairman of the nomination committee.3.5 Minutes shall be taken at the nomination committee's meetings  which shall be signed and adjusted by the chairman of the nomination committee and the member appointed by the nomination committee. The minutes shall be taken and kept in accordance with what is applicable for board minutes.4. Confidentiality4.1 A member of the nomination committee is subject to a duty of confidentiality regarding the Company's affairs and this obligation shall  at the Company's request  be confirmed by the member by signing a special confidentiality agreement between the member and the Company.5. Fee and reimbursement of costs5.1 Fees shall not be paid to members of the nomination committee.The Company shall be responsible for reasonable costs attributable to the nomination committee's work.Proposed resolutions by the Board of Directors3. Preparation and approval of the voting registerThe voting register  which is proposed for approval under clause 3 of the agenda is the voting register that has been prepared by the chairman  based on the annual general meeting share register and advance votes received  and which have been verified by the adjusters.5. Election of one or two adjustorsThe Board of Directors proposes that the minutes shall be adjusted by Stefan Andersson and Daniel Johnsson or  in the event of an impediment for one or both of them  the person or persons indicated by the Board of Directors. The adjustors' tasks also include checking the voting list and that advance votes received are correctly stated in the minutes of the Annual General Meeting.10. Resolution on allocation of the Company's results according to the adopted balance sheetThe Board of Directors proposes that the Annual General Meeting resolves that the Company's profit or loss is allocated according to the Board of Directors' proposal in the annual report. The Board of Directors further proposes that no dividend be paid for the financial year 2021.17. Resolution regarding presentation and approval of the Board of Directors report on paid and outstanding compensation to senior management (remuneration report).The Board of Directors proposes that the Annual General Meeting approves the report presented by the Board of Directors on compensation paid and outstanding to senior management  prepared in accordance with Chapter 8  Section 53a of the Swedish Companies Act.18. Resolution regarding guidelines for salary and other compensation to senior managementThe Board of Directors proposes the following guidelines for the determination of salaries and other compensation to senior management.These guidelines include board members  the CEO and members of IRLAB's company management (Management Group). The guidelines shall be applicable to compensation that is agreed and amendments made to previously agreed compensation  subsequent to the adoption of the guidelines at the Annual General Meeting 2022. The guidelines do not include compensation resolved by the Annual General Meeting.The guidelines' promotion of the Company's business strategy  long-term interest and sustainabilityThe Company's business strategy is to discover new drug candidates with the help of ISP (Integrative Screening Process) and develop them into a so-called clinical ""Proof of Concept"" when clear indications of efficacy  tolerability and safety are achieved and thereafter seek partnership with international pharmaceutical companies for further development  registration and marketing.For further detailed information about the Company's business strategy please refer to the Company's annual reports and the website.The work with drug development takes a long time which means that continuity as well as low employee turnover are important. Successful implementation of the Company's business strategy and safeguarding of the Company's long-term interest  including concern for the sustainability of the business  therefore assumes that the Company is able to recruit and retain qualified employees. To achieve this  it is necessary that the Company can offer good working conditions with competitive levels of compensation. These guidelines enables the Company's executives to be offered a competitive total compensation.Forms of compensation etc.In the Company  the market compensation consists of fixed cash salary  pension benefits and other benefits. In addition and independently of these guidelines  the Annual General Meeting may resolve on  for example  share and share price-related compensation.Cash variable compensation can be paid in extraordinary circumstances  provided that such extraordinary arrangements are limited in time and only made at the individual level as compensation for extraordinary work effort in addition to the person's ordinary duties. Such compensation may not be paid more than twice a year and per individual and may not exceed an amount in total corresponding to 25 percent of the fixed annual cash salary. Decision on such compensation shall be made by the board of directors on the proposal of the remuneration committee.The pension premiums for defined contribution pensions for the CEO and management group in the company vary greatly depending on  among other things  age  previous salary and employment conditions.For the CEO  pension benefits  including health insurance  must be defined-contribution. Any variable cash compensation shall not be pension-based. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.For other senior executives  pension benefits  including health insurance  shall be defined-contribution unless the executive is covered by a defined-benefit pension in accordance with mandatory collective agreement provisions. Variable cash compensation shall be pension-based to the extent it follows from mandatory collective agreement provisions that are applicable to the executive. The pension premiums for defined-contribution pensions may amount to a maximum of 40 percent of the fixed annual cash salary.Other benefits may include  among other things  life insurance  health insurance and car benefit. Such benefits may amount in total to a maximum of 10 percent of the fixed annual cash salary.Termination of employmentUpon termination of employment  the notice period may not exceed twelve months. Fixed cash salary during the notice period and severance pay may not exceed an amount in total corresponding to the fixed cash salary for two years. In the event of termination on the part of the executive  the termination period may be not exceed 18 months for the CEO and no longer than six months for the other senior executives.In addition  compensation may be paid for any undertaking to restrict competition. Such compensation shall compensate for any loss of income and shall only be paid to the extent that the previous executive is not entitled to severance pay. The compensation shall be based on the fixed cash salary at the time of termination and shall be paid during the period the undertaking regarding restriction of competition applies  which shall be no longer than six months after the termination of employment.Salary and terms of employment for employeesIn preparation of the Board of Directors' proposal for these compensation guidelines  salary and terms of employment for the Company's employees have been taken into consideration through information about employees' total compensation  compensation components and the increase and rate of increase over time has formed part of the remuneration committee's and Board of Directors' basis for decision in the evaluation of the equity of the guidelines and the restrictions that follow as a result of these. The development of the gap between compensation for senior executives and compensation for other employees will be detailed in the remuneration report.The decision-making process to establish  review and implement the guidelinesThe Board of Directors has established a remuneration committee. The committee's duties include preparing the Board of Director's decision on proposed guidelines for compensation to senior executives. The Board of Directors shall prepare proposals for new guidelines at least every four years and submit the proposal for resolution at the Annual General Meeting. The guidelines shall apply until new guidelines have been adopted by the Annual General Meeting. The remuneration committee shall also monitor and evaluate the application of guidelines for compensation to senior executives as well as current compensation structures and levels in the Company. The members of the remuneration committee are independent in relation to the Company and the company management. During consideration of and decisions on compensation-related issues by the Board of Directors  neither the CEO nor other persons in the company management shall attend  insofar as they are affected by the issues.Deviation from the guidelinesThe Board of Directors may decide to temporarily deviate from the guidelines in whole or in part  if in an individual case if there are special reasons to do so and a deviation is necessary to meet the Company's long-term interests  including its sustainability  or to ensure the Company's economic viability. As stated above  it is part of the remuneration committee's duties to prepare Board of Directors' decisions in compensation issues  which include decisions regarding deviations from the guidelines.Description of important changes to the guidelines and how the shareholders' views have been taken into account.These guidelines correspond to the guidelines adopted at the 2020 Annual General Meeting19. Resolution on adoption of new Articles of AssociationThe Board of Directors proposes that a new ¬ß 12 is added to the Articles of Association in order to give the Board of Directors the right to collect powers of attorney  and to allow advance voting (Sw. postr√∂stning) for future general meetings. The numbering of the subsequent parts of the Articles of Association will change as a consequence.Current wording Proposed wording Not applicable ¬ß 12 Collection of powers of attorney and advance votingThe Board of Directors may collect powers of attorney in the manner stipulated in Chapter 7 Section 4  second paragraph of the Swedish Companies Act (2005:551). The board may before a general meeting resolve to allow shareholders to exercise their voting rights in advance of the general meeting in accordance with what is stipulated in Chapter 7  Section 4a of the Swedish Companies Act (2005:551).The approval by the Annual General Meeting of this proposal in accordance with the above is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.20. Resolution regarding authorization of the Board of Directors to issue shares and/or convertibles;The Board of Directors proposes that the Annual General Meeting authorizes the Board of Directors to resolve  on one or several occasions  on issue of shares of series A and/or convertibles entitling to conversion to shares of series A during the time until the next Annual General Meeting for payment in cash and/or with terms regarding set-off or issue in kind or otherwise with terms and thereby deviate from the preferential right of the shareholders.The issues shall be done to a marketable issue price determined by the Board of Directors in consultation with the Company's financial advisers  if any  taking into consideration any marketable issue-discount  where applicable.The Board of Directors proposes that 5 166 630 shares of series A could be issued with or without the preferential right of the shareholders corresponding to a reduced shareholding for non-participating shareholders (dilution) amounting to just under 9.1 percent or an increase of the existing number of outstanding shares with just under 10 percent.The purpose of the authorization and the reason to deviate from the preferential right of the shareholders is that issues shall be possible for financing the Company's business  commercialisation and development of the Company's products and markets and/or acquisition of businesses  companies or parts of companies and/or enable a broadening of the owner base of the Company.The approval by the Annual General Meeting of this proposal is valid only if supported by shareholders representing at least 2/3 of both the votes cast and the votes represented at the meeting.21. Resolution regarding adjustment authorizationThe Board of Directors or the person appointed by the Board of Directors shall be authorized to make such minor amendments and clarifications of the resolution by the Annual General Meeting that may prove necessary in connection with registration of the resolutions.Number of shares and votesAt the time of this notice  the total number of shares in the Company amounts to 51 748 406  whereof 51 668 630 series A and 79 776 series B. The total number of votes amounts to 51 748 406. The Company holds no treasury shares.InformationWhere so requested by any shareholder and the Board of Directors deems that it can take place without serious harm to the Company  the Board of Directors and the CEO shall provide information regarding circumstances which may have an impact on the assessment of an item on the agenda and any circumstances which may have an impact on the assessment of the financial position of the Company. The obligation to provide information also refers to the Company's relationship to other Group companies and consolidated accounts as well as such relationships regarding Group companies as referred to above.Annual report and other documentsAccounting documents  auditors' report and other documents to be considered at the Annual General Meeting will be available at the Company's office at Arvid Wallgrens backe 20  413 46 G√∂teborg and on the Company's website  www.irlab.se  no later than three weeks prior to the Annual General Meeting. The documents are also be forwarded free of charge to the shareholders who request it and provide their address.Processing of personal dataFor information on how your personal data is processed  see https://www.euroclear.com/dam/ESwithLegal/Integritetspolicy-bolagsstammor-svenska.pdf.G√∂teborg in April 2022IRLAB Therapeutics ABThe Board of DirectorsFor more informationNicholas Waters  CEOPhone: +46 730 75 77 01E-mail: nicholas.waters@irlab.seViktor Siewertz  CFOPhone: +46 727 10 70 70E-mail: viktor.siewertz@irlab.seAbout IRLABIRLAB discovers and develops novel treatments of Parkinson's disease and other disorders of the brain. The company's most advanced drug candidates  mesdopetam (IRL790) and pirepemat (IRL752)  are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's disease. In 2021  IRLAB entered an exclusive and worldwide license with Ipsen for the development and marketing of mesdopetam.Through ISP  its proprietary research platform  IRLAB has discovered and developed all its experimental drug candidates and continues to discover innovative drug candidates for the treatment of disorders of the brain. In addition to IRLAB's strong clinical pipeline  IRLAB runs several preclinical programs with IRL942 and IRL757 currently in development towards Phase I. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.AttachmentsIRLAB AGM Notice 2022 English TranslationSOURCE: IRLAB TherapeuticsView source version on accesswire.com:",neutral,0.03,0.9,0.07,negative,0.04,0.26,0.7,True,English,"['Annual General Meeting', 'Notice', 'The', 'Shareholders', 'IRLAB Therapeutics AB √Örsst√§mma', 'Irlab √•rsst√§mma', 'Wallenberg Conference Center', 'P.O. Box', 'Arvid Wallgrens backe', 'other authorization document', 'equivalent authorization document', 'Annul General Meeting', 'Annual General Meeting', 'personal identity number', 'Euroclear Sweden AB', 'daytime telephone number', 'corporate registration number', 'maximum two advisors', 'Nominee registered shares', 'two persons', 'Computershare AB', 'annual report', 'Medicinaregatan 20 A', 'temporary rules', 'share register', 'legal entity', 'postal vote', 'due time', 'longer period', 'five years', 'relevant certificate', 'income statement', 'balance sheet', 'Gunnar Olsson', 'Carole Lemne', 'Lars Adlersson', 'Rein Piir', 'Martin Nicklasson', 'voting rights', 'voting register', 'advance voting', 'complete name', 'registration certificate', 'one year', 'Complete instructions', 'specific form', 'completed form', 'Wednesday 11 May', 'attorney forms', 'company registration', 'shareholder power', '3 May', '5 May', 'GOTHENBURG', 'ACCESSWIRE', 'April', 'IRLAB-A', 'FRA', '6IRA', 'shareholders', 'notice', '3.30 PM', 'board', 'accordance', 'intention', 'order', 'mail', 'Stockholm', 'proxy', 'se', 'website', 'information', 'BankID', 'votes', 'Anyone', 're-registration', 'validity', 'copy', 'notification', 'address', 'Business', 'agenda', 'Opening', 'Election', 'chairman', 'Preparation', 'approval', 'Resolution', 'broadcast', 'internet', 'minutes', 'Determination', 'auditor', 'group', 'adoption', 'allocation', 'results', 'discharge', 'liability', 'directors', 'CEO', '5.00', '102']",2022-04-11,2022-04-11,morningstar.com
2640,Euroclear,Bing API,https://www.livemint.com/news/india/how-india-s-much-hyped-global-bond-index-inclusion-unraveled-11649634409304.html,How India‚Äôs much-hyped global bond index inclusion unravelled,The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change,"For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping global wealth.The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn‚Äôt make any mention of it in her February budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt markets saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn‚Äôt likely for at least a year. Officials say a path forward isn‚Äôt possible until Group of 20 Nations reach a consensus on a country‚Äôs right to tax capital gains  another pressure point for India.‚ÄúFrom India‚Äôs perspective  we are losing an opportunity to tap a pool of liquidity and an investor base "" said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors‚Äô perspective  India is one of the largest EM bond markets that is yet to be included in major bond indexes.""With inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits "" he said.An About-FaceThe challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the Feb. 1 budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn‚Äôt reply to multiple requests for comment. A spokesperson for India‚Äôs finance ministry didn‚Äôt respond to an email seeking clarification.What Went WrongIn hindsight  officials said India‚Äôs reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi‚Äôs party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party‚Äôs traditional vote bank. Every year  they hold informal discussions with the government ahead of the budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors "" Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February budget speech.Looking AheadFor now  index inclusion appears all but impossible in the short term.In an interview with Bloomberg last month  Ajay Seth  the secretary of India‚Äôs economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India‚Äôs bond market. In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That‚Äôs a concern for the government as it plans to borrow a record amount from the markets to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal‚Äôs borrowing commences in April "" said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody‚Äôs Investors Service. ‚ÄúIf there are concrete steps toward bond index inclusion during the year  it could help to cap yields.""This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.Subscribe to Mint Newsletters * Enter a valid email * Thank you for subscribing to our newsletter.",neutral,0.06,0.72,0.22,negative,0.01,0.12,0.86,True,English,"['global bond index inclusion', 'India', 'Senior Asia Rates Strategist', 'largest EM bond markets', 'Prime Minister Narendra Modi', 'Finance Minister Nirmala Sitharaman', 'Powerful Hindu nationalist groups', 'dollar-denominated sovereign bond', 'eleventh hour concerns', 'Standard Chartered Plc', 'international clearing platforms', 'traditional vote bank', 'Swadeshi Jagran Manch', 'key tax exemptions', 'new financial year', 'contentious tax negotiations', 'risk diversification benefits', 'Local debt markets', 'Feb. 1 budget talk', 'global minimum rate', 'international fiscal policy', 'tax avoidance issues', 'international bond transactions', 'public OECD forums', 'crucial step change', 'February budget speech', 'major bond indexes', 'senior government officials', 'finance ministry official', 'foreign investors‚Äô perspective', 'India long bonds', 'senior official', 'Indian debt', 'a year', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'local investors', 'local businesses', 'global indexes', 'global wealth', 'Global investors', 'remarkable milestone', 'Citigroup Inc.', 'Policy makers', 'sudden silence', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'increasing clout', 'top bureaucrat', 'Ashwani Mahajan', 'Indian officials', 'securities transactions', 'Paris-based group', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'informal discussions', 'index inclusion', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 Nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'Face', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal', 'transfer', 'reason', 'advantages', 'leaders']",2022-04-11,2022-04-11,livemint.com
2641,Euroclear,Bing API,https://nz.finance.yahoo.com/news/notice-annual-general-meeting-acarix-100000735.html,Notice of Annual General Meeting in Acarix AB,"General Meeting in Acarix AB The shareholders of Acarix AB  reg. no. 559009-0667  (the ""Company"")  are hereby convened to the annual general meeting to be held on Wednesday 11 May 2022 at 10:00 AM at the Baker & McKenzie Advokatbyr√•'s office on Vasagatan 7 in Stockholm.","Acarix ABNotice of Annual General Meeting in Acarix ABThe shareholders of Acarix AB  reg. no. 559009-0667  (the ""Company"")  are hereby convened to the annual general meeting to be held on Wednesday 11 May 2022 at 10:00 AM at the Baker & McKenzie Advokatbyr√•'s office on Vasagatan 7 in Stockholm.Right to attend the annual general meeting and noticeShareholders wishing to attend the annual general meeting must:on the record date  which is Tuesday 3 May 2022  be registered in the share register maintained by Euroclear Sweden AB;notify the Company of their participation and any assistants (no more than two) in the annual general meeting no later than Thursday 5 May 2022. The notification shall be in writing to Acarix AB  Jungmansgatan 12  211 19 Malm√∂ or via e-mail: agm@acarix.com. The notification should state the name  personal/corporate identity number  shareholding  share classes address and telephone number and  when applicable  information about representatives  counsels and assistants. When applicable  complete authorization documents  such as registration certificates and powers of attorney for representatives and assistants  should be appended the notification.Nominee registered sharesShareholders  whose shares are registered in the name of a nominee  must temporarily register the shares in their own name at Euroclear Sweden AB. Shareholders whose shares are registered in the name of a nominee must  no later than on Tuesday 3 May 2022  via their nominee  temporarily register the shares in their own name in order to be entitled to participate at the general meeting. Voting registration requested by a shareholder in such time that the registration has been made by the relevant nominee no later than on Thursday 5 May 2022 will be considered in preparations of the share register.Proxy etc.Shareholders who are casting advance votes via proxy should submit a power of attorney  dated and signed by the shareholder  together with the advance vote. The proxy must not be more than one year old  however  the proxy may be older if it is stated that it is valid for a longer term  maximum five years. If the shareholder is a legal person  certificate of registration or other documents of authority shall be attached to the form. A form proxy will be available for downloading on the Company¬¥s website www.acarix.com.Story continuesProposed agenda:1 Opening of the meeting2 Election of the chairman of the general meeting3 Preparation and approval of voting list4 Election of one or two persons to certify the minutes5 Determination of whether the general meeting has been duly convened6 Approval of the agenda7 Presentation of the annual report and audit report and the group annual report and group audit report8 Resolutions regarding:a) adoption of income statement and balance sheet and group income statement and group balance sheet;b) appropriation of the Company's profit or loss in accordance with the adopted balance sheet and the adopted group balance sheet; andc) discharge of liability for the directors and the managing director9 Determination of the number of directors and auditors10 Determination of remuneration to the board of directors and the auditors11 Election of board of directors and auditors12 Resolution regarding adoption of principles for the nomination committee13 Resolution regarding guidelines for the determination of remuneration to senior executives14 Resolution regarding authorization for the board to issue shares  convertibles and/or warrants15 Resolution regarding an employee stock option program for senior executives  other employees and key individuals in the company and the group in Sweden  Denmark  Germany and USAa) Proposal regarding resolution to issue warrants employee stock optionsb) Proposal regarding resolution to issue warrants and approval of transfer of warrants16 Closing of the meetingProposals for resolutions:Item 2: Election of the chairman of the general meetingThe nomination committee proposes that Carl Isaksson  LL.M.  Baker & McKenzie Advokatbyr√• is appointed as chairman of the general meeting  or  in his absence  the person appointed by him.Item 8b) Appropriation of the Company's profit or loss in accordance with the adopted balance sheet and the adopted group balance sheetThe board of directors proposes that all funds available to the annual general meeting shall be carried forward.Items 9-11: Determination of the number of directors and auditors  remuneration to the board of directors and the auditors  election of board of directors and auditorsThe nomination committee proposes that the board shall consist of four directors. The nomination committee further proposes that the number of auditors shall be one registered accounting firm.The nomination committee that the remuneration is to be SEK 1 000 000 in total and shall be paid to the board of directors and the members of the established committees as follows (SEK 1 000 000 previous year):SEK 400 000 (SEK 400 000) to the chairman and SEK 200 000 (SEK 200 000) to the other directors; andSEK 0 (SEK 0) to the chair of the audit and remuneration committee  and the other members of the committees respectively.The nomination committee proposes that the auditor shall be entitled to a fee in accordance with approved invoice.The nomination committee proposes the re-election of Marlou Janssen-Counotte  Ulf Ros√©n  Fredrik Buch and Philip Siberg as directors of the board. Further  the nomination committee proposes the re-election of Philip Siberg as chairman of the board.The nomination committee further proposes the re-election of the registered audit firm √ñhrling PricewaterhouseCoopers AB as the Company's auditor for a period up until the end of the next annual general meeting. √ñhrling PricewaterhouseCoopers AB has announced that the authorized auditor Cecilia Andr√©n Dorselius continues as main responsible auditor.The nomination committee's complete proposal and motivated opinion as well as further information regarding the directors proposed for re-election is available at the Company's website www.acarix.com and will also be available in the annual report for 2021.Item 12: Resolution regarding adoption of principles for the nomination committeeThe nomination committee proposes that the following principles for the nomination committee are adopted.Role of the nomination committeeThe Company shall have a nomination committee with the task of preparing and proposing decisions to the shareholders' meetings on electoral and remuneration issues and  where applicable  procedural issues for the appointment of the subsequent nomination committee. The nomination committee is to propose:the chairman of the annual general meeting;candidates for the post of chairman and other directors of the board;fees and other remuneration for board work to each director;fees to members of committees within the board;election and remuneration of the Company auditor; andprinciples for the nomination committee.The nomination committee shall in its assessment of the evaluation of the board an in its proposal in particular take into consideration the requirement of diversity and breadth on the board and strive for equal gender distribution. Regardless of how they have been appointed  the members of the nomination committee are to promote the interests of all shareholders of the Company.Members of the nomination committeeThe nomination committee  which shall be appointed for the time until a new nomination committee has been appointed  shall consist of three members  of whom three shall be nominated by the Company's two largest shareholders with respect to voting power and the third shall be the chairman of the board. The chairman of the board shall as soon as reasonably practicable after the end of the third quarter  in an adequate manner  contact the two owner-registered largest shareholders  with respect to votes  according to the share register kept by Euroclear Sweden AB at that time and request that they  taken into consideration the circumstances  within a reasonable time which may not exceed 30 days  nominate in writing to the nomination committee that person whom the shareholder wishes to appoint as member of the nomination committee. If any of the three largest shareholders elects not to exercise their right to appoint a member of the nomination committee  the next shareholder in consecutive order shall be entitled to appoint a member of the nomination committee. In the case that several shareholders abstain their right to appoint a member of the nomination committee  the chairman of the board shall not be required to contact more than eight shareholders  unless its necessary in order to obtain a nomination committee consisting of a minimum of three members.Unless otherwise agreed between the members  the chairman of the nomination committee shall be nominated by the largest shareholder. A member of the board of directors shall never be the chairman of the nomination committee.If a shareholder who is has appointed a member of the nomination committee during the year ceases to be one of the Company's three largest shareholders  the member appointed by such shareholder shall resign from the nomination committee. Instead  a new shareholder among the three largest shareholders shall be entitled to independently and in its sole discretion appoint a member of the nomination committee. However  no marginal changes in shareholding and no changes in shareholding which occur later than three months prior to the annual general meeting shall lead to a change in the composition of the nomination committee  unless there are exceptional reasons.If a member of the nomination committee resigns before the nomination committee has completed its assignment  for reasons other than set out in above  the shareholder has appointed such member shall be entitled to independently and in its sole discretion appoint a replacement member. If the chairman of the board resigns from the board  his/her successor shall replace the chairman of the board also on the nomination committee.A change in the composition of the nomination committee shall be published without undue delay on the website of the Company.Announcement of the nomination committee membersThe chairman of the board shall ensure that the names of the members of the nomination committee  together with the names of the shareholders they have been nominated by  are published on the Company's website no later than six months before the annual general meeting.If a member leaves the nomination committee during the year  or if a new member is appointed  the nomination committee shall ensure that such information  including the corresponding information about the new nomination committee member  is published on the website.Shareholders' rights to submit proposals to the nomination committeeShareholders shall be entitled to propose board members for consideration by the nomination committee. The nomination committee shall provide the Company with information on how shareholders may submit recommendations to the nomination committee. Such information shall be announced on the Company's website.The chairman of the board of directors shall  as part of the work of the nomination committee  keep the nomination committee informed about the work of the board of directors  the need for particular qualifications and competences  etc.  which may be of importance for the work of the nomination committee.The nomination committee's proposals  work and feesWhen preparing its proposals  the nomination committee shall take into account that the board of directors is to have a composition appropriate to the Company's operations  phase of development and other relevant circumstances. The directors shall collectively exhibit diversity and breadth of qualifications  experience and background. The nomination committee shall further strive for equal gender distribution.The nomination committee shall provide the Company with its proposals for board members in such time that the Company can present the proposals in the notice of the shareholders' meeting where an election is to take place.When the notice of the shareholders' meeting is issued  the nomination committee shall issue a statement on the Company's website explaining its proposals regarding the composition of the board of directors. The nomination committee shall in particular explain its proposal against the background of the requirement to strive for an equal gender distribution. The statement is also to include an account of how the nomination committee has conducted its work. In case a resigning managing director is nominated for the position of chairman of the board of directors  the nomination committee shall specifically explain the reasons for such proposal.The nomination committee shall ensure that the following information on candidates nominated for election or re-election to the board of directors is posted on the Company's website at the latest when the notice to the shareholders' meeting is issued:year of birth  principal education and work experience;any work performed for the Company and other significant professional commitments;any holdings of shares and other financial instruments in the Company owned by the candidate or the candidate's related natural or legal persons;whether the nomination committee deems the candidate to be independent from the Company and its executive management  as well as of the major shareholders in the Company. If the committee considers a candidate independent regardless of the existence of such circumstances which  according to the criteria of the Swedish Code of Corporate Governance  may give cause to consider the candidate not independent  the nomination committee shall explain its proposal; andin the case of re-election  the year that the person was first elected to the board.Account of the work of the nomination committeeAll members of the nomination committee  where possible  and as a minimum one of the members  shall be present at the annual general meeting.The nomination committee shall at the annual general meeting  or other shareholders' meetings where an election is to be held  give an account of how it has conducted its work and explain its proposals against the background of what is provided about the composition of the board as set out above. The nomination committee shall in particular explain its proposal against the background of the requirement as set out above to strive for an equal gender distribution.Fees and CostsNo fee shall be payable by the Company to any member of the nomination committee. The Company shall bear all reasonable costs associated with the work of the nomination committee. Where necessary  the nomination committee may engage external consultants to assist in finding candidates with the relevant experience  and the Company shall bear the costs for such consultants. The Company shall also provide the nomination committee with the human resources needed to support the nomination committee's work.ConfidentialityA member of the nomination committee may not unduly reveal to anyone what he/she has learned during the discharge of his/her assignment as a nomination committee member. The duty of confidentiality applies to oral as well as written information and applies also after the assignment has terminated.A nomination committee member shall store all confidential materials that he/she receives by reason of the nomination committee assignment in a manner so that the materials are not accessible to third parties. After the assignment has terminated  a nomination committee member shall hand over to the chairman of the board all confidential materials that the nomination committee member has received in his/her capacity as nomination committee member and still has in his/her possession  including any copies of the materials  to the extent reasonably possible taking into account inter alia technical aspects.The chairman of the nomination committee may make public statements about the work of the nomination committee. No other nomination committee member may make statements to the press or otherwise make public statements regarding the Company and the Company group unless the chairman of the board has given permission thereto.Item 13: Resolution regarding guidelines for the determination of remuneration to senior executivesUpon recommendation of the remuneration committee  the board of directors of the Company proposes that the annual general meeting resolves to adopt the following guidelines for remuneration to senior executives.The guidelines shall apply to remuneration that has been agreed upon or to changes in already agreed remunerations after the guidelines have been adopted by the annual general meeting. The guidelines do not apply to remunerations that has been resolved by the general meeting and any remuneration through shares  warrants  convertibles or other share-related instruments such as synthetic options or employ stock options shall therefore be resolved by the general meeting.These guidelines apply to the CEO and other senior executives in the company group and all other remuneration to members of the board except fees to the board of directors.Regarding employment conditions that are governed by rules other than Swedish  appropriate adjustments may be made in order to comply with such mandatory rules or established local practice  whereby the general objectives of these guidelines shall  to the extent possible  be met.Remuneration may consist of fixed cash salary  possible variable cash compensation  other customary benefits and pension. The total annual cash remuneration  including pension benefits  must be market-based and competitive in the employment market and in the work area in which the employee is situated  taking into account the individual's qualifications and experience and that outstanding achievements are to be reflected in the total remuneration. Fixed cash salary and variable cash remuneration shall be related to the executive's responsibility and authority. The fixed cash salary shall be revised annually.Fixed and variable salary shall be related to the senior executive's responsibility and authority. The variable cash remuneration shall be based on the outcome of pre-determined targets and should be designed with the aim of achieving greater alignment of interest between the participating senior executive and the Company's shareholders.The variable cash remuneration shall be based on and be related to the outcome in relation to predetermined and measurable concrete defined objectives based on the Company's business strategy and the long-term business plan approved by the board of directors. The objectives may include financial objectives  either at the group or unit level  operational objectives as well as objectives for sustainability and social responsibility  employee engagement or customer satisfaction  as well as individualized quantitative or qualitative goals. These objectives must be established and documented annually in order to promote the long-term development of executives. The Company has established financial targets and KPI's based on strategic and business-critical initiatives and projects that ensure fulfillment in accordance with the business plan and business strategy for a sustainable continued business and safeguarding the Company's long-term interests.The variable remuneration shall amount to a maximum of 100 percent of the fixed salary. The fulfillment of criteria for payment of variable cash compensation shall be measurable over a period of one year. Terms for variable remuneration should be designed so that the board of directors may limit or omit payment of variable remuneration  provided that exceptional economic circumstances are at hand  if the board of directors finds the payments unreasonable and incompatible with the Company's responsible in relation to its shareholders. With respect to yearly bonuses  it should be possible to limit or omit payments  if the board of directors finds it motivated because of any other reasons.Additional variable cash compensation may be payable in exceptional circumstances  provided that such arrangements are time-limited and made only at the individual level. The purpose of such arrangements must be to recruit or retain executives  or as compensation for extraordinary work in addition to the person's ordinary duties. Such compensation shall not exceed an amount corresponding to 50 percent of the fixed annual cash salary and shall not be paid more than once per year and per individual. A decision on such remuneration shall be made by the board of directors on proposal from the remuneration committee.Pension payments shall be fee determined. Senior executives shall be entitled to pension commitments based on those that are customary in the country in which they are employed. The maximum pension commitment shall not exceed 20 percent of the fixed annual cash salary. Pension commitments will be secured through premiums paid to insurance companies.Other benefits may include: life insurance  health insurance and car benefit. Such benefits may amount to a maximum of 10 percent of the fixed annual cash salary.For executives who are stationed in a country other than their home country  additional remuneration and other benefits may be paid to a reasonable extent  taking into account the particular circumstances associated with such expatriation  whereby the overall purpose of these guidelines is to be met as far as possible. Such benefits may amount to a maximum of 20 percent of the fixed annual cash salary.Payment of consultancy fees and additional remuneration may be paid to directors after decision by the board of directors  if a director performs services on behalf of the Company  which do not constitute board work.Fixed salary during the notice period and severance pay shall in total not exceed an amount corresponding to a maximum of a two years' fixed salary.The board of directors shall be entitled to deviate from the guidelines in an individual case if there are special reasons for it.Decisions regarding salary and other remuneration to the managing director and other senior executives are prepared by the remuneration committee and resolved on by the board of directors.The total amount of remuneration granted or to be granted directly or indirectly by the Company to the senior executives is fully described in the consolidated financial accounts of the Company  as disclosed in its annual accounts for 2021  which is available at the Company's website  www.acarix.com.Item 14: Resolution regarding authorization for the board to issue shares  convertibles and/or warrantsThe board of directors of the Company proposes that the annual general meeting resolves to authorize the board of directors during the period up until the next annual general meeting  on one or more occasions  to resolve to issue shares  convertibles and/or warrants  with or without preferential rights for the shareholders  in the amount not exceeding twenty (20) percent of the total number of shares in the Company at the time of the annual general meeting  to be paid in cash  in kind and/or by way of set-off.The purpose for the board to resolve on issuances with deviation from the shareholders preferential rights in accordance with the above is primarily for the purpose to raise new capital to increase flexibility of the Company or in connection with acquisitions.Issuances of new shares under the authorization shall be made on customary terms and conditions based on current market conditions. If the board of directors finds it suitable in order to enable delivery of shares in connection with a share issuance as set out above it may be made at a subscription price corresponding to the shares quota value.The board of directors or anyone appointed by the board of directors is given the right to make the adjustments necessary in connection with the registration of the resolution at the Companies Registration Office.Item 15: Resolution regarding an employee stock option program for senior executives  other employees and key individuals in the company and the group in Sweden  Denmark  Germany and USABackground and motiveThe board of directors of the Company proposes that the annual general meeting resolves to establish an employee stock option program for senior executives  other employees and key individuals in the Company and the group in Sweden  Denmark  Germany and USA (the ""Employee Stock Option Program 2022/2026"") in accordance with the below.The purpose with the proposal is to create conditions to retain and increase motivation with senior executives  other employees and other key individuals in the Company and the group in Sweden  Denmark  Germany and USA. The board of directors believes that it is in the interest of all shareholders that senior executives  employees and other key individuals  which are assessed to be of importance for the development of the group have a long-term interest of a positive value growth in the Company's shares. A long-term ownership engagement is expected to stimulate increased interest in the business and the earnings development in general as well as increasing the motivation for the participants and aims to achieve increased alignment between the participant and the Company's shareholders. Furthermore  the program is expected to increase the possibility of recruiting competent personnel.In order to hedge the Company's obligations under the Employee Stock Option Program 2022/2026 and hedge the ancillary costs  the board of directors also proposes that the annual general meeting resolves on a directed issue of warrants  as well as an approval of transfer of warrants in accordance items 15a and 15b.Resolutions in accordance with items 15a and 15b below are taken as one decision and are thus conditional of each other.A presentation of other incentive programs  preparation of the proposal  costs for the programs and effects on key performance measures etc. are described below.Item 15a): Proposal regarding resolution to issue warrants employee stock optionsThe board of directors of the Company proposes that the annual general meeting resolves to establish Employee Stock Option Program 2022/2026 in accordance with the following main guidelines:The Employee Stock Option Program 2022/2026 shall consist of a maximum of 3 500 000 stock options.Each stock option confers the holder a right to acquire one new share in the Company against an exercise price corresponding to 130 percent of the average volume weighted price for the Company's share as quoted on Nasdaq First North Premier Growth Market during the period from and including 30 December 2022 up to and including 13 January 2023. The calculated exercise price shall be rounded off to nearest even hundredth of a SEK  whereupon SEK 0.005 will be rounded to SEK 0.01. The exercise price and number of shares that each stock option confers right to acquire may be re-calculated in the event of a bonus issue  reverse share split or share split  rights issue  etc.  whereby the re-calculation terms in the terms for Warrants 2022/2026 shall apply.The Employee Stock Option Program 2022/2026 shall be offered  at one or several occasions  to (i) all existing and future senior executives and other employees in the group's business in USA until and including 15 January 2023 and (ii) the existing and future key individuals that (personally or through companies) work in the group's business in Sweden  Denmark  Germany or USA as of the mentioned date and who are selected by the board of directors based on their importance for the group. Employees refers to full-time and part-time employees  but not hourly employees. A person who has entered into an employment agreement with the group but has not taken up his/her employment as of the mentioned date  shall not be regarded as an employee. An employee who has terminated the employment or has been dismissed by the mentioned date but is still employed  shall not be regarded as an employee.Senior executives and other employees within the Company and the group in Sweden  Denmark  Germany and USA will within the framework of Employee Stock Option Program 2022/2026 be offered stock options in three different categories in accordance with the following:A. The managing director may be offered a maximum of 700 000 stock options;B. Managers in the group consisting of up to four individuals  of which each may be offered a maximum of 500 000 stock options  totaling a maximum of 1 600 000 stock options;C. Key individuals in the group consisting of up to ten individuals  of which each may be offered a maximum of 200 000 stock options  totaling a maximum of 1 000 000 stock options; andD. Other employees and consultants in the group consisting of up to five individuals  of which each may be offered a maximum of 40 000 warrants  totaling a maximum of 200 000 warrants.Stock options offered to the categories above which are not accepted by the categories above  can later be offered to existing (who does not subscribe their full offered share) and future senior executives or other employees in the group in Sweden  Denmark  Germany and USA within the framework of the now proposed principles for allotment. Oversubscription may not occur. In the event that any individual within the abovementioned categories does not subscribe for their full share  such share may be transferred to another category.The Company's board of directors shall not be included in the Employee Stock Option Program 2022/2026.Notice of participation in the Employee Stock Option Program 2022/2026 shall be received by the Company on 15 January 2023 at the latest  with a right for the board of directors to prolong the time limit. Allotment of stock options to participants shall take place as soon as possible after the expiration of the notification period.The allotted stock options will be vested over a three-year period in accordance with the following:a) 40 percent of the allotted stock options will be vesting on 31 January 2023; andb) 60 percent of the allotted stock options will be vesting in linear quarterly instalments from 1 February 2023 up to and including 1 March 2026.Vesting requires that the participant is still active within the group and that the employment has not been terminated as of the date when the respective vesting occurs. If a participant ceases to be an employee or terminates his/her employment with the group before a vesting date  the already vested stock options may be exercised at the ordinary time for exercise as described below  but further vesting will not take place. If the employee's employment ceases due to dismissal from the employer's side  however  also vested options will lapse  unless the board of directors decides otherwise on a case-by-case basis.The stock options shall not constitute securities and shall not be able to be transferred or pledged. However  in the event of death  the rights constituted by vested stock options shall accrue to the beneficiaries of the holder of the stock options.The stock options shall be allotted without consideration.The holder can exercise allotted and vested stock options during the period from the vesting date up to and including 31 May 2026. The board of directors has the right to limit the number of dates for delivery of shares during the exercise period.Participation in the Employee Stock Option Program 2022/2026 requires that such participation is in accordance with applicable laws  as well as that such participation can be executed with reasonable administrative costs and financial efforts according to the Company's assessment.The stock options shall be governed by separate agreements with each participant. The board of directors shall be responsible for the preparation and management of the Employee Stock Option Program 2022/2026 within the above-mentioned substantial terms and guidelines. The board of directors has the right to  within the framework of the agreement with each participant  make the reasonable changes and adjustments of the terms and conditions of the stock options that are deemed suitable or appropriate as a result of local employment law or tax law or administrative conditions. This may mean  among other things  that continued vesting of stock options may take place in some cases when otherwise would not have been the case. The board of directors also has the right to advance vesting and the timing of exercise of stock options in certain cases  such as in the case of a public takeover offer  certain changes in ownership of the Company  liquidation  merger and similar measures. Finally  the board of directors has the right to  in extraordinary cases  limit the scope of  or prematurely terminate  the Employee Stock Option Program 2022/2026 in whole or in part.Item 15b): Proposal regarding resolution to issue warrants and approval of transfer of warrantsIn order to enable the Company's delivery of shares under the Employee Stock Option Program 2022/2026 as well as to hedge ancillary costs  primarily social security contributions  the board of directors proposes that the annual general meeting resolves on a directed issue of warrants of series 2022/2026 as well as an approval of transfer of warrants of series 2022/2026.The board of directors of the Company proposes that the annual general meeting resolves to issue a maximum of 3 500 000 warrants  which may result in a maximum increase in the Company's share capital of SEK 30 000. The warrants shall entitle to subscription of new shares in the Company.The following terms shall apply to the issuance:The warrants may  with deviation from the shareholders' preferential rights  be subscribed for by the Company and Acarix Incentives AB  reg. no 559102-0044  (the ""Subsidiary"") and any other group company.The warrants are issued at no consideration and shall be subscribed for through a separate subscription list no later than on 30 May 2022. The board of directors has the right to extend the time for subscription.Each warrant entitles to subscription of one new share in the Company during the period from 15 January 2023 up to an including 31 May 2026 or the earlier date set forth in the terms for the warrants.Each warrant entitles to subscribe for one new share in the Company against cash payment at a subscription price corresponding to 130 percent of the average volume weighted price for the Company's share as quoted on Nasdaq First North Premier Growth Market during the period from and including 30 December 2022 up to and including 13 January 2023. The calculated subscription price shall be rounded off to nearest even hundredth of a SEK  whereupon SEK 0.005 will be rounded to SEK 0.01. The subscription price may not be set below the shares' par value. Upon subscription of shares  the part of the subscription price that exceeds the quotient value of the previous shares shall be allocated to the non-restricted share premium fund.A new share subscribed for by exercise of a warrant has a right to dividends as of the first record day for dividends following registration of the new share issue with the Companies Registration Office and after the share has been registered in the share register maintained by Euroclear Sweden AB.The purpose of the issuance  and deviation from the shareholders' preferential rights  is to  within the framework of Employee Stock Option Program 2022/2026  secure delivery of shares to the participants of the program.The complete terms and conditions for the warrants are available at the Company at least three weeks prior to the meeting  including conditions regarding re-calculation  in certain cases  of the subscription price and the number of shares a warrant entitles to.The board of directors or a person nominated by it  shall be authorized to make such minor adjustments as may be required in connection with registration of the resolution with the Swedish Companies Registration Office and  if applicable  Euroclear Sweden AB.The board of directors further proposes that the annual general meeting resolves to approve that the Company  the Subsidiary  or any other group Company  may transfer warrants to the participants in the Employee Stock Option Program 2022/2026 without consideration in connection with exercise of the stock options in accordance with the terms set out in item 15a or in another way dispose of the warrants in order to be able to secure the Company's commitments and costs in relation to the Employee Stock Option Program 2022/2026. The board of directors shall not have the right to dispose of the warrants for any other purpose than to secure the Company's commitments and costs in connection with the Employee Stock Option Program 2022/2026.Preparation of incentive programs etc. (it is noted that this is not a topic for resolution)Proposal on Employee Stock Option Program 2022/2026 has been prepared by external advisors in consultation with the remuneration committee and the board of directors.Valuation and Costs and effects on key figuresEmploye e Stock Option Program 2022/2026Costs related to Employee Stock Option Program 2022/2026 will be recognised in accordance with IFRS 2  which means that the stock options are expensed as personnel costs during the vesting period.Based on the assumption that 100 percent of the options in the Employee Stock Option Program 2022/2026 will be allotted and an annual employee turnover rate of 10 percent  meaning that approximately 2 550 000 stock options will vest  the estimated total accounting salary costs for the options will amount to approximately SEK 720 000 during the time period 2022-2026  based on the actual value of the options at the time of calculation. The options do not have a market value since they are not transferable. However  the board of directors has calculated a theoretical value of the options in accordance with the Black Scholes formula. The calculations have been based on a by the board of directors estimated share price of SEK 0 68 per share  a risk-free interest rate of 0.95 percent and an assumed volatility of 40 percent. In accordance with this valuation  the value of the options in the Employee Stock Option Program 2022/2026 is approximately SEK 0.14 per option. Limitations in the disposal rights have not been taken into consideration in the valuation.Upon a positive development of the share price  the Employee Stock Option Program 2022/2026 may entail costs in the form of social security contributions. The total costs for social security contributions will depend on the employment form of the participant  the number of options that will be vested and on the value of the benefit that the participant finally will receive  i.e. on the value of the options when exercised 2024  but also in which countries the participants are resident and what rates that apply for social security contributions in these countries. Based on the assumption that all 3 500 000 options in Employee Stock Option Program 2022/2026 will be vested  an assumed share price of SEK 2 when the options are exercised and an assumed average social security rate of approximately 8.3 percent and an annual staff turnover of approximately 10 percent  the total costs for social security contributions will amount to approximately SEK 230 000.The Company's entire costs for social security contributions are proposed to be hedged through a directed issue of warrants in accordance with item 15b.The total cost for Employee Stock Option Program 2022/2026 will be distributed over the years 2022-2026. Since 40 percent of the options the first year and 60 percent vest in quarterly installments  the cost will be distributed unevenly over the period  with an emphasis at the beginning of the period.Given the above assumptions  including an assumed share price of 2 SEK at the time of exercise of the options  and that the program had been introduced in 2020 instead  it is calculated that the key figure earnings per share for full year 2021 would be unaffected.It shall be noted that all calculations above are preliminary  based on assumptions and are only intended to provide an illustration of what costs Employee Stock Option Program 2022/2026 may entail. Actual costs may therefore deviate from what has been stated above.Costs in the form of fees to external advisers and costs for administering Employee Stock Option Program 2022/2026 are estimated to amount to approximately SEK 200 000.Other outstanding share based incentive programsThe Company has previously established three incentive program  warrant series 2021/2025 (""Incentive Program 2021/2025"")  warrant series 2020/2023 (""Incentive Program 2020/2023"") and employee stock options of series 2021/2024 (""Employee Stock Option Program 2021/2024"").There are 2 000 000 outstanding warrants under the Employee Stock Option Program 2021/2024. Each such warrant entitles the holder to subscribe for one new share in the Company during the period from 1 June 2025 up to and including 31 August 2025.There are 2 000 000 outstanding warrants under the Incentive Program 2021/2025. Each such warrant entitles the holder to subscribe for one new share in the Company during the period from 1 June 2025 up to and including 31 August 2025.There are 3 000 000 outstanding warrants under the Incentive Program 2020/2023. Each such warrant entitles the holder to subscribe for one new share in the Company at a subscription price of SEK 1 17 during the period from 1 August 2023 up to and including 1 October 2023.For more information  see the Company's annual report for 2020.DilutionThe total number of registered shares and votes at the time of this proposal amount to 251 972 194.In case all warrants issued under Employee Stock Option Program 2022/2026 are exercised for subscription of new shares  the number of shares and votes in the Company will increase with 3 500 000 (with reservation for any re-calculation in accordance with the warrant terms and conditions)  which corresponds to a dilution of approximately 1.37 percent of the Company's share capital and votes (based on the current outstanding shares in the Company).The maximum dilution of Incentive Program 2020/2023  Warrant program 2021/2025  Employee Stock option Program 2021/2024 and Employee Stock Option Program 2022/2026 plus the other outstanding incentive programs in the Company is estimated to be a maximum of approximately 4.11 percent  assuming full subscription and exercise of all warrants offered and outstanding.Majority requirementsA resolution in accordance with item 14 requires support by shareholders holding not less than two-thirds of both the shares voted and of the shares represented at the general meeting.A resolution in accordance with item 15 requires support by shareholders holding not less than nine-tenths of both the shares voted and of the shares represented at the general meeting  due to the fact that the issue and transfer of warrants is made to persons who belong to one or more of the categories according to Ch. 16 of the Swedish Companies Act.Number of shares and votesThe total number of shares and votes in the Company as of the date hereof amounts to 251 972 194. The Company holds no own shares.Further informationCopies of accounts  audit report  complete proposals  proxy forms  and other documents that shall be available in accordance with the Swedish Companies Act are available at the Company at Jungmansgatan 12  211 19 in Malm√∂ and at the Company's website www.acarix.com  at least three (3) weeks in advance of the annual general meeting and will be sent to shareholders who request it and provide their e-mail or postal address. A statement on the nomination committee's proposal regarding the board of directors is available on the Company's website as from today and will be sent to shareholders who request this report and provide their e-mail or postal address.The shareholders hereby notified regarding the right to  at the annual general meeting  request information from the board of directors and managing director according to Ch. 7 ¬ß 32 of the Swedish Companies Act.Processing of personal dataFor information on how personal data is processed in relation the meeting  see the Privacy notice available on Euroclear Sweden AB's website:https://www.euroclear.com/dam/ESwithLegal/Privacy-notice-bolagsstammor-engelska.pdf* * * * *Malm√∂ in April 2022Acarix ABThe board of directorsAttachment",neutral,0.02,0.95,0.03,mixed,0.3,0.33,0.38,True,English,"['Annual General Meeting', 'Acarix AB', 'Notice', 'employee stock option program', 'one registered accounting firm', 'employee stock options', 'share classes address', 'group annual report', 'Annual General Meeting', 'group audit report', 'group income statement', 'group balance sheet', 'Euroclear Sweden AB', 'personal/corporate identity number', 'complete authorization documents', 'Nominee registered shares', 'other documents', 'share register', 'Acarix AB', 'McKenzie Advokatbyr√•', 'record date', 'advance votes', 'longer term', 'five years', 'voting list', 'two persons', 'managing director', 'nomination committee', 'senior executives', 'other employees', 'key individuals', 'Carl Isaksson', 'LL.M.', 'telephone number', 'relevant nominee', 'registration certificates', 'Voting registration', 'legal person', 'Thursday 5 May', 'four directors', 'form proxy', '11 May', 'Notice', 'shareholders', 'Company', 'Wednesday', '10:00 AM', 'Baker', 'office', 'Vasagatan', 'Stockholm', 'Right', 'Tuesday', 'participation', 'assistants', 'notification', 'writing', 'Jungmansgatan', 'Malm√∂', 'mail', 'name', 'shareholding', 'information', 'representatives', 'counsels', 'powers', 'attorney', 'order', 'time', 'preparations', 'authority', 'website', 'Story', 'agenda', '1 Opening', '2 Election', 'chairman', 'approval', '4 Election', 'minutes', '5 Determination', 'Presentation', '8 Resolutions', 'adoption', 'appropriation', 'profit', 'loss', 'accordance', 'discharge', 'liability', '9 Determination', 'auditors', '10 Determination', 'remuneration', 'board', '11 Election', 'principles', '13 Resolution', 'guidelines', '14 Resolution', 'convertibles', 'warrants', '15 Resolution', 'Denmark', 'Germany', 'USA', 'Proposal', 'transfer', 'Closing', 'Item', 'absence', 'funds', 'total', 'members', 'committees', 'SEK', '211', '7']",2022-04-11,2022-04-11,nz.finance.yahoo.com
2642,Euroclear,Bing API,https://www.finanznachrichten.de/nachrichten-2022-04/55745376-notice-to-annual-general-meeting-of-spago-nanomedical-ab-200.htm,Notice to Annual General Meeting of Spago Nanomedical AB,LUND  SWEDEN / ACCESSWIRE / April 11  2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)The shareholders of Spago Nanomedical AB (publ)  corporate registration number 556574-5048 are hereby summoned t,"LUND  SWEDEN / ACCESSWIRE / April 11  2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)The shareholders of Spago Nanomedical AB (publ)  corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Wednesday May 18  2022  at 4.00 p.m. CEST in the premises of Advokatfirman Cederquist at Hovslagargatan 3 in Stockholm.Right to attendShareholders wishing to attend the Annual General Meeting shall:be registered in the share register kept by Euroclear Sweden AB on Tuesday May 10  2022 and give notice of their intention to attend the Annual General Meeting of Spago Nanomedical no later than Thursday May 12  2022. Notice of attendance may be given:by e-mail to ursula.sorqvist@cederquist.se by mail to Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB  AGM 2022"")  or by phone +46 (0)8 522 065 34 between 9.00 a.m. and 4.00 p.m CEST.When giving notice of attendance  the shareholders shall state their name  address  daytime telephone number  personal identification number or company registration number and any assistants who shall participate (but not more than two).Nominee-registered sharesShareholders whose shares are nominee-registered must  to be entitled to exercise their voting rights and attend the Annual General Meeting  temporarily register such shares in their own names in the share register kept by Euroclear Sweden (so called voting right registration). The shareholders' register as of the record date  Tuesday May 10  2022  will consider voting right registrations made no later than the second banking day after May 10  2022. This means that shareholders should notify their nominee in this matter well in advance of this date.Proxy etc.Shareholders who wish to participate through a proxy representative should send power of attorneys  certificates of incorporation and other authorisation documents to Spago Nanomedical to the above address well in advance of the Annual General Meeting. Such original power of attorney shall be brought to the Annual General Meeting. A proxy form is available on the company's website  www.spagonanomedical.se.Personal data processingIn connection with the notice of attendance the company will process the personal data regarding shareholders that has been requested in accordance with the above. The personal data collected from the share register  notice of attendance at the Annual General Meeting and information on proxies and assistants will be used for registration  preparation of the voting list and  where applicable  minutes of the Annual General Meeting. The personal data will only be used for the Annual General Meeting. For further information on how your personal data is processed by the company and your rights  please see the company's website  www.spagonanomedical.se.Proposed agendaOpening of the Annual General Meeting. Election of chairman of the Annual General Meeting. Preparation and approval of the voting list. Election of one or two persons to verify the minutes. Approval of the agenda. Determination of whether the meeting has been duly convened. Presentation of the annual report and the auditor's report. Presentation by the CEO. Resolutions on adoption of the income statement and balance sheet. dispositions regarding the company's earnings in accordance with the adopted balance sheet. discharge from liability for the directors of the board and the CEO for the financial year 2021. Determination of the number of directors and deputy directors of the board. Determination of remuneration to the directors of the board and the auditors. Election of directors and chairman of the board of directors. Election of auditor. Resolution on adopting instructions to the nomination committee. Resolution on amendments to the articles of association. Resolution on authorisation for the board of directors to resolve to issue new shares. Closing of the Annual General Meeting.Proposed resolutionsItem 2. Election of chairman of the Annual General MeetingThe nomination committee proposes that Tone Myhre-Jensen  member of the Swedish Bar Association  is elected chairman of the Annual General Meeting  or  if she should be unable to attend the meeting  the person appointed by the nomination committee.Item 9. b) Resolution on dispositions regarding the company's earnings in accordance with the adopted balance sheetThe board of directors proposes that accumulated funds of KSEK 59 211  of which KSEK -39 071 are the results for the year  be transferred to new accounts.Item 10. Determination of the number of directors and deputy directors of the boardThe nomination committee proposes that the board of directors  for the period until the end of the next Annual General Meeting  shall consist of five directors with no deputies.Item 11. Determination of remuneration to the directors of the board and the auditorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that remuneration of SEK 200 000 (unchanged) shall be paid to the chairman of the board of directors and SEK 95 000 (unchanged) shall be paid to each of the other directors of the board.The nomination committee proposes that remuneration to the auditor shall be paid in accordance with approved invoices.Item 12. Election of directors and chairman of the board of directorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that Peter Leander  Sten Nilsson  Kari Gr√∏n√•s  Eugen Steiner and Nicklas Westerholm shall be re-elected as directors of the board.The nomination committee proposes that Eugen Steiner shall be re-elected as chairman of the board of directors.Further information about the proposed directors is available on the company's website  www.spagonanomedical.se.Item 13. Election of auditorThe nomination committee proposes that the registered accounting firm BDO M√§lardalen AB is re-elected as auditor for the period until the end of the next Annual General Meeting. BDO M√§lardalen AB has informed the nomination committee that if re-elected  J√∂rgen L√∂vgren  authorised public accountant  will continue to be the auditor in charge.Item 14. Resolution on adopting instructions to the nomination committeeThe nomination committee proposes that the Annual General Meeting resolves to adopt the following instructions for the nomination committee  to apply until the General Meeting decides otherwise.The nomination committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for resolutions:proposal for chairman of the meeting proposal for number of directors and deputy directors of the board proposal for directors and any deputy directors of the board proposal for chairman of the board of directors proposal for remuneration and other fees for board assignments to each of the board members and remuneration for committee work proposal for auditor (if applicable) proposal for fees for the auditor of the company  and proposal for instructions for the nomination committee's work and compositionThe nomination committee shall consist of at least three members and be formed in consultation with the largest shareholders of the company as per September 30th and who wish to appoint a member. It is the responsibility of the chairman of the board of directors to convene the nomination committee for its first meeting and to be available  when necessary  in the nomination committee's work. The chairman of the board of directors shall not be a member of the nomination committee. The nomination committee shall appoint a chairman for the nomination committee at its first meeting.The nomination committee is appointed for a period from the time it is formed until the next nomination committee is formed. If a member leaves its assignment prematurely  the nomination committee may appoint a new member. Provided that the shareholder who appointed the resigned member is still one of the largest shareholders in the company  the shareholder shall be asked to appoint a new member. If this shareholder refrains from appointing a new member  the nomination committee may ask the next shareholder in order of size of shareholding who has not previously appointed a member of the nomination committee. The chairman of the nomination committee shall  however  continue to contact shareholders next in turn if necessary for the nomination committee to consist of three members. If the ownership structure of the company changes  the nomination committee may choose to change its composition so that the nomination committee reflects the ownership structure of the company in an appropriate manner. However  the total number of members may never exceed five. Even if there are changes in the company's ownership structure  no changes need to be made in the composition of the nomination committee in the event of minor changes or if a change occurs less than three months before the Annual General Meeting  unless it is motivated due to special circumstances.Remuneration shall only be paid for costs attributable to contracting recruitment consultants in connection with the nomination committee's work and other potential direct costs that are necessary for the nomination committee to be able to fulfil its work. No remuneration shall be paid to the members of the nomination committee.The nomination committee shall annually evaluate these instructions and  if necessary  propose changes to the Annual General Meeting. These instructions shall apply until the Annual General Meeting decides otherwise.Item 15. Resolution on amendments to the articles of associationThe board of directors proposes that the Annual General Meeting resolves to change the articles of association's (i) ¬ß 4 so that the limits for the company's share capital are adjusted  and (ii) ¬ß 5 so that the limits for the number of shares are adjusted. ¬ß¬ß 4 and 5 of the articles of association will then have the following wordings:¬ß 4 Share capitalThe share capital shall amount to a minimum of SEK 40 000 000 and a maximum of SEK 160 000 000.¬ß 5 Number of sharesThe number of shares may not be fewer than 40 000 000 and not exceed 160 000 000.Item 16. Resolution on authorisation for the board of directors to resolve to issue new sharesThe board of directors proposes that the General Meeting resolves on authorisation for the board of directors to resolve to issue new shares in accordance with the following.The board of directors is authorised to  on one or several occasions before the next Annual General Meeting  resolve to issue new shares. Such issues of new shares may be made with or without deviation from the shareholders' preferential rights. By resolutions based on the authorisation to issue new shares  issues of shares without deviation from the shareholders' preferential rights may be made up to  in total  as many shares as falls within the limits of the articles of association at the time of exercise of the authorisation. By resolutions based on the authorisation to issue new shares  issues of shares with deviation from the shareholders' preferential rights may be made up to  in total  the number of shares corresponding to twenty (20) percent of the total number of outstanding shares in the company at the time of exercise of the authorisation the first time. The authorisation shall include the right to resolve on issues where payment is made in cash  by contribution in kind or by way of set-off. A cash issue or issue by way of set-off that is made with deviation from the shareholders' preferential rights shall be in line with market terms.The purpose of the authorisation and the reasons for potential deviations from the shareholders' preferential rights are that issues shall be able to be made in order to enable capital raisings if market conditions would be deemed appropriate and/or to broaden the ownership base of Spago Nanomedical by offering financial and industrial investors to invest in the company.Other informationMajority requirementsThe resolutions of the Annual General Meeting pursuant to items 15 and 16 above require that the resolutions are supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.Number of sharesSpago Nanomedical has a total of 41 182 287 shares with one vote each  thus a total of 41 182 287 votes.Shareholders' right to receive informationShareholders have the right to  if the board of directors believes that it can be done without significant damage to the company  receive information from the board of directors and the CEO regarding circumstances that may affect the assessment of a matter on the agenda or the company's financial situation. Shareholders who wish to submit questions in advance of the Annual General Meeting can do so in writing to Spago Nanomedical AB (publ)  c/o Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB (publ)  AGM 2022"") or by sending an e-mail to ursula.sorqvist@cederquist.se (state ""Spago Nanomedical AB (publ)  AGM 2022"" as the subject).DocumentsProxy forms  information regarding proposed board members  proposed new articles of association  accounting documents and auditor's report are available at Spago Nanomedical no later than from April 27  2022  and on the company's website www.spagonanomedical.se  and will also be sent free of charge to shareholders who so requests and states their postal or e-mail address. The documents are available at the Annual General Meeting.________________Lund  April 2022Spago Nanomedical AB (publ)The board of directorsFor further information  please contact Mats Hansen  CEO Spago Nanomedical AB  +46 46 811 88  mats.hansen@spagonanomedical.seSpago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information  see www.spagonanomedical.se.FNCA Sweden AB is the Certified Adviser of the company  +46 8 528 00 399  info@fnca.se.AttachmentsNotice to Annual General Meeting of Spago Nanomedical AB (publ)SOURCE: Spago NanomedicalView source version on accesswire.com:https://www.accesswire.com/696848/Notice-to-Annual-General-Meeting-of-Spago-Nanomedical-AB-publ",neutral,0.02,0.95,0.03,negative,0.05,0.38,0.57,True,English,"['Annual General Meeting', 'Spago Nanomedical AB', 'Notice', 'next Annual General Meeting', 'P.O. Box', 'second banking day', 'daytime telephone number', 'Ursula S√∂rqvist', 'other authorisation documents', 'Such original power', 'Swedish Bar Association', 'Spago Nanomedical AB', 'personal identification number', 'Personal data processing', 'Euroclear Sweden AB', 'voting right registrations', 'company registration number', 'annual report', 'voting list', 'corporate registration', 'share register', 'two persons', 'income statement', 'balance sheet', 'nomination committee', 'Tone Myhre-Jensen', 'new accounts', 'voting rights', 'Advokatfirman Cederquist', 'proxy representative', 'proxy form', 'Wednesday May', 'Thursday May', 'Nominee-registered shares', 'record date', 'financial year', 'new shares', 'deputy directors', 'five directors', ""shareholders' register"", 'LUND', 'ACCESSWIRE', 'April', 'FRA', '7UX', 'publ', 'premises', 'Hovslagargatan', 'Stockholm', 'Tuesday', 'notice', 'intention', 'attendance', 'mail', 'sorqvist', 'envelope', 'AGM', '9.00 a', 'CEST', 'name', 'address', 'assistants', 'matter', 'advance', 'attorneys', 'certificates', 'incorporation', 'website', 'spagonanomedical', 'connection', 'accordance', 'information', 'proxies', 'preparation', 'minutes', 'agenda', 'Opening', 'Election', 'chairman', 'approval', 'Determination', 'Presentation', 'auditor', 'CEO', 'Resolutions', 'adoption', 'dispositions', 'earnings', 'discharge', 'liability', 'board', 'remuneration', 'instructions', 'amendments', 'articles', 'Closing', 'Item', 'member', 'funds', 'KSEK', 'results', 'period', 'deputies', '4.00']",2022-04-05,2022-04-11,finanznachrichten.de
2643,Euroclear,Bing API,https://www.ndtv.com/business/how-governments-global-bond-index-inclusion-unraveled-report-2876993,How Government's Global Bond Index Inclusion Unraveled: Report,For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market.,Many believe global bond index inclusion isnt likely for at least a year.For months  India prepared for a remarkable milestone: getting its bonds listed on global indexes. Inclusion was perceived as a crucial step change for the $1 trillion market. Banks penciled in inflows of as much as $40 billion for a country that has long lagged behind peers in tapping international wealth.The timeline seemed so final that Citigroup Inc. advised its clients to buy Indian debt in anticipation that key tax exemptions would be announced to facilitate the change. Policy makers and analysts predicted inclusion as early as April 1  the start of the new financial year.So it came as a shock when Finance Minister Nirmala Sitharaman didn't make any mention of it in her February budget speech. The sudden silence puzzled traders. Within a day  Citi reversed its buy-call. Local debt markets saw the sharpest sell-off in almost two years. It was as if a plan had never existed.In interviews  Indian officials who were part of discussions described how politics and contentious tax negotiations intertwined to stall progress. Bankers worried about volatile inflows. Powerful Hindu nationalist groups raised eleventh hour concerns that exempting foreigners from taxes would lead to discrimination against domestic investors  according to the people  who asked not to be identified citing privacy rules.Now  many believe inclusion isn't likely for at least a year. Officials say a path forward isn't possible until Group of 20 nations reach a consensus on a country's right to tax capital gains  another pressure point for India.‚ÄúFrom India's perspective  we are losing an opportunity to tap a pool of liquidity and an investor base ‚Äù said Nagaraj Kulkarni  Senior Asia Rates Strategist at Standard Chartered Plc in Singapore. ‚ÄúFrom a foreign investors' perspective  India is one of the largest EM bond markets that is yet to be included in major bond indexes.‚ÄùWith inclusion shelved  ‚Äúinvestors lose out on a relatively high-yielding market that also offers risk diversification benefits ‚Äù he said.An About-FaceThe challenges facing India are partly structural.Global investors want India to get its bonds on international clearing platforms  which help settle securities transactions. For that to happen  Euroclear  one of the major ones  has pushed India to exempt the transactions from taxes to avoid compliance issues. Other countries using the platform follow that policy.In India  progress seemed steady. In September  a senior official from the finance ministry said most of the work had been done. Tax authorities appeared ready to exempt these transactions  according to a person familiar with the matter. Morgan Stanley predicted inclusion to some indexes as early as the second quarter of 2022. FTSE Russell put India on its watchlist.Sitharaman was supposed to reveal the change in the February 1 budget talk. Euroclear expected the tweak right up until the speech  according to a finance ministry official.When she said nothing  Euroclear was caught off-guard  the official said. So was the market: Citi quickly reversed its buy-call on India long bonds. Traders called the ministry searching for answers.Euroclear didn't reply to multiple requests for comment. A spokesperson for India's finance ministry didn't respond to an email seeking clarification.Bloomberg LP is the parent company of Bloomberg Index Services Limited (BISL)  which administers indexes that compete with indexes from other providers.What Went WrongIn hindsight  officials said India's reversal connects to an October announcement from the Organisation for Economic Co-operation and Development  the Paris-based group that develops international fiscal policy.To address tax avoidance issues  the OECD helped broker an agreement with 136 countries to implement a global minimum rate. India  which is a member of the group  took the position that countries had the right to tax capital gains based on the location of underlying assets.That created an optics problem. In discussions about index inclusion  the finance ministry had carved out a path to exempt international bond transactions from taxes. Now  Indian authorities had put forward a different perspective at public OECD forums. Around the beginning of 2022  the tax department  worried about this contradiction  made a decision not to follow through with the exemption  people familiar with the matter said.Meanwhile  in January  Hindu nationalist groups linked to Prime Minister Narendra Modi's party met with senior government officials. They argued that it was unfair for foreigners to receive tax waivers when local investors did not get similar benefits.These groups have enjoyed increasing clout since Modi rose to power in 2014  partly because they can influence local businesses -- his party's traditional vote bank. Every year  they hold informal discussions with the government ahead of the budget  one person said. In 2019  when the groups opposed a plan to issue a dollar-denominated sovereign bond  the proposal was scrapped. Their opposition contributed to the transfer of a top bureaucrat who supported it.‚ÄúThere is no reason why we should give advantages to foreign investors ‚Äù Ashwani Mahajan  one of the leaders of Swadeshi Jagran Manch  a Hindu nationalist group  told Bloomberg a few days before the February budget speech.Looking AheadFor now  index inclusion appears all but impossible in the short term.In a recent interview with Bloomberg  Ajay Seth  the secretary of India's economic affairs ministry  said index providers made last minute requests. Other officials said Euroclear kept moving its goal post  including tax changes beyond the capital gains issue.The inclusion delay has already impacted India's bond market. In recent months  yields rose amid a surge in global crude prices. Key banks are adjusting interest rates to keep pace with inflation. That's a concern for the government as it plans to borrow a record amount from the markets to bridge a wide fiscal gap.‚ÄúWith a large supply looming  yields on government securities are likely to harden once next fiscal's borrowing commences in April ‚Äù said Aditi Nayar  chief economist at ICRA Ltd.  the local unit of Moody's Investors Service. ‚ÄúIf there are concrete steps toward bond index inclusion during the year  it could help to cap yields.‚Äù,neutral,0.06,0.79,0.14,negative,0.01,0.14,0.84,True,English,"['Global Bond Index Inclusion', 'Government', 'Report', 'Senior Asia Rates Strategist', 'largest EM bond markets', 'Prime Minister Narendra Modi', 'Bloomberg Index Services Limited', 'Powerful Hindu nationalist groups', 'Finance Minister Nirmala Sitharaman', 'global bond index inclusion', 'dollar-denominated sovereign bond', 'eleventh hour concerns', 'Standard Chartered Plc', 'traditional vote bank', 'international clearing platforms', 'global minimum rate', 'key tax exemptions', 'contentious tax negotiations', 'risk diversification benefits', 'new financial year', 'Local debt markets', 'February 1 budget talk', 'tax avoidance issues', 'public OECD forums', 'international bond transactions', 'international fiscal policy', 'crucial step change', 'February budget speech', ""foreign investors' perspective"", 'major bond indexes', 'senior government officials', 'finance ministry official', 'India long bonds', 'senior official', 'Bloomberg LP', 'international wealth', 'Global investors', 'Indian debt', 'compliance issues', 'Tax authorities', 'tax department', 'tax waivers', 'similar benefits', 'global indexes', 'a year', 'local investors', 'local businesses', 'remarkable milestone', 'Citigroup Inc.', 'Policy makers', 'sudden silence', 'sharpest sell-off', 'two years', 'domestic investors', 'privacy rules', 'capital gains', 'pressure point', 'investor base', 'Nagaraj Kulkarni', 'Morgan Stanley', 'second quarter', 'FTSE Russell', 'multiple requests', 'parent company', 'other providers', 'October announcement', 'Economic Co-operation', 'underlying assets', 'optics problem', 'Indian authorities', 'different perspective', 'increasing clout', 'Indian officials', 'securities transactions', '$1 trillion market', 'high-yielding market', 'volatile inflows', 'one person', 'Other countries', 'Paris-based group', 'informal discussions', '136 countries', 'months', 'Banks', 'country', 'peers', 'timeline', 'clients', 'anticipation', 'analysts', 'April', 'start', 'shock', 'mention', 'traders', 'day', 'buy-call', 'plan', 'interviews', 'politics', 'progress', 'Bankers', 'foreigners', 'taxes', 'discrimination', 'people', 'path', '20 nations', 'consensus', 'right', 'opportunity', 'pool', 'liquidity', 'Singapore', 'Face', 'challenges', 'Euroclear', 'September', 'work', 'matter', 'watchlist', 'tweak', 'guard', 'answers', 'comment', 'spokesperson', 'email', 'clarification', 'BISL', 'hindsight', 'reversal', 'Organisation', 'Development', 'agreement', 'member', 'position', 'location', 'beginning', 'contradiction', 'decision', 'January', 'party', 'proposal']",2022-04-11,2022-04-11,ndtv.com
2644,Euroclear,Bing API,https://www.morningstar.com/news/accesswire/696848msn/notice-to-annual-general-meeting-of-spago-nanomedical-ab-publ,Notice to Annual General Meeting of Spago Nanomedical AB (publ),Shareholders wishing to attend the Annual General Meeting shall: be registered in the share register kept by Euroclear Sweden AB on Tuesday May 10  2022  and give notice of their intention to attend the Annual General Meeting of Spago Nanomedical no later than Thursday May 12 ,"LUND  SWEDEN / ACCESSWIRE / April 11  2022 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)The shareholders of Spago Nanomedical AB (publ)  corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Wednesday May 18  2022  at 4.00 p.m. CEST in the premises of Advokatfirman Cederquist at Hovslagargatan 3 in Stockholm.Right to attendShareholders wishing to attend the Annual General Meeting shall:be registered in the share register kept by Euroclear Sweden AB on Tuesday May 10  2022 and give notice of their intention to attend the Annual General Meeting of Spago Nanomedical no later than Thursday May 12  2022. Notice of attendance may be given:by e-mail to ursula.sorqvist@cederquist.se by mail to Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB  AGM 2022"")  or by phone +46 (0)8 522 065 34 between 9.00 a.m. and 4.00 p.m CEST.When giving notice of attendance  the shareholders shall state their name  address  daytime telephone number  personal identification number or company registration number and any assistants who shall participate (but not more than two).Nominee-registered sharesShareholders whose shares are nominee-registered must  to be entitled to exercise their voting rights and attend the Annual General Meeting  temporarily register such shares in their own names in the share register kept by Euroclear Sweden (so called voting right registration). The shareholders' register as of the record date  Tuesday May 10  2022  will consider voting right registrations made no later than the second banking day after May 10  2022. This means that shareholders should notify their nominee in this matter well in advance of this date.Proxy etc.Shareholders who wish to participate through a proxy representative should send power of attorneys  certificates of incorporation and other authorisation documents to Spago Nanomedical to the above address well in advance of the Annual General Meeting. Such original power of attorney shall be brought to the Annual General Meeting. A proxy form is available on the company¬¥s website  www.spagonanomedical.se.Personal data processingIn connection with the notice of attendance the company will process the personal data regarding shareholders that has been requested in accordance with the above. The personal data collected from the share register  notice of attendance at the Annual General Meeting and information on proxies and assistants will be used for registration  preparation of the voting list and  where applicable  minutes of the Annual General Meeting. The personal data will only be used for the Annual General Meeting. For further information on how your personal data is processed by the company and your rights  please see the company¬¥s website  www.spagonanomedical.se.Proposed agendaOpening of the Annual General Meeting. Election of chairman of the Annual General Meeting. Preparation and approval of the voting list. Election of one or two persons to verify the minutes. Approval of the agenda. Determination of whether the meeting has been duly convened. Presentation of the annual report and the auditor's report. Presentation by the CEO. Resolutions on adoption of the income statement and balance sheet. dispositions regarding the company¬¥s earnings in accordance with the adopted balance sheet. discharge from liability for the directors of the board and the CEO for the financial year 2021. Determination of the number of directors and deputy directors of the board. Determination of remuneration to the directors of the board and the auditors. Election of directors and chairman of the board of directors. Election of auditor. Resolution on adopting instructions to the nomination committee. Resolution on amendments to the articles of association. Resolution on authorisation for the board of directors to resolve to issue new shares. Closing of the Annual General Meeting.Proposed resolutionsItem 2. Election of chairman of the Annual General MeetingThe nomination committee proposes that Tone Myhre-Jensen  member of the Swedish Bar Association  is elected chairman of the Annual General Meeting  or  if she should be unable to attend the meeting  the person appointed by the nomination committee.Item 9. b) Resolution on dispositions regarding the company¬¥s earnings in accordance with the adopted balance sheetThe board of directors proposes that accumulated funds of KSEK 59 211  of which KSEK -39 071 are the results for the year  be transferred to new accounts.Item 10. Determination of the number of directors and deputy directors of the boardThe nomination committee proposes that the board of directors  for the period until the end of the next Annual General Meeting  shall consist of five directors with no deputies.Item 11. Determination of remuneration to the directors of the board and the auditorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that remuneration of SEK 200 000 (unchanged) shall be paid to the chairman of the board of directors and SEK 95 000 (unchanged) shall be paid to each of the other directors of the board.The nomination committee proposes that remuneration to the auditor shall be paid in accordance with approved invoices.Item 12. Election of directors and chairman of the board of directorsFor the period until the end of the next Annual General Meeting  the nomination committee proposes that Peter Leander  Sten Nilsson  Kari Gr√∏n√•s  Eugen Steiner and Nicklas Westerholm shall be re-elected as directors of the board.The nomination committee proposes that Eugen Steiner shall be re-elected as chairman of the board of directors.Further information about the proposed directors is available on the company¬¥s website  www.spagonanomedical.se.Item 13. Election of auditorThe nomination committee proposes that the registered accounting firm BDO M√§lardalen AB is re-elected as auditor for the period until the end of the next Annual General Meeting. BDO M√§lardalen AB has informed the nomination committee that if re-elected  J√∂rgen L√∂vgren  authorised public accountant  will continue to be the auditor in charge.Item 14. Resolution on adopting instructions to the nomination committeeThe nomination committee proposes that the Annual General Meeting resolves to adopt the following instructions for the nomination committee  to apply until the General Meeting decides otherwise.The nomination committee shall prepare proposals in the following matters to be submitted to the Annual General Meeting for resolutions:proposal for chairman of the meeting proposal for number of directors and deputy directors of the board proposal for directors and any deputy directors of the board proposal for chairman of the board of directors proposal for remuneration and other fees for board assignments to each of the board members and remuneration for committee work proposal for auditor (if applicable) proposal for fees for the auditor of the company  and proposal for instructions for the nomination committee¬¥s work and compositionThe nomination committee shall consist of at least three members and be formed in consultation with the largest shareholders of the company as per September 30th and who wish to appoint a member. It is the responsibility of the chairman of the board of directors to convene the nomination committee for its first meeting and to be available  when necessary  in the nomination committee¬¥s work. The chairman of the board of directors shall not be a member of the nomination committee. The nomination committee shall appoint a chairman for the nomination committee at its first meeting.The nomination committee is appointed for a period from the time it is formed until the next nomination committee is formed. If a member leaves its assignment prematurely  the nomination committee may appoint a new member. Provided that the shareholder who appointed the resigned member is still one of the largest shareholders in the company  the shareholder shall be asked to appoint a new member. If this shareholder refrains from appointing a new member  the nomination committee may ask the next shareholder in order of size of shareholding who has not previously appointed a member of the nomination committee. The chairman of the nomination committee shall  however  continue to contact shareholders next in turn if necessary for the nomination committee to consist of three members. If the ownership structure of the company changes  the nomination committee may choose to change its composition so that the nomination committee reflects the ownership structure of the company in an appropriate manner. However  the total number of members may never exceed five. Even if there are changes in the company's ownership structure  no changes need to be made in the composition of the nomination committee in the event of minor changes or if a change occurs less than three months before the Annual General Meeting  unless it is motivated due to special circumstances.Remuneration shall only be paid for costs attributable to contracting recruitment consultants in connection with the nomination committee's work and other potential direct costs that are necessary for the nomination committee to be able to fulfil its work. No remuneration shall be paid to the members of the nomination committee.The nomination committee shall annually evaluate these instructions and  if necessary  propose changes to the Annual General Meeting. These instructions shall apply until the Annual General Meeting decides otherwise.Item 15. Resolution on amendments to the articles of associationThe board of directors proposes that the Annual General Meeting resolves to change the articles of association's (i) ¬ß 4 so that the limits for the company's share capital are adjusted  and (ii) ¬ß 5 so that the limits for the number of shares are adjusted. ¬ß¬ß 4 and 5 of the articles of association will then have the following wordings:¬ß 4 Share capitalThe share capital shall amount to a minimum of SEK 40 000 000 and a maximum of SEK 160 000 000.¬ß 5 Number of sharesThe number of shares may not be fewer than 40 000 000 and not exceed 160 000 000.Item 16. Resolution on authorisation for the board of directors to resolve to issue new sharesThe board of directors proposes that the General Meeting resolves on authorisation for the board of directors to resolve to issue new shares in accordance with the following.The board of directors is authorised to  on one or several occasions before the next Annual General Meeting  resolve to issue new shares. Such issues of new shares may be made with or without deviation from the shareholders' preferential rights. By resolutions based on the authorisation to issue new shares  issues of shares without deviation from the shareholders' preferential rights may be made up to  in total  as many shares as falls within the limits of the articles of association at the time of exercise of the authorisation. By resolutions based on the authorisation to issue new shares  issues of shares with deviation from the shareholders' preferential rights may be made up to  in total  the number of shares corresponding to twenty (20) percent of the total number of outstanding shares in the company at the time of exercise of the authorisation the first time. The authorisation shall include the right to resolve on issues where payment is made in cash  by contribution in kind or by way of set-off. A cash issue or issue by way of set-off that is made with deviation from the shareholders' preferential rights shall be in line with market terms.The purpose of the authorisation and the reasons for potential deviations from the shareholders' preferential rights are that issues shall be able to be made in order to enable capital raisings if market conditions would be deemed appropriate and/or to broaden the ownership base of Spago Nanomedical by offering financial and industrial investors to invest in the company.Other informationMajority requirementsThe resolutions of the Annual General Meeting pursuant to items 15 and 16 above require that the resolutions are supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting.Number of sharesSpago Nanomedical has a total of 41 182 287 shares with one vote each  thus a total of 41 182 287 votes.Shareholders' right to receive informationShareholders have the right to  if the board of directors believes that it can be done without significant damage to the company  receive information from the board of directors and the CEO regarding circumstances that may affect the assessment of a matter on the agenda or the company's financial situation. Shareholders who wish to submit questions in advance of the Annual General Meeting can do so in writing to Spago Nanomedical AB (publ)  c/o Advokatfirman Cederquist  P.O. Box 1670  SE-111 96 Stockholm  Sweden  Att: Ursula S√∂rqvist (mark the envelope with ""Spago Nanomedical AB (publ)  AGM 2022"") or by sending an e-mail to ursula.sorqvist@cederquist.se (state ""Spago Nanomedical AB (publ)  AGM 2022"" as the subject).DocumentsProxy forms  information regarding proposed board members  proposed new articles of association  accounting documents and auditor's report are available at Spago Nanomedical no later than from April 27  2022  and on the company's website www.spagonanomedical.se  and will also be sent free of charge to shareholders who so requests and states their postal or e-mail address. The documents are available at the Annual General Meeting.________________Lund  April 2022Spago Nanomedical AB (publ)The board of directorsFor further information  please contact Mats Hansen  CEO Spago Nanomedical AB  +46 46 811 88  mats.hansen@spagonanomedical.seSpago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company¬¥s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical¬¥s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information  see www.spagonanomedical.se.FNCA Sweden AB is the Certified Adviser of the company  +46 8 528 00 399  info@fnca.se.AttachmentsNotice to Annual General Meeting of Spago Nanomedical AB (publ)SOURCE: Spago NanomedicalView source version on accesswire.com:",neutral,0.02,0.96,0.02,negative,0.05,0.38,0.57,True,English,"['Annual General Meeting', 'Spago Nanomedical AB', 'Notice', 'next Annual General Meeting', 'P.O. Box', 'second banking day', 'daytime telephone number', 'Ursula S√∂rqvist', 'other authorisation documents', 'Such original power', 'Swedish Bar Association', 'Spago Nanomedical AB', 'personal identification number', 'Personal data processing', 'Euroclear Sweden AB', 'voting right registrations', 'company registration number', 'annual report', 'voting list', 'corporate registration', 'share register', 'two persons', 'income statement', 'balance sheet', 'nomination committee', 'Tone Myhre-Jensen', 'new accounts', 'voting rights', 'Advokatfirman Cederquist', 'proxy representative', 'proxy form', 'Wednesday May', 'Thursday May', 'Nominee-registered shares', 'record date', 'financial year', 'new shares', 'deputy directors', 'five directors', ""shareholders' register"", 'LUND', 'ACCESSWIRE', 'April', 'FRA', '7UX', 'publ', 'premises', 'Hovslagargatan', 'Stockholm', 'Tuesday', 'notice', 'intention', 'attendance', 'mail', 'sorqvist', 'envelope', 'AGM', '9.00 a', 'CEST', 'name', 'address', 'assistants', 'matter', 'advance', 'attorneys', 'certificates', 'incorporation', 'website', 'spagonanomedical', 'connection', 'accordance', 'information', 'proxies', 'preparation', 'minutes', 'agenda', 'Opening', 'Election', 'chairman', 'approval', 'Determination', 'Presentation', 'auditor', 'CEO', 'Resolutions', 'adoption', 'dispositions', 'earnings', 'discharge', 'liability', 'board', 'remuneration', 'instructions', 'amendments', 'articles', 'Closing', 'Item', 'member', 'funds', 'KSEK', 'results', 'period', 'deputies', '4.00']",2022-04-11,2022-04-11,morningstar.com
2645,Euroclear,Twitter API,Twitter,How GoCodeGreen is aiming to make fintech software net-zero #AAA Websites Euroclear Fintech https://t.co/LX8V318vGl #regtech,nan,How GoCodeGreen is aiming to make fintech software net-zero #AAA Websites Euroclear Fintech https://t.co/LX8V318vGl #regtech,neutral,0.04,0.93,0.03,neutral,0.04,0.93,0.03,True,English,"['fintech software', 'AAA Websites', 'GoCodeGreen', 'LX8V318vGl', 'regtech', 'fintech software', 'AAA Websites', 'GoCodeGreen', 'LX8V318vGl', 'regtech']",2022-04-11,2022-04-11,Unknown
2646,Euroclear,Twitter API,Twitter,TD Bank  U.S. Bank putting car payments in the fast lane #AAA Websites Euroclear Fintech https://t.co/Ex7UIsVm55 #regtech,nan,TD Bank  U.S. Bank putting car payments in the fast lane #AAA Websites Euroclear Fintech https://t.co/Ex7UIsVm55 #regtech,neutral,0.01,0.96,0.03,neutral,0.01,0.96,0.03,True,English,"['U.S. Bank', 'TD Bank', 'car payments', 'fast lane', 'Fintech', 'Ex7UIsVm55', 'regtech', 'U.S. Bank', 'TD Bank', 'car payments', 'fast lane', 'Fintech', 'Ex7UIsVm55', 'regtech']",2022-04-11,2022-04-11,Unknown
2647,Clearstream,Google API,https://www.businesswire.com/news/home/20220411005507/en/State-Street-Announces-New-Capability-to-Support-Fund-Order-Services-in-Mexico,State Street Announces New Capability to Support Fund Order Services in Mexico,8 hours ago,BOSTON--(BUSINESS WIRE)--State Street Corporation (NYSE: STT) announced today that it has launched an integrated fund trading solution along with its custody offering for clients in Mexico. The secure online platform will allow for access to a broad range of investment funds in collaboration with Clearstream (Vestima¬Æ) providing fund order services through a single-entry point.Our fund order services offering will support connectivity with a wide range of transfer agents to meet clients‚Äô unique requirements  including the ability to manage both segregated and omnibus accounts. It will also allow State Street Bank to secure expansive product and jurisdictional coverage across Latin America (LATAM).‚ÄúWe are very pleased to announce this new capability for our clients ‚Äù said Marcia Rothschild  head of Latin America for State Street. ‚ÄúThis trading solution is a critical step towards further expanding our products and capabilities in Mexico.‚ÄùAdditional product features include a robust infrastructure underpinned by SWIFT  real-time monitoring of order status  a dedicated client service team and registration services and account opening support by Vestima¬Æ.State Street‚Äôs first live client in the region is Afore Profuturo.‚ÄúWe are delighted to be the first client onboarded to State Street‚Äôs new trading platform ‚Äù said Antonio Sibaja from Profuturo Afore. ‚ÄúThe new function will allow us to work more efficiently to give our clients a better pension and a better future.‚ÄùAbout State Street CorporationState Street Corporation (NYSE: STT) is one of the world's leading providers of financial services to institutional investors including investment servicing  investment management and investment research and trading. With $43.7 trillion in assets under custody and/or administration and $4.1 trillion* in assets under management as of December 31  2021  State Street operates globally in more than 100 geographic markets and employs approximately 39 000 worldwide. For more information  visit State Street's website at www.statestreet.com.*Assets under management as of December 30  2021 includes approximately $61 billion of assets with respect to SPDR¬Æ products for which State Street Global Advisors Funds Distributors  LLC (SSGA FD) acts solely as the marketing agent. SSGA FD and State Street Global Advisors are affiliated.About ProfuturoProfuturo is a 100% Mexican company belonging to Grupo Bal  specialized in managing retirement savings funds for Mexican workers and has more than six million clients. Profuturo has been managing the retirement of workers in the country for more than 25 years. The company was recognized for the third consecutive year as the Best Pension Administrator in Mexico by the specialized publication International Finance  and received the silver medal  the highest rating among the Afores by the company Morningstar. Likewise  the company signed an agreement with the CFA Global Institute to certify its entire investment and risk team in environmental  social  and corporate governance (ESG) criteria.,neutral,0.02,0.98,0.01,positive,0.68,0.3,0.02,True,English,"['Fund Order Services', 'State Street', 'New Capability', 'Mexico', 'State Street Global Advisors Funds Distributors', 'dedicated client service team', 'integrated fund trading solution', 'CFA Global Institute', 'secure online platform', 'account opening support', 'third consecutive year', 'State Street Corporation', 'State Street Bank', 'retirement savings funds', 'fund order services', 'Additional product features', 'first live client', 'Best Pension Administrator', 'new trading platform', 'clients‚Äô unique requirements', 'six million clients', 'investment funds', 'first client', 'risk team', 'order status', 'expansive product', 'registration services', 'financial services', 'new capability', 'new function', 'BUSINESS WIRE', 'broad range', 'single-entry point', 'wide range', 'transfer agents', 'omnibus accounts', 'jurisdictional coverage', 'Latin America', 'Marcia Rothschild', 'critical step', 'robust infrastructure', 'real-time monitoring', 'Antonio Sibaja', 'leading providers', 'institutional investors', 'investment servicing', 'investment research', '100 geographic markets', 'SSGA FD', 'marketing agent', 'Grupo Bal', 'specialized publication', 'International Finance', 'silver medal', 'highest rating', 'entire investment', 'corporate governance', 'ESG) criteria', 'custody offering', 'SPDR¬Æ products', 'Mexican workers', 'Afore Profuturo', 'Profuturo Afore', 'investment management', '100% Mexican company', 'BOSTON', 'NYSE', 'STT', 'Mexico', 'access', 'collaboration', 'Clearstream', 'Vestima¬Æ', 'connectivity', 'segregated', 'LATAM', 'head', 'capabilities', 'SWIFT', 'region', 'future', 'world', 'assets', 'administration', 'December', 'information', 'website', 'statestreet', 'respect', 'LLC', 'country', '25 years', 'Afores', 'Morningstar', 'agreement']",2022-04-11,2022-04-11,businesswire.com
2648,Clearstream,Google API,https://www.globalcustodian.com/state-street-fund-trading-solution-mexican-clients/,State Street launches fund trading solution for Mexican clients,4 hours ago,New solution involves partnership with Clearstream and will support connectivity with a range of transfer agents to meet clients‚Äô requirements.,neutral,0.02,0.97,0.01,neutral,0.03,0.97,0.01,True,English,"['fund trading solution', 'State Street', 'Mexican clients', 'New solution', 'transfer agents', 'clients‚Äô requirements', 'partnership', 'Clearstream', 'connectivity', 'range']",2022-04-11,2022-04-11,globalcustodian.com
2649,Clearstream,Google API,https://www.bloomingprairieonline.com/self-expanding-stents-market-share-size-trends-and-growth-2022-to-2027-abbott-balton-stryker-boston-scientific/,Self-Expanding Stents Market Share  Size  Trends and Growth 2022 to 2027,9 hours ago,‚ÄúSelf-Expanding Stents Market: Significant CAGR during 2022-2027New Research Report on Self-Expanding Stents Market which covers Market Overview  Future Economic Impact  Competition by Manufacturers  Supply (Production)  and Consumption AnalysisThe market research report on the global Self-Expanding Stents industry provides a comprehensive study of the various techniques and materials used in the production of Self-Expanding Stents market products. Starting from industry chain analysis to cost structure analysis  the report analyzes multiple aspects  including the production and end-use segments of the Self-Expanding Stents market products. The latest trends in the industry have been detailed in the report to measure their impact on the production of Self-Expanding Stents market products.With the present market standards revealed  the Self-Expanding Stents market research report has also illustrated the latest strategic developments and patterns of the market players in an unbiased manner. The report serves as a presumptive business document that can help the purchasers in the global market plan their next courses towards the position of the market‚Äôs future.Understand the influence of COVID-19 on the Self-Expanding Stents Market with our analysts monitoring the situation across the globe. Request NowGet sample of this report @ https://www.marketresearchupdate.com/sample/360428Leading key players in the Self-Expanding Stents market are ‚ÄìAbbott  Balton  Stryker  Boston Scientific  Braile  Cordis  Biotronik  Endo-Flex  Cook Medical  B. Braun  Andramed  Clearstream  Terumo Europe  ELLA-CS  Aesculap  EndocorProduct Types:MetallicNo-metallicOn the Basis of Application:Peripheral Nervous SystemDigestive SystemArteryRespiratory SystemUrologicalRegional Analysis For Self-Expanding Stents MarketNorth America (the United States  Canada  and Mexico)Europe (Germany  France  UK  Russia  and Italy)Asia-Pacific (China  Japan  Korea  India  and Southeast Asia)South America (Brazil  Argentina  Colombia  etc.)The Middle East and Africa (Saudi Arabia  UAE  Egypt  Nigeria  and South Africa)Get Discount on Self-Expanding Stents report @ https://www.marketresearchupdate.com/discount/360428The varying scenarios of the overall market have been depicted in this report  providing a roadmap of how the Self-Expanding Stents products secured their place in this rapidly-changing marketplace. Industry participants can reform their strategies and approaches by examining the market size forecast mentioned in this report. Profitable marketplaces for the Self-Expanding Stents Market have been revealed  which can affect the global expansion strategies of the leading organizations. However  each manufacturer has been profiled in detail in this research report.Self-Expanding Stents Market Effect Factors Analysis chapter precisely gives emphasis on Technology Progress/Risk  Substitutes Threat  Consumer Needs/Customer Preference Changes  Technology Progress in Related Industry  and Economic/Political Environmental Changes that draw the growth factors of the Market.The fastest & slowest growing market segments are pointed out in the study to give out significant insights into each core element of the market. Newmarket players are commencing their trade and are accelerating their transition in Self-Expanding Stents Market. Merger and acquisition activity forecast to change the market landscape of this industry.This report comes along with an added Excel data-sheet suite taking quantitative data from all numeric forecasts presented in the report.What‚Äôs in the offering: The report provides in-depth knowledge about the utilization and adoption of Self-Expanding Stents Industries in various applications  types  and regions/countries. Furthermore  the key stakeholders can ascertain the major trends  investments  drivers  vertical player‚Äôs initiatives  government pursuits towards the product acceptance in the upcoming years  and insights of commercial products present in the market.Full Report Link @ https://www.marketresearchupdate.com/industry-growth/self-expanding-stents-report-2022-2027-360428Lastly  the Self-Expanding Stents Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Self-Expanding Stents market.Contact Us:sales@marketresearchupdate.com‚Äú,neutral,0.01,0.99,0.0,neutral,0.05,0.91,0.04,True,English,"['Self-Expanding Stents Market Share', 'Size', 'Trends', 'Growth', 'Self-Expanding Stents Market Effect Factors Analysis chapter', 'Self-Expanding Stents market research report', 'slowest growing market segments', 'Self-Expanding Stents market products', 'global Self-Expanding Stents industry', 'Self-Expanding Stents Market study', 'Self-Expanding Stents products', 'Self-Expanding Stents Industries', 'cost structure analysis', 'The Middle East', 'Customer Preference Changes', 'Economic/Political Environmental Changes', 'Excel data-sheet suite', 'Self-Expanding Stents report', 'present market standards', 'market size forecast', 'industry chain analysis', 'latest strategic developments', 'Peripheral Nervous System', 'New Research Report', 'global expansion strategies', 'Full Report Link', 'presumptive business document', 'Endocor Product Types', 'Leading key players', 'Future Economic Impact', 'growth factors', 'global market', 'Consumption Analysis', 'Regional Analysis', 'commercial products', 'market players', 'end-use segments', 'Market Overview', 'overall market', 'market landscape', 'market growth', 'latest trends', 'leading organizations', 'product acceptance', 'comprehensive study', 'Digestive System', 'Respiratory System', 'key stakeholders', 'Industry participants', 'Related Industry', 'Significant CAGR', 'various techniques', 'multiple aspects', 'unbiased manner', 'next courses', 'Boston Scientific', 'Cook Medical', 'B. Braun', 'North America', 'United States', 'Southeast Asia', 'South America', 'Saudi Arabia', 'varying scenarios', 'changing marketplace', 'Profitable marketplaces', 'Technology Progress/Risk', 'Substitutes Threat', 'core element', 'acquisition activity', 'quantitative data', 'numeric forecasts', 'depth knowledge', 'various applications', 'major trends', 'vertical player', 'government pursuits', 'upcoming years', 'essential information', 'major challenges', 'overall details', 'precise verticals', 'upcoming companies', 'various aspects', 'Contact Us', 'business opportunities', 'Terumo Europe', 'South Africa', 'significant insights', 'Competition', 'Manufacturers', 'Supply', 'Production', 'materials', 'patterns', 'purchasers', 'position', 'influence', 'COVID', 'analysts', 'situation', 'globe', 'Request', 'sample', 'marketresearchupdate', 'Abbott', 'Balton', 'Stryker', 'Braile', 'Cordis', 'Biotronik', 'Endo-Flex', 'Andramed', 'Clearstream', 'ELLA-CS', 'Aesculap', 'Metallic', 'Basis', 'Artery', 'Urological', 'Canada', 'Mexico', 'Germany', 'France', 'UK', 'Russia', 'Italy', 'Asia-Pacific', 'China', 'Japan', 'Korea', 'India', 'Brazil', 'Argentina', 'Colombia', 'UAE', 'Egypt', 'Nigeria', 'Discount', 'roadmap', 'approaches', 'emphasis', 'fastest', 'trade', 'transition', 'Merger', 'offering', 'utilization', 'adoption', 'regions/countries', 'investments', 'drivers', 'initiatives', 'industry-growth', 'revenues', 'existing', 'domain']",2022-04-11,2022-04-11,bloomingprairieonline.com
2650,Clearstream,Google API,https://blackswanzine.com/self-expanding-stents-market-outlook-post-covid-19-scenario-by-2029-abbott-aesculap-stryker/,Self Expanding Stents Market Outlook: Post Covid-19 Scenario by 2029,8 hours ago,‚ÄúGet Sample Report Buy Complete ReportNew Jersey  N.J. ‚Äì Self Expanding Stents Market report focused on the comprehensive analysis of current and future prospects of the Self Expanding Stents industry. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies  geography expansion  research & development  and new product introduction strategies to execute further business expansion and growth during a forecast period. An in-depth analysis of past trends  future trends  demographics  technological advancements  and regulatory requirements for the Self Expanding Stents market has been done in order to calculate the growth rates for each segment and sub-segments.Get the PDF Sample Copy (Including FULL TOC  Graphs  and Tables) of this report @:https://www.a2zmarketresearch.com/sample-request/64048Competitive landscape:This Self Expanding Stents research report throws light on the major market players thriving in the market; it tracks their business strategies  financial status  and upcoming products.Top Key Vendors of this Market are:Abbott  Aesculap  Stryker  Andramed  Balton  Biotronik  Braile  Clearstream  Cordis  ELLA-CS  Endo-Flex  Endocor  Eucatech  HEXACATH  InSitu  iVascular  Medinol  MicroVention  Pauldrach  Phenox  Rontis  StentysVarious factors are responsible for the market‚Äôs growth trajectory  which are studied at length in the report. In addition  the report lists down the restraints that are posing threat to the global Self Expanding Stents market. This report is a consolidation of primary and secondary research  which provides market size  share  dynamics  and forecast for various segments and sub-segments considering the macro and micro environmental factors. It also gauges the bargaining power of suppliers and buyers  threat from new entrants and product substitutes  and the degree of competition prevailing in the market.The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Self Expanding Stents market‚Äôs trajectory between forecast periods. The cost analysis of the Global Self Expanding Stents Market has been performed while keeping in view manufacturing expenses  labor cost  and raw materials and their market concentration rate  suppliers  and price trend.Global Self Expanding Stents Market Segmentation:Market Segmentation: By TypeMental  PlasticMarket Segmentation: By ApplicationPeripheral Nervous System  Digestive System  Artery  Respiratory SystemThe report provides insights on the following pointers:Market Penetration: Comprehensive information on the product portfolios of the top players in the Self Expanding Stents market.Competitive Assessment: In-depth assessment of the market strategies  geographic and business segments of the leading players in the market.Product Development/Innovation: Detailed insights on the upcoming technologies  R&D activities  and product launches in the market.Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.Market Diversification: Exhaustive information about new products  untapped geographies  recent developments  and investments in the Self Expanding Stents market.Get Up to 30% Discount on the first purchase of this report @:https://www.a2zmarketresearch.com/discount/64048An assessment of the market attractiveness with regard to the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations  new developments  marketing strategies  branding techniques  and products of the key participants present in the global Self Expanding Stents market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.Reasons for buying this report:It offers an analysis of changing competitive scenarios.For making informed decisions in businesses  it offers analytical data with strategic planning methodologies.Researchers throw light on the dynamics of the market such as drivers  restraints  trends  and opportunities.It offers a regional analysis of Self Expanding Stents Market along with business profiles of several stakeholders.It offers a seven-year assessment of Self Expanding Stents Market.It helps in understanding the major key product segments.It offers massive data about trending factors that will influence the progress of the Self Expanding Stents Market.Table of ContentsGlobal Self Expanding Stents Market Research Report 2022 ‚Äì 2029Chapter 1 Self Expanding Stents Market OverviewChapter 2 Global Economic Impact on IndustryChapter 3 Global Market Competition by ManufacturersChapter 4 Global Production  Revenue (Value) by RegionChapter 5 Global Supply (Production)  Consumption  Export  Import by RegionsChapter 6 Global Production  Revenue (Value)  Price Trend by TypeChapter 7 Global Market Analysis by ApplicationChapter 8 Manufacturing Cost AnalysisChapter 9 Industrial Chain  Sourcing Strategy and Downstream BuyersChapter 10 Marketing Strategy Analysis  Distributors/TradersChapter 11 Market Effect Factors AnalysisChapter 12 Global Self Expanding Stents Market ForecastBuy Exclusive Report @: https://www.a2zmarketresearch.com/checkoutContact Us:Roger Smith1887 WHITNEY MESA DR HENDERSON  NV 89014sales@a2zmarketresearch.com+1 775 237 4147,neutral,0.01,0.98,0.01,mixed,0.34,0.2,0.45,True,English,"['Self Expanding Stents Market Outlook', 'Post Covid-19 Scenario', 'Global Self Expanding Stents Market Research Report', 'Global Self Expanding Stents Market Segmentation', 'Self Expanding Stents Market Overview', 'Self Expanding Stents research report', 'Self Expanding Stents Market report', 'Self Expanding Stents industry', 'major key product segments', 'new product introduction strategies', 'Global Economic Impact', 'Including FULL TOC', 'latest government guidelines', 'R&D activities', 'Up to 30% Discount', 'strategic planning methodologies', 'market concentration rate', 'major market players', 'Global Market Competition', 'PDF Sample Copy', 'key market players', 'micro environmental factors', 'Peripheral Nervous System', 'Top Key Vendors', 'value chain analysis', 'Global Supply', 'Global Production', 'secondary research', 'market strategies', 'key participants', 'market size', 'Market Penetration', 'Market Diversification', 'market attractiveness', 'top players', 'product substitutes', 'product portfolios', 'product launches', 'new players', 'Sample Report', 'various segments', 'business segments', 'Market Development', 'acquisition strategies', 'business strategies', 'leading players', 'marketing strategies', 'New Jersey', 'Various factors', 'new entrants', 'Digestive System', 'Respiratory System', 'new developments', 'trending factors', 'Complete Report', 'N.J.', 'comprehensive analysis', 'favorable fit', 'successive merger', 'geography expansion', 'business expansion', 'depth analysis', 'technological advancements', 'regulatory requirements', 'Competitive landscape', 'financial status', 'bargaining power', 'cost analysis', 'manufacturing expenses', 'labor cost', 'raw materials', 'price trend', 'Type Mental', 'following pointers', 'Comprehensive information', 'upcoming technologies', 'emerging markets', 'Exhaustive information', 'recent developments', 'first purchase', 'branding techniques', 'clear vision', 'competitive scenarios', 'informed decisions', 'analytical data', 'regional analysis', 'business profiles', 'several stakeholders', 'massive data', 'new products', 'Competitive Assessment', 'depth assessment', 'seven-year assessment', 'future prospects', 'forecast period', 'past trends', 'growth rates', 'upcoming products', 'Detailed insights', 'untapped geographies', 'future trends', 'growth trajectory', 'current', 'optimal', 'demographics', 'order', 'sub-segments', 'Graphs', 'Tables', 'a2zmarketresearch', 'sample-request', 'light', 'Abbott', 'Aesculap', 'Stryker', 'Andramed', 'Balton', 'Biotronik', 'Braile', 'Clearstream', 'Cordis', 'ELLA-CS', 'Endo-Flex', 'Endocor', 'Eucatech', 'HEXACATH', 'InSitu', 'iVascular', 'Medinol', 'MicroVention', 'Pauldrach', 'Phenox', 'Rontis', 'Stentys', 'length', 'addition', 'restraints', 'threat', 'consolidation', 'primary', 'share', 'dynamics', 'macro', 'suppliers', 'buyers', 'degree', 'influence', 'Plastic', 'Application', 'Artery', 'geographic', 'Innovation', 'investments', 'regard', 'publication', 'opportunities', 'Reasons', 'changing', 'businesses', 'Researchers', 'drivers', 'progress', 'Contents', 'Chapter', 'Manufacturers', 'Revenue', 'Consumption', 'Export', 'Import', 'Regions']",2022-04-11,2022-04-11,blackswanzine.com
2651,Clearstream,Google API,https://www.streetinsider.com/SEC+Filings/Form+424B2+ROYAL+BANK+OF+CANADA/19900506.html,Form 424B2 ROYAL BANK OF CANADA,1 hour ago,"Royal Bank of Canada Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-259205Pricing Supplement Dated April 7  2022 To the Prospectus Dated September 14  2021 andProspectus Supplement Dated September 14  2021 $400 000 000Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaThe notes (the ‚ÄúNotes‚Äù) are senior unsecured floating rate notes. Interest and the amount payable upon maturity of the Notes will be paid in cash as described in this pricing supplement.The Notes will be bail-inable notes (as defined in the accompanying prospectus supplement dated September 14  2021 ) and subject to conversion in whole or in part ‚Äì by means of a transaction or series of transactions and in one or more steps ‚Äì into common shares of the Bank or any of its affiliates under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act (the ‚ÄúCDIC Act‚Äù) and to variation or extinguishment in consequence  and subject to the application of the laws of the Province of Ontario and the federal laws of Canada applicable therein in respect of the operation of the CDIC Act with respect to the Notes.We may not redeem the Notes prior to their maturity. There is no sinking fund for the Notes. All payments on the Notes are subject to our credit risk.The CUSIP number for the Notes is 78016EZ91.The Notes will not be listed on any securities exchange.Investing in the Notes involves a number of risks. See ‚ÄúRisk Factors‚Äù on page P-5 of this pricing supplement and beginning on page S-2 of the prospectus supplement dated September 14  2021.The Notes are unsecured and are not savings accounts or insured deposits of a bank. The Notes are not insured or guaranteed by the Canada Deposit Insurance Corporation  the U.S. Federal Deposit Insurance Corporation or any other governmental agency or instrumentality of Canada or the United States.Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined that this pricing supplement is truthful or complete. Any representation to the contrary is a criminal offense.Per Note Total Price to public 100.000% $ 400 000 000 Underwriting discount 0.150% $ 600 000 Proceeds to Royal Bank of Canada 99.850% $ 399 400 000We will deliver the Notes in book-entry only form through the facilities of The Depository Trust Company (‚ÄúDTC‚Äù) (including through its indirect participants Euroclear  Clearstream and CDS Clearing and Depository Services Inc. (‚ÄúCDS‚Äù)) on or about April 14  2022  against payment in immediately available funds.Lead Managers and Joint Book RunnersRBC Capital Markets Citigroup Goldman Sachs & Co. LLC J.P. MorganKeyBanc Capital Markets US Bancorp Westpac Banking CorporationSenior Floating Rate Notes Due April 14  2025Royal Bank of CanadaTERMS OF THE NOTESWe describe the basic features of the Notes in the sections of the prospectus dated September 14  2021 called ‚ÄúDescription of Debt Securities‚Äù and prospectus supplement dated September 14  2021 called ‚ÄúDescription of the Notes We May Offer ‚Äù subject to and as modified by the provisions described below.Issuer: Royal Bank of Canada (the ‚ÄúBank‚Äù) Issue: Senior Global Medium-Term Notes  Series I Title of Series: Senior Floating Rate Notes  due April 14  2025 Principal Amount: US $400 000 000 Ranking: Senior Currency: U.S. Dollars Interest Rate: The interest rate for each period will be equal to the Base Rate plus the Spread. Base Rate: USD Compounded SOFR Index Rate Spread: 0.840% Minimum Denominations: $2 000 and integral multiples of $1 000 in excess thereof Pricing Date: April 7  2022 Issue Date: April 14  2022 Maturity Date: April 14  2025 CUSIP / ISIN / CommonCode: 78016EZ91 / US78016EZ911 / 246980349 Interest Payment Dates: Quarterly on the 14th of each January  April  July  and October  beginning July 14  2022  subject to the modified following business day convention described below under ‚ÄúPayment Convention.‚Äù Interest Period: Each quarterly period from  and including  an Interest Payment Date (or  in the case of the first Interest Period  April 14  2022) to  but excluding  the next Interest Payment Date (or  in the case of the final Interest Period  the Maturity Date)  subject to the modified following business day convention described below under ‚ÄúPayment Convention.‚Äù Record Dates for InterestPayments: The day immediately preceding each Interest Payment Date (or  if the Notes are held in definitive form  the fifteenth calendar day preceding each Interest Payment Date  whether or not a Business Day).P- 2Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaInterest PaymentDetermination Date: The date two U.S. Government Securities Business Days before each Interest Payment Date. Observation Period: In respect of each Interest Period  the period from  and including  the date two U.S. Government Securities Business Days preceding the first date in such Interest Period to  but excluding  the date two U.S. Government Securities Business Days preceding the Interest Payment Date (or in the final Interest Period  preceding the Maturity Date). Payment Convention: If any Interest Payment Date would otherwise fall on a day that is not a business day  then the interest payment date will be the next day that is a business day. However  if the next business day falls in the next calendar month  then the Interest Payment Date will be advanced to the next preceding day that is a business day. If the Maturity Date falls on a day that is not a business day  we will make the required payment of principal  premium  if any  and interest on the next succeeding business day  and no additional interest will accrue in respect of the payment made on that next succeeding business day. Business Day: Any weekday that is a U.S. Government Securities Business Day and is not a legal holiday in New York or Toronto and is not a date on which banking institutions in those cities are authorized or required by law or regulation to be closed. U.S. GovernmentSecurities Business Day: Any day except for a Saturday  a Sunday or a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in U.S. government securities. Day Count Convention: Actual / 360 Redemption at our Option: Not applicable. Canadian Bail-in PowersAcknowledgment: The Notes are bail-inable notes. See ‚ÄúSpecific Terms of the Notes‚ÄîAgreement with Respect to the Exercise of Canadian Bail-in Powers‚Äù. Repayment at Option ofHolder: Not applicable. Lead Managers and JointBook Runners: RBC Capital Markets  LLC  Citigroup Global Markets Inc.  Goldman Sachs & Co. LLC  J.P. Morgan Securities LLC  KeyBanc Capital Markets Inc.  U.S. Bancorp Investments  Inc. and Westpac Banking Corporation Calculation Agent: RBC Capital Markets  LLC Public Offering Price: 100.000% Underwriting Discount: 0.150% Clearance and Settlement: DTC (including through its indirect participants Euroclear  Clearstream and CDS  as described under ‚ÄúOwnership and Book-Entry Issuance‚Äù in the prospectus dated September 14  2021).P- 3Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaListing: The Notes will not be listed on any securities exchange or quotation system. Terms Incorporated in theMaster Note: All of the terms appearing above on pages P-2 and P-3 and P-4 under the caption ‚ÄúTerms of the Notes‚Äù of this pricing supplement and the terms appearing under the caption ‚ÄúSpecific Terms of the Notes‚Äù below. The Notes are part of a series of senior debt securities of the Bank entitled ‚ÄúSenior Global Medium-Term Notes  Series I.‚Äù The Notes will have the CUSIP No. 78016EZ91  the ISIN No. US78016EZ911 and the Common Code No. 246980349.P- 4Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaRISK FACTORSAn investment in the Notes is subject to the risks described below  as well as the risks described under ‚ÄúRisk Factors‚Äù in the accompanying prospectus  dated September 14  2021  and the accompanying prospectus supplement  dated September 14  2021. The Notes are not secured debt. You should carefully consider whether the Notes are suited to your particular circumstances. This pricing supplement should be read together with the accompanying prospectus  dated September 14  2021  and the accompanying prospectus supplement  dated September 14  2021. The information in the accompanying prospectus and the accompanying prospectus supplement is supplemented by  and to the extent inconsistent therewith replaced and superseded by  the information in this pricing supplement. This section describes certain significant risks relating to an investment in the Notes. We urge you to read the following information about these risks  together with the other information in this pricing supplement and the accompanying prospectus and accompanying prospectus supplement  before investing in the Notes.Investors Are Subject to Our Credit Risk  and Market Perceptions About Our Creditworthiness May Adversely Affect the Market Value of the Notes.Investors are dependent on our ability to pay all amounts due on the Notes on the interest payment dates and at maturity  and  therefore  investors are subject to our credit risk and to changes in the market‚Äôs view of our creditworthiness. Any decrease in the market‚Äôs view on or confidence in our creditworthiness is likely to adversely affect the market value of the Notes.The Market Value of the Notes May Be Influenced by Unpredictable Factors.The market value of your Notes may fluctuate between the date you purchase them and the Maturity Date. Several factors  many of which are beyond our control  will influence the market value of the Notes. Factors that may influence the market value of the Notes include:¬∑ supply and demand for the Notes  including inventory positions with the underwriters or any other market-maker;¬∑ interest rates in the market and expectations about future interest rates;¬∑ the creditworthiness of the Bank;¬∑ the time remaining to the maturity of the Notes; and¬∑ economic  financial  political  regulatory or judicial events that affect financial markets generally.The Notes Will Not Be Listed on Any Securities Exchange and Secondary Trading May Be Limited.The Notes will not be listed on any securities exchange. Therefore  there may be little or no secondary market for the Notes. The underwriters may  but are not obligated to  make a market in the Notes. Even if there is a secondary market  it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because we do not expect that other broker-dealers will participate significantly in the secondary market for the Notes  the price at which you may be able to trade your Notes is likely to depend on the price  if any  at which the underwriters are willing to transact. If at any time the underwriters were not to make a market in the Notes  it is likely that there would be no secondary market for the Notes. Accordingly  you should be willing to hold your Notes to maturity.P- 5Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaWe or Our Designee Will Make Determinations with respect to the Notes.We or our designee will make certain determinations with respect to the Notes as further described under the caption ‚ÄúSpecific Terms of the Notes.‚Äù In addition  if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred  we or our designee will make certain determinations with respect to the Notes in our or our designee‚Äôs sole discretion as further described under the section ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021. Any of these determinations may adversely affect the value of the Notes  the return on the Notes and the price at which you can sell such Notes. Moreover  certain determinations may require the exercise of discretion and the making of subjective judgments  such as with respect to Compounded SOFR Index or the occurrence or non-occurrence of a Benchmark Transition Event and any Benchmark Replacement Conforming Changes. These potentially subjective determinations may adversely affect the value of the Notes  the return on the Notes and the price at which you can sell such Notes. For further information regarding these types of determinations  see ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021.P- 6Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSPECIFIC TERMS OF THE NOTESPlease note that in this section entitled ‚ÄúSpecific Terms of the Notes ‚Äù references to ‚Äúholders‚Äù mean those who own Notes registered in their own names  on the books that we or the trustee maintain for this purpose  and not those who own beneficial interests in Notes registered in street name or in Notes issued in book-entry form through DTC or another depositary. Owners of beneficial interests in the Notes should read the section entitled ‚ÄúDescription of the Notes We May Offer‚ÄîLegal Ownership‚Äù in the accompanying prospectus supplement  dated September 14  2021  and ‚ÄúOwnership and Book-Entry Issuance‚Äù in the accompanying prospectus  dated September 14  2021.The Notes are part of a series of senior debt securities entitled ‚ÄúSenior Global Medium-Term Notes  Series I ‚Äù that we may issue under our senior indenture  dated as of October 23  2003  between the Bank and The Bank of New York Mellon  as successor to the corporate trust business of JPMorgan Chase Bank  N.A.  as trustee  as supplemented by a first supplemental indenture  dated as of July 21  2006  by a second supplemental indenture  dated as of February 28  2007  and by a third supplemental indenture  dated as of September 7  2018 and as further amended  from time to time (the ‚Äúindenture‚Äù). The Notes are described in the accompanying prospectus supplement. This pricing supplement summarizes financial and other terms that apply to the Notes. We describe terms that apply generally to all Series I Medium-Term Notes in ‚ÄúDescription of the Notes We May Offer‚Äù in the accompanying prospectus supplement. The terms described in this pricing supplement  and should be read in conjunction with  those described in the accompanying prospectus and accompanying prospectus supplement and  if the terms described here are inconsistent with those described there  the terms described here are controlling.Please note that the information about the price to the public and the net proceeds to the Bank on the front cover of this pricing supplement relates only to the initial sale of the Notes. If you have purchased the Notes in a market-making transaction after the initial sale  information about the price and date of sale to you will be provided in a separate confirmation of sale.In addition to the terms described on the front and inside cover of this pricing supplement  the following specific terms will apply to the Notes:InterestThe interest rate on the Notes for each period will be equal to USD Compounded SOFR Index (as defined in the accompanying prospectus supplement dated September 14  2021) plus a margin of 84.0 basis points. Interest will be payable quarterly in arrears on January 14  April 14  July 14 and October 14 of each year  beginning on July 14  2022 (each  an ‚ÄúInterest Payment Date‚Äù) and ending on the Maturity Date  subject to the modified following business day convention as described under the section ‚ÄúDescription of the Notes We May Offer‚ÄîInterest Rates‚ÄîInterest Payment Dates‚Äù in the accompanying prospectus supplement dated September 14  2021. The interest rate on the Notes will be calculated as described for SOFR Index Notes in the section ‚Äú Description of the Notes We May Offer‚ÄîInterest Rates‚ÄîSOFR Index Notes‚Äù in the accompanying prospectus supplement  dated September 14  2021.DefeasanceThere shall be no defeasance  full or covenant  applicable to the Notes.Payment at MaturityAt maturity you will receive an amount equal to the principal of your Notes plus any accrued and unpaid interest.P- 7Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaManner of Payment and DeliveryAny payment on the Notes at maturity will be made to accounts designated by you and approved by us  or at the office of the trustee in New York City  but only when the Notes are surrendered to the trustee at that office. We also may make any payment in accordance with the applicable procedures of the depositary.Calculation AgentPlease note that RBC Capital Markets  LLC is currently serving as the calculation agent for the Notes. We may change the calculation agent for the Notes at any time without notice and RBC Capital Markets  LLC may resign as calculation agent at any time upon sixty (60) days‚Äô written notice to the Bank.Agreement with Respect to the Exercise of Canadian Bail-in PowersBy its acquisition of an interest in any Note  each holder or beneficial owner of that Note is deemed to (i) agree to be bound  in respect of that Note  by the CDIC Act  including the conversion of that Note  in whole or in part ‚Äì by means of a transaction or series of transactions and in one or more steps ‚Äì into common shares of the Bank or any of its affiliates under subsection 39.2(2.3) of the CDIC Act and the variation or extinguishment of that Note in consequence  and by the application of the laws of the Province of Ontario and the federal laws of Canada applicable therein in respect of the operation of the CDIC Act with respect to that Note; (ii) attorn and submit to the jurisdiction of the courts in the Province of Ontario with respect to the CDIC Act and those laws; (iii) have represented and warranted to the Bank that the Bank has not directly or indirectly provided financing to the holder for the express purpose of investing in the Note; and (iv) acknowledge and agree that the terms referred to in paragraphs (i) and (ii)  above  are binding on that holder or beneficial owner despite any provisions in the indenture or that Note  any other law that governs that Note and any other agreement  arrangement or understanding between that holder or beneficial owner and the Bank with respect to that Note.Holders and beneficial owners of any Note will have no further rights in respect of that Note to the extent that Note is converted in a bail-in conversion  other than those provided under the bail-in regime  and by its acquisition of an interest in any Note  each holder or beneficial owner of that Note is deemed to irrevocably consent to the converted portion of the principal amount of that Note and any accrued and unpaid interest thereon being deemed paid in full by the Bank by the issuance of common shares of the Bank (or  if applicable  any of its affiliates) upon the occurrence of a bail-in conversion  which bail-in conversion will occur without any further action on the part of that holder or beneficial owner or the trustee; provided that  for the avoidance of doubt  this consent will not limit or otherwise affect any rights that holders or beneficial owners may have under the bail-in regime.See ‚ÄúDescription of Notes We May Offer‚ÄïSpecial Provisions Related to Bail-inable Notes‚Äù in the accompanying prospectus supplement dated September 14  2021 for a description of provisions applicable to the Notes as a result of Canadian bail-in powers.P- 8Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaADDITIONAL AMOUNTSWe will pay any amounts to be paid by us on the Notes without deduction or withholding for  or on account of  any and all present or future income  stamp and other taxes  levies  imposts  duties  charges  fees  deductions or withholdings (‚Äútaxes‚Äù) now or hereafter imposed  levied  collected  withheld or assessed by or on behalf of Canada or any Canadian political subdivision or authority that has the power to tax  unless the deduction or withholding is required by law or by the interpretation or administration thereof by the relevant governmental authority. At any time a Canadian taxing jurisdiction requires us to deduct or withhold for or on account of taxes from any payment made under or in respect of the Notes  we will pay such additional amounts (‚ÄúAdditional Amounts‚Äù) as may be necessary so that the net amounts received by each holder (including Additional Amounts)  after such deduction or withholding  shall not be less than the amount the holder would have received had no such deduction or withholding been required.However  no Additional Amounts will be payable with respect to a payment made to a holder of a Note  or of a right to receive payment in respect thereto (a ‚ÄúPayment Recipient‚Äù)  which we refer to as an ‚ÄúExcluded Holder ‚Äù in respect of any taxes imposed because the beneficial owner or Payment Recipient:(i) is someone with whom we do not deal at arm‚Äôs length (within the meaning of the Income Tax Act (Canada)) at the time of making such payment;(ii) is subject to such taxes by reason of its being connected presently or formerly with Canada or any province or territory thereof other than by reason of the holder‚Äôs activity in connection with purchasing such Note  the holding of such Note or the receipt of payments thereunder;(iii) is  or does not deal at arm‚Äôs length with a person who is  a ‚Äúspecified shareholder‚Äù (as defined in subsection 18(5) of the Income Tax Act (Canada)) of the Bank;(iv) presents such Note for payment (where presentation is required) more than 30 days after the relevant date (except to the extent that the holder thereof would have been entitled to such Additional Amounts on presenting a Note for payment on the last day of such 30 day period); for this purpose  the ‚Äúrelevant date‚Äù in relation to any payments on any Note means:(a) the due date for payment thereof  or(b) if the full amount of the monies payable on such date has not been received by the trustee on or prior to such due date  the date on which the full amount of such monies has been received and notice to that effect is given to holders of the Notes in accordance with the indenture;(v) could lawfully avoid (but has not so avoided) such withholding or deduction by complying  or requiring that any agent comply with  any statutory requirements necessary to establish qualification for an exemption from withholding or by making  or requiring that any agent make  a declaration of non-residence or other similar claim for exemption to any relevant tax authority; or(vi) is subject to deduction or withholding on account of any tax  assessment  or other governmental charge that is imposed or withheld by reason of the application of Sections 1471 through 1474 of the United States Internal Revenue Code of 1986 (or any successor provisions) (the ‚ÄúInternal Revenue Code‚Äù)  any regulation  pronouncement  or agreement thereunder  official interpretations thereof  or any law implementing an intergovernmental approach thereto  whether currently in effect or as published and amended from time to time.P- 9Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaFor the avoidance of doubt  we will not have any obligation to pay any holders Additional Amounts on any tax which is payable otherwise than by deduction or withholding from payments made under or in respect of the Notes.We will also make such withholding or deduction and remit the full amount deducted or withheld to the relevant authority in accordance with applicable law. We will furnish to the trustee  within 30 days after the date the payment of any taxes is due pursuant to applicable law  certified copies of tax receipts evidencing that such payment has been made or other evidence of such payment satisfactory to the trustee. We will indemnify and hold harmless each holder of Notes (other than an Excluded Holder) and upon written request reimburse each such holder for the amount of (x) any taxes so levied or imposed and paid by such holder as a result of payments made under or with respect to the Notes  and (y) any taxes levied or imposed and paid by such holder with respect to any reimbursement under (x) above  but excluding any such taxes on such holder‚Äôs net income or capital.U.S. FEDERAL INCOME TAX CONSIDERATIONSThe discussion below supplements the discussion under ‚ÄúTax Consequences‚ÄîUnited States Taxation‚Äù in the accompanying prospectus  dated September 14  2021  and is subject to the limitations and exceptions set forth therein. This discussion is only applicable to you if you are a U.S. holder (as defined in the accompanying prospectus). If you are not a U.S. holder  please consult your own tax advisor.In the opinion of our counsel  Sullivan & Cromwell LLP  your Notes should be treated as variable rate debt instruments for United States federal income tax purposes. Under this characterization  you should include the interest payments on the Notes in ordinary income at the time you receive or accrue such payments  depending on your method of accounting for tax purposes  and recognize capital gain or loss on the sale or retirement of your Notes equal to the difference between the amount you realize on the sale or retirement  excluding any amounts attributable to accrued but unpaid interest (which should be treated as interest payments)  and your tax basis in your Notes.For a further discussion of the variable rate debt instrument rules  please see the discussion under the heading ‚ÄúTax Consequences‚ÄîUnited States Taxation‚ÄîOriginal Issue Discount‚ÄîVariable Rate Debt Securities‚Äù in the accompanying prospectus.P- 10Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaCANADIAN FEDERAL INCOME TAX CONSIDERATIONSFor a discussion of the Canadian federal income tax consequences of owning the Notes  please see the section ‚ÄúTax Consequences‚Äî Canadian Taxation‚Äù in the accompanying prospectus  dated September 14  2021 and the section ‚ÄúCertain Income Tax Consequences‚ÄîCanadian Taxation‚Äù in the accompanying prospectus supplement  dated September 14  2021.BENEFIT PLAN INVESTOR CONSIDERATIONSA fiduciary of a pension  profit-sharing or other employee benefit plan (a ‚Äúplan‚Äù) subject to the Employee Retirement Income Security Act of 1974  as amended (‚ÄúERISA‚Äù)  should consider the fiduciary standards of ERISA in the context of the plan‚Äôs particular circumstances before authorizing an investment in the debt securities.Any purchaser or holder of debt securities or any interest therein will be deemed to have represented (both on behalf of itself and any plan) by its purchase and holding of the debt securities that either (1) it is not a plan and is not purchasing those debt securities on behalf of or with ‚Äúplan assets‚Äù of any plan or (2) the purchase and holding of the debt securities will not constitute a non-exempt prohibited transaction under ERISA or the Internal Revenue Code. In addition  any purchaser or holder of debt securities or any interest therein which is a non-ERISA arrangement will be deemed to have represented by its purchase or holding or  if applicable  exchange of the debt securities that its purchase and holding will not violate the provisions of any similar law.For a further discussion of benefit plan investor considerations  please see the discussion under the heading ‚ÄúBenefit Plan Investor Considerations‚Äù in the accompanying prospectus  dated September 14  2021.CLEARANCE AND SETTLEMENTThe Notes will settle through DTC  and its indirect participants Euroclear  Clearstream and CDS. For a description of DTC  Euroclear  Clearstream and CDS  see ‚ÄúOwnership and Book-Entry Issuance‚Äù in the accompanying prospectus  dated September 14  2021.P- 11Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)We have entered into a terms agreement  dated April 7  2022  with the underwriters pursuant to the Distribution Agreement  dated September 14  2021  among us and the agents party thereto for the purchase and sale of the Notes. We have agreed to sell to each of the underwriters  and each of the underwriters has agreed to purchase from us  the principal amount of the Notes shown opposite its name at the public offering price set forth above.Name Principal Amount of Notes RBC Capital Markets  LLC $ 72 000 000 Citigroup Global Markets Inc. $ 72 000 000 Goldman Sachs & Co. LLC $ 72 000 000 J.P. Morgan Securities LLC $ 72 000 000 KeyBanc Capital Markets Inc. $ 20 000 000 U.S. Bancorp Investments  Inc. $ 20 000 000 Westpac Banking Corporation $ 20 000 000 BNY Mellon Capital Markets  LLC $ 4 000 000 Capital One Securities  Inc. $ 4 000 000 Desjardins Securities Inc. $ 4 000 000 Fifth Third Securities  Inc. $ 4 000 000 Huntington Securities  Inc. $ 4 000 000 MUFG Securities Americas Inc. $ 4 000 000 National Bank of Canada Financial Inc. $ 4 000 000 Regions Securities LLC $ 4 000 000 Scotia Capital (USA) Inc. $ 4 000 000 Swedbank AB (publ) $ 4 000 000 Truist Securities  Inc. $ 4 000 000 Academy Securities  Inc. $ 4 000 000 R. Seelaus & Co.  LLC $ 2 000 000 Samuel A. Ramirez & Company  Inc. $ 2 000 000 Total $ 400 000 000Each of Westpac Banking Corporation  Desjardins Securities Inc. and Swedbank AB (publ) is not a U.S. registered broker-dealer and will not effect any offers or sales of any Notes in the United States unless it is through one or more U.S. registered broker-dealers as permitted by the regulations of the Financial Industry Regulatory Authority  Inc. (‚ÄúFINRA‚Äù).The underwriters may sell the Notes to certain dealers at the public offering price  less a concession that will not exceed 0.100% of their principal amount. The underwriters and those dealers may resell the Notes to other dealers at a reallowance discount that will not exceed 0.050% of their principal amount. After the initial offering of the Notes  the concession and reallowance discounts on the Notes may change. The offering of the Notes by the underwriters is subject to receipt and acceptance and subject to the underwriters‚Äô right to reject any order in whole or in part.We estimate that the total offering expenses for the Notes  excluding underwriting discounts and commissions  will be approximately $41 603.P- 12Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSubject to the terms and conditions of the terms agreement  the underwriters have agreed to purchase the Notes as principal  for their own account at a purchase price equal to the issue price specified on the front cover of this pricing supplement  less an underwriting discount of 0.150%. To the extent the underwriters resell Notes to a broker or dealer less a concession equal to the entire underwriting discount  such broker or dealer may be deemed to be an ‚Äúunderwriter‚Äù of the Notes as such term is defined in the Securities Act of 1933  as amended. The underwriters have advised us that  if they are unable to sell all the Notes at the public offering price  the underwriters propose to offer the Notes from time to time for sale in negotiated transactions or otherwise  at prices to be determined at the time of sale.In the future  the underwriters may repurchase and resell the Notes in market-making transactions. For more information about the plan of distribution  the Distribution Agreement (of which the terms agreement forms a part) and possible market-making activities; see ‚ÄúSupplemental Plan of Distribution‚Äù in the accompanying prospectus supplement dated September 14  2021.We expect that delivery of the Notes will be made against payment therefor on April 14  2022  which is the fifth scheduled business day following the trade date. Under Rule 15c6-1 of the Securities Exchange Act of 1934  trades in the secondary market generally are required to settle no later than two business days after the trade date  unless the parties to any such trade expressly agree otherwise at the time of the trade. Accordingly  purchasers who wish to trade Notes on any date more than two business days prior to delivery of the Notes hereunder will be required  by virtue of the fact that the Notes will initially settle in five business days (T + 5) to specify alternative settlement arrangements to prevent a failed settlement.Conflicts of InterestRBC Capital Markets  LLC is our affiliate  and is deemed to have a conflict of interest under FINRA Rule 5121. Accordingly  the offering of the Notes will conform to the requirements of FINRA Rule 5121. The underwriters  with the exception of Westpac Banking Corporation  Desjardins Securities Inc. and Swedbank AB (publ)  are members of FINRA. RBC Capital Markets  LLC is not permitted to sell the Notes to an account over which it exercises discretionary authority without the prior specific written approval of the account holder.The underwriters and their respective affiliates are full service financial institutions engaged in various activities  which may include securities trading  commercial and investment banking  financial advisory  investment management  investment research  principal investment  hedging  financing and brokerage activities. Certain of the underwriters and their respective affiliates have  from time to time  performed  and may in the future perform  various financial advisory and investment banking services for the Bank  for which they received or will receive customary fees and expenses.In the ordinary course of their various business activities  the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers  and such investment and securities activities may involve securities and/or instruments of the Bank. The underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold  or recommend to clients that they acquire  long and/or short positions in such securities and instruments.P- 13Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSelling RestrictionsEuropean Economic Area. PROHIBITION OF SALES TO EEA RETAIL INVESTORS. The Notes are not intended to be offered  sold or otherwise made available to  and should not be offered  sold or otherwise made available to  any retail investor in the European Economic Area (‚ÄúEEA‚Äù). For these purposes  the expression ‚Äúoffer"" includes the communication in any form and by any means of sufficient information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe the Notes  and a ‚Äúretail investor‚Äù means a person who is one (or more) of: (a) a retail client  as defined in point (11) of Article 4(1) of Directive 2014/65/EU  as amended (‚ÄúMiFID II‚Äù)Õæ or (b) a customer  within the meaning of Insurance Distribution Directive 2016/97/EU  as amended  where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID IIÕæ or (c) not a qualified investor as defined in Regulation (EU) 2017/1129 (the ‚ÄúProspectus Regulation‚Äù). Consequently  no key information document required by Regulation (EU) No 1286/2014  as amended (the ‚ÄúPRIIPs Regulation‚Äù) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared  and therefore  offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. This pricing supplement has been prepared on the basis that any offer of Notes in any Member State of the EEA or the UK will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of Notes. This pricing supplement is not a prospectus for the purposes of the Prospectus Regulation.United Kingdom. PROHIBITION OF SALES TO UK RETAIL INVESTORS.The Notes are not intended to be offered  sold or otherwise made available to  and should not be offered  sold or otherwise made available to  any retail investor in the United Kingdom (‚ÄúUK‚Äù). For these purposes  a retail investor means a person who is one (or more) of: (i) a retail client  as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the ‚ÄúEUWA‚Äù); or (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (the ‚ÄúFSMA‚Äù) and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97  where that customer would not qualify as a professional client  as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA (the ‚ÄúUK Prospectus Regulation‚Äù). Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the ‚ÄúUK PRIIPs Regulation‚Äù) for offering or selling the Notes or otherwise making them available to retail investors in the United Kingdom has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the United Kingdom may be unlawful under the UK PRIIPs Regulation. This pricing supplement has been prepared on the basis that any offer of Notes in the UK will be made pursuant to an exemption under the UK Prospectus Regulation from the requirement to publish a prospectus for offers of Notes. This pricing supplement is not a prospectus for the purposes of the UK Prospectus Regulation.This pricing supplement and any other material in relation to the Notes are only being distributed to  and are only directed at  persons in the UK that are qualified investors within the meaning of Article 2(1)(e) of the UK Prospectus Regulation that also (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005  as amended (the ‚ÄúOrder‚Äù)  (ii) who fall within Article 49(2)(a) to (d) of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as ‚Äúrelevant persons‚Äù). The Notes are only available to  and any invitation  offer or agreement to purchase or otherwise acquire such Notes will be engaged in only with  relevant persons. This pricing supplement and its contents should not be distributed  published or reproduced (in whole or in part) or disclosed by recipients to any other person in the UK. Any person in the UK that is not a relevant person should not act or rely on this pricing supplement or any of its contents.P- 14Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaHong Kong. The Notes may not be offered or sold in Hong Kong by means of any document other than (a) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (‚ÄúCompanies (Winding Up and Miscellaneous Provisions) Ordinance‚Äù) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (‚ÄúSecurities and Futures Ordinance‚Äù)  or (b) to ‚Äúprofessional investors‚Äù as defined in the Securities and Futures Ordinance and any rules made thereunder  or (c) in other circumstances which do not result in the document being a ‚Äúprospectus‚Äù as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance  and no advertisement  invitation or document relating to the Notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere)  which is directed at  or the contents of which are likely to be accessed or read by  the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Notes which are or are intended to be disposed of only to persons outside Hong Kong or only to ‚Äúprofessional investors‚Äù in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.Singapore. This pricing supplement and the accompanying prospectus and prospectus supplement have not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly  this pricing supplement  the accompanying prospectus and prospectus supplement and any other document or material in connection with the offer or sale  or invitation for subscription or purchase  of the Notes may not be circulated or distributed  nor may the Notes be offered or sold  or be made the subject of an invitation for subscription or purchase  whether directly or indirectly  to persons in Singapore other than (a) to an institutional investor (as defined in Section 4A of the Securities and Futures Act  Chapter 289 of Singapore (the ‚ÄúSFA‚Äù)) under Section 274 of the SFA  (b) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA  or any person pursuant to Section 275(1A) of the SFA  and in accordance with the conditions specified in Section 275 of the SFA or (c) otherwise pursuant to  and in accordance with the conditions of  any other applicable provision of the SFA  in each case subject to conditions set forth in the SFA.Where the Notes are subscribed or purchased under Section 275 of the SFA by a relevant person which is (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals  each of whom is an accredited investor  or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor  the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for six months after that corporation has acquired the Notes under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA)  (2) where such transfer arises from an offer in that corporation‚Äôs securities pursuant to Section 275(1A) or Section 276(4)(i)(B) of the SFA  (3) where no consideration is or will be given for the transfer  (4) where the transfer is by operation of law  (5) as specified in Section 276(7) of the SFA  or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.Notification under Section 309B(1)(c) of the SFA. The Bank has determined that the Notes are (a) prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and (b) Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).P- 15Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaSwitzerland. The Notes are not offered  sold or advertised  directly or indirectly  in  into or from Switzerland on the basis of a public offering and will not be listed on the SIX Swiss Exchange or any other offering or regulated trading facility in Switzerland. Accordingly  neither this pricing supplement  the accompanying prospectus and prospectus supplement nor other marketing material constitute a prospectus as defined in article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus as defined in article 32 of the Listing Rules of the SIX Swiss Exchange or any other regulated trading facility in Switzerland. Any resales of the Notes may only be undertaken on a private basis to selected individual investors in compliance with Swiss law. This pricing supplement  the accompanying prospectus or prospectus supplement may not be copied  reproduced  distributed or passed on to others or otherwise made available in Switzerland without our prior written consent. By accepting this pricing supplement  the accompanying prospectus or prospectus supplement or by subscribing to the notes  investors are deemed to have acknowledged and agreed to abide by these restrictions.Japan. The Notes have not been and will not be registered pursuant to Article 4  Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly  none of the Notes nor any interest therein may be offered or sold  directly or indirectly  in Japan or to  or for the benefit of  any ‚Äúresident‚Äù of Japan (which term as used herein means any person resident in Japan  including any corporation or other entity organized under the laws of Japan)  or to others for re-offering or resale  directly or indirectly  in Japan or to or for the benefit of a resident of Japan  except pursuant to an exemption from the registration requirements of  and otherwise in compliance with  the Financial Instruments and Exchange Act and any other applicable laws  regulations and ministerial guidelines of Japan in effect at the relevant time.Canada. Sales into Canada are permitted.P- 16Senior Floating Rate Notes Due April 14  2025Royal Bank of CanadaVALIDITY OF NOTESThe validity of the Notes will be passed upon for us by Sullivan & Cromwell LLP  New York  New York  as to matters of New York law  and by Norton Rose Fulbright Canada LLP  Toronto  Ontario  as to matters of Canadian law and applicable matters of Ontario law. Certain legal matters will be passed upon for the underwriters by Davis Polk & Wardwell LLP  New York  New York.WHERE YOU CAN FIND ADDITIONAL INFORMATIONYou should read this pricing supplement  together with the documents listed below  which together contain the terms of the Notes and supersede all prior or contemporaneous oral statements as well as any other written materials. You may access the following documents on the SEC Website at www.sec.gov as follows (or if such address has changed  by reviewing our filings for the relevant date on the SEC Website):¬∑ Series I MTN prospectus supplement dated September 14  2021:https://www.sec.gov/Archives/edgar/data/1000275/000121465921009472/rbcsupp911210424b3.htm¬∑ Prospectus dated September 14  2021:https://www.sec.gov/Archives/edgar/data/1000275/000121465921009470/rbc911212424b3.htmOur Central Index Key  or CIK  on the SEC Website is 1000275.P-17Exhibit 107.1The pricing supplement to which this Exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of the offering is $400 000 000.",neutral,0.01,0.99,0.01,negative,0.03,0.09,0.88,True,English,"['Form 424B2 ROYAL BANK', 'CANADA', 'US Bancorp Westpac Banking Corporation Senior Floating Rate Notes', 'two U.S. Government Securities Business Days', 'RBC Capital Markets Citigroup Goldman Sachs', 'U.S. Federal Deposit Insurance Corporation', 'U.S. Dollars Interest Rate', 'senior unsecured floating rate notes', 'Canada Deposit Insurance Corporation Act', 'Per Note Total Price', 'Senior Global Medium-Term Notes', 'SOFR Index Rate Spread', 'The Depository Trust Company', 'next Interest Payment Date', 'Interest Payment Determination Date', 'KeyBanc Capital Markets', 'Depository Services Inc', 'business day convention', 'other governmental agency', 'state securities commission', 'Joint Book Runners', 'J.P. Morgan', 'fifteenth calendar day', '246980349 Interest Payment Dates', 'final Interest Period', 'first Interest Period', 'accompanying prospectus supplement', 'page S', 'Senior Currency', 'Base Rate', 'federal laws', 'securities exchange', 'Debt Securities', 'Payment Convention', 'CDIC Act', 'first date', 'Exchange Commission', 'Record Dates', 'Pricing Date', 'Issue Date', 'Interest Payments', 'Pricing Supplement', 'The Notes', 'bail-inable notes', 'Registration Statement', 'common shares', 'sinking fund', 'credit risk', 'Risk Factors', 'savings accounts', 'insured deposits', 'United States', 'criminal offense', '400,000,000 Underwriting discount', 'indirect participants', 'available funds', 'Lead Managers', 'Co. LLC', 'basic features', 'Principal Amount', 'Minimum Denominations', 'integral multiples', 'Common Code', 'quarterly period', 'Observation Period', 'Maturity Date', 'Royal Bank', 'Bank‚Äù) Issue', 'CDS Clearing', 'definitive form', 'Series I', 'CUSIP number', 'Rule', 'September', 'cash', 'conversion', 'means', 'transaction', 'one', 'steps', 'affiliates', 'subsection', 'variation', 'extinguishment', 'consequence', 'application', 'Province', 'Ontario', 'respect', 'operation', 'risks', 'instrumentality', 'representation', 'contrary', 'public', 'Proceeds', 'book-entry', 'facilities', 'DTC', 'Euroclear', 'Clearstream', 'April', 'TERMS', 'sections', 'Description', 'provisions', 'Issuer', 'Title', 'excess', 'ISIN', 'US78016EZ911', '14th', 'January', 'July', 'October', 'following', 'case', '0.']",1990-05-06,2022-04-11,streetinsider.com
2652,Clearstream,Google API,https://www.defenseworld.net/2022/04/10/deutsche-borse-ag-otcmktsdboey-given-consensus-recommendation-of-hold-by-analysts.html,Deutsche B√∂rse AG (OTCMKTS:DBOEY) Given Consensus Recommendation of ‚ÄúHold‚Äù by Analysts,21 hours ago,Shares of Deutsche B√∂rse AG (OTCMKTS:DBOEY ‚Äì Get Rating) have been assigned a consensus recommendation of ‚ÄúHold‚Äù from the nine analysts that are currently covering the company  Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $170.24.A number of research firms recently issued reports on DBOEY. Morgan Stanley reduced their price objective on Deutsche B√∂rse from ‚Ç¨174.60 ($191.87) to ‚Ç¨171.20 ($188.13) and set an ‚Äúequal weight‚Äù rating for the company in a research report on Tuesday  February 15th. Exane BNP Paribas upgraded Deutsche B√∂rse from a ‚Äúneutral‚Äù rating to an ‚Äúoutperform‚Äù rating and set a ‚Ç¨180.00 ($197.80) price target for the company in a research report on Tuesday  March 15th. Zacks Investment Research lowered Deutsche B√∂rse from a ‚Äúbuy‚Äù rating to a ‚Äúhold‚Äù rating in a research report on Tuesday  March 22nd. Citigroup lowered Deutsche B√∂rse from a ‚Äúbuy‚Äù rating to a ‚Äúneutral‚Äù rating in a research report on Wednesday  January 26th. Finally  Royal Bank of Canada boosted their price target on Deutsche B√∂rse from ‚Ç¨150.00 ($164.84) to ‚Ç¨156.00 ($171.43) and gave the stock a ‚Äúsector perform‚Äù rating in a research report on Monday  February 28th.Get Deutsche B√∂rse alerts:Shares of OTCMKTS DBOEY traded up $0.15 during trading on Friday  reaching $18.20. The stock had a trading volume of 78 102 shares  compared to its average volume of 279 526. Deutsche B√∂rse has a one year low of $14.77 and a one year high of $18.44. The stock has a market cap of $34.58 billion  a PE ratio of 23.64 and a beta of 0.79. The firm‚Äôs 50 day moving average price is $17.37 and its two-hundred day moving average price is $16.91.Deutsche B√∂rse ( OTCMKTS:DBOEY Get Rating ) last released its quarterly earnings data on Wednesday  February 9th. The financial services provider reported $0.19 earnings per share (EPS) for the quarter  beating the Zacks‚Äô consensus estimate of $0.18 by $0.01. Deutsche B√∂rse had a return on equity of 18.26% and a net margin of 27.59%. The business had revenue of $1.35 billion during the quarter. On average  sell-side analysts expect that Deutsche B√∂rse will post 0.9 earnings per share for the current year.About Deutsche B√∂rse (Get Rating)Deutsche B√É¬∂rse AG operates as an exchange organization in Europe  the United States  and the Asia-Pacific. The company operates through seven segments: Eurex (Financial Derivatives)  EEX (Commodities)  360T (Foreign Exchange)  Xetra (Cash Equities)  Clearstream (Post-Trading)  IFS (Investment Fund Services)  and Qontigo (index and analytics business).Featured ArticlesReceive News & Ratings for Deutsche B√∂rse Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deutsche B√∂rse and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.03,0.63,0.35,negative,0.02,0.42,0.57,True,English,"['Deutsche B√∂rse AG', 'Consensus Recommendation', 'OTCMKTS', 'DBOEY', 'Hold', 'Analysts', 'two-hundred day moving average price', '50 day moving average price', 'FREE daily email newsletter', 'average 1-year price objective', 'Deutsche B√∂rse AG', 'Deutsche B√∂rse alerts', 'Deutsche B√É¬∂rse AG', 'Deutsche B√∂rse Daily', 'Five equities research analysts', 'concise daily summary', 'Exane BNP Paribas', 'Investment Fund Services', 'financial services provider', 'Zacks‚Äô consensus estimate', 'Zacks Investment Research', 'equal weight‚Äù rating', 'quarterly earnings data', 'Marketbeat Ratings reports', 'DBOEY Get Rating', 'average volume', 'price target', 'Cash Equities', 'email address', 'consensus recommendation', 'Financial Derivatives', 'MarketBeat.com', 'research firms', 'research report', 'nine analysts', 'sell-side analysts', ""analysts' ratings"", 'buy recommendation', 'Morgan Stanley', 'neutral‚Äù rating', 'outperform‚Äù rating', 'buy‚Äù rating', 'Royal Bank', 'sector perform', 'market cap', 'PE ratio', 'net margin', 'current year', 'exchange organization', 'United States', 'seven segments', 'Foreign Exchange', 'Featured Articles', 'related companies', 'hold recommendation', 'February 15th', 'hold‚Äù rating', 'February 9th', 'last year', 'March 15th', 'trading volume', 'one year', 'analytics business', 'latest news', 'OTCMKTS DBOEY', '$0.19 earnings', '0.9 earnings', 'Shares', 'company', 'stock', 'coverage', 'number', 'Tuesday', 'Citigroup', 'Wednesday', 'January', 'Canada', 'Monday', 'Friday', 'beta', 'EPS', 'return', 'equity', 'revenue', 'Europe', 'Asia-Pacific', 'Eurex', 'EEX', 'Commodities', '360T', 'Xetra', 'Clearstream', 'Post-Trading', 'IFS', 'Qontigo', 'index', '‚Ç¨', '0.00', '78', '18.', '27.59']",2022-04-10,2022-04-11,defenseworld.net
2653,Clearstream,Bing API,https://nz.finance.yahoo.com/news/state-street-announces-capability-support-123000559.html,State Street Announces New Capability to Support Fund Order Services in Mexico,State Street Corporation (NYSE: STT) announced today that it has launched an integrated fund trading solution along with its custody offering for clients in Mexico. The secure online platform will allow for access to a broad range of investment funds in collaboration with Clearstream (Vestima¬Æ) providing fund order services through a single-entry point.,"BOSTON  April 11  2022--(BUSINESS WIRE)--State Street Corporation (NYSE: STT) announced today that it has launched an integrated fund trading solution along with its custody offering for clients in Mexico. The secure online platform will allow for access to a broad range of investment funds in collaboration with Clearstream (Vestima¬Æ) providing fund order services through a single-entry point.Our fund order services offering will support connectivity with a wide range of transfer agents to meet clients‚Äô unique requirements  including the ability to manage both segregated and omnibus accounts. It will also allow State Street Bank to secure expansive product and jurisdictional coverage across Latin America (LATAM).""We are very pleased to announce this new capability for our clients "" said Marcia Rothschild  head of Latin America for State Street. ""This trading solution is a critical step towards further expanding our products and capabilities in Mexico.""Additional product features include a robust infrastructure underpinned by SWIFT  real-time monitoring of order status  a dedicated client service team and registration services and account opening support by Vestima¬Æ.State Street‚Äôs first live client in the region is Afore Profuturo.""We are delighted to be the first client onboarded to State Street‚Äôs new trading platform "" said Antonio Sibaja from Profuturo Afore. ""The new function will allow us to work more efficiently to give our clients a better pension and a better future.""About State Street CorporationState Street Corporation (NYSE: STT) is one of the world's leading providers of financial services to institutional investors including investment servicing  investment management and investment research and trading. With $43.7 trillion in assets under custody and/or administration and $4.1 trillion* in assets under management as of December 31  2021  State Street operates globally in more than 100 geographic markets and employs approximately 39 000 worldwide. For more information  visit State Street's website at www.statestreet.com.Story continues*Assets under management as of December 30  2021 includes approximately $61 billion of assets with respect to SPDR¬Æ products for which State Street Global Advisors Funds Distributors  LLC (SSGA FD) acts solely as the marketing agent. SSGA FD and State Street Global Advisors are affiliated.About ProfuturoProfuturo is a 100% Mexican company belonging to Grupo Bal  specialized in managing retirement savings funds for Mexican workers and has more than six million clients. Profuturo has been managing the retirement of workers in the country for more than 25 years. The company was recognized for the third consecutive year as the Best Pension Administrator in Mexico by the specialized publication International Finance  and received the silver medal  the highest rating among the Afores by the company Morningstar. Likewise  the company signed an agreement with the CFA Global Institute to certify its entire investment and risk team in environmental  social  and corporate governance (ESG) criteria.View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005507/en/ContactsMedia:Brendan PaulBpaul2@statestreet.com+1-401-644-9182",neutral,0.02,0.98,0.01,positive,0.71,0.25,0.04,True,English,"['Fund Order Services', 'State Street', 'New Capability', 'Mexico', 'State Street Global Advisors Funds Distributors', 'dedicated client service team', 'integrated fund trading solution', 'CFA Global Institute', 'secure online platform', 'account opening support', 'third consecutive year', 'State Street Bank', 'State Street Corporation', 'retirement savings funds', 'fund order services', 'Additional product features', 'first live client', 'Best Pension Administrator', 'new trading platform', 'clients‚Äô unique requirements', 'six million clients', 'investment funds', 'first client', 'risk team', 'order status', 'expansive product', 'registration services', 'financial services', 'new capability', 'new function', 'BUSINESS WIRE', 'broad range', 'single-entry point', 'wide range', 'transfer agents', 'omnibus accounts', 'jurisdictional coverage', 'Latin America', 'Marcia Rothschild', 'critical step', 'robust infrastructure', 'real-time monitoring', 'Antonio Sibaja', 'leading providers', 'institutional investors', 'investment servicing', 'investment research', '100 geographic markets', 'SSGA FD', 'marketing agent', 'Grupo Bal', 'specialized publication', 'International Finance', 'silver medal', 'highest rating', 'entire investment', 'corporate governance', 'ESG) criteria', 'source version', 'Contacts Media', 'Brendan Paul', 'custody offering', 'SPDR¬Æ products', 'Mexican workers', 'Afore Profuturo', 'Profuturo Afore', 'investment management', '100% Mexican company', 'BOSTON', 'April', 'NYSE', 'STT', 'Mexico', 'access', 'collaboration', 'Clearstream', 'Vestima¬Æ', 'connectivity', 'segregated', 'LATAM', 'head', 'capabilities', 'SWIFT', 'region', 'future', 'world', 'assets', 'administration', 'December', 'information', 'website', 'statestreet', 'Story', 'respect', 'LLC', 'country', '25 years', 'Afores', 'Morningstar', 'agreement', 'businesswire', 'Bpaul2']",2022-04-11,2022-04-11,nz.finance.yahoo.com
2654,Clearstream,Twitter API,Twitter,@PhilippeMurer Clearstream...,nan,@PhilippeMurer Clearstream...,neutral,0.15,0.8,0.05,neutral,0.15,0.8,0.05,True,English,"['PhilippeMurer Clearstream', 'PhilippeMurer Clearstream']",2022-04-11,2022-04-11,Unknown
2655,Deutsche Boerse,Google API,https://www.defenseworld.net/2022/04/10/deutsche-borse-ag-otcmktsdboey-given-consensus-recommendation-of-hold-by-analysts.html,Deutsche B√∂rse AG (OTCMKTS:DBOEY) Given Consensus Recommendation of ‚ÄúHold‚Äù by Analysts,21 hours ago,Shares of Deutsche B√∂rse AG (OTCMKTS:DBOEY ‚Äì Get Rating) have been assigned a consensus recommendation of ‚ÄúHold‚Äù from the nine analysts that are currently covering the company  Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $170.24.A number of research firms recently issued reports on DBOEY. Morgan Stanley reduced their price objective on Deutsche B√∂rse from ‚Ç¨174.60 ($191.87) to ‚Ç¨171.20 ($188.13) and set an ‚Äúequal weight‚Äù rating for the company in a research report on Tuesday  February 15th. Exane BNP Paribas upgraded Deutsche B√∂rse from a ‚Äúneutral‚Äù rating to an ‚Äúoutperform‚Äù rating and set a ‚Ç¨180.00 ($197.80) price target for the company in a research report on Tuesday  March 15th. Zacks Investment Research lowered Deutsche B√∂rse from a ‚Äúbuy‚Äù rating to a ‚Äúhold‚Äù rating in a research report on Tuesday  March 22nd. Citigroup lowered Deutsche B√∂rse from a ‚Äúbuy‚Äù rating to a ‚Äúneutral‚Äù rating in a research report on Wednesday  January 26th. Finally  Royal Bank of Canada boosted their price target on Deutsche B√∂rse from ‚Ç¨150.00 ($164.84) to ‚Ç¨156.00 ($171.43) and gave the stock a ‚Äúsector perform‚Äù rating in a research report on Monday  February 28th.Get Deutsche B√∂rse alerts:Shares of OTCMKTS DBOEY traded up $0.15 during trading on Friday  reaching $18.20. The stock had a trading volume of 78 102 shares  compared to its average volume of 279 526. Deutsche B√∂rse has a one year low of $14.77 and a one year high of $18.44. The stock has a market cap of $34.58 billion  a PE ratio of 23.64 and a beta of 0.79. The firm‚Äôs 50 day moving average price is $17.37 and its two-hundred day moving average price is $16.91.Deutsche B√∂rse ( OTCMKTS:DBOEY Get Rating ) last released its quarterly earnings data on Wednesday  February 9th. The financial services provider reported $0.19 earnings per share (EPS) for the quarter  beating the Zacks‚Äô consensus estimate of $0.18 by $0.01. Deutsche B√∂rse had a return on equity of 18.26% and a net margin of 27.59%. The business had revenue of $1.35 billion during the quarter. On average  sell-side analysts expect that Deutsche B√∂rse will post 0.9 earnings per share for the current year.About Deutsche B√∂rse (Get Rating)Deutsche B√É¬∂rse AG operates as an exchange organization in Europe  the United States  and the Asia-Pacific. The company operates through seven segments: Eurex (Financial Derivatives)  EEX (Commodities)  360T (Foreign Exchange)  Xetra (Cash Equities)  Clearstream (Post-Trading)  IFS (Investment Fund Services)  and Qontigo (index and analytics business).Featured ArticlesReceive News & Ratings for Deutsche B√∂rse Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deutsche B√∂rse and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.03,0.63,0.35,negative,0.02,0.42,0.57,True,English,"['Deutsche B√∂rse AG', 'Consensus Recommendation', 'OTCMKTS', 'DBOEY', 'Hold', 'Analysts', 'two-hundred day moving average price', '50 day moving average price', 'FREE daily email newsletter', 'average 1-year price objective', 'Deutsche B√∂rse AG', 'Deutsche B√∂rse alerts', 'Deutsche B√É¬∂rse AG', 'Deutsche B√∂rse Daily', 'Five equities research analysts', 'concise daily summary', 'Exane BNP Paribas', 'Investment Fund Services', 'financial services provider', 'Zacks‚Äô consensus estimate', 'Zacks Investment Research', 'equal weight‚Äù rating', 'quarterly earnings data', 'Marketbeat Ratings reports', 'DBOEY Get Rating', 'average volume', 'price target', 'Cash Equities', 'email address', 'consensus recommendation', 'Financial Derivatives', 'MarketBeat.com', 'research firms', 'research report', 'nine analysts', 'sell-side analysts', ""analysts' ratings"", 'buy recommendation', 'Morgan Stanley', 'neutral‚Äù rating', 'outperform‚Äù rating', 'buy‚Äù rating', 'Royal Bank', 'sector perform', 'market cap', 'PE ratio', 'net margin', 'current year', 'exchange organization', 'United States', 'seven segments', 'Foreign Exchange', 'Featured Articles', 'related companies', 'hold recommendation', 'February 15th', 'hold‚Äù rating', 'February 9th', 'last year', 'March 15th', 'trading volume', 'one year', 'analytics business', 'latest news', 'OTCMKTS DBOEY', '$0.19 earnings', '0.9 earnings', 'Shares', 'company', 'stock', 'coverage', 'number', 'Tuesday', 'Citigroup', 'Wednesday', 'January', 'Canada', 'Monday', 'Friday', 'beta', 'EPS', 'return', 'equity', 'revenue', 'Europe', 'Asia-Pacific', 'Eurex', 'EEX', 'Commodities', '360T', 'Xetra', 'Clearstream', 'Post-Trading', 'IFS', 'Qontigo', 'index', '‚Ç¨', '0.00', '78', '18.', '27.59']",2022-04-10,2022-04-11,defenseworld.net
2656,Deutsche Boerse,Google API,https://www.etfstream.com/news/bnp-paribas-am-eyes-germany-etf-push-with-double-hire/,BNP Paribas AM eyes Germany ETF push with double hire,16 hours ago,BNP Paribas AM eyes Germany ETF push with double hireBNP Paribas Asset Management (BNPP AM) has made a double hire within its sales team as the firm looks to expand its ETF business in Germany.Former MSCI index coverage vice president Benjamin Ertler has been named as senior sales manager while Martin Walentowitz also joins as a sales manager.Ertler joins having spent five years at MSCI  most recently servicing German banks and asset managers.Prior to MSCI  he was a sales associate at STOXX  part of Deutsche Boerse and spent almost a decade at Deutsche Bank as a private banking adviser.Walentowitz joins having previously worked in the firm‚Äôs wealth management arm as an investment manager for over three years.Before this  he spent five years at Deutsche Bank  latterly as an investment adviser in its wealth management division.Both Ertler and Walentowitz will report to BNPP AM‚Äôs head of business development for ETF and index solutions for Germany  Austria and Switzerland Claus Hecher.The pair will be responsible for growing the French asset manager‚Äôs ETF franchise in the German market  targeting wealth management  private banking and retail distribution.Furthermore  they will continue to develop the group‚Äôs index solutions integrating ESG and decarbonisation into its ETF range.Germany is one of Europe‚Äôs fastest-growing ETF markets  with a market share of 27% ($432bn)  ahead of the UK‚Äôs 25% ($400bn) and almost double its next biggest rival Italy  which has a market share of 14% ($224bn)  according to Blackwater Search and Advisory.Germany asserts itself as ETF powerhouse following retail investment boomCommenting on the appointments  Hecher said: ‚ÄúTheir considerable experience of the German ETF market  combined with their excellent knowledge of the specific needs of German private banks and the asset management industry  will be very important for the growth of our business in this market.‚ÄùLast week  BNPP AM expanded its ESG range with the launch of the BNP Paribas Easy JPM ESG Green Social and Sustainability IG EUR Bond ETF (ASRQ).It follows the launch of two thematic ETFs by BNP PAM last month. The BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF (ASRP) and BNP Paribas Easy ECPI Global Hydrogen Economy UCITS ETF (ASRS).Related articles,neutral,0.02,0.93,0.04,positive,0.72,0.25,0.03,True,English,"['BNP Paribas AM', 'Germany ETF', 'double hire', 'The BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF', 'BNP Paribas Easy ECPI Global Hydrogen Economy UCITS ETF', 'BNP Paribas Easy JPM ESG Green Social', 'Former MSCI index coverage vice president', 'Sustainability IG EUR Bond ETF', 'BNP Paribas Asset Management', 'BNP Paribas AM', 'growing ETF markets', 'next biggest rival', 'asset management industry', 'two thematic ETFs', 'wealth management arm', 'wealth management division', 'French asset manager', 'German ETF market', 'BNP PAM', 'retail investment boom', 'senior sales manager', 'private banking adviser', 'German private banks', 'ESG range', 'ETF franchise', 'ETF range', 'ETF powerhouse', 'ETF business', 'index solutions', 'Germany ETF', 'German banks', 'asset managers', 'investment manager', 'investment adviser', 'German market', 'retail distribution', 'BNPP AM', 'sales team', 'sales associate', 'double hire', 'five years', 'Deutsche Boerse', 'Deutsche Bank', 'three years', 'market share', 'Blackwater Search', 'considerable experience', 'excellent knowledge', 'specific needs', 'Related articles', 'Benjamin Ertler', 'Both Ertler', 'business development', 'Claus Hecher', 'Martin Walentowitz', 'firm', 'STOXX', 'part', 'decade', 'head', 'Austria', 'Switzerland', 'pair', 'group', 'decarbonisation', 'Europe', 'UK', 'Italy', 'Advisory', 'appointments', 'growth', 'launch', 'ASRQ', 'ASRP', 'ASRS']",2022-08-04,2022-04-11,etfstream.com
2657,Deutsche Boerse,Google API,https://www.express.co.uk/news/politics/1593971/eu-plot-city-of-london-clearing-houses-uk-trade-market-brexit-mairead-mccuinness,EU plot to raid ¬£560trillion London market dealt hammerblow ‚Äì Europe's banks launch attack,1 day ago,"Jacob Rees-Mogg says EU was ‚Äòvery cross‚Äô about BrexitFREE now and never miss the top politics stories again SUBSCRIBE Invalid email Sign up fornow and never miss the top politics stories again We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More infoBrussels vowed to reduce the EU's ""excessive dependence"" on the City and its ‚Ç¨660 trillion (¬£563trillion) clearing market but the European Banking Federation (EBF) has now said the European Commission's proposal would cause ""serious market disruption"".Clearing houses act as middlemen in derivatives trades between banks. Since the 2008 financial crisis  they are a vital part of the financial system. The City is Europe's largest centre for clearing activity  with London Stock Exchange's LCH unit in London clearing about 90 percent of euro interest rate derivatives. Brexit made clearing a strong battleground. In line with Brussels' desire for control over euro-denominated trades to build ""strategic autonomy"" in capital markets  after the UK's departure it insisted EU banks would be shut out of London  with an initial deadline of January 2020. This was however repeatedly pushed back over concerns about financial stability and reduced access to products such as mortgages. Brexit LIVE: ‚ÄòSome isolation  some clown!‚Äô Brexit-bashers savaged as UK takes centre stageMcGuinness  executive EU Commission financial services chief  wants less EU 'dependence' on UKIn January  Mairead McGuinness  financial services chief at the executive European Commission  was forced to allow EU-based banks and money managers to clear trades in London until June 2025 after failing to persuade banks and their customers to shift the activity from the UK capital to Deutsche Boerse's Eurex in Frankfurt fast enough. An abrupt end to cross-border clearing would have disrupted markets  but EU officials believe three years will be long enough to allow the build-up of European capacity to replace the trade. After Ms McGuinness launched a consultation for measures to lower the EU's reliance ""on systemic third-country clearinghouses and to improve the attractiveness of EU-based clearing houses""  the EBF advised against the ""forced relocation"" plans.City of London: Europe's largest centre for clearing activityThe trade body said: ""EBF would like to highlight that any forced relocation strategy or other coercive measures will not achieve  and would likely undermine  the objective of a competitive and resilient EU clearing [market]."" The federation concluded: ""We ask the European Commission to only consider measures that make clearing in the EU more attractive  without disproportionally undermining other market participants that are key to the fair and efficient provision of clearing services."" In a speech at the European Central Bank in Frankfurt on Wednesday  Ms McGuinness  an Irish conservative  compared the EU's dependence on the City of London with its reliance on Russian oil and gas.Trending",negative,0.02,0.12,0.86,mixed,0.09,0.14,0.77,True,English,"['¬£560trillion London market', 'EU plot', 'hammerblow', 'Europe', 'banks', 'attack', 'executive EU Commission financial services chief', 'euro interest rate derivatives', 'executive European Commission', 'top politics stories', 'systemic third-country clearinghouses', 'serious market disruption', 'other market participants', 'forced relocation"" plans', 'European Central Bank', 'other coercive measures', 'centre stage McGuinness', 'European Banking Federation', 'London Stock Exchange', ""less EU 'dependence"", 'EU-based clearing houses', 'clearing services', '2008 financial crisis', 'financial system', 'financial stability', 'derivatives trades', 'European capacity', 'relocation strategy', 'clearing market', 'largest centre', 'Mairead McGuinness', 'Ms McGuinness', 'Jacob Rees-Mogg', 'Invalid email', '3rd parties', 'More info', 'excessive dependence', 'vital part', 'LCH unit', 'strong battleground', 'strategic autonomy', 'initial deadline', 'EU-based banks', 'money managers', 'Deutsche Boerse', 'abrupt end', 'EU officials', 'three years', 'efficient provision', 'Irish conservative', 'Russian oil', 'cross-border clearing', 'euro-denominated trades', 'capital markets', 'EU banks', 'trade body', 'Brexit LIVE', 'The City', 'UK capital', 'sign-up', 'content', 'ways', 'understanding', 'adverts', 'time', 'Brussels', '‚Ç¨660 trillion', 'EBF', 'proposal', 'middlemen', 'activity', '90 percent', 'desire', 'control', 'departure', 'January', 'concerns', 'access', 'products', 'mortgages', 'isolation', 'clown', 'Brexit-bashers', 'June', 'customers', 'Eurex', 'Frankfurt', 'build-up', 'consultation', 'reliance', 'attractiveness', 'objective', 'competitive', 'fair', 'speech', 'Wednesday', 'gas', 'Trending']",2022-04-10,2022-04-11,express.co.uk
2658,Deutsche Boerse,Twitter API,Twitter,"#IRSH Monday morning RNS $IRSH ""Stabilisation Notice - DEUTSCHE BOERSE""https://t.co/8tcqaUPEFb",nan,"#IRSH Monday morning RNS $IRSH ""Stabilisation Notice - DEUTSCHE BOERSE""https://t.co/8tcqaUPEFb",neutral,0.01,0.92,0.07,neutral,0.01,0.92,0.07,True,English,"['Stabilisation Notice', 'DEUTSCHE BOERSE', 'RNS', 'IRSH', '8tcqaUPEFb', 'Stabilisation Notice', 'DEUTSCHE BOERSE', 'RNS', 'IRSH', '8tcqaUPEFb']",2022-04-11,2022-04-11,Unknown
2659,Deutsche Boerse,Twitter API,Twitter,"#IRSH Monday morning RNS $IRSH ""Stabilisation Notice - DEUTSCHE BOERSE""https://t.co/8tcqaUy3ND",nan,"#IRSH Monday morning RNS $IRSH ""Stabilisation Notice - DEUTSCHE BOERSE""https://t.co/8tcqaUy3ND",neutral,0.01,0.93,0.06,neutral,0.01,0.93,0.06,True,English,"['Stabilisation Notice', 'DEUTSCHE BOERSE', 'RNS', 'IRSH', '8tcqaUy3ND', 'Stabilisation Notice', 'DEUTSCHE BOERSE', 'RNS', 'IRSH', '8tcqaUy3ND']",2022-04-11,2022-04-11,Unknown
2660,EuroNext,NewsApi.org,https://finance.yahoo.com/news/lectra-lectra-confirms-eligibility-pea-075400768.html,Lectra: Lectra confirms its eligibility for PEA-PME scheme,Lectra confirms its eligibility for PEA-PME scheme Paris  April 11  2022 ‚Äì Lectra (FR0000065484 LSS)  a company listed on the regulated market Euronext Paris...,LECTRALectra confirms its eligibility for PEA-PME schemeParis  April 11  2022 ‚Äì Lectra (FR0000065484 LSS)  a company listed on the regulated market Euronext Paris (compartment B)  confirms  based on the consolidated financial statements of its last fiscal year ended December 31  2021  its eligibility for inclusion in French SME equity savings plans ‚ÄúPEA-PME‚Äù for the next twelve months.Lectra complies with the criteria for the inclusion of companies in the PEA-PME savings plans set in Article L.221-32-2 of the French Monetary and Financial Code  i.e. having less than 5 000 employees and a total revenue below 1 5 billion euros or total assets below 2 billion euros.As a consequence  investment in Lectra shares can be made through PEA-PME savings accounts  relief specifically applicable to investments in small and mid-cap companies  benefiting from the same tax advantages as the traditional Equity Savings Plan (PEA).For companies that breathe life into our wardrobes  car interiors  furniture and more  Lectra crafts the premium technologies that facilitate the digital transformation of their industry. Lectra‚Äôs offer empowers brands  manufacturers and retailers from design to production  providing them with the market respect and peace of mind they deserve. Founded in 1973  the company reported revenues of 388 million euros in 2021 and is listed on Euronext (LSS).In June 2021  Lectra acquired Gerber Technology  a USA-based company founded in 1968. Like Lectra  Gerber Technology develops software and automation solutions for fashion  automotive  furniture and other businesses across the globe.For more information  please visit www.lectra.com .Lectra ‚Äì World Headquarters: 16‚Äì18  rue Chalgrin ‚Ä¢ 75016 Paris ‚Ä¢ FranceTel. +33 (0)1 53 64 42 00 ‚Äì www.lectra.comA French Soci√©t√© Anonyme with capital of ‚Ç¨37 742 959 ‚Ä¢ RCS Paris B 300 702 305Attachment,neutral,0.02,0.96,0.01,positive,0.59,0.4,0.01,True,English,"['PEA-PME scheme', 'Lectra', 'eligibility', 'A French Soci√©t√© Anonyme', 'French SME equity savings plans', 'traditional Equity Savings Plan', 'PEA-PME savings plans', 'last fiscal year', 'next twelve months', 'PEA-PME savings accounts', 'same tax advantages', 'consolidated financial statements', 'RCS Paris B', 'French Monetary', 'compartment B', 'Financial Code', 'PEA-PME scheme', 'Article L.', 'total revenue', '1,5 billion euros', 'total assets', '2 billion euros', 'car interiors', 'premium technologies', 'digital transformation', '388 million euros', 'Gerber Technology', 'automation solutions', 'other businesses', 'World Headquarters', 'rue Chalgrin', 'FR0000065484 LSS', 'market respect', 'mid-cap companies', 'USA-based company', 'Euronext Paris', 'Lectra shares', 'eligibility', 'April', 'inclusion', 'criteria', 'less', '5 000 employees', 'consequence', 'investment', 'relief', 'small', 'life', 'wardrobes', 'furniture', 'industry', 'offer', 'brands', 'manufacturers', 'retailers', 'design', 'production', 'peace', 'mind', 'revenues', 'June', 'software', 'fashion', 'automotive', 'globe', 'information', 'France', 'Tel.', 'capital', 'Attachment']",2022-04-11,2022-04-11,finance.yahoo.com
2661,EuroNext,NewsApi.org,https://finance.yahoo.com/news/trust-stamp-announces-winners-trusted-080000032.html,Trust Stamp Announces Winners of Trusted Rwanda Hackathon,The 2022 Trusted Rwanda Hackathon welcomed applications from around the world with one common theme: using privacy-first biometric  identity  and data...,The 2022 Trusted Rwanda Hackathon welcomed applications from around the world with one common theme: using privacy-first biometric  identity  and data-protecting tokenization technologies to further innovate powerful solutions for AfricaKigali  April 11  2022 (GLOBE NEWSWIRE) -- Trust Stamp (Nasdaq: IDAI  Euronext Growth: AIID ID)  the Privacy-First Identity CompanyTM providing AI-powered trust and identity services used globally across multiple sectors  today announces winners of the 2022 Trusted Rwanda Hackathon following the hybrid event which brought five competitors and an esteemed panel of judges together for the final pitch competition in the first week of April.Applicants were challenged to leverage Trust Stamp‚Äôs secure identity and data tokenization technology through simple API integration to transform their technology solutions in Africa while speaking to today‚Äôs pressing topics of biometrics  regulatory compliance  privacy  cyber security  and more. Trust Stamp narrowed a global applicant pool down to five finalists and worked with each participant to help craft their innovations during a month-long development period.Trust Stamp Chief Innovation Officer Raman Narayanswamy comments  ‚ÄúThe fantastic response from applicants and the diversity of solutions targeted at unique local and global needs highlights the significant role of privacy-first identity frameworks in delivering modern  accessible  and secure services across industries and geographies.‚ÄùOn April 5th  Trust Stamp welcomed the finalists virtually and in person to present their solutions to a judging panel comprised of private and public-sector experts in identity and digital transformation  including Jean Claude Niyokwizera of Rwanda's National Identification Agency  Rodrigue Ruhashya of the Rwanda Ministry of ICT and Innovation  and Philip Kakuru of MTN Rwanda  who received a panel nomination from Philip Lucky of the Rwanda Development Board. The finalists and winners include:Story continuesFIRST PLACE  iLabs International / Uqu.do : Earning the highest recognition for its proposed privacy-preserving cross-border identity wallet ecosystem with EU-Africa interoperability  this digital identity company wins access to Trust Stamp‚Äôs APIs and development support to bring the innovation to life.SECOND PLACE  SSINTAR : In the proposed metaverse environment modeled on Kigali  avatars establish trust by verifying identity with Trust Stamp‚Äôs secure and streamlined identity technology.THIRD PLACE  Imbehe : A rising startup in the health data services space  Imbehe proposed a digital health wallet that enables patients to securely access their insurance and health information with the protection of biometric authentication.Santech Rwanda : This technology solutions provider pitched an e-visitor platform that seamlessly verifies identity at event registration and the point of entry using secure biometric tools.Fiinanza: With a crowdfunding platform that enables communities to support their local businesses  Fiinanza presented its transformative financial solution elevated further with secure  trusted transactions.‚ÄúWe would like to thank the panel of judges for their expert insights and each participant for their dedication throughout the last two months. The 2022 Trusted Rwanda Hackathon participants are pioneering technical advancement in Africa  and we look forward to further growing Trust Stamp Rwanda in the coming year alongside this incredibly innovative and talented community ‚Äù added Narayanswamy.EnquiriesTrust Stamp Email: Shareholders@truststamp.ai Gareth Genner  Chief Executive Officer Nisha Naik  Executive VP of Communications Davy (Euronext Growth Advisor) Tel: +353 1 679 6363 Barry Murphy Investor Relations Tel: +1 212-671-1021 Crescendo Communications Email: idai@crescendo-ir.comAbout Trust StampTrust Stamp  the Privacy-First Identity CompanyTM  is a global provider of AI-powered identity services for use in multiple sectors including banking and finance  regulatory compliance  government  real estate  communications  and humanitarian services. Its technology empowers organizations with advanced biometric identity solutions that reduce fraud  protect personal data privacy  increase operational efficiency  and reach a broader base of users worldwide through its unique data transformation and comparison capabilities.Located in seven countries across North America  Europe  Asia  and Africa  Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI) and Euronext Growth in Dublin (Euronext Growth: AIID ID). Founded in 2016 by Gareth Genner and Andrew Gowasack  the company now employs over 100 people.Safe Harbor Statement: Caution Concerning Forward-Looking RemarksAll statements in this release that are not based on historical fact are ‚Äúforward-looking statements‚Äù including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933  as amended  and Section 21E of the Securities Exchange Act of 1934  as amended. The information in this announcement may contain forward-looking statements and information related to  among other things  the company  its business plan and strategy  and its industry. These statements reflect management‚Äôs current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company‚Äôs actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements  which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.,neutral,0.06,0.91,0.03,mixed,0.62,0.22,0.16,True,English,"['Trusted Rwanda Hackathon', 'Trust Stamp', 'Winners', 'privacy-preserving cross-border identity wallet ecosystem', 'The 2022 Trusted Rwanda Hackathon participants', 'Private Securities Litigation Reform Act', 'Barry Murphy Investor Relations', 'Trust Stamp Chief Innovation Officer', 'health data services space', 'growing Trust Stamp Rwanda', 'advanced biometric identity solutions', 'Trust Stamp Trust Stamp', 'Chief Executive Officer', 'Securities Exchange Act', 'digital health wallet', 'one common theme', 'data-protecting tokenization technologies', 'final pitch competition', 'simple API integration', 'Jean Claude Niyokwizera', 'National Identification Agency', 'transformative financial solution', 'last two months', 'pioneering technical advancement', 'Safe Harbor Statement', 'secure, trusted transactions', 'month-long development period', 'data tokenization technology', 'Rwanda Development Board', 'Trust Stamp Email', 'global applicant pool', 'Privacy-First Identity CompanyTM', 'privacy-first identity frameworks', 'personal data privacy', 'unique data transformation', 'ai Gareth Genner', 'secure biometric tools', 'streamlined identity technology', 'Nasdaq Capital Market', 'AI-powered identity services', 'Euronext Growth Advisor', 'digital identity company', 'technology solutions provider', 'Crescendo Communications Email', 'Securities Act', 'privacy-first biometric', 'AI-powered trust', 'digital transformation', 'health information', 'Rwanda Ministry', 'MTN Rwanda', 'Santech Rwanda', 'global provider', 'Stamp trades', 'secure services', 'biometric authentication', 'secure identity', 'development support', 'humanitarian services', 'unique local', 'Executive VP', 'global needs', 'powerful solutions', 'GLOBE NEWSWIRE', 'AIID ID', 'multiple sectors', 'hybrid event', 'five competitors', 'first week', 'pressing topics', 'regulatory compliance', 'cyber security', 'fantastic response', 'significant role', 'modern, accessible', 'public-sector experts', 'Rodrigue Ruhashya', 'Philip Kakuru', 'Philip Lucky', 'FIRST PLACE', 'iLabs International', 'Uqu.do', 'highest recognition', 'EU-Africa interoperability', 'SECOND PLACE', 'metaverse environment', 'THIRD PLACE', 'rising startup', 'visitor platform', 'event registration', 'crowdfunding platform', 'local businesses', 'expert insights', 'coming year', 'talented community', 'Nisha Naik', 'Communications Davy', 'real estate', 'operational efficiency', 'broader base', 'comparison capabilities', 'seven countries', 'North America', 'Andrew Gowasack', 'Forward-Looking Remarks', 'historical fact', 'Section 27A', 'Section 21E', 'esteemed panel', 'judging panel', 'panel nomination', 'Raman Narayanswamy', 'looking statements', 'five finalists', 'April 5th', 'applications', 'world', 'Kigali', 'IDAI', 'winners', 'judges', 'Applicants', 'today', 'biometrics', 'innovations', 'diversity', 'industries', 'geographies', 'ICT', 'Story', 'APIs', 'life', 'SSINTAR', 'avatars', 'Imbehe', 'patients', 'insurance', 'protection', 'point', 'entry', 'Fiinanza', 'communities', 'dedication', 'innovative', 'Enquiries', 'Shareholders', 'truststamp', 'use', 'banking', 'finance', 'government', 'organizations', 'fraud', 'Europe', 'Asia', 'Dublin', '100 people', 'Caution', 'release', 'meaning', 'provisions']",2022-04-11,2022-04-11,finance.yahoo.com
2662,EuroNext,NewsApi.org,https://finance.yahoo.com/news/essilorluxottica-luxottica-undertakes-acquire-90-183500893.html,EssilorLuxottica: Luxottica undertakes to acquire 90.9% of Fedon to enter the packaging and eyeglass cases industry,Luxottica undertakes to acquire 90.9% of Fedon to enter the packaging and eyeglass cases industry Pursuant to article 17 of Regulation (EU) 596/2014 by...,"EssilorLuxotticaLuxottica undertakes to acquire 90.9% of Fedon to enter the packaging and eyeglass cases industryPursuant to article 17 of Regulation (EU) 596/2014 by Giorgio Fedon & Figli S.p.A. on behalf of Luxottica Group S.p.A. and of the Sellers (as defined hereinafter)Milan  Italy (April 11  2022 - 8:30 pm) - Luxottica Group S.p.A. (""Luxottica"")  a company subject to the management and coordination of EssilorLuxottica S.A.  announced today that it has entered into a preliminary sale and purchase agreement for the acquisition of a total of no. 1 727 141 shares of the company Giorgio Fedon & Figli S.p.A. (""Issuer"" or ""Company"")  listed on Euronext Growth Milan  the market organized and managed by Borsa Italiana S.p.A.  representing 90.9% of the share capital of the Company (""Agreement"").The Agreement was entered into with the relevant shareholders of the Company (i.e. CL & GP S.r.l.  Piergiorgio Fedon  Sylt S.r.l.  Italo Fedon  Laura Corte Metto  Francesca Fedon  Roberto Fedon  Flora Fedon and Rossella Fedon)  as well as other non-relevant shareholders (hereinafter collectively the ""Sellers"").The transaction represents a step forward in EssilorLuxottica's vertical integration strategy  aimed at achieving the highest quality standards along the entire value chain and optimizing the service for the benefit of all industry players.Thanks to cutting-edge technologies and dedicated innovations  the acquisition will allow to better fit the eyewear and spectacles with the cases and packaging to ensure maximum protection and integrity of the product  for the benefit of the final consumer.Furthermore  EssilorLuxottica will also leverage on the Company to pursue its sustainability strategy  investing in the recyclability and circularity of the packaging materials produced by the Company.Pursuant to the Agreement  completion of the sale and purchase (""Closing"") is subject to the fulfilment of certain conditions precedent  as customary in transactions of this kind  including the obtainment of applicable antitrust clearances  the renewal of the board of directors of the Issuer  as well as the management bodies of the companies of the group and the insertion of the voluntary reference to article 111 (Diritto di Acquisto) of Legislative Decree no. 58/1998 (""TUF"") in the bylaws of the Company  for the purpose of allowing the right of squeeze-out upon holding a shareholding equal to at least 90% of the share capital (""Conditions Precedent"").Story continuesThe purchase price agreed and to be paid on the Closing date to the Sellers  in proportion to the respective shareholdings  is equal to Euro 17.03 for each share and therefore to an aggregate of Euro 29.4 million. The agreed price includes a premium of 135% over the last official price of the Company's shares recorded on April 8  2022 (last trading day preceding the date of entry into the Agreement) as well as a premium of 114% over the weighted average of the official price of the Issuer's shares in the 12 months preceding the date of April 8  2022.It is expected that the Conditions Precedent may be fulfilled and the Closing may take place by the end of June 2022.In the event of completion of the transaction  Luxottica will hold a shareholding equal to 90.9% of the Issuer's share capital and will be required to launch  pursuant to Article 9 (Disposizioni in materia di offerta pubblica di acquisto) of the bylaws of the Company and of art. 6-bis of the Euronext Growth Issuers' Regulation  a mandatory tender offer on all outstanding shares of the Company (""MTO"")  at the same price of Euro 17.03 per share.The MTO is aimed at delisting the Company.***The press release is available on the respective websites of EssilorLuxottica and the Company and on www.1info.it .Attachment",neutral,0.01,0.97,0.02,mixed,0.35,0.35,0.3,True,English,"['eyeglass cases industry', 'EssilorLuxottica', 'Fedon', 'packaging', 'Borsa Italiana S.p.A.', 'Luxottica Group S.p.A.', 'Figli S.p.A.', 'GP S.r.l.', 'Sylt S.r.l.', ""Euronext Growth Issuers' Regulation"", 'EssilorLuxottica S.A.', 'Euronext Growth Milan', 'Laura Corte Metto', 'highest quality standards', 'entire value chain', 'applicable antitrust clearances', 'mandatory tender offer', 'offerta pubblica di', 'other non-relevant shareholders', 'vertical integration strategy', 'Diritto di Acquisto', 'eyeglass cases industry', 'last official price', 'materia di', 'industry players', 'sustainability strategy', 'cutting-edge technologies', 'dedicated innovations', 'maximum protection', 'final consumer', 'voluntary reference', 'Legislative Decree', 'respective shareholdings', 'same price', 'press release', 'respective websites', 'Giorgio Fedon', 'Italo Fedon', 'Francesca Fedon', 'Roberto Fedon', 'Flora Fedon', 'Rossella Fedon', 'purchase price', 'share capital', 'preliminary sale', 'management bodies', 'The MTO', 'packaging materials', 'Conditions Precedent', 'outstanding shares', 'purchase agreement', 'Closing date', '1,727,141 shares', 'article', 'behalf', 'Sellers', 'Italy', 'April', 'company', 'coordination', 'acquisition', 'total', 'market', 'transaction', 'step', 'service', 'benefit', 'eyewear', 'spectacles', 'integrity', 'product', 'recyclability', 'circularity', 'completion', 'fulfilment', 'kind', 'obtainment', 'renewal', 'board', 'directors', 'companies', 'insertion', 'TUF', 'bylaws', 'purpose', 'right', 'Story', 'proportion', 'aggregate', 'premium', 'trading', 'entry', 'average', '12 months', 'place', 'June', 'event', 'Disposizioni', 'art.', 'www', 'info', 'Attachment', '8:30']",2022-04-11,2022-04-11,finance.yahoo.com
2663,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220411005632/en/Poxel-Announces-PXL770-Awarded-FDA-Fast-Track-Designation-for-X-linked-Adrenoleukodystrophy,Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy,LYON  France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516)  a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) a‚Ä¶,"LYON  France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516)  a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders  is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN)  the most common form of X-linked adrenoleukodystrophy (ALD). PXL770 is a novel  first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator that is preparing to enter into a Phase 2a clinical Proof-of-Concept (POC) biomarker study midyear  subject to additional financing.Poxel CEO  Thomas Kuhn  commented: ""Having PXL770 awarded Fast Track Designation by the FDA soon after our other promising product  PXL065  is a strong recognition of the potential of both our programs in adrenoleukodystrophy  a significant unmet medical need. Poxel aims at developing innovative treatments to improve the life of patients with serious and rare chronic diseases with metabolic pathophysiology  and the Fast Track Designation could offer PXL770 the ability to substantially accelerate the approval timeline in ALD. We are preparing the next steps to initiate our two Phase 2a clinical studies midyear  with results anticipated early 2023.‚ÄùFast Track Designation (FTD)FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.FTD provides Poxel with substantially enhanced access to FDA  including opportunities for face-to-face meetings and written consultations throughout the remaining development of PXL770.Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission  which may result in faster product approval.FTD also allows for 'rolling review'  whereby Poxel may submit completed sections of the NDA as they become available  rather than at the end of development.Next StepsThe Phase 2a clinical POC biomarker studies for Poxel‚Äôs two products  PXL770 and PXL065  in X-linked ALD are  subject to additional financing  anticipated to begin midyear  with results anticipated early 2023.Fast Track DesignationIntroduced under the FDA Modernization Act (1997)  Fast Track Designation (FTD) may be awarded by the FDA to investigational drugs which treat a serious or life-threatening condition  and which fill an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy. The FDA notes that 'the purpose of the Fast Track program is to get important new drugs to the patient earlier1‚Äù. FTD must be requested by the sponsor company and must be accompanied by a detailed review of both preclinical and clinical data.The key benefits of FTD comprise enhanced access to the FDA  with regular and more frequent opportunities for consultation and discussion. In addition  drugs with FTD may be eligible for Accelerated Approval  in which a new medicine is approved prior to the availability of definitive data  and Priority Review  in which the standard 10-month review process is reduced to six months. Drugs with FTD may also enter a 'rolling review' of their NDA submission  in which sections are submitted and reviewed as they become available  substantially expediting the approval process.About ALDX-linked adrenoleukodystrophy (ALD) is an orphan neurometabolic disease caused by mutations in the ABCD1 gene which encodes for a key protein that is required for metabolism of very long chain fatty acids (VLCFA) by peroxisomes (cellular organelles). ALD is the most common leukodystrophy with a prevalence similar to hemophilia ‚Äì up to 1/10 000 individuals in the general population have ALD [https://rarediseases.org]. Forms of this disease include cerebral ALD (C-ALD) and adrenomyeloneuropathy (AMN) which is the most common form ‚Äì typically occurring in adolescence through adulthood. AMN is characterized by chronic and progressive distal axonopathy involving the long tracts of the spinal cord and to a lesser extent the peripheral nerves resulting in progressive stiffness and weakness in the legs  impaired gait and balance  incontinence  and loss of sensation. Nearly all men with a diagnosis of ALD will develop AMN  and many women also present with features of AMN with a later onset. C-ALD is characterized by inflammatory demyelination of cells in the brain and typically afflicts children  but many men with AMN may also develop cerebral disease; these white matter brain lesions lead to severe neurologic deficits and death. There are no approved medicines for ALD (other than glucocorticoid supplements for associated adrenal insufficiency). C-ALD when first detected in early childhood  can be treated with hematopoietic stem cell transplantation. HSCT is currently limited to early stage of C-ALD and this procedure is at risk of severe adverse reactions.About Poxel SAPoxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH  PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770  a first-in-class direct AMPK activator  has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH  which met its objectives. For the rare inherited metabolic disorder  adrenoleukodystrophy (ALD)  the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG¬Æ (Imeglimin)  Poxel‚Äôs first-in-class lead product that targets mitochondrial dysfunction  has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan  China  South Korea  Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris  Poxel is headquartered in Lyon  France  and has subsidiaries in Boston  MA  and Tokyo  Japan.For more information  please visit: www.poxelpharma.comAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company‚Äôs control. These statements may include  without limitation  any statements preceded by  followed by or including words such as ‚Äútarget ‚Äù ‚Äúbelieve ‚Äù ‚Äúexpect ‚Äù ‚Äúaim ‚Äù ‚Äúintend ‚Äù ‚Äúmay ‚Äù ‚Äúanticipate ‚Äù ‚Äúestimate ‚Äù ‚Äúplan ‚Äù ‚Äúproject ‚Äù ‚Äúwill ‚Äù ‚Äúcan have ‚Äù ‚Äúlikely ‚Äù ‚Äúshould ‚Äù ‚Äúwould ‚Äù ‚Äúcould‚Äù and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company‚Äôs control that could cause the Company‚Äôs actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.1 For more information on the Fast Track Designation  see: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-reviewithfast-track",neutral,0.01,0.96,0.03,mixed,0.11,0.24,0.65,True,English,"['FDA Fast Track Designation', 'PXL770 Awarded', 'X-linked Adrenoleukodystrophy', 'Poxel', 'Phase 2a clinical POC biomarker studies', 'direct adenosine monophosphate-activated protein kinase', 'two Phase 2a clinical studies', 'Phase 2a clinical Proof', 'hematopoietic stem cell transplantation', 'clinical stage biopharmaceutical company', 'long chain fatty acids', 'white matter brain lesions', 'significant unmet medical need', 'standard 10-month review process', 'unmet medical needs', 'U.S. Food', 'Fast Track Designation', 'other promising product', 'Fast Track program', 'severe neurologic deficits', 'associated adrenal insufficiency', 'progressive distal axonopathy', 'rare metabolic disorders', 'rare chronic diseases', 'faster product approval', 'New Drug Application', 'orphan neurometabolic disease', 'FDA Modernization Act', 'important new drugs', 'chronic serious diseases', 'clinical data', 'two products', 'key protein', 'approval process', 'sponsor company', 'long tracts', 'new medicine', 'Drug Administration', 'progressive stiffness', 'metabolic pathophysiology', 'Priority Review', 'rolling review', 'detailed review', 'approval timeline', 'Accelerated Approval', 'BUSINESS WIRE', 'innovative treatments', 'non-alcoholic steatohepatitis', 'common form', 'AMPK) activator', 'additional financing', 'Thomas Kuhn', 'strong recognition', 'next steps', 'pharmaceutical products', 'life-threatening conditions', 'face meetings', 'written consultations', 'key benefits', 'definitive data', 'six months', 'ABCD1 gene', 'cellular organelles', 'common leukodystrophy', '1/10,000 individuals', 'general population', 'spinal cord', 'lesser extent', 'peripheral nerves', 'many women', 'inflammatory demyelination', 'cerebral disease', 'glucocorticoid supplements', 'early childhood', 'X-linked adrenoleukodystrophy', 'NDA) submission', 'NDA submission', 'investigational drugs', 'enhanced access', 'frequent opportunities', 'many men', 'remaining development', 'available therapy', 'POXEL SA', 'Poxel CEO', 'X-linked ALD', 'cerebral ALD', 'The FDA', 'LYON', 'Euronext', 'NASH', 'FTD', 'PXL770', 'patients', 'adrenomyeloneuropathy', 'AMN', 'novel', 'class', 'Concept', 'PXL06', 'potential', 'programs', 'ability', 'results', 'sections', 'end', 'midyear', 'none', 'purpose', 'preclinical', 'regular', 'discussion', 'mutations', 'metabolism', 'VLCFA', 'peroxisomes', 'prevalence', 'hemophilia', 'rarediseases', 'Forms', 'C-ALD', 'adolescence', 'adulthood', 'weakness', 'legs', 'gait', 'balance', 'incontinence', 'loss', 'sensation', 'diagnosis', 'features', 'later', 'onset', 'cells', 'children', 'death', 'medicines', 'HSCT']",2022-04-11,2022-04-11,businesswire.com
2664,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220411005399/en/Verimatrix-Announces-Participation-in-Three-NAB-Show-Sessions-April-24-26-in-Las-Vegas,Verimatrix Announces Participation in Three NAB Show Sessions  April 24-26 in Las Vegas,AIX-EN-PROVENCE  France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News: Verimatrix  (Euronext Paris: VMX)  the leader in powering the modern connected world with people-centered security  today announced the following NAB Show sessions taking place at the Las ‚Ä¶,"AIX-EN-PROVENCE  France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News:Verimatrix  (Euronext Paris: VMX)  the leader in powering the modern connected world with people-centered security  today announced the following NAB Show sessions taking place at the Las Vegas Convention Center and featuring the following Verimatrix experts:1. Sunday  April 24  1:00 ‚Äì 1:30 PM ‚Äì ""Secure  Value-Add Partnerships that are Now Possible Thanks to Modern SaaS Platforms"" featuring Sebastian Braun  Senior Director of Product Management2. Monday  April 25  2:30 ‚Äì 3:00 PM ‚Äì ‚ÄúThreat Defense for Media & Entertainment: How to Close the Open Door in Security Walls to Prevent the Enterprise from Being Compromised"" featuring Jon Samsel  Senior Vice President of Global Marketing3. Tuesday  April 26  11:30 ‚Äì 12:00 PM ‚Äì ""The State of Piracy Today and the New Battlefront Against Industrial Scale Content Theft"" featuring Sebastian Braun  Senior Director of Product ManagementVerimatrix will also feature its latest news surrounding the Verimatrix Secure Delivery Platform as well as its Threat Defense and Anti-Piracy solutions at Kiosk W2513 and Meeting Room W4833MR. To schedule an in-person meeting during this year‚Äôs NAB Show  contact Verimatrix here.Additionally  during the NAB Show  Verimatrix is set to unveil a white paper it commissioned with Caretta Research  ‚ÄúProtect or Plunder: Surgical Strikes to Disrupt Industrial-scale Piracy‚Äù  that details the latest shifts and trends in digital piracy ‚Äì along with precision countermeasures that are now possible. The full paper will be available for download beginning Monday  April 25 at www.verimatrix.com.‚ÄúAs Verimatrix continues its modernization strategy to offer pioneering cloud-based ecosystems that uniquely bring together cybersecurity and anti-piracy technologies  we‚Äôre answering a clear need to address today‚Äôs interwoven business requirements throughout media and entertainment and numerous other industries ‚Äù said Asaf Ashkenazi  Chief Operating Officer and President at Verimatrix. ‚ÄúThis year‚Äôs NAB Show serves as a timely and ideal setting to further build on this effort via new and expanded discussions with prospective partners and users seeking to efficiently and cost-effectively secure their content  applications or devices while offering powerful  memorable user experiences.‚ÄùAbout VerimatrixVerimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content  applications  and devices with intuitive  people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports  to sensitive financial and healthcare data  to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster  scale easily  protect valuable revenue streams  and win new business. Visit www.verimatrix.com.",neutral,0.02,0.97,0.01,positive,0.78,0.21,0.01,True,English,"['Three NAB Show Sessions', 'Las Vegas', 'Verimatrix', 'Participation', 'April', 'Las Vegas Convention Center', 'powerful, memorable user experiences', 'Industrial Scale Content Theft', 'Verimatrix Secure Delivery Platform', 'Secure, Value-Add Partnerships', 'pioneering cloud-based ecosystems', 'numerous other industries', 'Chief Operating Officer', 'live streaming sports', 'valuable revenue streams', 'Meeting Room W4833MR', 'interwoven business requirements', 'New Battlefront Against', 'Modern SaaS Platforms', 'mission-critical mobile applications', 'NAB Show sessions', 'Senior Vice President', 'person meeting', 'BUSINESS WIRE', 'Senior Director', 'new business', 'digital content', 'compelling content', 'SAN DIEGO', 'Regulatory News', 'Euronext Paris', 'Sebastian Braun', 'Product Management', 'Threat Defense', 'Open Door', 'Jon Samsel', 'Global Marketing', 'The State', 'latest news', 'Anti-Piracy solutions', 'Kiosk W2513', 'white paper', 'Caretta Research', 'Surgical Strikes', 'latest shifts', 'precision countermeasures', 'full paper', 'modernization strategy', 'anti-piracy technologies', 'clear need', 'Asaf Ashkenazi', 'ideal setting', 'intuitive, people-centered', 'Leading brands', 'premium movies', 'sensitive financial', 'healthcare data', 'trusted connections', 'people-centered security', 'Security Walls', 'frictionless security', 'Industrial-scale Piracy', 'digital piracy', 'prospective partners', 'Verimatrix experts', 'AIX-EN-PROVENCE', 'France', 'VMX', 'leader', 'world', 'following', 'place', 'Sunday', 'April', '1:30 PM', 'Monday', '3:00 PM', 'Media', 'Entertainment', 'Enterprise', 'Tuesday', '12:00 PM', 'year', 'Protect', 'Plunder', 'trends', 'download', 'cybersecurity', 'timely', 'effort', 'discussions', 'users', 'devices', 'everything', 'customers', 'millions', 'consumers', '1:00', '2:30', '11:30']",2022-04-11,2022-04-11,businesswire.com
2665,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220411005791/en/NANOBOTIX%C2%A0New-Preclinical-Immunotherapy-Data-Show-Boosted-Anti-Tumor-Immune-Activation-via-Triple-Blockade-of-PD-1-LAG-3-and-TIGIT-When-Combined-With-Radiotherapy-Activated-NBTXR3,NANOBOTIX:¬†New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1  LAG-3  and TIGIT When Combined With Radiotherapy-Activated NBTXR3,PARIS & CAMBRIDGE  Mass.--(BUSINESS WIRE)--Regulatory News: NANOBOTIX (Euronext : NANO ‚Äì‚Äì NASDAQ: NBTX ‚Äì the ‚Äò‚ÄòCompany‚Äô‚Äô)  a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer  t‚Ä¶,PARIS & CAMBRIDGE  Mass.--(BUSINESS WIRE)--Regulatory News:NANOBOTIX (Euronext : NANO ‚Äì‚Äì NASDAQ: NBTX ‚Äì the ‚Äò‚ÄòCompany‚Äô‚Äô)  a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer  today announced new data from an open-label preclinical study evaluating the combination of first-in-class radioenhancer  NBTXR3  with the triple blockade of PD-1  LAG-3  and TIGIT (‚ÄúCombination therapy‚Äù). The data were published via E-Poster presentation at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)  held April 8-13  2022  by researchers from The University of Texas MD Anderson Cancer Center (MD Anderson).‚ÄúWe believe that the potential immune priming effect of radiotherapy-activated NBTXR3 could prove to be a game-changer for cancer immunotherapy ‚Äù said Laurent Levy  co-founder and chairman of the executive board at Nanobiotix. ‚ÄúOur view is that while new immunotherapy treatment modalities with the potential to improve outcomes for patients continue to emerge  they remain reliant upon an underlying immune response. This new preclinical gene expression data showing that the addition of NBTXR3 enhanced activity in key immune pathways associated with innate and adaptive immunity  and outperformed all other combinations in efficacy  survival  and induction of long-term anti-cancer memory  adds to a growing body of support for NBTXR3 as a product candidate that could potentially help expand the benefits of immunotherapy to larger share of the patients we serve.‚ÄùPRECLINICAL DATA ON IMMUNOTHERAPY BLOCKADE PLUS RADIOTHERAPY-ACTIVATED NBTXR3Previously reported preclinical and clinical data evaluating NBTXR3 in combination with diverse immune checkpoint inhibitors (ICIs) including anti-PD-1  anti-CTLA-4  anti-LAG-3  and anti-TIGIT suggest that  after activation by radiotherapy  the radioenhancer may induce an ‚Äúimmune priming‚Äù effect that could help improve and expand the benefits of ICIs to more patients.This new analysis  presented at AACR  assessed immune gene expression associated with multiple combinations of NBTXR3  anti-PD-1  anti-LAG-3  and anti-TIGIT.Key Findings Include:The Combination therapy outperformed all other tested treatment regimens in efficacy  survival  and induction of long-term anti-cancer memoryThe Combination therapy significantly promoted the upregulation of mRNA transcripts involved in innate immunity  the humoral response  B cell function  dendritic cell function  and antigen processing within primary  irradiated tumors relative to untreated controlsWithin non-irradiated tumors  the Combination therapy produced elevations in multiple immune-related pathways that were significantly higher than those produced by other treatment combinations and these pathways included both adaptive and innate immunity; B  T  natural killer  and dendritic cell function; and antigen processingThe Combination therapy promoted immune activation at the irradiated site  abscopal immune responses are improved with the addition of LAG-3 and TIGIT to PD-1 and radiotherapy-activated NBTXR3  and the data suggest that the Combination therapy may be effective against metastatic cancers***About NBTXR3NBTXR3 is a novel  potentially first-in-class oncology product  composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The product candidate‚Äôs physics-based mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy  subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the MoA  Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination  particularly  with immune checkpoint inhibitors.NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored phase I dose escalation and dose expansion study has produced favorable safety data and early signs of efficacy. In February 2020  the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy  with or without cetuximab  for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.Nanobiotix has also prioritized an Immuno-Oncology development program‚Äîbeginning with a Company sponsored phase I clinical study  evaluating NBTXR3 activated by radiotherapy in combination with anti-PD-1 checkpoint inhibitors for patients with locoregional recurrent or recurrent/metastatic HNSCC and for patients with lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy  either na√Øve or resistant to prior PD-1 (either primary or secondary as per SITC criteria).Given the Company‚Äôs focus areas  and balanced against the scalable potential of NBTXR3  Nanobiotix has engaged in strategic collaborations to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy  in 2019 Nanobiotix entered into a broad  comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several phase I and phase II studies to evaluate NBTXR3 across tumor types and therapeutic combinations. In 2021  the Company entered into an additional strategic collaboration agreement with LianBio to support its global phase III study in Asia along with four future registrational studies.About NANOBIOTIXNanobiotix is a late-stage clinical biotechnology company pioneering disruptive  physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company‚Äôs philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.Incorporated in 2003  Nanobiotix is headquartered in Paris  France. The company also has subsidiaries in Cambridge  Massachusetts (United States)  France  Spain  Germany and Switzerland.Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate‚Äì NBTXR3 ‚Äîwhich is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify¬Æ.For more information about Nanobiotix  visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.DisclaimerThis press release contains certain ‚Äúforward-looking‚Äù statements within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as ‚Äúat this time ‚Äù ‚Äúanticipate ‚Äù ‚Äúbelieve ‚Äù ‚Äúexpect ‚Äù ‚Äúintend ‚Äù ‚Äúon track ‚Äù ‚Äúplan ‚Äù ‚Äúscheduled ‚Äù and ‚Äúwill ‚Äù or the negative of these and similar expressions. These forward-looking statements  which are based on our management‚Äôs current expectations and assumptions and on information currently available to management  include statements about the timing and progress of clinical trials  the timing of our presentation of data  the results of our preclinical and clinical studies and their potential implications. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However  these forward-looking statements are subject to numerous risks and uncertainties  including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive early clinical results and the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore  many other important factors  including those described in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 8  2022 under ‚ÄúItem 3.D. Risk Factors‚Äù and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit√© des March√©s Financiers ‚Äì the AMF) on April 8  2022  each as updated in our Half-Year Financial Report filed with the AMF and the SEC on September 8  2021 (a copy of which is available on www.nanobiotix.com)  as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results  performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law  we assume no obligation to update these forward-looking statements publicly  or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements  even if new information becomes available in the future.,neutral,0.01,0.96,0.02,positive,0.47,0.36,0.17,True,English,"['New Preclinical Immunotherapy Data', 'Anti-Tumor Immune Activation', 'Triple Blockade', 'Radiotherapy-Activated NBTXR3', 'NANOBOTIX', 'PD-1', 'LAG-3', 'TIGIT', 'Texas MD Anderson Cancer Center', 'new preclinical gene expression data', 'functionalized hafnium oxide nanoparticles', 'phase I dose escalation', 'regulatory Fast Track designation', 'phase I clinical study', 'diverse immune checkpoint inhibitors', 'significant tumor cell death', 'potential immune priming effect', 'new immunotherapy treatment modalities', 'immune gene expression', 'immune priming‚Äù effect', 'dose expansion study', 'B cell function', 'dendritic cell function', 'squamous cell carcinoma', 'abscopal immune responses', 'open-label preclinical study', 'long-term anti-cancer memory', 'one-time intratumoral injection', 'United States Food', 'Immuno-Oncology development program', 'underlying immune response', 'primary development pathway', 'anti-PD-1 checkpoint inhibitors', 'favorable safety data', 'key immune pathways', 'multiple immune-related pathways', 'class oncology product', 'adaptive immune response', 'primary, irradiated tumors', 'clinical-stage biotechnology company', 'The Combination therapy', 'other treatment combinations', 'new data', 'clinical data', 'new analysis', 'primary cancer', 'Regulatory News', 'multiple combinations', 'The University', 'humoral response', 'cancer immunotherapy', 'immune activation', 'Key Findings', 'treatment possibilities', 'Cancer Research', 'treatment regimens', 'radiation therapy', 'other combinations', 'product candidate', 'irradiated site', 'solid tumor', 'scalable potential', 'IMMUNOTHERAPY BLOCKADE', 'anti-PD-1 therapy', 'BUSINESS WIRE', 'physics-based approaches', 'class radioenhancer', 'triple blockade', 'E-Poster presentation', '2022 Annual Meeting', 'American Association', 'Laurent Levy', 'executive board', 'adaptive immunity', 'growing body', 'larger share', 'mRNA transcripts', 'antigen processing', 'untreated controls', 'natural killer', 'metastatic cancers', 'physics-based mechanism', 'therapeutic combination', 'advanced head', 'early signs', 'Drug Administration', 'platinum-based chemotherapy', 'locoregional recurrent', 'liver metastases', 'SITC criteria', 'focus areas', 'innate immunity', 'advanced HNSCC', 'recurrent/metastatic HNSCC', 'radiotherapy-activated NBTXR', 'prior PD-1', 'NBTXR3, Nanobiotix', 'PARIS', 'CAMBRIDGE', 'Mass', 'NANOBOTIX', 'Euronext', 'NASDAQ', 'patients', 'LAG-3', 'TIGIT', 'AACR', 'April', 'researchers', 'game-changer', 'founder', 'chairman', 'view', 'outcomes', 'addition', 'activity', 'efficacy', 'survival', 'induction', 'support', 'benefits', 'ICIs', 'upregulation', 'elevations', 'novel', 'action', 'MoA', 'neck', 'sponsored', 'February', 'investigation', 'cetuximab', 'lung', 'strateg']",2022-04-11,2022-04-11,businesswire.com
2666,EuroNext,NewsApi.org,https://finance.yahoo.com/news/dassault-syst-mes-publish-first-161000810.html,Dassault Syst√®mes to publish its First Quarter 2022 Results  Webcast and Conference Call on April 27th  2022,Press ReleaseVELIZY-VILLACOUBLAY  France ‚Äî April 11th  2022 Dassault Syst√®mes to publish its First Quarter 2022 Results Webcast and Conference Call on April ...,Press ReleaseVELIZY-VILLACOUBLAY  France ‚Äî April 11th  2022Dassault Syst√®mes to publish itsFirst Quarter 2022 Results Webcast and Conference Call on April 27th  2022Dassault Syst√®mes (Euronext Paris: FR0014003TT8  DSY.PA)  the 3DEXPERIENCE Company  world leader in 3D design software  3D Digital Mock Up and Product Lifecycle Management (PLM) solutions  will publish its operating performance for the first quarter 2022  ended March 31st  2022  on Wednesday  April 27th  2022.The management of Dassault Syst√®mes will present the earnings by webcast at 10.00 Paris time ‚Äì 09.00 London time  and will then host a conference call at 09.00 New York time ‚Äì 15.00 Paris time ‚Äì 14.00 London time.Both the webcast and the conference call will be available live and as replay on Dassault Syst√®mes‚Äô investor website at https://investor.3ds.com.ABOUT DASSAULT SYST√àMESDassault Syst√®mes  the 3DEXPERIENCE Company  is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications  our customers push the boundaries of innovation  learning and production to achieve a more sustainable world for patients  citizens  and consumers. Dassault Syst√®mes brings value to more than 300 000 customers of all sizes  in all industries  in more than 140 countries. For more information  visit www.3ds.comDassault Syst√®mes Investor Relations Team FTI Consulting Fran√ßois-Jos√© Bordonado /B√©atrix Martinez:+33 1 61 62 69 24/70 21USA & Canada: callie.gauzer@3ds.com Arnaud de Cheffontaines: +33 1 47 03 69 48Jamie Rickett/Elena Kalinskaya: +44 2037271600¬© Dassault Syst√®mes. All rights reserved. 3DEXPERIENCE  the Compass icon  the 3DS logo  CATIA  BIOVIA  GEOVIA  SOLIDWORKS  3DVIA  ENOVIA  NETVIBES  MEDIDATA  CENTRIC PLM  3DEXCITE  SIMULIA  DELMIA  and IFWE are commercial trademarks or registered trademarks of Dassault Syst√®mes  a French ‚Äúsoci√©t√© europ√©enne‚Äù (Versailles Commercial Register # B 322 306 440)  or its subsidiaries in the United States and/or other countries.Story continuesAttachment,neutral,0.01,0.96,0.02,positive,0.56,0.36,0.08,True,English,"['Dassault Syst√®mes', 'First Quarter 2022 Results', 'Conference Call', 'April 27th', 'Webcast', 'Dassault Syst√®mes Investor Relations Team', 'French ‚Äúsoci√©t√© europ√©enne', 'Dassault Syst√®mes‚Äô investor website', '3D Digital Mock Up', 'collaborative 3D virtual environments', '3D design software', 'virtual twin experiences', 'Fran√ßois-Jos√© Bordonado', 'B√©atrix Martinez', 'Arnaud de Cheffontaines', 'Versailles Commercial Register', '09.00 New York time', 'First Quarter 2022 Results', 'Product Lifecycle Management', 'commercial trademarks', '10.00 Paris time', '09.00 London time', '15.00 Paris time', '14.00 London time', 'Press Release', 'Conference Call', 'Euronext Paris', 'world leader', 'PLM) solutions', 'operating performance', 'human progress', 'sustainable innovations', 'real world', 'sustainable world', 'FTI Consulting', 'Jamie Rickett', 'Elena Kalinskaya', 'Compass icon', 'CENTRIC PLM', 'registered trademarks', 'United States', '3DEXPERIENCE Company', '3DEXPERIENCE platform', 'April 11th', 'April 27th', 'other countries', '3DS logo', '140 countries', 'VELIZY-VILLACOUBLAY', 'France', 'Webcast', 'DSY', 'March', 'Wednesday', 'earnings', 'replay', 'catalyst', 'business', 'people', 'applications', 'customers', 'boundaries', 'learning', 'production', 'patients', 'citizens', 'consumers', 'value', 'sizes', 'industries', 'information', 'USA', 'Canada', 'gauzer', 'rights', 'CATIA', 'BIOVIA', 'GEOVIA', 'SOLIDWORKS', '3DVIA', 'ENOVIA', 'NETVIBES', 'MEDIDATA', '3DEXCITE', 'SIMULIA', 'DELMIA', 'IFWE', 'subsidiaries', 'Story', 'Attachment', '¬©']",2022-04-11,2022-04-11,finance.yahoo.com
2667,EuroNext,NewsApi.org,https://finance.yahoo.com/news/agfa-gevaert-share-buyback-program-154000024.html,Agfa-Gevaert: Share buyback program ‚Äì regulated information,Mortsel  Belgium ‚Äì April 11  2022 ‚Äì 5:40 p.m. CET Within the framework of the share buyback program which was announced in the press release of March 10...,Agfa-GevaertMortsel  Belgium ‚Äì April 11  2022 ‚Äì 5:40 p.m. CETWithin the framework of the share buyback program which was announced in the press release of March 10  2021  Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels.The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12  2020.Agfa-Gevaert NV has requested a financial intermediary to repurchase Agfa-Gevaert shares for a maximum amount of 50 000 000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until March 31  2022  effective as from April 1  2021.On March 8  2022  the Board of Directors decided that the 2021 Share Buyback will be extended through March 31  2023 (the ‚ÄòExtended Share Buyback Program 2021‚Äô).As a result of the decision of the Board of Directors on March 9  2021  the company  by notarial deed dated March 30  2022  cancelled a total of 2 299 218 treasury shares. This decision was taken in accordance with the authorization granted to the Board of Directors by the Extraordinary General Meeting of Shareholders on May 12  2020. As a consequence  the new number of outstanding shares (denominator) is 158 207 488.On transaction date April 8  2022  the Agfa-Gevaert Group held 535 970 own shares  which represents 0.34% of the total number of shares of the Group.Detailed operations per day:Transaction date Number ofshares Averageprice (‚Ç¨) Minimumprice (‚Ç¨) Maximumprice (‚Ç¨) Totalprice (‚Ç¨) April 4  2022 49 462 3.6746 3.6500 3.6950 181 753.07 April 5  2022 60 454 3.7028 3.6650 3.7300 223 849.07 April 6  2022 67 000 3.7593 3.7150 3.7950 251 873.90 April 7  2022 63 200 3.8274 3.7800 3.8500 241 891.68 April 8  2022 60 104 3.8627 3.8400 3.8800 232 163.72 Total 300 220 3.7690 1 131 530.64Since the beginning of the share buyback program until April 8th  2022  based on the transaction date  the Agfa-Gevaert Group bought 10 079 672 own shares  representing 6.01% of the total outstanding shares on April 1  2021.Story continuesAbout AgfaThe Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions  HealthCare IT  Digital Print & Chemicals and Offset Solutions. They develop  manufacture and market analogue and digital systems for the healthcare sector  for specific industrial applications and for the printing industry. In 2021  the Group realized a turnover of 1 760 million Euro.Contact:Viviane DictusDirector Corporate CommunicationT +32 (0) 3 444 71 24E viviane.dictus@agfa.comJohan JacobsCorporate Press Relations ManagerT +32 (0)3/444 80 15E johan.jacobs@agfa.comAttachment,neutral,0.01,0.97,0.02,mixed,0.29,0.33,0.37,True,English,"['Share buyback program', 'regulated information', 'Agfa-Gevaert', 'initial discretionary mandate agreement', 'Corporate Press Relations Manager', 'Extended Share Buyback Program', 'Extraordinary General Meeting', 'specific industrial applications', 'Viviane Dictus Director', 'Transaction date Number', 'The Agfa-Gevaert Group', '2021 Share Buyback', 'total outstanding shares', 'press release', 'Corporate Communication', 'new number', 'total number', 'Agfa-Gevaert Mortsel', 'Agfa-Gevaert NV', 'Euronext Brussels', 'financial intermediary', 'maximum amount', 'notarial deed', 'Detailed operations', 'imaging technology', 'IT solutions', 'four divisions', 'Radiology Solutions', 'HealthCare IT', 'Digital Print', 'Offset Solutions', 'digital systems', 'healthcare sector', 'printing industry', 'Minimum price', 'Maximum price', 'Total price', 'Agfa-Gevaert shares', '2,299,218 treasury shares', 'leading company', '1,760 million Euro', 'April 8th', 'Johan Jacobs', '50,000,000 Euro', 'Belgium', 'CET', 'framework', 'March', 'purchase', 'market', 'authorization', 'Board', 'Directors', 'Shareholders', 'May', 'behalf', 'terms', 'validity', 'result', 'decision', 'accordance', 'consequence', 'denominator', 'day', 'beginning', 'Story', '150 years', 'experience', 'Chemicals', 'analogue', 'turnover', 'Contact', 'Attachment', '5:40', '535,970', '10,079,672']",2022-04-11,2022-04-11,finance.yahoo.com
2668,EuroNext,NewsApi.org,https://finance.yahoo.com/news/coface-sa-combined-shareholders-meeting-154500647.html,COFACE SA: Combined Shareholders‚Äô Meeting 17th May 2022 at 02.00pm,COFACE SA: Combined Shareholders‚Äô Meeting 17th May 2022 at 02.00pm Paris  11 April 2022 ‚Äì 17.45 Coface SA's shareholders are hereby informed that the...,"Coface SACOFACE SA: Combined Shareholders‚Äô Meeting 17th May 2022 at 02.00pmParis  11 April 2022 ‚Äì 17.45Coface SA's shareholders are hereby informed that the Combined Shareholders‚Äô Meeting will be held on Tuesday  17th May 2022 at 02.00pm at the Group‚Äôs headquarters and registered office:1 Place Costes et Bellonte92270 Bois-Colombes - FranceThe notice of meeting containing the agenda and draft resolutions was published in the Bulletin des Annonces L√©gales Obligatoires (French Bulletin of Mandatory Legal Notices - BALO) No.43 on 11th April 2022 (announcement No. 2200839).Shareholders may attend the meeting regardless of the number of shares they own  under the conditions described in the notice of meeting.We advise the shareholders to:To vote on the resolutions by post or online  using either the postal voting form or the Votaccess platform. They can also appoint the Chairman to represent them;To submit written questions to the Chairman of the Board of Directors by registered letter with acknowledgement of receipt or electronically to the following address: investors@coface.com (including evidence of their shareholding) on the 11th of May  at the latest. To be taken into account  these questions must be accompanied by a book-entry certificate justifying the share ownership.All documents that must be disclosed for this meeting will be available to the shareholders  within the legal deadlines  on COFACE SA institutional website (www.coface.com) and more precisely under ""Investors/General Assembly"" (https://www.coface.com/Investors/General-Assembly).CONTACTSANALYSTS / INVESTORSThomas JACQUET: +33 1 49 02 12 58 ‚Äì thomas.jacquet@coface.comBeno√Æt CHASTEL: +33 1 49 02 22 28 ‚Äì benoit.chastel@coface.comMEDIA RELATIONSSaphia GAOUAOUI: +33 1 49 02 14 91 ‚Äì saphia.gaouaoui@coface.comCorentin HENRY: +33 1 49 02 23 94 - corentin.henry@coface.comFINANCIAL CALENDAR 2021/2022(subject to change)Q1-2022 results: 28 April 2022 (after market close)Annual General Shareholders‚Äô Meeting 2021: 17 May 2022H1-2022 results: 28 July 2022 (after market close)9M-2022 results: 27 October 2022 (after market closeStory continuesFINANCIAL INFORMATIONThis press release  as well as COFACE SA‚Äôs integral regulatory information  can be found on the Group‚Äôs website:http://www.coface.com/InvestorsFor regulated information on Alternative Performance Measures (APM)  please refer to our Interim Financial Report for S1-2021 and our 2021 Universal Registration Document (see part 3.7 ‚ÄúKey financial performance indicators‚Äù)COFACE: FOR TRADEWith 75 years of experience and the most extensive international network  Coface is a leader in trade credit insurance and adjacent specialty services  including Factoring  Single Risk insurance  Bonding and Information services. Coface‚Äôs experts work to the beat of the global economy  helping ~50 000 clients build successful  growing  and dynamic businesses across the world. Coface helps companies in their credit decisions. The Group's services and solutions strengthen their ability to sell by protecting them against the risks of non-payment in their domestic and export markets. In 2021  Coface employed ~4 538 people and registered a turnover of ‚Ç¨1.57 billion.www.coface.comCOFACE SA is quoted in Compartment A of Euronext ParisCode ISIN: FR0010667147 / Mn√©monique : COFADISCLAIMER - Certain declarations featured in this press release may contain forecasts that notably relate to future events  trends  projects or targets. By nature  these forecasts include identified or unidentified risks and uncertainties  and may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these declarations. Please refer to chapter 5 ‚ÄúMain risk factors and their management within the Group‚Äù of the Coface Group's 2021 Universal Registration Document filed with AMF on 6 April 2022 under the number D.22-0244 in order to obtain a description of certain major factors  risks and uncertainties likely to influence the Coface Group's businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts  or provide new information on future events or any other circumstance.Attachment",neutral,0.01,0.97,0.02,mixed,0.14,0.28,0.58,True,English,"['Combined Shareholders‚Äô Meeting 17th', 'COFACE SA', '02.00pm', 'Annonces L√©gales Obligatoires', 'Euronext Paris Code ISIN', 'Key financial performance indicators', 'Annual General Shareholders‚Äô Meeting', 'Combined Shareholders‚Äô Meeting 17th', 'COFACE SA institutional website', 'Alternative Performance Measures', 'postal voting form', '2021 Universal Registration Document', 'extensive international network', 'Single Risk insurance', 'Interim Financial Report', 'Mandatory Legal Notices', 'Beno√Æt CHASTEL', 'Main risk factors', 'integral regulatory information', 'trade credit insurance', 'adjacent specialty services', 'The Coface Group', 'FINANCIAL INFORMATION', 'FINANCIAL CALENDAR', 'legal deadlines', 'benoit.chastel', 'FOR TRADE', 'credit decisions', 'many factors', 'major factors', '17th May', 'The Group', 'regulated information', 'Information services', 'new information', 'registered office', '1 Place Costes', 'Bellonte 92270 Bois-Colombes', 'Votaccess platform', 'following address', 'book-entry certificate', 'share ownership', 'Investors/General Assembly', 'MEDIA RELATIONS', 'Corentin HENRY', 'corentin.henry', 'Q1-2022 results', 'H1-2022 results', '9M-2022 results', 'press release', 'global economy', 'export markets', 'Compartment A', 'Mn√©monique', 'future events', 'significant discrepancy', 'real results', 'other circumstance', 'draft resolutions', 'French Bulletin', 'dynamic businesses', 'Certain declarations', 'unidentified risks', 'Thomas JACQUET', 'Saphia GAOUAOUI', '11th April', '17 May', '11 April', '28 April', '6 April', '02.00pm', 'Tuesday', 'headquarters', 'France', 'agenda', 'BALO', 'No.', 'announcement', 'number', 'shares', 'conditions', 'Chairman', 'questions', 'Board', 'Directors', 'letter', 'acknowledgement', 'receipt', 'evidence', 'shareholding', 'account', 'documents', 'General-Assembly', 'CONTACTS', 'ANALYSTS', '27 October', 'Story', 'APM', 'S1', '75 years', 'experience', 'leader', 'Factoring', 'Bonding', 'experts', 'beat', '~50,000 clients', 'world', 'companies', 'ability', 'payment', 'domestic', '~4,538 people', 'turnover', 'DISCLAIMER', 'forecasts', 'trends', 'projects', 'targets', 'nature', 'uncertainties', 'rise', 'chapter', 'management', 'AMF', 'order', 'description', 'intention', 'obligation', 'update', 'Attachment', '1 49 02']",2022-04-11,2022-04-11,finance.yahoo.com
2669,EuroNext,NewsApi.org,https://finance.yahoo.com/news/societe-generale-ceases-activities-russia-060100104.html,Societe Generale ceases its activities in Russia and signs an agreement to sell Rosbank and its Russian Insurance subsidiaries,SOCIETE GENERALE CEASES ITS ACTIVITIES IN RUSSIA AND SIGNS AN AGREEMENT TO SELL ROSBANK AND ITS RUSSIAN INSURANCE SUBSIDIARIESPress release Paris  11 April...,Soci√©t√© G√©n√©raleSOCIETE GENERALE CEASES ITS ACTIVITIES IN RUSSIA AND SIGNS AN AGREEMENT TO SELL ROSBANK AND ITS RUSSIAN INSURANCE SUBSIDIARIESPress releaseParis  11 April 2022  8 amSociete Generale ceases its banking and insurance activities in Russia and announces the signing of a sale and purchase agreement to sell its entire stake in Rosbank and the Group‚Äôs Russian insurance subsidiaries to Interros Capital  the previous shareholder of Rosbank. With this agreement  concluded after several weeks of intensive work  the Group would exit(1) in an effective and orderly manner from Russia  ensuring continuity for its employees and clients.This contemplated transaction  which remains subject to the approval of the relevant regulatory and anti-trust authorities  will be conducted in compliance with the legal and regulatory obligations in force. The closing of this operation should occur in the coming weeks.The impact of the disposal of Rosbank and the Group‚Äôs Russian insurance activities on the Group's CET1 ratio is expected to be around 20 basis points based on the net value of the disposed assets as of December 31  2021(2). It would mainly result from the impact of the write-off of the net book value of the disposed assets  largely offset by  on the one hand  the deconsolidation of the local exposure to Russia (~EUR 15.4 billion of exposure at default as of December 31  2021(3)) and on the other  a payment in favor of Societe Generale including notably the repayment by the purchaser of the subordinated debt granted by Societe Generale to its subsidiary.Pro-forma this transaction  the Group‚Äôs CET 1 ratio would remain comfortably above the Group‚Äôs guidance. As a reminder  the Group's CET1 ratio was 13.7% as of December 31  2021  i.e. 470 basis points above the minimum regulatory requirement.This contemplated disposal would lead to the accounting in the Group‚Äôs income statement(4) of the following main items:the write-off of the net book value of the divested activities (~EUR 2 billion ( 5 ) );an exceptional non-cash item with no impact on the Group‚Äôs capital ratio (~EUR 1.1 billion(5))  which corresponds to the normative reversal of the conversion reserve in the Group‚Äôs income statement.Story continuesThe Group confirms its distribution policy for the 2021 financial year i.e. the cash dividend of EUR 1.65 per share  subject to the approval of the Combined General meeting of shareholders on 17 May 2022  and the announced share buyback program for an amount of approximately EUR 915 million(6).(1) ALD Automotive OOO  which operates in Russia and through its branches in Kazakhstan  and ALD Belarus LLC no longer conclude any new commercial transactions.(2) Value as of December 31  2021 based on a EUR/RUB exchange rate of 85.(3) Equivalent to ~EUR 10.7 billion of Risk Weighted Asset as of December 31  2021.(4) Accounted in ‚Äúnet profit or loss on other assets‚Äù.(5) Based on non-audited estimated data as of February 28  2022 and a EUR/RUB exchange rate of 92. The final impact would be calculated based on the data and the foreign exchange rate at the closing date. The accounting period would depend on the closing date.(6) Subject to usual approvals from ECB and Combined General meeting.Press Contacts:Societe GeneraleJean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.comFanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.comSociete GeneraleSociete Generale is one of the leading European financial services groups. Based on a diversified and integrated banking model  the Group combines financial strength and proven expertise in innovation with a strategy of sustainable growth. Committed to the positive transformations of the world‚Äôs societies and economies  Societe Generale and its teams seek to build  day after day  together with its clients  a better and sustainable future through responsible and innovative financial solutions.Active in the real economy for over 150 years  with a solid position in Europe and connected to the rest of the world  Societe Generale has over 131 000 members of staff in 66 countries and supports on a daily basis 26 million individual clients  businesses and institutional investors around the world by offering a wide range of advisory services and tailored financial solutions. The Group is built on three complementary core businesses:French Retail Banking which encompasses the Societe Generale  Credit du Nord and Boursorama brands. Each offers a full range of financial services with omnichannel products at the cutting edge of digital innovation;International Retail Banking  Insurance and Financial Services to Corporates  with networks in Africa  Russia  Central and Eastern Europe and specialised businesses that are leaders in their markets;Global Banking and Investor Solutions  which offers recognised expertise  key international locations and integrated solutions.Societe Generale is included in the principal socially responsible investment indices: DJSI (Europe)  FTSE4Good (Global and Europe)  Bloomberg Gender-Equality Index  Refinitiv Diversity and Inclusion Index  Euronext Vigeo (Europe and Eurozone)  STOXX Global ESG Leaders indexes  and the MSCI Low Carbon Leaders Index (World and Europe).In case of doubt regarding the authenticity of this press release  please go to the end of Societe Generale‚Äôs newsroom page where official Press Releases sent by Societe Generale can be certified using blockchain technology. A link will allow you to check the document‚Äôs legitimacy directly on the web page.For more information  you can follow us on Twitter @societegenerale or visit our website www.societegenerale.com.Attachment,neutral,0.02,0.8,0.18,mixed,0.2,0.3,0.5,True,English,"['Russian Insurance subsidiaries', 'Societe Generale', 'activities', 'agreement', 'Rosbank', 'Soci√©t√© G√©n√©rale', 'leading European financial services groups', 'socially responsible investment indices', 'three complementary core businesses', 'following main items', 'exceptional non-cash item', 'Combined General meeting', 'ALD Automotive OOO', 'ALD Belarus LLC', 'new commercial transactions', 'EUR/RUB exchange rate', 'Risk Weighted Asset', 'foreign exchange rate', 'Credit du Nord', 'key international locations', 'Bloomberg Gender-Equality Index', 'RUSSIAN INSURANCE SUBSIDIARIES', 'French Retail Banking', 'International Retail Banking', 'minimum regulatory requirement', 'innovative financial solutions', 'tailored financial solutions', 'net book value', 'share buyback program', 'integrated banking model', '26 million individual clients', 'Russian insurance activities', 'SOCIETE GENERALE CEASES', 'net value', 'integrated solutions', 'advisory services', '2021 financial year', 'financial strength', 'net profit', 'Investor Solutions', 'relevant regulatory', 'regulatory obligations', 'specialised businesses', 'divested activities', 'Press release', 'entire stake', 'Interros Capital', 'previous shareholder', 'several weeks', 'intensive work', 'orderly manner', 'anti-trust authorities', 'coming weeks', 'CET1 ratio', '20 basis points', 'one hand', 'subordinated debt', 'CET 1 ratio', '470 basis points', 'income statement', 'capital ratio', 'normative reversal', 'conversion reserve', 'distribution policy', 'cash dividend', 'usual approvals', 'Press Contacts', 'proven expertise', 'sustainable growth', 'positive transformations', 'sustainable future', 'real economy', 'solid position', 'daily basis', 'institutional investors', 'wide range', 'Boursorama brands', 'full range', 'omnichannel products', 'cutting edge', 'recognised expertise', 'Global Banking', 'ITS ACTIVITIES', 'closing date', 'local exposure', 'accounting period', 'Jean-Baptiste Froville', 'Fanny Rouby', 'digital innovation', 'purchase agreement', 'other assets', 'final impact', 'Eastern Europe', 'The Group', 'SELL', 'ROSBANK', 'Paris', '11 April', 'signing', 'sale', 'effective', 'continuity', 'employees', 'compliance', 'legal', 'force', 'operation', 'disposal', 'December', 'write-off', 'deconsolidation', 'default', 'payment', 'favor', 'purchaser', 'subsidiary', 'guidance', 'reminder', 'Story', 'shareholders', '17 May', 'amount', 'branches', 'Kazakhstan', 'loss', 'data', 'February', 'ECB', 'socgen', 'diversified', 'strategy', 'world', 'societies', 'economies', 'teams', 'day', '150 years', 'rest', '131,000 members', 'staff', '66 countries', 'Corporates', 'networks', 'Africa', 'Central', 'leaders', 'markets', 'DJSI', 'FTSE4Good']",2022-04-11,2022-04-11,finance.yahoo.com
2670,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220411005064/en/Globalgig-Selects-Thales-to-Enable-Global-Immediate-and-Resilient-Connectivity-for-Massive-IoT-Deployments,Globalgig Selects Thales to Enable Global  Immediate and Resilient Connectivity for Massive IoT Deployments,PARIS LA D√âFENSE--(BUSINESS WIRE)--Thales announces a new partnership with Globalgig  the Global Connectivity Service Provider  for the world‚Äôs first deployment of Thales Adaptive Connect  an innovative solution that supports the smart connection of massive f‚Ä¶,PARIS LA D√âFENSE--(BUSINESS WIRE)--Thales announces a new partnership with Globalgig  the Global Connectivity Service Provider  for the world‚Äôs first deployment of Thales Adaptive Connect  an innovative solution that supports the smart connection of massive fleets of IoT devices. Based on eSIM (embedded SIM) technology  Thales Adaptive Connect effectively enables IoT devices to connect and use the most appropriate subscription as soon as powered up in the field.By 2025  an estimated one billion eSIM enabled IoT devices will be deployed worldwide. Unlike consumer products  IoT devices are usually positioned in remote and unattended locations. To support this expected massive IoT deployment stake  Globalgig decided to go for Thales remote connectivity management solution to address this global need.Indeed  Thales Adaptive Connect is designed specifically to deliver the flexibility required by the IoT sector ‚Äì leveraging built-in eSIM and remote subscription management. Any device at rest or in movement can be activated remotely eliminating the need to preload mobile subscription on the production line. With the new solution  Global Connectivity Service Providers - such as Globalgig - and Group of Operators can offer immediate and seamless remote connectivity to IoT Service providers  with no impact on device manufacturing and logistics operations.As a result Thales Adaptive Connect delivers compelling benefits to IoT and Global Connectivity Service Providers supporting the deployment of new valuable services  as well as device manufacturers  as one device can now serve all markets. All stakeholders will find it much easier to roll-out innovative and affordable IoT use cases for their end users and customers  thanks to a service continuity assured by Thales.Mark Castle  Chief Revenue Officer for Globalgig UK  said: ‚ÄúThales Adaptive Connect is the only solution of its kind on the market. Fitting perfectly with our commitment to innovation and transformation  it represents an unprecedented opportunity to offer exceptional connectivity services throughout the IoT ecosystem. We have already signed up a number of major clients.‚ÄùEmmanuel Unguran  SVP Mobile Connectivity Solutions at Thales said: ‚ÄúEnabling a myriad of exciting use cases  ranging from smart metering to smart cities  massive IoT deployments are set to transform the quality of everyday life. By partnering with Globalgig for the first ever deployment of Thales Adaptive Connect  we are dramatically streamlining the process of creating  connecting and supporting these IoT devices. Quite simply  Thales Adaptive Connect is going to make the future happen faster.‚ÄùAbout ThalesThales (Euronext Paris: HO) is a global leader in advanced technologies  investing in digital and ‚Äúdeep tech‚Äù innovations ‚Äì connectivity  big data  artificial intelligence  cybersecurity and quantum technologies ‚Äì to build a confident future crucial for the development of our societies. The Group provides its customers ‚Äì businesses  organizations and governments ‚Äì in the defense  aeronautics  space  transport  and digital identity and security domains with solutions  services and products that help them fulfil their critical role  consideration for the individual being the driving force behind all decisions.Thales has 81 000 employees in 68 countries. In 2021  the Group generated sales of ‚Ç¨16.2 billion.PLEASE VISITThales GroupDigital Identity & Security,neutral,0.01,0.98,0.01,positive,0.62,0.37,0.01,True,English,"['Massive IoT Deployments', 'Global, Immediate', 'Resilient Connectivity', 'Globalgig', 'Thales', 'one billion eSIM enabled IoT devices', 'Thales remote connectivity management solution', 'PARIS LA D√âFENSE', 'Global Connectivity Service Provider', 'affordable IoT use cases', 'SVP Mobile Connectivity Solutions', 'massive IoT deployment stake', 'exciting use cases', 'IoT Service providers', 'seamless remote connectivity', 'remote subscription management', 'embedded SIM) technology', 'Chief Revenue Officer', 'deep tech‚Äù innovations', 'exceptional connectivity services', 'massive IoT deployments', 'Thales Adaptive Connect', 'first ever deployment', 'new valuable services', 'one device', 'service continuity', 'mobile subscription', 'global leader', 'first deployment', 'massive fleets', 'Euronext Paris', 'new solution', 'IoT sector', 'IoT ecosystem', 'global need', 'new partnership', 'appropriate subscription', 'BUSINESS WIRE', 'innovative solution', 'smart connection', 'unattended locations', 'production line', 'logistics operations', 'compelling benefits', 'end users', 'Mark Castle', 'unprecedented opportunity', 'major clients', 'Emmanuel Unguran', 'smart metering', 'smart cities', 'everyday life', 'advanced technologies', 'big data', 'artificial intelligence', 'quantum technologies', 'critical role', 'driving force', 'Thales Group', 'device manufacturing', 'device manufacturers', 'digital identity', 'consumer products', 'confident future', 'The Group', 'security domains', 'Globalgig UK', 'world', 'field', 'flexibility', 'rest', 'movement', 'Operators', 'immediate', 'impact', 'result', 'markets', 'stakeholders', 'customers', 'kind', 'commitment', 'transformation', 'number', 'myriad', 'quality', 'process', 'cybersecurity', 'development', 'societies', 'businesses', 'organizations', 'governments', 'defense', 'aeronautics', 'space', 'transport', 'consideration', 'individual', 'decisions', '81,000 employees', '68 countries', 'sales', 'PLEASE', '2025']",2022-04-11,2022-04-11,businesswire.com
2671,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-gbp-nav-053000146.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 08 Apr 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 28.6215 ¬£ 24.8424 Estimated MTD return 0.58 % 0.61 % Estimated YTD return -1.98 % -1.83 % Estimated ITD return 186.22 % 148.42 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 23.00 N/A Premium/discount to estimated NAV -19.64 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.49 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 316 588 130 254 Held in treasury N/A N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.4056 Class GBP A Shares (estimated) ¬£ 132.2833The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.Story continuesThis is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.0,mixed,0.12,0.31,0.56,True,English,"['BGHL', 'GBP', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'A N/A Average Price', 'Class GBP A Shares', 'N/A Sterling Shares Amsterdam', 'London Stock Exchange plc', 'treasury N/A N/A Shares', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'A N/A Range', 'US Investment Company Act', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'NAV N', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Apr', 'returns', 'AEX', 'LSE', 'Transactions', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'Story', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-04-11,2022-04-11,finance.yahoo.com
2672,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-eur-nav-053000390.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 08 Apr 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 28.6215 ¬£ 24.8424 Estimated MTD return 0.58 % 0.61 % Estimated YTD return -1.98 % -1.83 % Estimated ITD return 186.22 % 148.42 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 23.00 N/A Premium/discount to estimated NAV -19.64 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.49 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 316 588 130 254 Held in treasury N/A N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 247.4056 Class GBP A Shares (estimated) ¬£ 132.2833The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.Story continuesThis is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,0.99,0.01,mixed,0.12,0.31,0.56,True,English,"['BGHL', 'EUR', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'Class GBP A Shares', 'A N/A Average Price', 'N/A Sterling Shares Amsterdam', 'London Stock Exchange plc', 'treasury N/A N/A Shares', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'A N/A Range', 'Euro Shares Amsterdam', 'US Investment Company Act', 'GAVAUDAN HOLDING LIMITED', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Emmanuel Gavaudan', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'NAV N', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Apr', 'returns', 'AEX', 'LSE', 'Transactions', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'Story', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-04-11,2022-04-11,finance.yahoo.com
2673,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/wolters-kluwer-and-courtroom-insight-extend-partnership-to-the-almanac-of-the-federal-judiciary-301522760.html,Wolters Kluwer and Courtroom Insight Extend Partnership to the Almanac of the Federal Judiciary,The partnership provides access to judge profiles and verified attorney reviews for legal professionals NEW YORK  April 11  2022 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. and Courtroom Insight today announced the extension of their partnership  n‚Ä¶,"Courtroom Insight is a customized knowledge management solution that enables law firms to capture  share and analyze critical information about arbitrators  expert witnesses  judges and attorneys. In 2021  Wolters Kluwer and Courtroom Insight announced plans to give mutual customers access to Wolters Kluwer's labor arbitration content. More recently  the company provided users with seamless access from Kluwer Arbitration to Courtroom Insight. This latest expansion of their partnership into the Almanac of the Federal Judiciary is Wolters Kluwer's latest move to provide eligible customers with access to a rich and comprehensive database of legal content.""The next step in our successful partnership with Courtroom Insight provides our customers with valuable information on federal judges  from district courts to the Supreme Court  to enable better preparation and increase the chances of a successful case "" said Ken Crutchfield  Vice President & General Manager of Legal Markets at Wolters Kluwer Legal & Regulatory U.S. ""We are pleased that we have been able to give our mutual customers multiple points of access to content through Wolters Kluwer and Courtroom Insight  extending efficient workflow solutions for legal professionals backed by deep domain expertise.""The Almanac of the Federal Judiciary is a trusted solution containing information on federal judges  including those sitting on the Supreme Court  Appellate Courts  Districts Courts  Bankruptcy Courts  and Specialized Courts. Customers can view reviews by attorneys who have practiced in front of that judge  the judge's financial disclosure information  and a history of cases that the judge has presided over. The new partnership extension will allow legal professionals to better prepare for cases by researching the presiding judges with reputable material. Mutual customers of Wolters Kluwer and Courtroom Insight will have access to this resource.""Through our enhanced partnership with Wolters Kluwer  our clients can access deeper insights about judges  including biographical data and attorney evaluations "" said Mark Torchiana  CEO of Courtroom Insight. ""By combining internal research and evaluations with the critical information found in the Almanac of the Federal Judiciary  our shared customers can confidently research comprehensive judge profiles to inform their legal strategies.""To learn more  visit: https://almanacofthefederaljudiciary.com/DashboardAbout Courtroom InsightCourtroom Insight  headquartered in San Ramon  California  offers the leading knowledge management solution that enables law firms to capture  share and analyze critical information about expert witnesses  arbitrators and judges. For further information  please visit https://www.courtroominsight.com or https://www.linkedin.com/company/courtroom-insight/About Wolters Kluwer Legal & Regulatory U.S.Wolters Kluwer (WKL) is a global leader in professional information  software solutions  and services for the healthcare; tax and accounting; governance  risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Wolters Kluwer reported 2021 annual revenues of ‚Ç¨4.8 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 19 800 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).For more information  visit www.wolterskluwer.com  follow us on LinkedIn  Twitter  Facebook  and YouTube.MEDIA CONTACT:Linda GharibDirector  Brand & CommunicationsWolters Kluwer Legal & Regulatory U.S.Tel: +1 (646) 887-7962Email: [email protected]SOURCE Wolters Kluwer Legal & Regulatory U.S.",neutral,0.02,0.98,0.01,positive,0.63,0.35,0.02,True,English,"['Wolters Kluwer', 'Courtroom Insight', 'Federal Judiciary', 'Partnership', 'Almanac', 'Alphen aan den Rijn', 'Level 1 American Depositary Receipt', 'customized knowledge management solution', 'leading knowledge management solution', 'deep domain knowledge', 'deep domain expertise', 'Linda Gharib Director', 'Regulatory U.S.', 'efficient workflow solutions', 'financial disclosure information', 'new partnership extension', 'Wolters Kluwer shares', 'labor arbitration content', 'comprehensive judge profiles', 'Wolters Kluwer Legal', 'mutual customers access', 'trusted solution', 'Kluwer Arbitration', 'regulatory sectors', 'comprehensive database', 'software solutions', 'expert solutions', 'legal content', 'Legal Markets', 'legal professionals', 'legal strategies', 'Courtroom Insight', 'law firms', 'expert witnesses', 'latest expansion', 'Federal Judiciary', 'latest move', 'next step', 'district courts', 'Supreme Court', 'successful case', 'Ken Crutchfield', 'Vice President', 'General Manager', 'multiple points', 'Appellate Courts', 'Districts Courts', 'Bankruptcy Courts', 'Specialized Courts', 'reputable material', 'deeper insights', 'biographical data', 'Mark Torchiana', 'internal research', 'San Ramon', 'global leader', 'critical decisions', 'specialized technology', '2021 annual revenues', 'Euronext Amsterdam', 'Euronext 100 indices', 'ADR) program', 'counter market', 'MEDIA CONTACT', 'critical information', 'valuable information', 'professional information', 'successful partnership', 'seamless access', 'eligible customers', 'federal judges', 'presiding judges', 'attorney evaluations', 'The Almanac', 'arbitrators', 'attorneys', 'plans', 'company', 'users', 'rich', 'preparation', 'chances', 'reviews', 'front', 'history', 'cases', 'resource', 'clients', 'CEO', 'almanacofthefederaljudiciary', 'Dashboard', 'California', 'courtroominsight', 'linkedin', 'courtroom-insight', 'WKL', 'services', 'healthcare', 'tax', 'accounting', 'governance', 'risk', 'compliance', 'group', '180 countries', 'operations', '40 countries', '19,800 people', 'Netherlands', 'AEX', 'ADRs', 'WTKWY', 'wolterskluwer', 'Twitter', 'Facebook', 'YouTube', 'Brand', 'Communications', 'Tel', 'Email']",2022-04-11,2022-04-11,prnewswire.com
2674,EuroNext,NewsApi.org,https://finance.yahoo.com/news/gasunie-hes-international-vopak-join-060000504.html,Gasunie  HES International and Vopak join forces to develop an import terminal for a hydrogen carrier in the port of Rotterdam,Gasunie  HES International and Vopak join forces to develop an import terminal for a hydrogen carrier in the port of Rotterdam 11 April 2022  Rotterdam...,Koninklijke Vopak N.V.Gasunie  HES International and Vopak join forces to develop an import terminal for a hydrogen carrier in the port of Rotterdam11 April 2022  Rotterdam/Groningen  the NetherlandsGasunie  HES International (HES) and Vopak will be working together to develop an import terminal for green ammonia as a hydrogen carrier. The companies have signed a cooperation agreement to that effect. The cooperation is a response to growing global demand for the import and storage of green energy. This quarter  work will be started on the basic design of the import terminal. The terminal  that will operate on the Maasvlakte under the name ACE Terminal  will be operational from 2026.Green hydrogen is seen as an essential element of the future renewable energy mix. Demand for green hydrogen is growing in the energy sector  the transport sector and the petrochemical industry  both in the Netherlands and Germany. An import terminal for green ammonia will make a vital contribution to the import of hydrogen  an essential link in the hydrogen chain  alongside hydrogen production  transport and storage. A reliable logistic chain is essential for developing the market for green hydrogen and for achieving the climate goals for 2030 and 2050.Ammonia as hydrogen carrierIn addition to the production of green hydrogen in the Netherlands  there will also be demand in Northwestern Europe for the large-scale import of green hydrogen  in order to meet future demand. Green ammonia as a hydrogen carrier will play a vital role. Reacting green hydrogen with nitrogen forms green ammonia  allowing the hydrogen to be efficiently and safely transported in large volumes. The ammonia can then be stored and converted again to green hydrogen. Green ammonia is also immediately usable as CO2-free fuel for example for shipping or as a raw material for example for the production of fertiliser.Strategic locationAt the intended location on Rotterdam‚Äôs Maasvlakte  vessels from all over the world can moor to discharge green ammonia  and in the initial phase possibly also blue ammonia. Use can be made of the existing infrastructure and the logistic facilities of the Port of Rotterdam. The site offers space for the development of an installation for converting ammonia into hydrogen. In the future  this installation will be connected to the national hydrogen network of Gasunie  that can serve the future hydrogen market in Northwestern Europe.Joining forcesOn the Maasvlakte  HES operates a strategic location with quayside capacity and direct access from the sea. Gasunie has at this location infrastructure of existing storage tanks and a system of pipelines. Vopak  with six ammonia terminals around the world  has extensive experience in the safe storage of ammonia. By joining forces  an attractive starting point will be established from which within just a few years  the partners will be able to realise the import location for green ammonia in Rotterdam. The eventual investment decision still has to be taken  and will be based among others on customer contracts and the necessary permits  including the EIA procedure.Market consultationThe service proposition will entail an independent open access terminal infrastructure  in which the partners will not own the green ammonia. A market consultation procedure is soon to be launched  in which interested parties can announce their interest in the supply  storage and transhipment of green ammonia and hydrogen. Initial discussions are already underway with international market parties.-----Story continuesAbout HES InternationalContributing to the world of tomorrow  that‚Äôs what we do at HES. With 18 terminals in 6 countries at strategic located ports in Europe we are an important switch in the continuous delivery of essential building blocks for our everyday life needed to develop  sustain and improve the world around us. Our professional staff of 1 450 ensure that bulk commodities are safely stored  handled and processed 24/7 for customers from all corners of the globe.We pursue sustainable growth of our Agri & Minerals and liquid product portfolio as well as an expansion of our processing activities through expansion of our existing sites  greenfield development and the acquisition of operating terminals. In addition we have a strong focus on adjacent business opportunities that arise from the energy transition such as hydrogen  refrigerated gases and chemical recycling. We want to create long-term growth and value for all our stakeholders including employees  customers  shareholders and the communities and countries in which we operate. This is underpinned by our focus on safety and our core values of integrity  respect  accountability  openness and entrepreneurialism.HES International is headquartered in Rotterdam and has already been carefully handling bulk raw materials since 1908. Macquarie Asset Management  via Macquarie European Infrastructure Fund 5  and West Street Infrastructure Partners III  managed by the Goldman Sachs Asset Management Infrastructure business  each indirectly control 50% of the shares of HES International B.V. For more information  please visit www.hesinternational.euAbout GasunieGasunie is a European energy-infrastructure company. Gasunie‚Äôs network is one of the largest high-pressure pipeline networks in Europe  comprising over 17 000 kilometres of pipeline in the Netherlands and northern Germany. Gasunie provides natural and green gas transport services through its subsidiaries  Gasunie Transport Services B.V. (GTS) in the Netherlands and Gasunie Deutschland in Germany. With its cross-border gas infrastructure and services  Gasunie facilitates TTF  which has become the leading European gas trading point. Gasunie also provides other gas infrastructure services  including gas storage and LNG. Gasunie wants to help accelerate the transition to a CO2-neutral energy supply and believes that gas-related innovations  for instance in the form of renewable gases such as hydrogen and green gas  can make an important contribution. Both existing and new gas infrastructure play a key role here. Gasunie also plays an active part in the development of other energy infrastructure to support the energy transition. For more information  please visit www.gasunie.nl/en/About VopakRoyal Vopak is the world‚Äôs leading independent tank storage company. We store vital products with care. With over 400 years of history and a focus on sustainability  we ensure safe  clean and efficient storage and handling of bulk liquid products and gases for our customers. By doing so  we enable the delivery of products that are vital to our economy and daily lives  ranging from chemicals  oils  gases and LNG to biofuels and vegoils. We are determined to develop key infrastructure solutions for the world‚Äôs changing energy systems  while simultaneously investing in digitalization and innovation. Vopak is listed on the Euronext Amsterdam and is headquartered in Rotterdam  the Netherlands. For more information  please visit www.vopak.comContact detailsHES InternationalEsther Erkelens  Communications Manager  e.erkelens@hesinternational.euGasunieRoland Kroes  Corporate Communications  r.e.a.kroes@gasunie.nl +31(0)6 1020 2894Loek Caris  Investor Relations  a.j.p.caris@gasunie.nl  + 31(0)6 28 975 615VopakLiesbeth Lans  Manager External Communication  global.communication@vopak.comFatjona Topciu  Head of Investor Relations  +31(0)10 400 2776  investor.relations@vopak.comAttachment,neutral,0.01,0.98,0.01,positive,0.65,0.3,0.05,True,English,"['HES International', 'import terminal', 'hydrogen carrier', 'Gasunie', 'Vopak', 'forces', 'Rotterdam', 'Goldman Sachs Asset Management Infrastructure business', 'West Street Infrastructure Partners III', 'independent open access terminal infrastructure', 'Macquarie European Infrastructure Fund', 'Koninklijke Vopak N.V.', 'future renewable energy mix', 'Macquarie Asset Management', 'adjacent business opportunities', 'attractive starting point', 'eventual investment decision', 'liquid product portfolio', 'essential building blocks', 'reliable logistic chain', 'bulk raw materials', 'national hydrogen network', 'growing global demand', 'market consultation procedure', 'international market parties', 'existing storage tanks', 'six ammonia terminals', 'future hydrogen market', 'existing infrastructure', 'location infrastructure', 'direct access', 'green energy', 'energy sector', 'logistic facilities', 'EIA procedure', 'interested parties', 'bulk commodities', 'energy transition', 'hydrogen chain', 'essential element', 'essential link', 'existing sites', 'ACE Terminal', 'future demand', 'import terminal', 'basic design', 'petrochemical industry', 'vital contribution', 'climate goals', 'vital role', 'nitrogen forms', 'large volumes', 'CO2-free fuel', 'intended location', 'initial phase', 'quayside capacity', 'extensive experience', 'customer contracts', 'necessary permits', 'service proposition', 'Initial discussions', 'important switch', 'continuous delivery', 'everyday life', 'professional staff', 'sustainable growth', 'processing activities', 'operating terminals', 'refrigerated gases', 'chemical recycling', 'long-term growth', 'core values', 'hydrogen carrier', 'Green hydrogen', 'green ammonia', 'blue ammonia', 'HES International', 'large-scale import', 'import location', 'Northwestern Europe', 'Strategic location', 'safe storage', 'cooperation agreement', 'transport sector', 'greenfield development', 'strong focus', 'hydrogen production', '18 terminals', 'Gasunie', 'forces', 'Rotterdam', 'April', 'Netherlands', 'companies', 'effect', 'response', 'Maasvlakte', 'name', 'Germany', 'addition', 'order', 'example', 'shipping', 'fertiliser', 'vessels', 'world', 'Use', 'space', 'installation', 'sea', 'system', 'pipelines', 'years', 'others', 'supply', 'transhipment', 'Story', 'tomorrow', '6 countries', 'ports', 'customers', 'corners', 'globe', 'Agri', 'Minerals', 'expansion', 'acquisition', 'stakeholders', 'employees', 'shareholders', 'communities', 'safety', 'integrity', 'respect', 'accountability', 'openness', 'entrepreneurialism']",2022-04-11,2022-04-11,finance.yahoo.com
2675,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220411005562/en/Medidata-Wins-Citeline-Awards-for-myMedidata-the-Most-Comprehensive-Patient-Portal-for-Decentralized-Clinical-Trials-and-its-Holistic-Digital-Oversight-Solution-to-Enable-Clinical-Monitoring-Strategies,Medidata Wins Citeline Awards for myMedidata  the Most Comprehensive Patient Portal for Decentralized Clinical Trials  and its Holistic Digital Oversight Solution to Enable Clinical Monitoring Strategies,NEW YORK--(BUSINESS WIRE)--Medidata recognized by Citeline for technology innovations to engage patients  optimize clinical trials  and accelerate development of new medicines.,NEW YORK--(BUSINESS WIRE)--Medidata  a Dassault Syst√®mes company  is pleased to announce that it was recognized for its outstanding accomplishments in life sciences by the Citeline Awards:Best Patient-Facing Technology Initiative for myMedidata  a single-destination web-based portal for patients to engage pre-trial  in-trial  and post-trial  built for patients  by patients.for myMedidata  a single-destination web-based portal for patients to engage pre-trial  in-trial  and post-trial  built for patients  by patients. Best Sponsor-Facing Technology Initiative for Medidata‚Äôs Digital Oversight Solution  which facilitates clinical trial data oversight and monitoring  improving timelines  cost  and quality in the execution of decentralized clinical trials (DCTs).The Citeline Awards celebrate critical achievements across the spectrum of key R&D activities  from successes in early and late-stage research  to advances in technological tools  to innovations in trial design and execution. Medidata was presented with the awards in a ceremony held on April 7 in Boston.myMedidata was recognized as a powerful  intuitive  patient-centric portal. The Citeline Best Patient-facing Technology Initiative recognizes the growing role of technology in facilitating participation in clinical trials and is awarded to the product which best advances patient data collection and improves overall patient experience. myMedidata enables patients to seamlessly connect with any online device to virtually learn about  enroll in and participate in clinical trial activities. It is the industry‚Äôs single most comprehensive  integrated tool set for all aspects of clinical research. It is built on Medidata‚Äôs industry leading Rave EDC (Electronic Data Capture) system  currently in use at more clinical research sites globally than any other system.Medidata‚Äôs Digital Oversight Solution was commended for its transformative impact on all core activities of the trial process. Medidata‚Äôs Digital Oversight Solution has a unique position in the market  unifying risk management  centralized monitoring  and a robust clinical trial management system (CTMS) on one platform. This solution makes it possible for study teams to prepare for and analyze high volumes of data  at scale and in time to take action. The technology can move teams away from delayed  reactive methodologies to proactive and predictive strategies  as well as optimize physical and virtual interactions with clinical sites.Sastry Chilukuri  co-CEO of Medidata  said  ‚Äú The patient‚Äôs interest is at the core of what we do  which is why we have worked hard to pioneer products that make clinical trials more accessible and engaging. As the first company to leverage digital health technologies for DCTs  we are proud to have received the Citeline Awards for myMedidata and Medidata‚Äôs Digital Oversight Solution. We will continue to support the movement toward trial decentralization with ever-expanding offerings  which deliver high quality data and improve the patient experience.‚ÄùMedidata is a wholly owned subsidiary of Dassault Syst√®mes  which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform  from research to commercialization.About MedidataMedidata is leading the digital transformation of life sciences  creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical  biotech  medical device and diagnostics companies  and academic researchers accelerate value  minimize risk  and optimize outcomes. More than one million registered users across 1 900+ customers and partners access the world's most trusted platform for clinical development  commercial  and real-world data. Medidata  a Dassault Syst√®mes company (Euronext Paris: FR0014003TT8  DSY.PA)  is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.About Dassault Syst√®mesDassault Syst√®mes  the 3DEXPERIENCE Company  is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications  our customers push the boundaries of innovation  learning and production. Dassault Syst√®mes brings value to more than 300 000 customers of all sizes  in all industries  in more than 140 countries. For more information  visit www.3ds.com.3DEXPERIENCE  the Compass icon  the 3DS logo  CATIA  BIOVIA  GEOVIA  SOLIDWORKS  3DVIA  ENOVIA  NETVIBES  MEDIDATA  CENTRIC PLM  3DEXCITE  SIMULIA  DELMIA  and IFWE are commercial trademarks or registered trademarks of Dassault Syst√®mes  a French ‚Äúsoci√©t√© europ√©enne‚Äù (Versailles Commercial Register # B 322 306 440)  or its subsidiaries in the United States and/or other countries.,neutral,0.08,0.91,0.01,positive,0.77,0.22,0.01,True,English,"['Holistic Digital Oversight Solution', 'Comprehensive Patient Portal', 'Decentralized Clinical Trials', 'Clinical Monitoring Strategies', 'Citeline Awards', 'Medidata', 'The Citeline Best Patient-facing Technology Initiative', 'French ‚Äúsoci√©t√© europ√©enne', 'robust clinical trial management system', 'Best Sponsor-Facing Technology Initiative', 'powerful, intuitive, patient-centric portal', 'key R&D activities', 'collaborative 3D virtual environments', 'industry leading Rave EDC', 'Electronic Data Capture) system', 'one million registered users', 'Dassault Syst√®mes company', 'clinical trial data oversight', 'The Citeline Awards', 'single-destination web-based portal', 'comprehensive, integrated tool', 'virtual twin experiences', 'digital health technologies', 'Digital Oversight Solution', 'decentralized clinical trials', 'patient data collection', 'clinical trial activities', 'New York City', 'Versailles Commercial Register', 'overall patient experience', 'high quality data', 'clinical research sites', 'other system', 'clinical sites', 'risk management', 'one platform', 'virtual interactions', 'first company', 'registered trademarks', 'real-world data', 'clinical development', '3DEXPERIENCE Company', 'digital transformation', 'core activities', 'high volumes', 'trial design', 'trial process', 'trial decentralization', 'outstanding accomplishments', 'life sciences', 'critical achievements', 'late-stage research', 'technological tools', 'growing role', 'online device', 'transformative impact', 'unique position', 'reactive methodologies', 'predictive strategies', 'Sastry Chilukuri', 'expanding offerings', 'personalized medicine', 'first end', 'end scientific', 'medical device', 'diagnostics companies', 'academic researchers', 'trusted platform', 'Euronext Paris', 'human progress', 'Compass icon', 'CENTRIC PLM', 'commercial trademarks', 'United States', '3DEXPERIENCE platform', 'BUSINESS WIRE', 'business platform', 'centralized monitoring', 'study teams', 'sustainable innovations', '3DS logo', 'other countries', 'real world', '1,900+ customers', '140 countries', '300,000 customers', 'Medidata', 'patients', 'post-trial', 'timelines', 'cost', 'execution', 'DCTs', 'spectrum', 'successes', 'early', 'advances', 'ceremony', 'April', 'Boston', 'participation', 'product', 'aspects', 'market', 'CTMS', 'scale', 'proactive', 'physical', 'CEO', 'interest', 'movement', 'subsidiary', 'commercialization', 'hope', 'millions', 'evidence', 'insights', 'biotech', 'value', 'outcomes', 'More', 'partners', 'DSY', 'offices', 'needs', 'catalyst', 'people', 'applications', 'boundaries', 'learning', 'sizes', 'industries', 'information', 'CATIA', 'BIOVIA', 'GEOVIA', 'SOLIDWORKS', '3DVIA', 'ENOVIA', 'NETVIBES', '3DEXCITE', 'SIMULIA', 'DELMIA', 'IFWE', 'subsidiaries']",2022-04-11,2022-04-11,businesswire.com
2676,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/absolut-invites-coachella-fans-to-meet-in-the-metaverse-with-the-launch-of-absolutland-301522421.html,Absolut Invites Coachella Fans to Meet in the Metaverse with the Launch of Absolut.Land,The Official Vodka of Coachella Merges the IRL & Virtual World with a One-of-a-Kind Experience NEW YORK  April 11  2022 /PRNewswire/ -- Marking its 10th year as the Official Vodka of Coachella  Absolut is extending the festival experience into the metaverse w‚Ä¶,"Whether in person or across the globe  mixing with others is only a click away with Absolut's new virtual destination  Absolut.Land  accessible to anyone (21+)  anywhere  anytime. This must-see celebration is a convergence of art  fashion  music and  of course  cocktails to bring friends together in-person and/or digitally over love of festival culture.""As a brand born to mix  Absolut is centered on bringing the world together through shared experiences and empowering social interaction that unlock a sense of belonging ‚Äì no matter who you are and where in the world you may be "" said Pam Forbus  SVP  Chief Marketing Officer  Pernod Ricard North America. ""To reach our consumers everywhere  the metaverse was a natural progression and we're so excited to introduce Absolut.Land as a space of belonging for all!""Absolut.Land features innovative experiences inspired by Absolut's products  heritage and passion points  including:The Anti-Gravity Dance Floor ensures every entrance to Absolut.Land is grand. The gravity-defying mosh pit extends the length of the signature Absolut bottle facade  allowing fans to seamlessly flow from floor-to-floor. Avatars will embody the spirit of the festival grounds when they first walk into the Absolut.Land experience.ensures every entrance to Absolut.Land is grand. The gravity-defying mosh pit extends the length of the signature Absolut bottle facade  allowing fans to seamlessly flow from floor-to-floor. Avatars will embody the spirit of the festival grounds when they first walk into the Absolut.Land experience. The Absolut Bar is the heart of Absolut.Land and home to its resident bartender  this serves as the center of mixing the IRL with the metaverse. Fans near and far can find all they need to know at this central hub from the code-of-conduct and how-tos  to  of course  cocktails.is the heart of Absolut.Land and home to its resident bartender  this serves as the center of mixing the IRL with the metaverse. Fans near and far can find all they need to know at this central hub from the code-of-conduct and how-tos  to  of course  cocktails. The Citron Media Room inspired by Absolut's Citrus portfolio is colorfully designed to mix with others and get the download on the latest happenings from exclusive content in the Absolut Tent on the festival ground  to NFT wearables and highlights of the weekend.inspired by Absolut's Citrus portfolio is colorfully designed to mix with others and get the download on the latest happenings from exclusive content in the Absolut Tent on the festival ground  to NFT wearables and highlights of the weekend. The Garden is Absolut.Land's open air space where fans can discover collectibles that hero the ingredients for the hero cocktails and hidden portals to other experiences within the immersive space.is Absolut.Land's open air space where fans can discover collectibles that hero the ingredients for the hero cocktails and hidden portals to other experiences within the immersive space. The Museum Gallery   a nod to Absolut's history in rich visual arts  Absolut.Land's quiet sanctuary showcases Absolut iconic art through the decades. This is a moment for fans of Absolut's past to engage with Absolut's future.  a nod to Absolut's history in rich visual arts  Absolut.Land's quiet sanctuary showcases Absolut iconic art through the decades. This is a moment for fans of Absolut's past to engage with Absolut's future. The Selfie Room   featuring a colorful backdrop inspired by Absolut's iconic ""BORN TO MIX"" campaign  allows fans to capture their one-of-a-kind experience and share for a chance to win the ultimate Coachella NFT collectible.  featuring a colorful backdrop inspired by Absolut's iconic ""BORN TO MIX"" campaign  allows fans to capture their one-of-a-kind experience and share for a chance to win the ultimate Coachella NFT collectible. The PRIDE Tunnel   fans can access the all-out rave paying homage to Absolut's longtime involvement within and in support of the LGBTQ+ community.  fans can access the all-out rave paying homage to Absolut's longtime involvement within and in support of the LGBTQ+ community. The Rainbow Rave  an all-out dance party  grounded by a disco-inspired dance floor and powered by PRIDE  celebrates the community and features music from LGBTQ+ artists. Consumers can share their dance moves on social for a chance to be surprise and delighted with Pride theme exclusive Absolut.Land wearables!an all-out dance party  grounded by a disco-inspired dance floor and powered by PRIDE  celebrates the community and features music from LGBTQ+ artists. Consumers can share their dance moves on social for a chance to be surprise and delighted with Pride theme exclusive Absolut.Land wearables! The Outlook  the best view ‚Äì where the possibilities are endless in Absolut.Land and so are the views. This is a moment for guests to see the size and scale of the Absolut.Land experience across the metaverse!Plus  the power of Human Connections to unlock surprise moments like Absolut bottle collectibles hidden throughout the space  product promos and unique metaverse experiences. Over shared virtual drinks  festival-goers will have the chance to unlock one-of-a-kind avatar wearables from the cult-favorite  whimsical handbag and jewelry brand ‚Äì Susan Alexandra ‚Äì with the newly launched Susan Alexandra for Absolut Collection. Avatars within the space will also be able to seek out and access secret portals that just might ""teleport"" fans to Coachella Valley for an IRL VIP experience during the festival's second weekend.*Absolut also pays homage to its one-source Swedish heritage  partnering with headliner Swedish House Mafia amid their highly anticipated return to the festival stage after ten years. Dropping on April 15  the supergroup's newest album  Paradise Again  will be played on a custom jukebox within Absolut.Land. The album set the inspiration for the Absolut x Swedish House Mafia Paradise (Again) Paloma  which music and cocktail lovers alike can find in the metaverse  onsite at the festival or at home with a specialty cocktail kit available for a limited-time only. Fans cannot only grab a virtual drink  but also purchase this cocktail to be delivered right to their door  powered by one of the Absolut.Land vending machines.""We wanted to mix with our fans in a way that's really innovative and different  and what's bigger than the metaverse "" said Swedish House Mafia ‚Äì Axwell  Steve Angello and Sebastian Ingrosso. ""When we hit the headline stage at the festival on Friday  you can also find us in Absolut.Land to listen and dance to our newly dropped Paradise Again album over the Swedish Paloma cocktail we created with Absolut.""On-the-ground festival goers can join the metaverse too by taking over the Absolut.Land bartender avatar at an interactive kiosk in the tent. IRL guests can mix virtual cocktails  chat up fellow avatars and surprise and delight by gifting NFT wearables all live. Absolut's physical tent has been designed in parallel to its online counterpart with a geometric layout  bold color schemes  art installations  and content streamed from Absolut.Land. To learn more  please visit AbsolutLand.com .*No purchase necessary to enter or win. Purchasing a product will not improve your chances of winning. Must be legal resident of the (50) U.S. or D.C.  age 21 or older as of date of entry. Registration begins at 12:00a ET on 4/15/2022 and ends at 11:59p ET on 4/29/2022. (Note: to be eligible for grand prize drawing  entries must be received by 11:59p on 4/17/2022.) To enter  and for complete official rules including eligibility  how to participate  and prize details  visit www.AbsolutLand.com and follow the instructions. Maximum one grand prize award: trip for two to Coachella IRL (ARV: $4 500). Odds of winning based upon total number of eligible entries received. No alcoholic beverage is part of any prize award. Void wherever prohibited or restricted by law. Sponsor: Pernod Ricard  250 Park Avenue  New York  NY 10177.ENJOY RESPONSIBLYABSOLUT¬Æ. PRODUCT OF SWEDEN. 40% ALC./VOL. ¬©2021. IMPORTED BY ABSOLUT SPIRITS CO.  NEW YORK  NY.ABOUT PERNOD RICARD USA¬ÆPernod Ricard USA is the premium spirits and wine company in the U.S.  and the largest subsidiary of Paris  France-based Pernod Ricard SA.  the world's second-largest spirits and wine company. Pernod Ricard employs approximately 19 000 people worldwide  is listed on Euronext (Ticker: RI) and is part of the CAC 40 index. The company's leading spirits include such prestigious brands as Absolut¬Æ Vodka  Avi√≥n¬Æ Tequila  Chivas Regal¬Æ Scotch Whisky  The Glenlivet¬Æ Single Malt Scotch Whisky  Jameson¬Æ Irish Whiskey  Kahl√∫a¬Æ Liqueur  Malibu¬Æ  Martell¬Æ Cognac  Olmeca Altos¬Æ Tequila   Beefeater¬Æ Gin  Del Maguey¬Æ Single Village Mezcal  Monkey 47¬Æ Gin  Plymouth¬Æ Gin  Seagram's¬Æ Extra Dry Gin  Malfy¬Æ Gin  Hiram Walker¬Æ Liqueurs  Midleton¬Æ Irish Whiskey  Powers¬Æ Irish Whiskey  Redbreast¬Æ Irish Whiskey  Aberlour¬Æ Single Malt Scotch Whisky; Lillet¬Æ; Smithworks¬Æ Vodka  Jefferson's¬Æ Bourbon  Smooth Ambler¬Æ Whiskey  Rabbit Hole¬Æ Whiskey  Pernod¬Æ and Ricard¬Æ; such superior wines as Jacob's Creek¬Æ  Kenwood¬Æ Vineyards  Campo Viejo¬Æ and Brancott Estate¬Æ; and such exquisite champagnes and sparkling wines as Perrier-Jou√´t¬Æ Champagne  G.H. Mumm‚Ñ¢ Champagne and Mumm Napa¬Æ sparkling wines.Pernod Ricard USA is headquartered in New York  New York  and has more than 700 employees across the country. As ""creators of conviviality "" we are committed to sustainable and responsible business practices in service of our customers  consumers  employees and the planet. Pernod Ricard USA urges all adults to consume its products responsibly and has an active program to promote responsible drinking. For more information on this  please visit: www.responsibility.org .CONTACTJoanna Hein[email protected]Kate Valauri[email protected]SOURCE Pernod Ricard USA",neutral,0.03,0.96,0.01,positive,0.74,0.25,0.01,True,English,"['Coachella Fans', 'Absolut.Land', 'Metaverse', 'Launch', 'iconic ""BORN TO MIX"" campaign', 'Pernod Ricard North America', 'ultimate Coachella NFT collectible', 'The Citron Media Room', 'signature Absolut bottle facade', 'The Anti-Gravity Dance Floor', 'The Selfie Room', 'new virtual destination', 'Chief Marketing Officer', 'gravity-defying mosh pit', 'The Museum Gallery', 'rich visual arts', 'The PRIDE Tunnel', 'open air space', 'The Absolut Bar', 'disco-inspired dance floor', 'Pride theme exclusive', 'empowering social interaction', 'The Rainbow Rave', 'Absolut iconic art', 'Absolut bottle collectibles', 'Absolut.Land experience', 'NFT wearables', 'The Garden', 'The Outlook', 'kind experience', 'dance party', 'dance moves', 'exclusive content', 'Land wearables', 'festival culture', 'Pam Forbus', 'natural progression', 'passion points', 'festival grounds', 'resident bartender', 'central hub', 'Citrus portfolio', 'latest happenings', 'immersive space', 'quiet sanctuary', 'colorful backdrop', 'longtime involvement', 'LGBTQ+ artists', 'best view', 'Human Connections', 'surprise moments', 'Absolut Tent', 'innovative experiences', 'other experiences', 'LGBTQ+ community', 'hero cocktails', 'person', 'globe', 'others', 'celebration', 'convergence', 'fashion', 'music', 'course', 'friends', 'love', 'brand', 'world', 'sense', 'belonging', 'SVP', 'consumers', 'metaverse', 'products', 'heritage', 'entrance', 'length', 'fans', 'Avatars', 'spirit', 'heart', 'center', 'IRL', 'code', 'conduct', 'download', 'highlights', 'weekend', 'ingredients', 'portals', 'history', 'decades', 'past', 'future', 'chance', 'homage', 'support', 'possibilities', 'views', 'guests', 'size', 'scale', 'promos', 'uniqu']",2022-04-11,2022-04-11,prnewswire.com
2677,EuroNext,NewsApi.org,https://allafrica.com/stories/202204110198.html,Morocco: Thales Launches Its Sixth Cyber Security Operations Center in Morocco to Serve the African Continent,[New Dawn] Thales strengthens its status as a cybersecurity leader with the creation of a new Security Operations Center on the African continent  based in Morocco.,"Thales strengthens its status as a cybersecurity leader with the creation of a new Security Operations Center on the African continent  based in Morocco.This operations center provides Moroccan and African administrations and businesses with effective supervision resources in the field of cybersecurity.Increasingly targeted by cyber-attacks  the continent's businesses witnessed a rise in risk exposure during the pandemic with a broader field of attack.PARIS  France  7 April 2022 -/African Media Agency (AMA)/-Thales is opening a new Cyber Security Operations Center (SOC) in Morocco  the sixth in its international network. This center will provide real-time protection against cyber-attacks in the country and across the African continent as a whole.The digital transformation of African societies  as illustrated by the extensive use of mobile payments across the continent  and the rise in teleworking due to the health crisis  have had a major impact on Africa's vulnerability to cyber-attacks. While businesses  administrations and individuals are becoming increasingly connected  this trend must be accompanied by an increase in the level of protection in order to tackle the multiplication and sophistication of attacks. Outside the financial sector  all sectors are affected  including the most important ones  such as government services but also water distribution  energy and telecommunications.Furthermore  a new legal framework is driving African businesses to equip themselves with a means of supervision in the field of cybersecurity. Thales  which is already present in Morocco  is thus strengthening its cyber expertise on the continent.The SOCs combine 24/7 threat detection and analysis capabilities and deliver responses in compliance with the country's cybersecurity infrastructure and policies. There are six SOCs located in Canada  France  Hong Kong  the Netherlands  the United Kingdom and now Morocco  and they currently form an international network operating according to the ""follow the sun"" model which offers continuous support to more than a hundred clients around the world  with an unequaled level of responsiveness and flexibility.""Thales is proud to be able to strengthen its expertise and know-how in the field of cybersecurity in Morocco. The launch of this SOC demonstrates the Group's aspirations to support the development of security facilities in Africa  while closely matching its customers' needs. As well as our analysis capacities  we offer businesses access to a hybrid consultancy and monitoring solution for their activity  thus demonstrating our commitment to fostering skills and autonomy over the long term""  Hicham Alj  Managing Director of Thales Morocco.Thales offers its customers more than 20 years' expertise in the field of cybersecurity  in particular SOC solutions  combined with an extensive portfolio of solutions: cyber auditing and consulting  integration of cybersecurity solutions developed by Thales as well as solutions from leading publishers  and simulation of Penetration Testing and Red Teaming attacks.In Africa  the Group supports its customers in ensuring compliance with regulations and technical processes  assessing cyber risks and their level of maturity  investigating and anticipating cyber crises and neutralizing complex attacks.Distributed by African Media Agency (AMA) on behalf of Thales.About ThalesThales (Euronext Paris: HO) is a global leader in advanced technologies  investing in digital and ""deep tech"" innovations - connectivity  big data  artificial intelligence  cybersecurity and quantum technologies - to build a confident future crucial for the development of our societies. The Group provides its customers - businesses  organizations and governments - in the defense  aeronautics  space  transport  and digital identity and security domains with solutions which help them fulfill their critical role  with the individual being the driving force behind all decisions.Close Sign up for free AllAfrica Newsletters Get the latest in African news delivered straight to your inbox Top Headlines Morocco ICT By submitting above  you agree to our privacy policy. Success! Almost finished... We need to confirm your email address. To complete the process  please follow the instructions in the email we just sent you. Error! Error! There was a problem processing your submission. Please try again later.Thales has 81 000 employees in 68 countries. In 2021  the Group posted a turnover of EUR 16.2 billion.VISITThales GroupCybersecurity Operational Center | Thales GroupThe original source-language text of this announcement is the official  authoritative version. Translations are provided as an accommodation only  and should be cross-referenced with the source-language text  which is the only version of the text intended to have legal effect.",neutral,0.03,0.95,0.02,mixed,0.26,0.12,0.62,True,English,"['Sixth Cyber Security Operations Center', 'African Continent', 'Morocco', 'Thales', 'inbox Top Headlines Morocco ICT', 'new Cyber Security Operations Center', 'VISITThales GroupCybersecurity Operational Center', 'new Security Operations Center', 'new legal framework', '24/7 threat detection', 'a hundred clients', 'deep tech"" innovations', 'free AllAfrica Newsletters', 'African Media Agency', 'effective supervision resources', 'Red Teaming attacks', 'official, authoritative version', 'original source-language text', 'security facilities', 'security domains', 'cyber auditing', 'cyber risks', 'cyber crises', 'legal effect', 'cyber expertise', 'African news', 'risk exposure', 'international network', 'extensive use', 'mobile payments', 'health crisis', 'major impact', 'financial sector', 'government services', 'water distribution', 'The SOCs', 'analysis capabilities', 'six SOCs', 'Hong Kong', 'United Kingdom', 'sun"" model', 'continuous support', 'analysis capacities', 'hybrid consultancy', 'monitoring solution', 'long term', 'Hicham Alj', 'Managing Director', 'extensive portfolio', 'leading publishers', 'Penetration Testing', 'technical processes', 'complex attacks', 'global leader', 'advanced technologies', 'big data', 'artificial intelligence', 'quantum technologies', 'confident future', 'critical role', 'driving force', 'privacy policy', 'digital transformation', ""20 years' expertise"", 'digital identity', 'African administrations', 'African societies', 'African continent', 'real-time protection', 'Euronext Paris', 'email address', 'The Group', 'cybersecurity leader', 'cybersecurity infrastructure', 'unequaled level', 'African businesses', ""customers' needs"", 'broader field', 'Thales Morocco', 'cybersecurity solutions', 'SOC solutions', 'status', 'creation', 'Moroccan', 'cyber-attacks', 'pandemic', 'France', 'AMA', 'country', 'teleworking', 'vulnerability', 'individuals', 'trend', 'increase', 'order', 'multiplication', 'sophistication', 'sectors', 'important', 'energy', 'telecommunications', 'means', 'responses', 'compliance', 'policies', 'Canada', 'Netherlands', 'world', 'responsiveness', 'flexibility', 'know-how', 'launch', 'aspirations', 'development', 'access', 'activity', 'commitment', 'skills', 'autonomy', 'consulting', 'integration', 'simulation', 'regulations', 'maturity', 'behalf', 'connectivity', 'organizations', 'governments', 'defense', 'aeronautics', 'space', 'transport', 'decisions', 'Success', 'instructions', 'Error', 'problem', 'submission', '81,000 employees', '68 countries', 'turnover', 'announcement', 'Translations', 'accommodation']",2022-04-11,2022-04-11,allafrica.com
2678,EuroNext,Google API,https://www.defenseworld.net/2022/04/11/euronext-otcmktseuxtf-now-covered-by-credit-suisse-group.html,Euronext (OTCMKTS:EUXTF) Now Covered by Credit Suisse Group,12 hours ago,Credit Suisse Group initiated coverage on shares of Euronext (OTCMKTS:EUXTF ‚Äì Get Rating) in a research note released on Thursday  The Fly reports. The brokerage issued an outperform rating on the stock.A number of other brokerages have also commented on EUXTF. Barclays began coverage on shares of Euronext in a research note on Thursday  February 3rd. They issued an equal weight rating for the company. HSBC raised shares of Euronext from a hold rating to a buy rating and set a $104.00 target price on the stock in a report on Thursday  December 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company‚Äôs stock. According to MarketBeat.com  Euronext has an average rating of Buy and an average price target of $104.00.Get Euronext alerts:OTCMKTS:EUXTF opened at $94.05 on Thursday. Euronext has a fifty-two week low of $84.46 and a fifty-two week high of $121.53. The firm has a 50-day simple moving average of $92.98 and a two-hundred day simple moving average of $101.40.Euronext N.V.  together with its subsidiaries  operates securities and derivatives exchanges in Continental Europe  Ireland  and Norway. The company offers a range of exchange and corporate services  including security listings  cash and derivatives trading  and market data dissemination. It also provides listing venues and cash equities trading venues; and various marketplaces  including multilateral trading facilities for investors  broker-dealers  and other market participants to meet directly to buy and sell cash equities  fixed income securities  and exchange traded products.Further ReadingReceive News & Ratings for Euronext Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Euronext and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.01,0.98,0.01,negative,0.06,0.34,0.61,True,English,"['Credit Suisse Group', 'Euronext', 'OTCMKTS', 'EUXTF', 'two-hundred day simple moving average', '50-day simple moving average', 'FREE daily email newsletter', 'Two equities research analysts', 'cash equities trading venues', 'Credit Suisse Group', 'market data dissemination', 'multilateral trading facilities', 'concise daily summary', 'average price target', 'other market participants', 'equal weight rating', 'fixed income securities', 'Euronext N.V.', 'average rating', '$104.00 target price', 'derivatives trading', 'listing venues', 'email address', 'research note', 'other brokerages', ""analysts' ratings"", 'Euronext Daily', 'Get Rating', 'outperform rating', 'hold rating', 'The Fly', 'derivatives exchanges', 'Continental Europe', 'corporate services', 'security listings', 'various marketplaces', 'related companies', 'buy rating', 'fifty-two week', 'latest news', 'Euronext alerts', 'MarketBeat.com', 'coverage', 'shares', 'OTCMKTS', 'EUXTF', 'Thursday', 'stock', 'number', 'Barclays', 'February', 'company', 'HSBC', 'report', 'December', 'firm', 'subsidiaries', 'Ireland', 'Norway', 'range', 'investors', 'broker-dealers', 'traded', 'products', 'Reading']",2022-04-11,2022-04-11,defenseworld.net
2679,EuroNext,Google API,https://www.veon.com/media/media-releases/2022/veons-banglalink-launches-digital-services-marketplace-applink/,VEON's Banglalink Launches Digital Services Marketplace 'AppLink',5 hours ago,"Amsterdam  11th April 2022 - VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides mobile connectivity and services  today announces that Banglalink  its mobile operator in Bangladesh  has launched AppLink  a digital services marketplace aimed at connecting Banglalink customers with local developers. It provides customers with convenient purchase facilities and offers new earning opportunities for developers.AppLink provides a streamlined approach for local developers to make apps available for download by Banglalink customers and gives them a convenient way to monetize their apps while following local regulations. Local developers will be provided with online tools to present and monetize their apps  with published apps sorted into different categories such as health  education  sports  agriculture  public service  entertainment  and business. Banglalink customers will be able to purchase apps through their mobile balance.""Innovation is at the core of our digital operator strategy. Nowhere is that more evident than in Bangladesh  a market with enormous potential that is undergoing a digital transformation "" states Kaan Terzioglu  CEO of VEON Group. ""We serve markets with 680 million people across nine operators with 220 million customers and  through local initiatives such as AppLink  contribute to the development of countries' digital economies.""With over 4 500 software companies and more than 300 000 ICT specialists and software developers in Bangladesh1  AppLink will provide a marketplace for the country's technology talent  including a strong community of young developers  to Banglalink's 13 million smartphone users.Zunaid Ahmed Palak MP  Bangladesh's Honourable State Minister  ICT Division  stated: ""Banglalink is known for taking exemplary digital initiatives for the country's youth. This time  it has created a digital platform that will encourage young developers to deliver apps for our local market. This is an example of how large corporate organisations can contribute to the growth of our IT sector by empowering young professionals.""Banglalink's AppLink mirrors other developments by VEON mobile operators to bring innovative digital services to mobile users. These include Toffee  a highly successful entertainment application launched in 2019 that is now used by 6.4 million people in Bangladesh; Health Hub  a recently launched digital health aggregator platform within Banglalink's self-care app; and JazzCash  VEON's mobile banking service in Pakistan that has 15.2 million customers21 Source: Dcastalia2 customer numbers as of 31st December 2021",neutral,0.01,0.98,0.01,positive,0.65,0.33,0.02,True,English,"['Digital Services Marketplace', 'VEON', 'Banglalink', 'AppLink', 'Zunaid Ahmed Palak MP', 'digital health aggregator platform', 'new earning opportunities', 'Honourable State Minister', 'large corporate organisations', ""countries' digital economies"", 'global digital operator', 'digital operator strategy', 'convenient purchase facilities', 'exemplary digital initiatives', 'innovative digital services', 'successful entertainment application', 'mobile banking service', '13 million smartphone users', 'digital services marketplace', 'VEON mobile operators', 'digital platform', 'digital transformation', 'mobile users', 'convenient way', 'public service', 'nine operators', 'local initiatives', 'mobile connectivity', 'mobile balance', 'Health Hub', '680 million people', '6.4 million people', '15.2 million customers2', 'streamlined approach', 'local regulations', 'online tools', 'different categories', 'enormous potential', 'Kaan Terzioglu', '220 million customers', '4,500 software companies', '300,000 ICT specialists', 'technology talent', 'strong community', 'ICT Division', 'IT sector', 'young professionals', 'other developments', 'self-care app', '2 customer numbers', '31st December', 'local developers', 'software developers', 'young developers', 'VEON Ltd', 'VEON Group', 'Euronext Amsterdam', 'local market', 'Banglalink customers', '11th', 'NASDAQ', 'Bangladesh', 'AppLink', 'apps', 'download', 'education', 'sports', 'agriculture', 'business', 'Innovation', 'core', 'Nowhere', 'CEO', 'markets', 'country', 'youth', 'example', 'growth', 'Toffee', 'JazzCash', 'Pakistan', '1 Source', 'Dcastalia']",2022-04-11,2022-04-11,veon.com
2680,EuroNext,Google API,https://www.marketscreener.com/quote/stock/FARMAE-S-P-A-63216147/news/Farmae-S-p-A-BUY-BACK-PLAN-SUBMITTED-TO-THE-SHAREHOLDERS-MEETING-40025120/,Farmae S p A : BUY-BACK PLAN SUBMITTED TO THE SHAREHOLDERS' MEETING,3 hours ago,"Press releaseBUY-BACK PLAN SUBMITTED TO THE SHAREHOLDERS' MEETINGViareggio  11 April 2022 - Farma√® S.p.A. - a company listed on the Euronext Growth Milanmarket of Borsa Italiana  a leading integrated platform in Italy in the healthcare  beauty and wellness sectors - (the ""Company"") announces that the Board of Directors  which met today  resolved to submit for approval to the forthcoming Shareholders' Meeting (see press release of 31 March 2022  available in the Investor Relations section of the Company's website www.farmaegroup.it)  inter alia  the authorisation to purchase and subsequently dispose of treasury shares pursuant to Articles 2357 et seq. of the Italian Civil Code  as well as article 25-bis of the Euronext Growth Milan Regulation  in light of the reasons and according to the procedures and terms illustrated below.Reasons for the request for authorisationThe authorisation for the purchase and disposal (intended  by way of example and not limited to  as sale  exchange  contribution and/or other use) of treasury shares is appropriate in order to allow the Company to: (a) use treasury shares within the scope of transactions connected to ordinary operations or projects consistent with the strategies that the Company intends to pursue  in relation to which the opportunity to exchange shares arises  with the main objective therefore of acquiring a portfolio of treasury shares that can be used for extraordinary financial operations and/or other uses deemed to be of financial-management and strategic interest for the Company; the aim therefore is of finalising corporate integration transactions with potential strategic partners  exchanges of shareholdings or commercial and/or professional agreements deemed to be strategic for the Company; and (b) intervene (where possible and provided for by the applicable legal and regulatory provisions)  in compliance with the provisions in force  including through intermediaries  to contain abnormal movements in prices and to regularise the trend of trading and prices  in the face of momentary distortions linked to excessive volatility or poor trading liquidity or  more generally  to support the liquidity of the stock and the efficiency of the market.Maximum number  category and nominal value of the shares to which the authorisation refersThe Board of Directors' proposal is to authorise the Board of Directors to purchase ordinary (fully paid) shares of the Company  in one or more tranches  in an amount freely determinable by the Board of Directors up to a maximum of 700 000 (treasury) shares  in compliance with the laws and regulations in force at the date of the transaction.Pursuant to Article 2357  paragraph 3 of the Italian Civil Code  the nominal value of the shares purchased may not exceed one fifth of the Company's share capital  taking into account for this purpose any shares held by its subsidiaries.Maximum purchase outlayThe maximum purchase outlay for the transaction for which the Board of Directors has requested authorisation is set at Euro 12 000 000. Pursuant to Article 2357 of the Italian Civil Code  the purchase of treasury shares is allowed within the limits of the distributable profits and available reserves resulting from the last approved financial statements and may only concern fully paid-up shares.Duration of the Meeting's authorisationThe Board of Directors has proposed that the authorisation to purchase treasury shares be granted for the maximum duration allowed by Article 2357  paragraph 2  of the Italian Civil Code  and therefore for a period of 18 months from the date of the relevant shareholders' meeting resolution  with the power of the Board of Directors to proceed with the authorised transactions on one or more occasions and at any time  as freely determined by the Board of Directors itself  in compliance with applicable regulations.The authorisation to dispose of treasury shares in portfolio has been requested without a time limit  due to the absence of limits in this sense in the current legal provisions and the opportunity to allow the Board of Directors to make use of the maximum flexibility  also in terms of time.Minimum and maximum considerationThe Board of Directors has proposed that the purchase price of the shares be identified on a case-by-case basis  considering the method chosen to carry out the transaction and in compliance with any regulatory requirements or accepted market practices (which may be applicable to the Company or used by it)  but in any event not less than 10% lower and not more than 10% higher than the arithmetic mean of the official prices recorded by the Company's shares on the Euronext Growth Milan multilateral trading system during the five trading days prior to each individual purchase transaction - except in cases where the shares are exchanged  contributed  assigned or other acts of disposition other than in cash  whereby the economic terms of the transaction will be determined  in compliance with applicable regulations  based on the nature and characteristics of the transaction - and in any case in compliance with the terms and conditions established by Delegated Regulation (EU) no. 2019/1052 and other applicable regulations (including those of a European or supranational nature) and the aforementioned accepted practices (where applicable)  without prejudice to the possibility of exceeding these limits in the event of extremely low liquidity in the market  again under the conditions mentioned in the aforementioned regulations.As regards the acts of disposal and/or use of treasury shares  the proposal was that they be carried out at the price or  in any case  according to criteria and conditions determined by the Board of Directors  having regard to the methods actually used  the trend in share prices in the period preceding the transaction and the best interests of the Company.Way of executing transactionsThe Board of Directors has proposed that authorisation be granted for the purchase of treasury shares according to any of the methods permitted by current regulations  to be identified on a case-by-case basis at the discretion of the Board of Directors itself (or the person delegated to do so)  and therefore including by means of a public purchase or exchange offer or by means of purchases made on the Euronext Growth Milan market through an intermediary meeting all the legal requirements  who will be given the relevant mandate by the Board of Directors  in accordance with market practices that do not allow the direct matching of proposed purchases with specific proposed sales.With regard to transactions involving the disposal and/or use of treasury shares  the Board of Directors has proposed that the authorisation should allow for the adoption of any method that may be appropriate in relation to the purposes pursued  to be carried out also through intermediaries  in compliance with the applicable national and EU laws and regulations.***The Board of Directors has also approved an explanatory report on this matter  drawn up on a voluntary basis  which - together with the notice of call and the other documentation relating to the forthcoming General Meeting - will be made available to the public within the terms and according to the procedures set forth by law  at the Company's registered office and on the Company's website www.farmaegroup.it (section ""Governance"" - ""Shareholders' Meetings"") to which reference is made.***This press release is available in the Investor Relations section of the Company's website www.farmaegroup.it.***Established in Viareggio in 2014 and listed since July 2019 on Euronext Growth Milan market of Borsa Italiana  Farma√® is a media platform and a benchmark  a leader in Italy in the Healthcare  Beauty and Wellness sectors. Farma√® Group today controls Farma√®  AmicaFarmacia  Beauty√®  Sanort and the media company Valnan Communications. The Group places the customer at the centre of its circular activities  responding immediately  quickly and pragmatically to every need  ensuring a unique customer experience  regardless of the purchase channel used. Farma√® Group is also the primary reference for industries investing in the millions of visitors to online platforms  thus recognizing the Group's main brands as true Media.For further information:",neutral,0.02,0.96,0.02,negative,0.04,0.13,0.83,True,English,"['Farmae S', 'BUY-BACK PLAN', ""SHAREHOLDERS' MEETING"", 'THE', 'Euronext Growth Milan multilateral trading system', 'Euronext Growth Milan Regulation', 'Farma√® S.p.A.', ""relevant shareholders' meeting resolution"", 'five trading days', 'leading integrated platform', 'Investor Relations section', 'Italian Civil Code', ""forthcoming Shareholders' Meeting"", 'potential strategic partners', 'poor trading liquidity', 'extraordinary financial operations', 'corporate integration transactions', 'current legal provisions', 'Maximum purchase outlay', 'individual purchase transaction', 'strategic interest', 'applicable legal', 'financial statements', 'purchase price', 'Maximum number', 'maximum flexibility', 'maximum consideration', 'Press release', 'BUY-BACK PLAN', 'Borsa Italiana', 'wellness sectors', 'ordinary operations', 'main objective', 'other uses', 'professional agreements', 'regulatory provisions', 'abnormal movements', 'momentary distortions', 'excessive volatility', 'nominal value', 'share capital', 'distributable profits', 'available reserves', 'case basis', 'regulatory requirements', 'arithmetic mean', 'other acts', 'applicable regulations', 'maximum duration', 'treasury shares', 'treasury) shares', 'up shares', 'one fifth', 'time limit', 'market practices', 'official prices', 'economic terms', ""Directors' proposal"", 'The Board', 'Viareggio', 'April', 'company', 'Italy', 'beauty', 'approval', '31 March', 'website', 'farmaegroup', 'authorisation', 'Articles 2357', 'light', 'reasons', 'procedures', 'request', 'disposal', 'way', 'example', 'sale', 'exchange', 'contribution', 'order', 'scope', 'projects', 'strategies', 'opportunity', 'portfolio', 'financial-management', 'aim', 'shareholdings', 'commercial', 'compliance', 'force', 'intermediaries', 'trend', 'face', 'stock', 'efficiency', 'category', 'tranches', 'amount', 'laws', 'date', 'Article 2357', 'paragraph', 'account', 'purpose', 'subsidiaries', 'limits', 'last', 'period', '18 months', 'power', 'occasions', 'absence', 'sense', 'Minimum', 'method', 'event', 'cases', 'disposition', 'cash', 'nature', 'characteristics']",2022-04-11,2022-04-11,marketscreener.com
2681,EuroNext,Google API,https://www.biospace.com/article/releases/nicox-s-ncx-470-dolomites-phase-2-results-published-in-journal-of-glaucoma-/,Nicox‚Äôs NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma,14 hours ago,Press Release Nicox‚Äôs NCX 470 Dolomites Phase 2 Results Published in Journal of GlaucomaApril 11  2022 ‚Äì release at 7:30 am CETSophia Antipolis  FranceNicox SA (Euronext Paris: FR0013018124  COX)  an international ophthalmology company  today announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma  the official journal of the World Glaucoma Association. The publication ‚ÄúA Randomized  Controlled Comparison of NCX 470 (0.021%  0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study‚Äù¬ª is available by clicking here. NCX 470 is currently in two Phase 3 clinical trials.Dolomites was a dose-response Phase 2 clinical trial comparing three concentrations of NCX 470 ophthalmic solution (0.021%  0.042%  and 0.065%) to latanoprost ophthalmic solution  0.005% in 433 patients with open-angle glaucoma or ocular hypertension. Aligned with previously reported topline results on Dolomites  NCX 470 0.065% achieved statistical superiority compared to latanoprost 0.005% at all time-matched points measured on day 28  with a peak improvement in intraocular pressure (IOP) lowering of 1.4 mmHg greater than latanoprost. All tested concentrations of NCX 470 were statistically non-inferior to latanoprost and the dose response of NCX 470 showed improved IOP lowering with each incremental concentration. NCX 470 was safe and well-tolerated with no drug-related serious adverse events and no evidence of treatment-related systemic side effects.‚ÄúAs presented at the American Glaucoma Societyin February 2020 by Dr David Wirta  the Dolomites Phase 2 data demonstrate that NCX 470  a monotherapy with a dual mechanism of action  has the potential to be a new standard of care for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.‚Äù said Doug Hubatsch  Chief ScientificOfficer of Nicox. ‚ÄúWe are pleased to be able to share the results of this Phase 2trial in apeer-reviewed publication with the international glaucoma community.We are looking forward to the results of the subsequent Phase 3trials of NCX 470 ‚Äì Mont Blanc and Denali ‚Äì which use a higher dose of NCX 470  based on the results of an initial adaptive design dose-ranging phaseof the Mont Blanc trial.‚ÄùNCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials  Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once-daily dosed NCX 470 ophthalmic solution 0.1% over latanoprost ophthalmic solution 0.005% (first marketed as Xalatan)  the most prescribed prostaglandin analog in the U.S. for patients with open-angle glaucoma or ocular hypertension. About NCX 470 NCX 470 is a novel  potential best-in-class  nitric oxide (NO)-donating prostaglandin analog in development to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Glaucoma is a group of ocular diseases in which the optic nerve is injured  leading to peripheral and  ultimately  central visual field loss and it can eventually lead to blindness if not treated. It is frequently linked to abnormally high IOP (~90% of patients) due to blockage or malfunction of the eye‚Äôs aqueous humor drainage system in the front of the eye. In 2020  worldwide sales of treatments targeting glaucoma were over $6.0 billion out of a $24.3 billion worldwide market for ophthalmic drugs.NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. Bimatoprost  marketed under the brand name LUMIGAN¬Æ by Allergan  Inc.  is one of the leading products in the class of prostaglandin analogs  the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox‚Äôs lead program in clinical development is NCX 470  a novel nitric oxide-donating prostaglandin analog  for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251  a proprietary formulation of fluticasone  for dry eye disease. Nicox generates revenue from VYZULTA¬Æ in glaucoma  licensed exclusively worldwide to Bausch + Lomb  and ZERVIATE¬Æ in allergic conjunctivitis  licensed in multiple geographies  including to Eyevance Pharmaceuticals  LLC  in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.Nicox is headquartered in Sophia Antipolis  France  is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare  CAC Pharma & Bio and Next 150 indexes.For more information on Nicox  its products or pipeline  please visit: www.nicox.com. Analyst coverageBryan  Garnier & Co Dylan van Haaften Paris  FranceEdison Investment Research Pooya Hemami London  UKH.C. Wainwright & Co Yi Chen New York  U.S.Kepler Cheuvreux Damien Choplain Paris  France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally  the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. ContactsNicoxGavin SpencerExecutive Vice President  Chief Business Officer& Head of Corporate DevelopmentT +33 (0)4 97 24 53 00communications@nicox.comInvestors & MediaUnited States & EuropeLifeSci Advisors  LLCSandya von der WeidT +41 78 680 05 38svonderweid@lifesciadvisors.com Forward-Looking Statements The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates  directors  officers  employees  advisers or agents  do not undertake  nor do they have any obligation  to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox‚Äôs business are presented in the 3rd chapter of the ‚ÄòDocument d‚Äôenregistrement universel  rapport financier annuel et rapport de gestion 2020‚Äô filed with the French Autorit√© des March√©s Financiers (AMF) on March 1  2021 and in the 2nd chapter of the amendment to the ‚ÄúDocument d‚ÄôEnregistrement Universel  rapport financier annuel et rapport de gestion 2020‚Äù filed with the AMF on December 9  2021 which are available on Nicox‚Äôs website (www.nicox.com). Nicox S.A.Drakkar 2B√¢t D  2405 route des DolinesCS 10313  Sophia Antipolis06560 Valbonne  FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24 53 99Attachment,neutral,0.01,0.97,0.02,mixed,0.39,0.1,0.51,True,English,"['NCX 470 Dolomites Phase 2 Results', 'Nicox', 'Journal', 'Glaucoma', 'initial adaptive design dose-ranging phaseof', 'two multi-regional Phase 3 glaucoma clinical trials', 'novel nitric oxide-donating prostaglandin analog', 'A Randomized, Controlled Comparison', 'drug-related serious adverse events', 'treatment-related systemic side effects', 'central visual field loss', 'aqueous humor drainage system', 'South East Asian markets', 'two Phase 3 clinical trials', 'dose-response Phase 2 clinical trial', 'Dylan van Haaften Paris', 'Dolomites Phase 2 clinical trial', 'France Edison Investment Research', 'Nicox Nicox S.A.', 'subsequent Phase 3trials', 'NCX 470 Dolomites Phase 2 Results', 'Dolomites Phase 2 data', 'Dr David Wirta', 'Pooya Hemami Lo', 'class, nitric oxide', 'The Dolomites Study', '$24.3 billion worldwide market', 'international ophthalmology company', 'Mont Blanc trial', 'World Glaucoma Association', 'American Glaucoma Societyin', 'international glaucoma community', 'two trials', 'dry eye disease', 'latanoprost ophthalmic solution', 'NCX 470 ophthalmic solution', 'Phase 2trial', 'clinical development', 'prostaglandin analogs', 'Euronext Paris', 'U.S.', 'worldwide sales', 'ophthalmic drugs', 'open-angle glaucoma', 'Sophia Antipolis', 'ocular hypertension', 'statistical superiority', 'time-matched points', 'peak improvement', 'intraocular pressure', 'dose response', 'incremental concentration', 'dual mechanism', 'new standard', 'Doug Hubatsch', 'Chief ScientificOfficer', 'higher dose', 'ocular diseases', 'optic nerve', 'brand name', 'innovative solutions', 'ocular health', 'lead program', 'proprietary formulation', 'allergic conjunctivitis', 'multiple geographies', 'Eyevance Pharmaceuticals', 'Ocumension Therapeutics', 'Compartment C', 'Mid Caps', 'Ticker symbol', 'CAC Healthcare', 'CAC Pharma', 'Next 150 indexes', 'Analyst coverage', 'Nicox SA', 'topline results', 'high IOP', 'Press Release', 'three concentrations', 'apeer-reviewed publication', 'leading products', 'official journal', 'IOP lowering', 'Nicox.', 'NCX 4251', 'April', 'CET', 'patients', 'day', 'evidence', 'February', 'monotherapy', 'action', 'potential', 'Denali', 'objective', 'Xalatan', 'group', 'peripheral', 'blindness', 'blockage', 'malfunction', 'front', 'treatments', 'bimatoprost', 'instillation', 'LUMIGAN', 'Allergan', 'IOP-lowering', 'vision', 'fluticasone', 'revenue', 'VYZULTA¬Æ', 'Bausch', 'Lomb', 'ZERVIATE¬Æ', 'Chinese', 'majority', 'Bio', 'information', 'pipeline', 'Bryan', 'Garnier', '7:30', '1.4']",2022-04-11,2022-04-11,biospace.com
2682,EuroNext,Google API,https://finance.yahoo.com/news/oxurion-announces-upcoming-pre-clinical-050000717.html,Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting,15 hours ago,Oxurion NVLeuven  BELGIUM  Boston  MA  US ‚Äì 11 April 2022 ‚Äì 7.00 AM CET ‚Äì Oxurion NV (Euronext Brussels: OXUR)  a biopharmaceutical company developing next generation standard of care ophthalmic therapies  with a clinical stage portfolio in vascular retinal disorders  will be presenting pre-clinical data from a study evaluating THR-687 for treatment of diabetic macular edema (DME) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver  Colorado on May 1-4th and virtually on May 11-12th. The presentation will review pre-clinical data supporting THR-687 providing protection against retinal vascular permeability  inflammation and reactive gliosis in the diabetic rat.THR-687 is a highly selective pan-RGD integrin antagonist that is initially being developed as a potential first line therapy for DME patients and may have the potential to deliver improved treatment outcomes for patients with wet macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is currently evaluating THR-687 in a two-part Phase 2 clinical trial (‚ÄúINTEGRAL‚Äù) in patients with DME. Part A dose optimization data from the INTEGRAL trial is anticipated in the first half of 2022. If successful  the efficacy and safety of THR-687 versus aflibercept (the current standard of care) will be evaluated in Part B of the INTEGRAL Phase 2 clinical trial in both treatment-na√Øve and treatment-experienced patients with DME. The pre-clinical data supports the view that THR-687 provides protection in the diabetic rat against retinal vascular permeability  inflammation and reactive gliosis.Details of the presentation:TITLE: THR-687  a potent pan-RGD integrin antagonist  protects against retinal vascular permeability  inflammation and reactive gliosis in the diabetic ratPRESENTER: Tine Van Bergen  Senior Scientist  Oxurion NVPRESENTATION DATE AND TIME: Tuesday  May 3  2022  12:47 p.m. ETStory continuesAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME)  the leading cause of vision loss in diabetic patients worldwide as well as other conditions  including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered ‚Äúforward-looking‚Äù. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company‚Äôs Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichael DillenChief Business OfficerTel: +32 479 783583michael.dillen@oxurion.comEUMEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel: +44 203 928 6900oxurion@medistrava.comUSICR WestwickeChristopher BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com,neutral,0.01,0.97,0.02,mixed,0.13,0.35,0.52,True,English,"['Upcoming Pre-Clinical Data Presentation', 'Diabetic Macular Edema', 'ARVO) Annual Meeting', 'Oxurion', 'THR-6', 'Treatment', '2022 Association', 'Research', 'Vision', 'Ophthalmology', 'applicable U.S. state securities laws', 'U.S. Securities Act', 'selective pan-RGD integrin antagonist', 'potent pan-RGD integrin antagonist', 'potent plasma kallikrein inhibitor', 'two-part Phase 2 clinical trial', 'INTEGRAL Phase 2 clinical trial', 'potential first line therapy', 'wet age-related macular degeneration', 'clinical stage portfolio', 'wet macular degeneration', 'vascular retinal disorders', 'retinal vascular permeability', 'retinal vein occlusion', 'Tine Van Bergen', 'retinal vascular disorders', 'two novel therapeutics', 'Chief Executive Officer', 'next generation standard', 'ARVO) Annual Meeting', 'leading global franchise', 'dose optimization data', 'potential new standard', 'care ophthalmic therapies', 'Chief Business Officer', 'diabetic macular edema', 'improved treatment outcomes', 'Such forward-looking statements', 'INTEGRAL trial', 'Oxurion NV Leuven', 'first half', 'anti-VEGF therapy', 'current standard', 'leading cause', 'Annual Report', 'wet AMD', 'diabetic rat', 'new information', 'pre-clinical data', '7.00 AM CET', 'Euronext Brussels', 'upcoming Association', 'reactive gliosis', 'treatment-na√Øve', 'Senior Scientist', 'other conditions', 'successful development', 'suboptimal response', 'corporate operations', 'press release', 'current expectations', 'future events', 'other reason', 'other factors', 'actual results', 'United States', 'David Dible', 'Sylvie Berrebi', 'Frazer Hall', 'diabetic patients', 'More information', 'Important information', 'Additional information', 'biopharmaceutical company', 'The Company', 'treatment-experienced patients', 'Part B', 'various risks', 'MEDiSTRAVA Consulting', 'ICR Westwicke', 'Christopher Brinzey', 'PRESENTATION DATE', 'vision loss', 'DME patients', 'Tom Graney', 'Michael Dillen', 'DME.', 'BELGIUM', 'Boston', '11 April', 'study', 'THR', 'Research', 'Ophthalmology', 'Denver', 'Colorado', 'May', 'protection', 'inflammation', 'efficacy', 'safety', 'aflibercept', 'view', 'Details', 'TITLE', 'PRESENTER', 'TIME', 'Tuesday', 'Story', 'ME-RVO', 'uncertainties', 'assurance', 'obligation', 'offer', 'invitation', 'sale', 'purchase', 'assets', 'jurisdiction', 'registration', 'compliance', 'exemption', 'accordance', 'Tel', '2022', '12:47', '49', '87', '32']",2022-04-11,2022-04-11,finance.yahoo.com
2683,EuroNext,Google API,https://www.marketscreener.com/quote/stock/LECTRA-4769/news/Lectra-Lectra-confirms-its-eligibility-for-PEA-PME-scheme-40019553/,Lectra: Lectra confirms its eligibility for PEA-PME scheme,13 hours ago,Lectra confirms its eligibility for PEA-PME schemeParis  April 11  2022 ‚Äì Lectra (FR0000065484 LSS)  a company listed on the regulated market Euronext Paris (compartment B)  confirms  based on the consolidated financial statements of its last fiscal year ended December 31  2021  its eligibility for inclusion in French SME equity savings plans ‚ÄúPEA-PME‚Äù for the next twelve months.Lectra complies with the criteria for the inclusion of companies in the PEA-PME savings plans set in Article L.221-32-2 of the French Monetary and Financial Code  i.e. having less than 5 000 employees and a total revenue below 1 5 billion euros or total assets below 2 billion euros.As a consequence  investment in Lectra shares can be made through PEA-PME savings accounts  relief specifically applicable to investments in small and mid-cap companies  benefiting from the same tax advantages as the traditional Equity Savings Plan (PEA).For companies that breathe life into our wardrobes  car interiors  furniture and more  Lectra crafts the premium technologies that facilitate the digital transformation of their industry. Lectra‚Äôs offer empowers brands  manufacturers and retailers from design to production  providing them with the market respect and peace of mind they deserve. Founded in 1973  the company reported revenues of 388 million euros in 2021 and is listed on Euronext (LSS).In June 2021  Lectra acquired Gerber Technology  a USA-based company founded in 1968. Like Lectra  Gerber Technology develops software and automation solutions for fashion  automotive  furniture and other businesses across the globe.For more information  please visit www.lectra.com .Lectra ‚Äì World Headquarters: 16‚Äì18  rue Chalgrin ‚Ä¢ 75016 Paris ‚Ä¢ FranceTel. +33 (0)1 53 64 42 00 ‚Äì www.lectra.comA French Soci√©t√© Anonyme with capital of ‚Ç¨37 742 959 ‚Ä¢ RCS Paris B 300 702 305Attachment,neutral,0.02,0.96,0.01,positive,0.59,0.4,0.01,True,English,"['PEA-PME scheme', 'Lectra', 'eligibility', 'A French Soci√©t√© Anonyme', 'French SME equity savings plans', 'traditional Equity Savings Plan', 'PEA-PME savings plans', 'last fiscal year', 'next twelve months', 'PEA-PME savings accounts', 'same tax advantages', 'consolidated financial statements', 'RCS Paris B', 'French Monetary', 'Financial Code', 'PEA-PME scheme', 'Article L.', 'total revenue', '1,5 billion euros', 'total assets', '2 billion euros', 'car interiors', 'premium technologies', 'digital transformation', '388 million euros', 'Gerber Technology', 'automation solutions', 'other businesses', 'World Headquarters', 'rue Chalgrin', 'FR0000065484 LSS', 'market respect', 'mid-cap companies', 'USA-based company', 'Euronext Paris', 'Lectra shares', 'eligibility', 'compartment', 'inclusion', 'criteria', 'less', '5 000 employees', 'consequence', 'investment', 'relief', 'small', 'life', 'wardrobes', 'furniture', 'industry', 'offer', 'brands', 'manufacturers', 'retailers', 'design', 'production', 'peace', 'mind', 'revenues', 'June', 'software', 'fashion', 'automotive', 'globe', 'information', 'France', 'Tel.', 'capital', 'Attachment']",2022-04-11,2022-04-11,marketscreener.com
2684,EuroNext,Google API,https://hardwoodparoxysm.com/maire-tecnimont-new-contract-in-the-us-worth-185-million/,Maire Tecnimont New Contract in the US Worth $185 Million,13 hours ago,(Teleborsa) ‚Äì Meyer Technemonta group included in Euronext Milan and active in the transformation of natural resources  has been awarded new project To produce Diesel Exhaust Fluid Urea (DEF) in United State by the same manufacturer that recently awarded the Italian company a project to build a blue ammonia plant in the United States. Contract value is approx 185 million dollars. The scope of the contract includes the supply of technology  all engineering activities  the supply of materials and equipment  as well as the supervision of works.The DEF urea plant  which will be based on proprietary Stamicarbon technology  includes a 1 500 tpd unit as well as related facilities and ancillary units  including a carbon dioxide purification plant. The The station is expected to be completed in 2025. Once complete  the plant will receive ammonia from the blue ammonia plant mentioned above. The plant will produce AdBlue  a high-purity urea solution known in Europe as AdBlue.‚ÄúThis new grant within days of the contract for the blue ammonia project confirms Our continued growth in the downstream market in the United Stateswith innovative projects to reduce the carbon footprint of plants ‚Äì commentCEO Pierroberto Folgiero These two decades in quick succession are a perfect example of our technology-driven strategy: leveraging the synergies in our group through Stamicarbon‚Äôs undisputed leadership in urea technology  Tecnimont‚Äôs strong skills as an EPCM contractor and our deep knowledge of the market energy company and its players.‚Äù,neutral,0.02,0.95,0.03,neutral,0.07,0.91,0.02,True,English,"['Maire Tecnimont New Contract', 'US', 'Diesel Exhaust Fluid Urea', 'carbon dioxide purification plant', 'high-purity urea solution', 'commentCEO Pierroberto Folgiero', 'Meyer Technemonta group', 'blue ammonia plant', 'market energy company', 'DEF urea plant', 'blue ammonia project', 'proprietary Stamicarbon technology', 'carbon footprint', 'urea technology', 'Italian company', 'downstream market', 'Euronext Milan', 'natural resources', 'new project', 'United State', 'same manufacturer', 'engineering activities', '1,500 tpd unit', 'related facilities', 'ancillary units', 'new grant', 'continued growth', 'innovative projects', 'two decades', 'quick succession', 'perfect example', 'technology-driven strategy', 'undisputed leadership', 'strong skills', 'EPCM contractor', 'deep knowledge', 'Contract value', 'Teleborsa', 'transformation', '185 million', 'scope', 'supply', 'materials', 'equipment', 'supervision', 'works', 'The', 'station', 'AdBlue', 'Europe', 'days', 'plants', 'synergies', 'Tecnimont', 'players']",2022-04-11,2022-04-11,hardwoodparoxysm.com
2685,EuroNext,Google API,https://blackswanzine.com/equity-management-software-market-to-witness-astonishing-growth-by-2031/,Equity Management Software Market to Witness Astonishing Growth by 2031 ‚Äì Blackswan Real Estate,10 hours ago,A new Market Research from Marketreports.info  the Global Equity Management Software Market  is expected to show tremendous growth in the coming years. Analysts also analyzed the ongoing trends in Equity Management Software and the opportunities for growth in the industries. These shareholders include the following manufacturers of Outdoors Advertising: Carta  Certent  Solium  Imagineer Technology Group  Capdesk  Computershare  Koger  Altvia Solutions  Preqin Solutions  Gust  Global Shares  TruEquity  Eqvista  Euronext. The Worldwide Equity Management Software Market Research Report provides a picture of the competitive landscape of the international market. The report conveys the details resulting from the analysis of the focused market. Initially  the Equity Management Software Market report shares key aspects of the industry with the details of the impact and Equity Management Software industry experts maintain a consistent survey with innovative trends  Market share and cost.Request Sample of Equity Management Software@: marketreports.info/sample/6346/Equity Management SoftwareThe main sources are mainly industry experts in the core and related industries and manufacturers involved in all sectors of the industry supply chain. The bottom-up approach is used to plan the market size of Equity Management Software based on end-user industry and region in terms of value/volume. With the help of data  we support the primary market through the three-dimensional survey procedure and the first interview and data verification through expert telephone  determine the individual market share and size  and confirm with this study.Top Companies covered in the report: Carta  Certent  Solium  Imagineer Technology Group  Capdesk  Computershare  Koger  Altvia Solutions  Preqin Solutions  Gust  Global Shares  TruEquity  Eqvista  EuronextMarket segment by Type  the product can be split into‚Äì Basic?$Under 50/Month?‚Äì Standard($50-100/Month?‚Äì Senior?Above $100/Month?Market segment by Application  split into‚Äì Start-Ups‚Äì Private Corporation‚Äì Listed Company‚Äì Financial Team‚Äì OtherRegional Analysis:‚Ä¢ North America‚Ä¢ Europe‚Ä¢ Asia Pacific‚Ä¢ Latin America‚Ä¢ Middle East and AfricaKey Research:The main sources are industry experts from the Equity Management Software industry  including management organizations  processing organizations  and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. The qualities of this study in the industry experts industry  such as CEO  vice president  marketing director  technology and innovation director  founder and key executives of key core companies and institutions in major biomass waste containers around the world in the extensive primary research conducted for this study We interviewed to acquire and verify both sides and quantitative aspects.The research provides answers to the following key questions:1) Who are the key Top Competitors in the Equity Management Software Market?Following are list of players: Carta  Certent  Solium  Imagineer Technology Group  Capdesk  Computershare  Koger  Altvia Solutions  Preqin Solutions  Gust  Global Shares  TruEquity  Eqvista  Euronext2) What is the expected Market size and growth rate of the Outdoors Advertising market for the period 2022-2030?** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our industry experts can get in touch with you.3) Which Are The Main Key Regions Cover in Equity Management Software Reports?Geographically  this report is segmented into several key Regions  consumption  revenue (million USD)  and market share and growth rate of Equity Management Software in these regions  from 2022 to 2030 (forecast)  covering North America  Europe  Asia-Pacific  MEA and rest of the world.Ask for discounts @ marketreports.info/discount/6346/Equity Management SoftwareTable of ContentsGlobal Equity Management Software Market Research Report 2022-2030  by Manufacturers  Regions  Types and Applications1 Study Coverage1.1 Equity Management Software Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Equity Management Software Market by Type1.5 Equity Management Software Market by Application1.6 Study Objectives1.7 Years Considered2 Executive Summary2.1 Global Equity Management Software Production2.2 Equity Management Software Growth Rate (CAGR) 2022-20302.3 Analysis of Competitive Landscape2.4 Market Drivers  Trends and Issues3 Equity Management Software Market Size by Manufacturers3.1 Equity Management Software Production by Manufacturers3.2 Equity Management Software Revenue by Manufacturers3.3 Equity Management Software Price by Manufacturers3.4 Mergers & Acquisitions  Expansion Plans4 Equity Management Software Production by Regions4.1 Global Equity Management Software Production by Regions4.2 United States4.3 Europe4.4 China4.5 Japan4.6 Rest of the world5 Equity Management Software Consumption by Regions5.1 Global Equity Management Software Consumption by Regions5.2 North America5.2 Mexico5.3 Europe5.4 Asia Pacific5.5 Central & South America5.6 Middle East and Africa6 Market Size by Type6.1 Global Equity Management Software Breakdown Data by Type6.2 Global Equity Management Software Revenue by Type6.3 Equity Management Software Price by Type7 Equity Management Software Market Size by Application7.1 Overview7.2 Global Equity Management Software Breakdown Dada by Application8 Manufacturers Profiles9 Production Forecasts9.1 Equity Management Software Production and Revenue Forecast9.2 Equity Management Software Production and Revenue Forecast by Regions9.3 Equity Management Software Key Producers Forecast9.4 Forecast by Type10 Consumption Forecast10.1 Consumption Forecast by Application10.2 Equity Management Software Consumption Forecast by Regions10.3 North America Market Consumption Forecast10.4 Europe Market Consumption Forecast10.5 Asia Pacific Market Consumption Forecast10.6 Central & South America Market Consumption Forecast10.7 Middle East and Africa Market Consumption Forecast11 Upstream  Industry Chain and Downstream Customers Analysis11.1 Analysis of Equity Management Software Upstream Market11.2 Equity Management Software Industry Chain Analysis11.3 Marketing & Distribution11.4 Equity Management Software Distributors11.5 Equity Management Software Customers12 Opportunities & Challenges  Threat and Affecting Factors12.1 Market Opportunities12.2 Market Challenges12.3 Porter's Five Forces Analysis13 Key Findings14 Appendix14.1 Research Methodology14.2 Author Details14.3 DisclaimerPurchase the research report @ marketreports.info/checkout?buynow=6346/Equity Management SoftwareNote: Regional Breakdown & Sectional purchase Available We provide Pie chats Best Customize Reports as per specific Requirements.About UsMarketreports.info is a global market research and consulting service provider specialized in offering wide range of business solutions to their clients including market research reports  primary and secondary research  demand forecasting services  focus group analysis and other services. We understand that how data is important in today's competitive environment and thus  we have collaborated with industry's leading research providers who works continuously to meet the ever-growing demand for market research reports throughout the year.Contact Us:Carl Allison (Head of Business Development)Tiensestraat 32/0302 3000 Leuven  Belgium.Market Reportsphone: +44 141 628 5998Email: sales@marketreports.infoWebsite: www.marketreports.info,neutral,0.06,0.92,0.01,neutral,0.03,0.94,0.03,True,English,"['Equity Management Software Market', 'Blackswan Real Estate', 'Astonishing Growth', 'Witness', 'The Worldwide Equity Management Software Market Research Report', 'Global Equity Management Software Market Research Report', 'Global Equity Management Software Production', 'Equity Management Software Market report', '3 Equity Management Software Market Size', 'Equity Management Software industry experts', '2.2 Equity Management Software Growth Rate', '3.1 Equity Management Software Production', '4 Equity Management Software Production', 'Equity Management Software Reports', 'Equity Management Software Table', '3.3 Equity Management Software Price', '1.5 Equity Management Software Market', 'Equity Management Software Revenue', 'major biomass waste containers', 'new Market Research', 'extensive primary research', 'analytical services providers', '1.2 Key Market Segments', 'individual market share', 'Imagineer Technology Group', 'three-dimensional survey procedure', 'Outdoors Advertising market', 'industry supply chain', 'following key questions', 'key Top Competitors', 'industry experts industry', 'several key Regions', 'key core companies', 'Main Key Regions', 'Key Research', 'management organizations', 'Global Shares', 'primary market', 'international market', '2.4 Market Drivers', 'Top Companies', 'major sources', 'end-user industry', 'industry organizations', 'key aspects', 'key executives', 'consistent survey', 'value chain', 'tremendous growth', 'main sources', 'Altvia Solutions', 'Preqin Solutions', 'competitive landscape', 'bottom-up approach', 'first interview', 'expert telephone', 'Private Corporation', 'Listed Company', 'Financial Team', 'North America', 'Asia Pacific', 'Latin America', 'Middle East', 'processing organizations', 'future prospects', 'vice president', 'marketing director', 'innovation director', 'quantitative aspects', 'million USD', '2 Executive Summary', 'Expansion Plans', 'United States', '1.3 Key Manufacturers', 'following manufacturers', 'ongoing trends', 'innovative trends', 'data verification', 'confidential data', 'coming years', 'Request Sample', 'related industries', 'quantitative information', 'CAGR figures', 'Marketreports.info', 'Regional Analysis', '1 Study Coverage', '1.6 Study Objectives', '1.7 Years', '2.3 Analysis', 'Analysts', 'opportunities', 'shareholders', 'Carta', 'Certent', 'Solium', 'Capdesk', 'Computershare', 'Koger', 'Gust', 'TruEquity', 'Eqvista', 'Euronext', 'picture', 'details', 'focused', 'impact', 'cost', 'sectors', 'terms', 'volume', 'help', 'Type', 'Application', 'Start-Ups', 'Other', 'Europe', 'Africa', 'qualitative', 'qualities', 'CEO', 'founder', 'institutions', 'sides', 'answers', 'players', 'period', 'Values', 'XX', 'touch', 'consumption', 'forecast', 'Asia-Pacific', 'MEA', 'rest', 'discounts', 'Contents', 'Issues', 'Mergers', 'Acquisitions', 'China', 'Japan', '3.4']",2022-04-11,2022-04-11,blackswanzine.com
2686,EuroNext,Bing API,https://uk.news.yahoo.com/gaussin-presents-worlds-first-hydrogen-172300186.html,GAUSSIN Presents World's First Hydrogen-Powered Fuel Cell Automated Guided Vehicles (AGV H2) for Ports Application,The AGV H2 follows the launch of GAUSSIN‚Äôs hydrogen-powered fuel cell ATM and APM vehicles H√âRICOURT  France  March 16  2022--(BUSINESS WIRE)--GAUSSIN (EURONEXT GROWTH ALGAU - FR0013495298)  a pioneer in the clean and intelligent transport of goods and ...,"The AGV H2 follows the launch of GAUSSIN‚Äôs hydrogen-powered fuel cell ATM and APM vehiclesH√âRICOURT  France  March 16  2022--(BUSINESS WIRE)--GAUSSIN (EURONEXT GROWTH ALGAU - FR0013495298)  a pioneer in the clean and intelligent transport of goods and people  announces the launch of the world's first hydrogen-powered fuel cell Automated Guided Vehicles (AGV H2) for seaports. These new vehicles complement GAUSSIN‚Äôs range of hydrogen-powered vehicles following the release of the hydrogen-powered fuel cell ATM and APM. The AGV can be autonomously driven in infra-structureless and mixed traffic environment. It will help port operators switch to zero-emission immediately and provide longer operating hours  shorter and less frequent refuelling  as well as quiet and efficient transportation.GAUSSIN‚Äôs state-of-the-art  complementary solution for port operatorsPorts traditionally rely on diesel-powered trucks and tractors operating in a cluster environment are involved in moving cargo to and from ships. This contributes significantly to CO2 emissions. Many feasibility studies have shown that ports are ideal locations for hydrogen-powered transport trucks and container handling equipment as they are a natural place for hydrogen transportation  storage  and refuelling sites for various applications. With hydrogen production costs dropping more than 50% since 2015  hydrogen-powered fuel cell vehicles are now a viable solution for port operators to meet both the operation efficiency and green targets.A new vehicle with strong performancesThe H2 AGV shows strong and distinctive performance  which are detailed below:Application: ContainersPayload: 65tMaximum speed: 25 km/hDrive line: 4x4Front axle capacity: 50tRear axle capacity: 50tTraction motor: 2*226kW permanent magnetFuel Cell: 45kWH2 tank capacity: 20kg @350barBattery capacity: 60kwhAutonomy with H2: 15 hoursAdditional autonomy with Batteries: 3 hours""Once again  we are expanding our range of hydrogen-powered fuel cell products to support the zero-emission drive in the port sector. We believe our H2 AGV will contribute significantly to the operation efficiency expected in this demanding environment "" said Christophe Gaussin  CEO of GAUSSIN.Story continuesNext stepsOpen Days in H√©ricourt: March 17 & 18Meet4Hydrogen in Toulon: March 23-24H2 Racing Truck World Tour in Marseille: March 25GAUSSIN Investor Days in H√©ricourt: March 28-29-30Paris Investor Access: April 4H2 Racing Truck World Tour √† Zeebrugge: April 6Publication of 2021 results: April 26Advanced Clean Transportation (ACT) Expo in Los Angeles: May 9 to 12About GAUSSINGAUSSIN is an engineering company that designs  assembles and sells innovative products and services in the transport and logistics field. Its know-how encompasses cargo and passenger transport  autonomous technologies allowing for self-driving solutions such as Automotive Guided Vehicles  and the integration all types of batteries  electric and hydrogen fuel cells in particular. With more than 50 000 vehicles worldwide  GAUSSIN enjoys a strong reputation in four fast-expanding markets: port terminals  airports  logistics and people mobility. The group has developed strategic partnerships with major global players in order to accelerate its commercial penetration: Siemens Postal  Parcel & Airport Logistics in the airport field  Bollor√© Ports and ST Engineering in ports and Bluebus for people mobility. GAUSSIN has broadened its business model with the signing of license agreements accelerating the diffusion of its technology throughout the world. The acquisition of METALLIANCE confirms the emergence of an international group present in all segments of intelligent and clean vehicles.In October 2021  GAUSSIN won the Dubai World Challenge for Self-Driving Transport.In January 2022  GAUSSIN successfully completed the 2022 Dakar Rally with its H2 Racing Truck  the first hydrogen-powered vehicle to enter the race and generate zero CO2 emissions.In March 2022  Christophe Gaussin was named ""Hydrogen Personality of the year"" at the Hydrog√©nies - Troph√©es de l'hydrog√®ne ceremony held at the French National Assembly.GAUSSIN has been listed on Euronext Growth in Paris since 2010.More information on www.gaussin.com.For more information on GAUSSIN  go to www.gaussin.com* This document may contain forward-looking information. Such forward-looking information refers to future prospects  developments and strategies of Gaussin and is based on an analysis of expected future results and estimates of amounts that are not yet determinable to date. Forward-looking information naturally contains elements of risk and uncertainty relative to events and therefore dependent on circumstances which may or may not occur in the future. Gaussin draws your attention to the fact that forward-looking information provides no guarantee concerning its future performance or financial situation  financial results or trends in the sector in which Gaussin operates  and which may significantly differ from those proposed or suggested in the forward-looking statements contained in this presentation. Furthermore  even though the financial position of Gaussin  its performance and trends in the sector in which Gaussin operates comply with the forward-looking information contained in this presentation  such performance or trends may not be a reliable indication of the company‚Äôs future performance or prospects. Gaussin is not committed to updating or confirming analysts' expectations or estimates or to publicly correcting any information or event in order to reflect an event or circumstance eventually occurring following this presentation.View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005847/en/ContactsGAUSSINChristophe Gaussin  invest@gaussin.com+33(0)3.84.46.13.45Ulysse CommunicationNicolas Daniels  ndaniels@ulysse-communication.com+33(0)6.63.66.59.22Charles Courbet  ccourbet@ulysse-communication.com+33(0)6.28.93.03.06LHA Investor Relations ‚Äì USAJody Burfening  jburfening@lhai.com(212) 838-3777RooneyPartners - USAJeanene Timberlake  jtimberlake@rooneypartners.com(646) 770-8858",neutral,0.01,0.99,0.0,mixed,0.43,0.31,0.26,True,English,"['First Hydrogen-Powered Fuel Cell Automated Guided Vehicles', 'AGV H', 'Ports Application', 'GAUSSIN', 'World', 'first hydrogen-powered fuel cell Automated Guided Vehicles', 'H2 Racing Truck World Tour', 'hydrogen-powered fuel cell ATM', 'Next steps Open Days', 'hydrogen-powered fuel cell products', 'hydrogen-powered fuel cell vehicles', 'first hydrogen-powered vehicle', 'Automotive Guided Vehicles', 'hydrogen fuel cells', 'H2 tank capacity', 'Many feasibility studies', 'container handling equipment', '2*226kW permanent magnet', 'four fast-expanding markets', 'major global players', 'Dubai World Challenge', 'French National Assembly', 'Front axle capacity', 'Rear axle capacity', 'hydrogen production costs', 'less frequent refuelling', 'hydrog√®ne ceremony', 'The AGV H2', 'The H2 AGV', 'hydrogen-powered transport trucks', 'mixed traffic environment', 'EURONEXT GROWTH ALGAU', 'Paris Investor Access', 'zero CO2 emissions', 'GAUSSIN Investor Days', 'longer operating hours', 'Advanced Clean Transportation', 'Such forward-looking information', 'expected future results', 'hydrogen-powered vehicles', 'hydrogen transportation', 'innovative products', 'new vehicles', 'clean vehicles', 'Battery capacity', 'diesel-powered trucks', 'refuelling sites', 'Hydrog√©nies', 'APM vehicles', 'efficient transportation', 'cluster environment', 'demanding environment', 'H√âRICOURT', 'BUSINESS WIRE', 'port operators', 'complementary solution', 'ideal locations', 'natural place', 'various applications', 'viable solution', 'operation efficiency', 'green targets', 'distinctive performance', 'Containers Payload', 'Maximum speed', 'Drive line', 'Traction motor', 'ACT) Expo', 'Los Angeles', 'engineering company', 'passenger transport', 'autonomous technologies', 'self-driving solutions', 'port terminals', 'strategic partnerships', 'commercial penetration', 'Siemens Postal', 'airport field', 'ST Engineering', 'business model', 'license agreements', 'Self-Driving Transport', '2022 Dakar Rally', 'Troph√©es', 'More information', 'future prospects', 'future performance', 'financial situation', 'financial results', 'strong performances', 'logistics field', 'strong reputation', 'people mobility', 'Airport Logistics', 'intelligent transport', 'Additional autonomy', 'zero-emission drive', 'port sector', 'international group', 'Bollor√© Ports', 'Christophe Gaussin', '50,000 vehicles', '2021 results', '15 hours', '3 hours', 'APM.', 'launch', 'France', 'pioneer', 'goods', 'seaports', 'range', 'release', 'infra-structureless', 'shorter', 'quiet', 'tractors', 'cargo', 'storage', '25 km', '4x4', '50t', '45kW', '20kg', 'Batteries', 'CEO', 'Story', 'March', 'Meet4Hydrogen', 'Toulon', 'Marseille', 'April', 'Zeebrugge', 'Publication', 'May', 'services', 'know-how', 'integration', 'types', 'electric', 'airports', 'order', 'Parcel', 'Bluebus', 'signing', 'diffusion', 'technology', 'acquisition', 'METALLIANCE', 'emergence', 'segments', 'October', 'January', 'race', 'year', 'document', 'developments', 'strategies', 'analysis', 'estimates', 'amounts', 'date', 'elements', 'risk', 'uncertainty', 'events', 'circumstances', 'attention', 'fact', 'guarantee', 'trends']",2022-04-11,2022-04-11,uk.news.yahoo.com
2687,EuroNext,Bing API,https://us.acrofan.com/detail.php?number=645424,Genomic Vision Announces New Financing Line with Winance  Subject to Prior Approval of the Company's Shareholders,Genomic Vision (FR0011799907 ‚Äì GV ‚Äì the ‚ÄúCompany‚Äù) (Paris:GV)  a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome  today announces the implementation of a new financing line with Winance providing for the provision ,"BAGNEUX  France--(BUSINESS WIRE)--Regulatory News:Genomic Vision (FR0011799907 ‚Äì GV ‚Äì the ‚ÄúCompany‚Äù) (Paris:GV)  a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome  today announces the implementation of a new financing line with Winance providing for the provision  subject to the prior approval of the Company's shareholders and the conditions for drawing down each tranche (in particular that the share price is not lower than the nominal value)  of a maximum of 15 financing tranches of ‚Ç¨2 million each  i.e. up to ‚Ç¨30 million. This financing line is intended to enable the Company to finance its activities and development over at least the next three years.In order to limit the risk that the share price would fall below the nominal value  with the consequence of suspending any drawdown under the financing facility  the extraordinary general meeting would also be asked to reduce the nominal value of a share of the Company to 0.01 euro. The Company invites all its shareholders to attend this general meeting in order to express their opinion on the resolutions to be presented. In this respect  and given the difficulty of reaching a sufficient quorum  the Company will apply to the Commercial Court for the appointment of an ad-hoc proxy to represent shareholders who are not present or represented at this General Meeting.As of the date of this press release  the Company has a cash position of ‚Ç¨1.2 million  giving it a cash horizon at the end of May 2022  in the absence of an additional drawdown on the financing line set up in June 2020  which the Company can no longer use.Dominique Remy-Renou  CEO and President of Genomic Vision  comments: ‚ÄúWe are delighted to be continuing our cooperation with Winance  our long-standing financier  via this major agreement that could enable us to continue our development strategy and to reach a new milestone. The results obtained over the last two years by our R&D teams in the development of new products aimed notably at the bioproduction of innovative therapies and development of potential aging and cancer biomarkers should allow us to take up a position on these markets. The financial resources will be used to expand our services portfolio and accelerate the development of these new applications. We want to make the use of our technology more accessible and automated for our clients on the research  drug industry and in-vitro diagnostics markets. This ramping up will be supported by the implementation of a strengthened organization for our R&D teams and the deployment of a sales team to accelerate our growth driven by these markets that we believe are seeing substantial demand for innovative solutions‚Äù.Objectives of the operationThis financing that would be provided by Winance aims to meet the Company‚Äôs requirements  which have been evaluated at approximately ‚Ç¨30 million for the coming three years. These investment and growth financing requirements are based on the following key strategic priorities:- 48% would be devoted to the consolidation and strengthening of the R&D teams  the continuation of ongoing projects and the expansion of the portfolio of applications:1/Development of new high value-added solutions meeting the needs of the following markets:Genome analysis and editing  and bioproduction Research: fundamental and clinical focusing on oncology and age-related illnesses In-vitro diagnostics: HPV  FSHD and other new tests to come.2/ Improvement in the performances of the instrumentation to make it more accessible:Development of integrated systems  from the preparation of samples to the delivery and interpretation of results Automation of the instrumentation to allow its use in routine procedures.- 27% would be devoted to the consolidation and strengthening of the Sales  Support & Marketing teams:Broadening of the field coverage to meet international market needs  primarily in the United States and Europe Signing of structuring partnerships with third parties to diversify our expertise and accelerate our programs.- The remaining 25% would be devoted to covering running costs  external expenses and more generally expenses not assigned to the various elements listed above including executive compensation.The Company would be committed to draw the first four tranches of OCABSA convertible notes with warrants  representing a total net receipt of  subject to the conditions precedent indicated in the contract being met1:8 million euros after the deduction of the entire commitment fee of Winance if it is paid in the form of additional convertible notes with warrants (see below for further information on this fee)  orof 5.9 million euros should Winance‚Äôs commitment fee be paid in cash The payment of these first four tranches would extend the Company‚Äôs financing horizon through to mid-2023.Previous contract signed with Winance in June 2020The current contract with Winance concerning financing of up to ‚Ç¨12 million was only partially used to the tune of ‚Ç¨6 million gross (‚Ç¨5.7 million net after the deduction of the commitment fee due with respect to this contract) and notably allowed the Company to:- Continue pre-existing projects and implement new R&D projects that are ongoing today - Identify and work with new partners for the production of our products - Put in place and accelerate the Services activity - Revitalize the management team and incorporate new talent - Lay the cornerstones of a highly ambitious new strategy.The purpose of this new financing contract is to replace the contract signed in 2020  which can no longer be used and in any case would have expired in June 2022. Prior to the announcement of the implementation of the previous contract on June 12  2020  the share price was ‚Ç¨0.4 and the market capitalization was ‚Ç¨19 million. These figures were ‚Ç¨0.11 and ‚Ç¨7 million respectively at April 8  2022  a total of 17.7 million shares  representing 35% of the share capital at the date of implementation of the first contract  being issued to date under this contract.Terms of the operationThe effective implementation of this financing line is subject to the prior approval of Genomic Vision‚Äôs shareholders at an Extraordinary General Meeting organized in early May 2022 (the ‚ÄúEGM‚Äù).Subject to the EGM‚Äôs approval  Genomic Vision‚Äôs Executive Board should decide to issue a minimum of four tranches and could opt for the issuance of a maximum of fifteen tranches of bonds convertible into ordinary shares to which a share subscription warrant is attached (the ‚ÄúWarrants‚Äù and  together with the shares to which they are attached  the ‚ÄúOCABSA‚Äù convertible notes with equity warrants)  of ‚Ç¨2 million tranches (the amount of each tranche may be increased by mutual consent up to ‚Ç¨4 million on the basis of the Company‚Äôs share price)  within the limit of a bond issue of up to ‚Ç¨30 million over a 60-month period.The OCABSA would be subscribed to by Winance or any affiliated entity (together with its affiliated entities  the ‚ÄúInvestor‚Äù) within the framework of an issue that would be reserved for the latter.The Investor is not intending to retain the shares issued with respect to the financing line or to become a significant shareholder in the Company  but to sell them on the market as soon as possible.The Investor has no vocation to preserve the titles and remain permanently shareholder of the company but to sell them progressively on the market over reasonable timeframe.The legal terms  the main characteristics of the various instruments and the Company and Investor‚Äôs main obligations are described in the Appendix to this press release.The issuance of one or more tranches of OCABSA convertible notes with warrants attached will result in the drawing up of a prospectus requiring a visa from the AMF stock market authority  insofar as the likely resulting number of shares would exceed 20% of the capital over 12 months.Indicative schedule of the operationMid-April 2022 Convening of the EGM to decide to reduce the nominal value of a share to 0.01 euro and to approve the reserved issue of OCABSA to the Investor Mid-May 2022 EGM Mid-May 2022 Genomic Vision Executive Board meeting to decide on the issuance of the first tranche of OCABSA  subject to the EGM‚Äôs approval Mid-May 2022 The Investor subscribes to the first tranche of OCABSA for ‚Ç¨2 000 000The Company will publish another press release when the first tranche of OCABSA convertible notes with equity warrants attached is issued.AppendixLegal framework of the operationThe OCABSA would be issued in accordance with the provisions of article L. 225-138 of the French commercial code  with shareholders‚Äô preferential subscription rights being waived in favor of Winance.Main characteristics of the notes convertible into sharesThe convertible notes will have to be subscribed to by the Investor within ten (10) working days of the Executive Board‚Äôs decision  subject to standard conditions being met  it being specified that the Company will have to comply with a cooling off period that may not exceed a number of trading days between two tranche drawdowns determined by the following formula:V / (k x T 60 Daily); where V=amount of the tranche envisaged  k=0 25; and T 60 Daily = Average daily volume over the previous 60 trading sessions.The convertible notes will have a nominal value of 1 euro each and will be subscribed to at 96% of their par value. They will bear no interest and will have a maturity of 24 months from their issuance. When they reach maturity  the convertible notes will automatically expire and will have to be reimbursed in cash at their nominal value.They will also have to be reimbursed should certain incidences of default (as defined in the issuance contract2) occur  with a penalty equal to 2% of their nominal value.The notes may be converted into Genomic Vision shares at their holder‚Äôs discretion according to the following conversion ratio:N = Vn / P‚ÄúN‚Äù corresponding to the number of new Genomic Vision ordinary shares to be issued upon conversion of one convertible note‚ÄúVn‚Äù corresponding to the amount of debt represented by the convertible note (nominal value of one convertible note  i.e.1 euro);‚ÄúP‚Äù corresponding to 92% of the lowest daily volume-weighted average price of a Genomic Vision share (as reported by Bloomberg  or any equivalent provider should no figure be published by Bloomberg) over the ten (10) trading days immediately preceding the day the Company receives a request to convert the convertible note in question. P may not be lower than the nominal value of a Genomic Vision share  or ‚Ç¨0.10 euro to date  it also being specified that the next Shareholders‚Äô Meeting will be asked to reduce this nominal value to ‚Ç¨0.01 (this is not a prerequisite for the implementation of the financing line).The convertible notes may not be divested by their holder without the Company‚Äôs prior consent  except for transfers to one or more of the Investor‚Äôs affiliates. Moreover  the convertible notes will not be the subject of a request for admission to trading on the Euronext regulated market in Paris and will therefore not be listed.Main characteristics of the warrants attached to the convertible notesThe share subscription warrants attached to the convertible notes will give the holder the right to subscribe to two (2) ordinary shares for every five (5) share subscription warrants.The warrants will immediately be detached from the notes. They may not be divested by their holder without the Company‚Äôs prior consent  except for transfers to one or more of the Investor‚Äôs affiliates. Furthermore  the share subscription warrants will not be the subject of a request for admission to trading on the Euronext regulated market in Paris and will therefore not be listed.The warrants can be exercised for a period of 5 years from their issuance (the ‚ÄúExercise Period‚Äù).The strike price of each warrant (rounded to the nearest euro cent if necessary) will be equal to 130% of the lowest daily volume-weighted average price of a Genomic Vision share (as reported by Bloomberg  or any equivalent provider should no figure be published by Bloomberg) over the ten (10) trading days immediately preceding the issuance of the notes to which the warrant in question was attached  without the exercise price of a warrant able to be lower than the nominal value of a Company share.Based on a share price of 0.11 euros  the theoretical value of a warrant would be 0.078 euros.Commitment feeIn consideration of the Investor‚Äôs commitment to fund each drawdown on the financing line  the Company has agreed to pay the Investor a total commitment fee equal to ‚Ç¨2.1 million that will be spread equally over the drawdown of the first four tranches of OCABSA convertible notes with equity warrants  payable via the offsetting of a portion of the subscription price of the OCABSA or via the issuance of additional OCABSA.New shares resulting from the conversion of notes or the exercise of warrantsThe new shares issued upon conversion of notes or exercise of warrants will carry immediate and current dividend rights (""jouissance courante""). They will carry the same rights as those attached to the Company‚Äôs ordinary shares and will be admitted to trading on the Euronext regulated market in Paris under the same listing line (ISIN FR0011799907).The Company will maintain an updated summary of the outstanding convertible notes and share subscription warrants and the number of shares in circulation on its website (www.genomicvision.com).Theoretical impact of the OCABSA issue based on the lowest daily volume-weighted average price of Genomic Vision shares over the ten trading days prior to April 11  2022  i.e. ‚Ç¨0.11For guidance purposes  the impact of the issue of the first drawdown and of all the OCABSAs would be as follows:Impact of the issue on equity per share (based on equity as stated in the half-year accounts to June 30  2021 prepared in accordance with International Financial Reporting Standards (IFRS) and the number of shares making up the Company‚Äôs share capital at March 27  2022  i.e. 67 931 364 shares):Equity per share at June 30  2021 (in euros) Undiluted basis Diluted basis (*) 1st tranche all tranches 1sttranche all tranches Before the issue 0.06 0.15 After issuance of 20 000 000 (1st tranche) or 300 000 000 (all tranches) new shares resulting from the conversion of the convertible notes alone 0.07 0.09 0.14 0.11 After issuance of 8 000 000 (1st tranche) or 120 000 000 (all tranches) new shares resulting from the exercise of the warrants alone 0.06 0.11 0.15 0.14 After issuance of 28 000 000 (1st tranche) or 420 000 000 (all tranches) new shares resulting from the conversion of the convertible notes and exercise of the warrants 0.07 0.10 0.14 0.12 After issuance of 33 250 000 (1st tranche plus fee on first tranche) or 441 000 000 (all tranches and total fee) new shares resulting from the conversion of the convertible notes and exercise of the warrants 0.07 0.10 0.13 0.11Impact of the issue on the stake of a shareholder currently holding 1% of the Company‚Äôs share capital:Shareholder‚Äôs stake (%) Undiluted basis Diluted basis (*) 1st tranche all tranches 1st tranche all tranches Before the issue 1% 1% After issuance of 20 000 000 (1st tranche) or 300 000 000 (all tranches) new shares resulting from the conversion of the convertible notes alone 0.77% 0.18% 0.79% 0.20% After issuance of 8 000 000 (1st tranche) or 120 000 000 (all tranches) new shares resulting from the exercise of the warrants alone 0.89% 0.36% 0.90% 0.38% After issuance of 28 000 000 (1st tranche) or 420 000 000 (all tranches) new shares resulting from the conversion of the convertible notes and exercise of the warrants 0.71% 0.14% 0.73% 0.15% After issuance of 33 250 000 (1st tranche plus fee on first tranche) or 441 000 000 (all tranches and total fee) new shares resulting from the conversion of the convertible notes and exercise of the warrants 0.67% 0.13% 0.69% 0.15%(*) assuming full exercise of the share subscription warrants and ‚Äúbons de souscription de parts de cr√©ateur d‚Äôentreprise‚Äù (Business Creator Share Warrants) issued and attributed by the Company  exercisable or not  giving the right to subscribe to 6 806 514 and 276 809 new shares respectively.The main risks associated with this financing are notably the following:the total amount of subscriptions to the convertible notes and the new shares the exercise of warrants would give right to is not guaranteed and will notably depend on market conditions at the time of each drawing; in particular  the drawings would be interrupted if the stock market price of a share of the Company fell below the par value;shareholders will see their stake in the Company diluted significantly as a result of the issuance of new shares issued upon conversion of the convertible notes and/or exercise of the warrants by the Investor ‚Äì the dilution that could result from these issuances of new shares is illustrated above;the volatility and liquidity of the Company‚Äôs shares may fluctuate significantly;sales of the new shares issued upon conversion of the convertible notes and/or exercise of the warrants are likely to occur on the market very quickly after their issuance and to have a significant negative impact on the Company‚Äôs share price  as the Investor does not intend to remain a shareholder.in the absence of sufficient liquidity  Winance may no longer be able to sell the shares resulting from the conversion of the convertible bonds and/or the exercise of the warrants on the market  which would call into question this source of financing.***ABOUT WINANCEWinance is a global equity investor in SMEs that have a unique competitive advantage and a capacity to deliver short and long-term growth  in order to enable these companies to finance themselves competitively for growth and/or working capital needs.Website: www.winance.com***ABOUT GENOMIC VISIONGENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications  in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools  based on DNA combing technology and artificial intelligence  provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell  for early cancer detection and the diagnosis of genetic diseases. Genomic Vision  based near Paris in Bagneux  is a public listed company listed in compartment C of Euronext‚Äôs regulated market in Paris (Euronext: GV ‚Äì ISIN: FR0011799907).For further information  please visit www.genomicvision.comMember of the CAC¬Æ Mid & Small and CAC¬Æ All-Tradable indexesFORWARD LOOKING STATEMENTThis press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However  there can be no assurance that such forward-looking statements will be verified  which statements are subject to numerous risks  including the risks set forth in the ‚ÄúRisk Factors‚Äù section of the universal registration document filed with the AMF on February 9  2021 under reference number R.21-002  available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions  financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results  financial conditions  performance or achievements of Genomic Vision to be materially different from such forward-looking statements.This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe  or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.1 including the absence of defaults  significant negative change or change in control of the Company  listing of the Company‚Äôs shares and meeting of the Company‚Äôs contractual commitments.2 Default events notably include the delisting of the Company‚Äôs shares from Euronext  a change in the Company‚Äôs control and the occurrence of a material adverse change.Genomic VisionDominique Remy-RenouCEOTel.: +33 1 49 08 07 51investisseurs@genomicvision.comUlysse CommunicationPress RelationsBruno ArabianTel.: +33 1 42 68 29 70barabian@ulysse-communication.comNewCapInvestor Relations& Strategic CommunicationsTel.: +33 1 44 71 94 94gv@newcap.euCopyright ¬© acrofan/Business Wire All Right Reserved",neutral,0.01,0.97,0.02,mixed,0.3,0.28,0.43,True,English,"['New Financing Line', 'Genomic Vision', 'Prior Approval', 'Winance', 'Company', 'Shareholders', 'following key strategic priorities', 'new high value-added solutions', 'next three years', 'last two years', 'coming three years', 'OCABSA convertible notes', 'total net receipt', 'R&D teams', 'other new tests', 'first four tranches', 'additional convertible notes', 'international market needs', 'extraordinary general meeting', 'entire commitment fee', 'new financing line', 'vitro diagnostics markets', 'growth financing requirements', 'innovative solutions', 'following markets', 'Marketing teams', '15 financing tranches', 'new milestone', 'new products', 'new applications', 'BUSINESS WIRE', 'Regulatory News', 'Genomic Vision', 'prior approval', 'nominal value', 'financing facility', 'sufficient quorum', 'Commercial Court', 'ad-hoc proxy', 'press release', 'additional drawdown', 'Dominique Remy-Renou', 'long-standing financier', 'major agreement', 'innovative therapies', 'potential aging', 'cancer biomarkers', 'financial resources', 'drug industry', 'sales team', 'substantial demand', 'ongoing projects', 'clinical focusing', 'age-related illnesses', 'integrated systems', 'routine procedures', 'field coverage', 'United States', 'structuring partnerships', 'third parties', 'running costs', 'various elements', 'executive compensation', '8 million euros', '5.9 million euros', 'financing horizon', 'share price', 'cash horizon', 'Previous contract', 'current contract', 'Paris:GV', 'external expenses', 'biotechnology company', 'The Company', 'cash position', 'development strategy', 'services portfolio', 'Genome analysis', 'BAGNEUX', 'France', 'tools', 'control', 'changes', 'implementation', 'Winance', 'provision', 'shareholders', 'conditions', 'maximum', 'activities', 'order', 'risk', 'consequence', '0.01 euro', 'opinion', 'resolutions', 'respect', 'difficulty', 'appointment', 'date', 'end', 'May', 'absence', 'June', 'CEO', 'President', 'cooperation', 'results', 'bioproduction', 'use', 'clients', 'research', 'ramping', 'organization', 'deployment', 'Objectives', 'investment', 'consolidation', 'strengthening', 'continuation', 'expansion', 'editing', 'fundamental', 'oncology', 'HPV', 'FSHD', 'Improvement', 'performances', 'instrumentation', 'preparation', 'samples', 'delivery', 'interpretation', 'Automation', 'Support', 'Broadening', 'Europe', 'Signing', 'expertise', 'programs', 'warrants', 'precedent', 'deduction', 'information', 'payment', 'mid-20', 'tune']",2022-04-11,2022-04-11,us.acrofan.com
2688,EuroNext,Bing API,https://menafn.com/1103993818/Agfa-Gevaert-Share-buyback-program-regulated-information,Agfa-Gevaert: Share buyback program regulated information,Within the framework of the share buyback program which was announced in the press release of March 10  2021  Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels.,(MENAFN- GlobeNewsWire - Nasdaq) English DutchMortsel  Belgium ‚Äì April 11  2022 ‚Äì 5:40 p.m. CETWithin the framework of the share buyback program which was announced in the press release of March 10  2021  Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels.The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12  2020.Agfa-Gevaert NV has requested a financial intermediary to repurchase Agfa-Gevaert shares for a maximum amount of 50 000 000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until March 31  2022  effective as from April 1  2021.On March 8  2022  the Board of Directors decided that the 2021 Share Buyback will be extended through March 31  2023 (the 'Extended Share Buyback Program 2021').As a result of the decision of the Board of Directors on March 9  2021  the company  by notarial deed dated March 30  2022  cancelled a total of 2 299 218 treasury shares. This decision was taken in accordance with the authorization granted to the Board of Directors by the Extraordinary General Meeting of Shareholders on May 12  2020. As a consequence  the new number of outstanding shares (denominator) is 158 207 488.On transaction date April 8  2022  the Agfa-Gevaert Group held 535 970 own shares  which represents 0.34% of the total number of shares of the Group.Detailed operations per day:Transaction date Number ofshares Averageprice (‚Ç¨) Minimumprice (‚Ç¨) Maximumprice (‚Ç¨) Totalprice (‚Ç¨) April 4  2022 49 462 3.6746 3.6500 3.6950 181 753.07 April 5  2022 60 454 3.7028 3.6650 3.7300 223 849.07 April 6  2022 67 000 3.7593 3.7150 3.7950 251 873.90 April 7  2022 63 200 3.8274 3.7800 3.8500 241 891.68 April 8  2022 60 104 3.8627 3.8400 3.8800 232 163.72 Total 300 220 3.7690 1 131 530.64Since the beginning of the share buyback program until April 8th  2022  based on the transaction date  the Agfa-Gevaert Group bought 10 079 672 own shares  representing 6.01% of the total outstanding shares on April 1  2021.About AgfaThe Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions  HealthCare IT  Digital Print & Chemicals and Offset Solutions. They develop  manufacture and market analogue and digital systems for the healthcare sector  for specific industrial applications and for the printing industry. In 2021  the Group realized a turnover of 1 760 million Euro.Contact:Viviane DictusDirector Corporate CommunicationT +32 (0) 3 444 71 24EJohan JacobsCorporate Press Relations ManagerT +32 (0)3/444 80 15EAttachment20220411_SBB_53_ENAttachments 20220411_SBB_53_EN...,neutral,0.02,0.96,0.02,negative,0.02,0.3,0.67,True,English,"['buyback program regulated information', 'Agfa-Gevaert', 'initial discretionary mandate agreement', 'Corporate Press Relations Manager', 'Extended Share Buyback Program', 'English Dutch Mortsel', 'Extraordinary General Meeting', 'specific industrial applications', 'Viviane Dictus Director', 'Transaction date Number', 'The Agfa-Gevaert Group', '2021 Share Buyback', 'total outstanding shares', 'press release', 'Corporate Communication', 'new number', 'total number', 'Agfa-Gevaert NV', 'MENAFN- GlobeNewsWire', 'Euronext Brussels', 'financial intermediary', 'maximum amount', 'notarial deed', 'Detailed operations', 'Average price', 'Minimum price', 'Maximum price', 'Total price', 'imaging technology', 'IT solutions', 'four divisions', 'Radiology Solutions', 'HealthCare IT', 'Digital Print', 'Offset Solutions', 'digital systems', 'healthcare sector', 'printing industry', 'Johan Jacobs', 'Agfa-Gevaert shares', '2,299,218 treasury shares', 'leading company', '1,760 million Euro', 'April 8th', '50,000,000 Euro', 'Nasdaq', 'Belgium', 'CET', 'framework', 'March', 'purchase', 'market', 'authorization', 'Board', 'Directors', 'Shareholders', 'May', 'behalf', 'terms', 'validity', 'result', 'decision', 'accordance', 'consequence', 'denominator', 'day', 'beginning', '150 years', 'experience', 'Chemicals', 'analogue', 'turnover', 'Contact', 'Attachment', 'SBB', '5:40', '535,970', '10,079,672']",2022-04-11,2022-04-11,menafn.com
2689,EuroNext,Bing API,https://ca.news.yahoo.com/nfl-biosciences-notice-allowance-patent-160000218.html,NFL BIOSCIENCES: Notice of allowance of its patent in China,Notice of allowance of its patent in China NFL BIOSCIENCES (Euronext Growth Paris ‚Äì FR0014003XT0 ‚Äì ALNFL)  a biopharmaceutical company developing botanical drugs for the treatment of addictions  is announcing that it has received the notice of allowance from the Chinese National Intellectual Property Administration (CNIPA) for issuing its patent (Chinese application no.,NFL BIOSCIENCES: Notice of allowance of its patent in ChinaNFL BIOSCIENCES (Euronext Growth Paris ‚Äì FR0014003XT0 ‚Äì ALNFL)  a biopharmaceutical company developing botanical drugs for the treatment of addictions  is announcing that it has received the notice of allowance from the Chinese National Intellectual Property Administration (CNIPA) for issuing its patent (Chinese application no.201780033409.5) for NFL-101  a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves  focused primarily on smoking cessation. This patent will protect the innovation that NFL-101 is based on through to 2036 in China.NFL Biosciences has adopted a knowledge management and protection strategy that led it to submit two patent families granting it exclusive rights to its drug candidate NFL-101. This product patent  initially registered and approved in France  concerns an ‚Äúaqueous extract of tobacco leaves and its use for the treatment of dependence‚Äù. The innovation that NFL-101 is based on is therefore protected through to 2036 in France and the United States  with China to follow soon. National registration applications are also in the review phase in the following regions and countries: Japan  Canada  South Korea  Australia  Brazil  India  Indonesia  Israel  Mexico  Philippines  Eurasia  Saudi Arabia  United Arab Emirates and Nigeria.China is the country with the highest number of smokers worldwide  at over 300 million people  and around 50% of its male population smoke. If no action is taken  it is expected to see a 44% increase in smoking-related cancer deaths among men between 2020 and 2040  representing an excess mortality of 8.6 million deaths in 20 years1. Reducing smoking therefore involves significant stakes for the entire country and is an integral part of the Healthy China initiative  which aims to improve the Chinese population‚Äôs health and is targeting a 20% reduction in the overall smoking rate by 2030 for instance.Story continues‚ÄúNearly one of every three cigarettes smoked worldwide is smoked in China. Having a product patent will give us a strong level of protection as we move forward with our strategy over the coming years. This patent further strengthens the protection of the innovation behind our drug candidate NFL-101 in China  which is one of the core target markets with the global approach rolled out by NFL Biosciences. It was very important for us to have robust intellectual property in place on this high-potential market‚Äù  confirms Bruno Lafont  Chief Operating Officer and co-founder of NFL Biosciences.About NFL BiosciencesNFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new  natural  safer and more effective therapeutic solutions to the entire world population  including low- and middle-income countries. Its most advanced product  called NFL-101  is a standardized  nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural  safe  easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301  a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders.The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 ‚Äì ALNFL). Find out more at www.nflbiosciences.comContactsBruno Lafont ‚Äì info@nflbiosciences.com - +33 4 11 93 76 67 Agence Calyptus ‚Äì nflbio@calyptus.net - +33 1 53 65 68 681 ‚ÄúSmoking-related cancer death among men and women in an ageing society (China 2020‚Äì2040): a population-based modelling study‚Äù  Sept. 2021: https://tobaccocontrol.bmj.com/content/early/2021/09/01/tobaccocontrol-2020-056444Attachment,neutral,0.01,0.88,0.11,mixed,0.29,0.26,0.45,True,English,"['NFL BIOSCIENCES', 'Notice', 'allowance', 'patent', 'China', 'standardized, nicotine-free tobacco leaf extract', 'Chinese National Intellectual Property Administration', 'nicotine-free botanical drug candidate', 'robust intellectual property', 'National registration applications', 'Euronext Growth Paris', 'core target markets', 'Chief Operating Officer', 'effective therapeutic solutions', 'Smoking-related cancer death', 'population-based modelling study', 'botanical drug candidates', 'drug development project', 'United Arab Emirates', 'new, natural, safer', 'natural drug candidate', 'overall smoking rate', 'cannabis use disorders', 'entire world population', 'two patent families', 'Healthy China initiative', ""NFL Biosciences' ambition"", 'aqueous extract', 'Chinese population', 'botanical drugs', 'Chinese application', 'tobacco leaves', 'natural proteins', 'United States', '8.6 million deaths', 'male population', 'biopharmaceutical company', 'smoking cessation', 'knowledge management', 'exclusive rights', 'review phase', 'following regions', 'South Korea', 'Saudi Arabia', 'highest number', '300 million people', 'excess mortality', 'significant stakes', 'entire country', 'integral part', 'three cigarettes', 'strong level', 'global approach', 'high-potential market', 'Bruno Lafont', 'Montpellier area', 'advanced product', 'personalized alternative', 'alcohol consumption', 'ageing society', 'product patent', 'coming years', 'middle-income countries', 'Agence Calyptus', 'protection strategy', '20 years', 'Notice', 'allowance', 'ALNFL', 'treatment', 'addictions', 'CNIPA', 'innovation', 'NFL-101', 'France', 'dependence', 'Japan', 'Canada', 'Australia', 'Brazil', 'India', 'Indonesia', 'Israel', 'Mexico', 'Philippines', 'Eurasia', 'Nigeria', 'smokers', 'action', '44% increase', 'Reducing', '20% reduction', 'instance', 'Story', 'place', 'founder', 'NFL-30', 'shares', 'FR0014003XT0', 'nflbiosciences', 'Contacts', 'women', 'Sept.', 'tobaccocontrol', 'bmj', 'Attachment']",2022-04-11,2022-04-11,ca.news.yahoo.com
2690,EuroNext,Bing API,https://www.tmcnet.com/tmcnet/mobile-world-congress/news/2022/04/11/9580502.htm,Verimatrix Announces Participation in Three NAB Show Sessions  April 24-26 in Las Vegas,Verimatrix Announces Participation in Three NAB Show Sessions  April 24-26 in Las Vegas. Regulatory News: Verimatrix  (Euronext Paris: VMX)  the leader in powering the modern conn,"[April 11  2022] Verimatrix Announces Participation in Three NAB Show Sessions  April 24-26 in Las Vegas Regulatory News: Verimatrix  (Euronext Paris: VMX)  the leader in powering the modern connected world with people-centered security  today announced the following NAB Show sessions taking place at the Las Vegas Convention Center and featuring the following Verimatrix experts: 1. Sunday  April 24  1:00 - 1:30 PM - ""Secure  Value-Add Partnerships that are Now Possible Thanks to Modern SaaS Platforms"" featuring Sebastian Braun  Senior Director of Product Management 2. Monday  April 25  2:30 - 3:00 PM - ""Threat Defense for Media & Entertainment: How to Close the Open Door in Security Walls to Prevent the Enterprise from Being Compromised"" featuring Jon Samsel  Senior Vice President of Global Marketing 3. Tuesday  April 26  11:30 - 12:00 PM - ""The State of Piracy Today and the New Battlefront Against Industrial Scale Content Theft"" featuring Sebastian Braun  Senior Director of Product ManagementVerimatrix will also feature its latest news surrounding the Verimatrix Secure Delivery Platform as well as its Threat Defense and Anti-Piracy solutions at Kiosk W2513 and Meeting Room W4833MR. To schedule an in-person meeting during this year's NAB Show  contact Verimatrix here. Additionally  during the NAB Show  Verimatrix is set to unveil a white paper it commissioned with Caretta Research  ""Protect or Plunder: Surgical Strikes to Disrupt Industrial-scale Piracy""  that details the latest shifts and trends in digital piracy - along with precision countermeasures that are now possible. The full paper will be available for download beginning Monday  April 25 at www.verimatrix.com. ""As Verimatrix continues its modernization strategy to offer pioneering cloud-based ecosystems that uniquely bring together cybersecurity and anti-piracy technologies  we're answering a clear need to address today's interwoven business requirements throughout media and entertainment and numerous other industries "" said Asaf Ashkenazi  Chief Operating Officer and President at Verimatrix. ""This year's NAB Show serves as a timely and ideal setting to further build on this effort via new and expanded discussions with prospective partners and users seeking to efficiently and cost-effectively secure their content  applications or devices while offering powerful  memorable user experiences."" About VerimatrixVerimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content  applications  and devices with intuitive  people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports  to sensitive financial and healthcare data  to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster  scale easily  protect valuable revenue streams  and win new business. Visit www.verimatrix.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005399/en/[ Back To Mobile World Congress's Homepage ]",neutral,0.02,0.97,0.01,mixed,0.52,0.29,0.19,True,English,"['Three NAB Show Sessions', 'Las Vegas', 'Verimatrix', 'Participation', 'April', 'Las Vegas Convention Center', 'Las Vegas Regulatory News', 'powerful, memorable user experiences', 'Three NAB Show Sessions', 'following NAB Show sessions', 'Verimatrix Secure Delivery Platform', 'Industrial Scale Content Theft', 'Secure, Value-Add Partnerships', 'pioneering cloud-based ecosystems', 'numerous other industries', 'Chief Operating Officer', 'live streaming sports', 'valuable revenue streams', 'Meeting Room W4833MR', 'interwoven business requirements', 'Modern SaaS Platforms', 'Mobile World Congress', 'following Verimatrix experts', 'critical mobile applications', 'modern connected world', 'Senior Vice President', 'latest news', 'person meeting', 'Senior Director', 'digital content', 'compelling content', 'new business', 'Euronext Paris', 'Sebastian Braun', 'Product Management', 'Threat Defense', 'Open Door', 'Jon Samsel', 'Global Marketing', 'The State', 'Anti-Piracy solutions', 'Kiosk W2513', 'white paper', 'Caretta Research', 'Surgical Strikes', 'latest shifts', 'precision countermeasures', 'full paper', 'modernization strategy', 'anti-piracy technologies', 'clear need', 'Asaf Ashkenazi', 'ideal setting', 'expanded discussions', 'intuitive, people-centered', 'Leading brands', 'premium movies', 'sensitive financial', 'healthcare data', 'trusted connections', 'source version', 'people-centered security', 'Security Walls', 'frictionless security', 'New Battlefront', 'Industrial-scale Piracy', 'digital piracy', 'prospective partners', 'April', 'Participation', 'VMX', 'leader', 'place', 'Sunday', '1:30 PM', 'Monday', '3:00 PM', 'Media', 'Entertainment', 'Enterprise', 'Tuesday', '12:00 PM', 'year', 'Protect', 'Plunder', 'trends', 'download', 'cybersecurity', 'today', 'timely', 'effort', 'users', 'devices', 'everything', 'mission', 'customers', 'millions', 'consumers', 'businesswire', 'Homepage', '1:00', '2:30', '11:30']",2022-04-11,2022-04-11,tmcnet.com
2691,EuroNext,Bing API,https://nz.finance.yahoo.com/news/sidetrade-named-leader-first-gartner-155400954.html,Sidetrade named as a Leader in the first Gartner¬Æ 2022 Magic Quadrant‚Ñ¢ for Integrated Invoice-to-Cash Applications,Global AI-powered Order-to-Cash platform  Sidetrade  today announced it has been recognized as one of three Leaders in the Gartner Magic Quadrant for Integrated Invoice-to-Cash Applications.1 Gartner describes the position of Leader as ‚Äúthe strongest position to influence the market‚Äôs growth and direction.,SidetradeGlobal AI-powered Order-to-Cash platform  Sidetrade   today announced it has been recognized as one of three Leaders in the Gartner Magic Quadrant for Integrated Invoice-to-Cash Applications.1Gartner describes the position of Leader as ‚Äúthe strongest position to influence the market‚Äôs growth and direction.‚Äù In addition  ‚Äúthey demonstrate a market-defining vision of how integrated I2C applications can help CFOs achieve their business objectives of improving cash flow while enabling efficiencies and predictive capabilities within their AR operations.‚ÄùTen vendors were assessed on several critical solution capabilities including collections  customer invoicing  deductions & disputes  as well as wider factors including product innovation  strategy and efficiencies.Sidetrade‚Äôs CEO and founder  Olivier Novasque  commented: ‚ÄúSince our inception 22 years ago  Sidetrade has not stopped innovating or leading the way forward for the Order-to-Cash (O2C) industry: we were the first 100% SaaS platform on the O2C market; in the mid-2010s  we were ahead of the AI curve when we began aggregating billions of B2B transactions within our unrivalled data lake (which enabled us to make our ‚ÄúAugmented‚Äù capabilities a reality within our product); and again in 2015  we were the first to market with a true AI-powered O2C virtual assistant - also known as Aimie.‚ÄúToday  this Gartner recognition - which positions Sidetrade as one of three Leaders ‚Äì is  in our opinion  a testament to all our teams‚Äô hard work  as well to all our customers who have supported us throughout our journey taking the O2C market to the next level.‚ÄùThis Leader positioning for Sidetrade is the latest in a long line of industry recognitions  including:Story continuesIn the fallout from the pandemic  cash culture has been positioned higher on business leaders‚Äô agendas  as companies look to secure and accelerate cash flow generation and establish a 360¬∞ vision in the Order-to-Cash cycle.Now that intelligent technologies support changing methods of delivering enterprise business capabilities  CFOs have a vested interest in including these intelligent technologies in their new roles and new challenges  or risk missing opportunities to optimize value and drive growth.Sidetrade provides next-generation AI to companies worldwide and across all industries  including behemoths such as Micro Focus  Tech Data  XPO logistics  Expedia and many more. Its AI technology is powered by its unrivalled data lake of over $4.6 trillion B2B payment experiences and more than 593 million invoices.Sidetrade‚Äôs Chief Product Officer  Rob Harvey added: ‚ÄúWith Aimie - our AI virtual assistant - Finance leaders can rely on a global and proven solution from Sidetrade  enabling them to do business with confidence and successfully streamline their Order-to-Cash processes to dramatically increase their efficiencies and accelerate cash flow generation.‚ÄùFrom a corporate perspective  Sidetrade has seen impressive growth since its launch in 2000  most recently reporting on its 2021 annual results which saw a series of record-breaking announcements  including strong growth in SaaS revenue  a new bookings record set  and a promising year of continued growth ahead in 2022.For more information on today's announcement  download a copy of the Gartner Magic Quadrant for Integrated Invoice-to-Cash Applications here .[1] Gartner  Magic Quadrant for ‚ÄúIntegrated Invoice-to-Cash Applications  Nisha Bhandare  Mark D. McDonald  Tamara Shipley  6 April 20222 Gartner  Market Guide for Integrated Invoice-to-Cash Applications  By Nisha Bhandare   17 May 2021Gartner Disclaimer:Gartner does not endorse any vendor  product or service depicted in our research publications  and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties  expressed or implied  with respect to this research  including any warranties of merchantability or fitness for a particular purpose.Gartner and Magic Quadrant are registered trademarks of Gartner  Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.Media relationsBecca Parlby+44 7824 5055 84 / bparlby@sidetrade.comAbout Sidetrade (www.ww.sidetrade.com)Sidetrade (Euronext Growth: ALBFR.PA) provides a SaaS platform dedicated to securing and accelerating cash flow. Sidetrade‚Äôs next-generation AI  nicknamed Aimie  analyzes $4 600 million worth of B2B payment transactions daily in the Sidetrade Cloud to predict customer payment behavior and attrition risk of more than 21 million companies worldwide. Aimie recommends the best cash collection strategies  intelligently automates actions on the Order-to-Cash process  and dematerializes customer transactions to enhance productivity  performance and working capital management. Aimie is a real gamechanger in augmented intelligence - a system whereby individuals and machines work together faster and smarter  in complementary ways. Sidetrade has a global reach  with 250 talented employees based in Paris  London  Birmingham  Dublin  Houston  and Calgary  serving global businesses in 80 countries. Amongst them: Tech Data  KPMG  Nespresso  Hearst  Expedia  Manpower  Securitas  Randstad  Engie  Veolia  Inmarsat  and Bidfood.For further information  visit us at www.sidetrade.com and follow us on Twitter @Sidetrade.In the event of any discrepancy between the French and English versions of this press release  only the English version is to be taken into account.Attachment,neutral,0.01,0.98,0.0,mixed,0.37,0.29,0.34,True,English,"['first Gartner¬Æ 2022 Magic Quadrant‚Ñ¢', 'Integrated Invoice', 'Cash Applications', 'Sidetrade', 'Leader', 'true AI-powered O2C virtual assistant', 'new bookings record set', '$4.6 trillion B2B payment experiences', 'best cash collection strategies', 'several critical solution capabilities', 'AI virtual assistant', 'teams‚Äô hard work', 'Mark D. McDonald', 'working capital management', 'B2B payment transactions', 'customer payment behavior', 'unrivalled data lake', 'enterprise business capabilities', 'Chief Product Officer', 'cash flow generation', 'first 100% SaaS platform', 'business leaders‚Äô agendas', 'Global AI-powered Order', 'integrated I2C applications', 'Gartner Magic Quadrant', 'Gartner research publications', 'B2B transactions', 'predictive capabilities', 'proven solution', 'O2C market', 'customer transactions', 'new roles', 'new challenges', 'Tech Data', 'Cash platform', 'Cash Applications', 'customer invoicing', 'SaaS revenue', 'three Leaders', 'business objectives', 'Finance leaders', 'Integrated Invoice', 'AI curve', 'cash culture', 'Cash cycle', 'next-generation AI', 'AI technology', 'Cash processes', 'AR operations', 'wider factors', 'Olivier Novasque', 'next level', 'long line', 'intelligent technologies', 'changing methods', 'vested interest', 'missing opportunities', 'Micro Focus', 'XPO logistics', '593 million invoices', 'Rob Harvey', 'corporate perspective', '2021 annual results', 'record-breaking announcements', 'promising year', 'Nisha Bhandare', 'Tamara Shipley', 'technology users', 'highest ratings', 'other designation', 'research organization', 'particular purpose', 'U.S.', 'Media relations', 'Becca Parlby', '$4,600 million worth', 'attrition risk', 'real gamechanger', 'augmented intelligence', 'product innovation', 'Market Guide', 'Gartner recognition', 'impressive growth', 'strong growth', 'continued growth', 'Gartner Disclaimer', 'Euronext Growth', 'strongest position', 'market-defining vision', 'Ten vendors', 'Leader positioning', 'industry recognitions', 'all warranties', '21 million companies', 'Sidetrade Cloud', '2 Gartner', '360¬∞ vision', 'direction', 'addition', 'CFOs', 'efficiencies', 'collections', 'deductions', 'disputes', 'strategy', 'CEO', 'founder', 'inception', 'way', 'mid-2010s', 'billions', 'Aimie', 'opinion', 'testament', 'customers', 'journey', 'Story', 'fallout', 'pandemic', 'value', 'industries', 'behemoths', 'Expedia', 'confidence', 'launch', 'series', 'information', 'today', 'copy', '6 April', 'service', 'statements', 'respect', 'merchantability', 'fitness', 'trademarks', 'affiliates', 'permission', 'rights', 'bparlby', 'ALBFR', 'productivity', 'performance']",2022-04-11,2022-04-11,nz.finance.yahoo.com
2692,EuroNext,Bing API,https://uk.finance.yahoo.com/news/ferrari-n-v-periodic-report-154500790.html,FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM,Ferrari N.V. (NYSE/EXM: RACE) (‚ÄúFerrari‚Äù or the ‚ÄúCompany‚Äù) informs that the Company has purchased  under the sixth tranche of the common share buyback program announced on March 3  2022 (‚ÄúSixth Tranche‚Äù) ,Ferrari N.V.Maranello (Italy)  April 11  2022 ‚Äì Ferrari N.V. (NYSE/EXM: RACE) (‚ÄúFerrari‚Äù or the ‚ÄúCompany‚Äù) informs that the Company has purchased  under the sixth tranche of the common share buyback program announced on March 3  2022 (‚ÄúSixth Tranche‚Äù)  additional common shares - reported in aggregate form  on a daily basis - on Euronext Milan (EXM) as follows:TradingDate(dd/mm/yyyy)Stock ExchangeNumber of common shares purchasedAverage price per shareexcluding fees(‚Ç¨)Consideration excluding fees(‚Ç¨)05/04/2022 EXM 10 770 208.3179 2 243 583.50 06/04/2022 EXM 14 407 202.4619 2 916 868.50 07/04/2022 EXM 10 442 201.5519 2 104 605.40 08/04/2022 EXM 5 122 201.8376 1 033 812.40Total- 40 741 203.6982 8 298 869.80(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchaseSince the announcement of the Sixth Tranche of the buyback program dated March 3  2022 till April 8  2022  the total invested consideration has been:Euro 40 613 712.35 for No. 215 916 common shares purchased on the EXMUSD 9 990 538.84 (Euro 9 133 362.89*) for No. 52 571 common shares purchased on the NYSE.As of April 8  2022  the Company held in treasury No. 10 696 692 common shares equal to 4.16% of the total issued share capital including the common shares and the special voting shares  net of shares assigned under the Company‚Äôs equity incentive plan.Since January 1  2019 until April 8  2022  the Company has purchased a total of 5 576 974 own common shares on EXM and NYSE  excluding transactions for Sell to Cover  for a total consideration of Euro 853 167 641.79.A comprehensive overview of the transactions carried out under the buyback program  as well as the details of the above transactions  are available on Ferrari‚Äôs corporate website under the Buyback Programs section ( https://www.ferrari.com/en-EN/corporate/buyback-programs ).Attachment,neutral,0.02,0.96,0.03,neutral,0.03,0.93,0.04,True,English,"['FERRARI N.V.', 'PERIODIC REPORT', 'BUYBACK PROGRAM', 'THE', 'EUR/USD exchange reference rate', 'Ferrari N.V. Maranello', 'common share buyback program', 'European Central Bank', 'equity incentive plan', 'Buyback Programs section', 'special voting shares', 'additional common shares', 'No. 215,916 common shares', 'No. 52,571 common shares', 'Stock Exchange', '10,696,692 common shares', 'treasury No.', 'share capital', 'sixth tranche', 'aggregate form', 'daily basis', 'Euronext Milan', 'Average price', 'comprehensive overview', 'Trading Date', 'corporate website', 'total consideration', 'Italy', 'April', 'NYSE/EXM', 'RACE', 'Company', 'March', 'Number', 'fees', 'purchase', 'announcement', 'January', 'transactions', 'Sell', 'Cover', 'details', 'buyback-programs', 'Attachment', '5,576,974']",2022-04-11,2022-04-11,uk.finance.yahoo.com
2693,EuroNext,Bing API,https://finance.yahoo.com/news/poxel-announces-pxl770-awarded-fda-154500910.html,Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy,POXEL SA (Euronext: POXEL - FR0012432516)  a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders ,"LYON  France  April 11  2022--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516)  a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders  is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN)  the most common form of X-linked adrenoleukodystrophy (ALD). PXL770 is a novel  first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator that is preparing to enter into a Phase 2a clinical Proof-of-Concept (POC) biomarker study midyear  subject to additional financing.Poxel CEO  Thomas Kuhn  commented: ""Having PXL770 awarded Fast Track Designation by the FDA soon after our other promising product  PXL065  is a strong recognition of the potential of both our programs in adrenoleukodystrophy  a significant unmet medical need. Poxel aims at developing innovative treatments to improve the life of patients with serious and rare chronic diseases with metabolic pathophysiology  and the Fast Track Designation could offer PXL770 the ability to substantially accelerate the approval timeline in ALD. We are preparing the next steps to initiate our two Phase 2a clinical studies midyear  with results anticipated early 2023.""Fast Track Designation (FTD)FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.FTD provides Poxel with substantially enhanced access to FDA  including opportunities for face-to-face meetings and written consultations throughout the remaining development of PXL770.Drugs with FTD are eligible to apply for Accelerated Approval and Priority Review at the time of a New Drug Application (NDA) submission  which may result in faster product approval.FTD also allows for 'rolling review'  whereby Poxel may submit completed sections of the NDA as they become available  rather than at the end of development.Next StepsStory continuesThe Phase 2a clinical POC biomarker studies for Poxel‚Äôs two products  PXL770 and PXL065  in X-linked ALD are  subject to additional financing  anticipated to begin midyear  with results anticipated early 2023.Fast Track DesignationIntroduced under the FDA Modernization Act (1997)  Fast Track Designation (FTD) may be awarded by the FDA to investigational drugs which treat a serious or life-threatening condition  and which fill an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy. The FDA notes that 'the purpose of the Fast Track program is to get important new drugs to the patient earlier1"". FTD must be requested by the sponsor company and must be accompanied by a detailed review of both preclinical and clinical data.The key benefits of FTD comprise enhanced access to the FDA  with regular and more frequent opportunities for consultation and discussion. In addition  drugs with FTD may be eligible for Accelerated Approval  in which a new medicine is approved prior to the availability of definitive data  and Priority Review  in which the standard 10-month review process is reduced to six months. Drugs with FTD may also enter a 'rolling review' of their NDA submission  in which sections are submitted and reviewed as they become available  substantially expediting the approval process.About ALDX-linked adrenoleukodystrophy (ALD) is an orphan neurometabolic disease caused by mutations in the ABCD1 gene which encodes for a key protein that is required for metabolism of very long chain fatty acids (VLCFA) by peroxisomes (cellular organelles). ALD is the most common leukodystrophy with a prevalence similar to hemophilia ‚Äì up to 1/10 000 individuals in the general population have ALD [https://rarediseases.org]. Forms of this disease include cerebral ALD (C-ALD) and adrenomyeloneuropathy (AMN) which is the most common form ‚Äì typically occurring in adolescence through adulthood. AMN is characterized by chronic and progressive distal axonopathy involving the long tracts of the spinal cord and to a lesser extent the peripheral nerves resulting in progressive stiffness and weakness in the legs  impaired gait and balance  incontinence  and loss of sensation. Nearly all men with a diagnosis of ALD will develop AMN  and many women also present with features of AMN with a later onset. C-ALD is characterized by inflammatory demyelination of cells in the brain and typically afflicts children  but many men with AMN may also develop cerebral disease; these white matter brain lesions lead to severe neurologic deficits and death. There are no approved medicines for ALD (other than glucocorticoid supplements for associated adrenal insufficiency). C-ALD when first detected in early childhood  can be treated with hematopoietic stem cell transplantation. HSCT is currently limited to early stage of C-ALD and this procedure is at risk of severe adverse reactions.About Poxel SAPoxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology  including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH  PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770  a first-in-class direct AMPK activator  has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH  which met its objectives. For the rare inherited metabolic disorder  adrenoleukodystrophy (ALD)  the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG¬Æ (Imeglimin)  Poxel‚Äôs first-in-class lead product that targets mitochondrial dysfunction  has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan  China  South Korea  Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris  Poxel is headquartered in Lyon  France  and has subsidiaries in Boston  MA  and Tokyo  Japan.For more information  please visit: www.poxelpharma.comAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company‚Äôs control. These statements may include  without limitation  any statements preceded by  followed by or including words such as ""target "" ""believe "" ""expect "" ""aim "" ""intend "" ""may "" ""anticipate "" ""estimate "" ""plan "" ""project "" ""will "" ""can have "" ""likely "" ""should "" ""would "" ""could"" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company‚Äôs control that could cause the Company‚Äôs actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.1 For more information on the Fast Track Designation  see: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-reviewithfast-trackView source version on businesswire.com: https://www.businesswire.com/news/home/20220411005632/en/ContactsInvestor relations / MediaAur√©lie BozzaInvestor Relations & Communication Senior Directoraurelie.bozza@poxelpharma.com+33 6 99 81 08 36Elizabeth WooSenior Vice President  Investor Relations & Communicationelizabeth.woo@poxelpharma.comNewCapEmmanuel Huynh or Arthur Rouill√©poxel@newcap.eu+33 1 44 71 94 94",neutral,0.01,0.96,0.03,mixed,0.16,0.25,0.58,True,English,"['FDA Fast Track Designation', 'PXL770 Awarded', 'X-linked Adrenoleukodystrophy', 'Poxel', 'Phase 2a clinical POC biomarker studies', 'direct adenosine monophosphate-activated protein kinase', 'two Phase 2a clinical studies', 'Phase 2a clinical Proof', 'hematopoietic stem cell transpla', 'clinical stage biopharmaceutical company', 'long chain fatty acids', 'white matter brain lesions', 'significant unmet medical need', 'standard 10-month review process', 'unmet medical needs', 'U.S. Food', 'Fast Track Designation', 'other promising product', 'Fast Track program', 'severe neurologic deficits', 'progressive distal axonopathy', 'rare metabolic disorders', 'faster product approval', 'New Drug Application', 'orphan neurometabolic disease', 'FDA Modernization Act', 'important new drugs', 'rare chronic diseases', 'clinical data', 'two products', 'key protein', 'approval process', 'sponsor company', 'long tracts', 'new medicine', 'Drug Administration', 'progressive stiffness', 'metabolic pathophysiology', 'Priority Review', 'rolling review', 'detailed review', 'approval timeline', 'Accelerated Approval', 'BUSINESS WIRE', 'innovative treatments', 'non-alcoholic steatohepatitis', 'common form', 'AMPK) activator', 'additional financing', 'Thomas Kuhn', 'strong recognition', 'next steps', 'pharmaceutical products', 'life-threatening conditions', 'face meetings', 'written consultations', 'key benefits', 'definitive data', 'six months', 'ABCD1 gene', 'cellular organelles', 'common leukodystrophy', '1/10,000 individuals', 'general population', 'spinal cord', 'lesser extent', 'peripheral nerves', 'many women', 'inflammatory demyelination', 'cerebral disease', 'glucocorticoid supplements', 'adrenal insufficiency', 'early childhood', 'serious diseases', 'X-linked adrenoleukodystrophy', 'NDA) submission', 'NDA submission', 'investigational drugs', 'enhanced access', 'frequent opportunities', 'many men', 'The FDA', 'remaining development', 'available therapy', 'POXEL SA', 'Poxel CEO', 'X-linked ALD', 'cerebral ALD', 'LYON', 'France', 'April', 'Euronext', 'NASH', 'FTD', 'PXL770', 'patients', 'adrenomyeloneuropathy', 'AMN', 'novel', 'class', 'Concept', 'PXL06', 'potential', 'programs', 'ability', 'results', 'sections', 'end', 'Story', 'midyear', 'none', 'purpose', 'preclinical', 'regular', 'discussion', 'mutations', 'metabolism', 'VLCFA', 'peroxisomes', 'prevalence', 'hemophilia', 'rarediseases', 'Forms', 'C-ALD', 'adolescence', 'adulthood', 'weakness', 'legs', 'gait', 'balance', 'incontinence', 'loss', 'sensation', 'diagnosis', 'features', 'onset', 'cells', 'children', 'death', 'medicines']",2022-04-11,2022-04-11,finance.yahoo.com
2694,EuroNext,Twitter API,Twitter,$Euronext [15s. delayed]: Issued Press Release on April 11  04:00:00: Trust Stamp Announces Winners of Trusted Rwan‚Ä¶ https://t.co/RXdGWDg7KG,nan,$Euronext [15s. delayed]: Issued Press Release on April 11  04:00:00: Trust Stamp Announces Winners of Trusted Rwan‚Ä¶ https://t.co/RXdGWDg7KG,neutral,0.02,0.93,0.05,neutral,0.02,0.93,0.05,True,English,"['Press Release', 'Trust Stamp', 'Trusted Rwan', 'April', 'Winners', 'RXdGWDg7KG', 'Press Release', 'Trust Stamp', 'Trusted Rwan', 'April', 'Winners', 'RXdGWDg7KG']",2022-04-11,2022-04-11,Unknown
2695,EuroNext,Twitter API,Twitter,@GweebarraG @NipperMads @Orsted @imelda_hurley @cdp @coilltenews @anbordpleanala@corporateknight @euronext_ie‚Ä¶ https://t.co/wKoPsM4iNT,nan,@GweebarraG @NipperMads @Orsted @imelda_hurley @cdp @coilltenews @anbordpleanala@corporateknight @euronext_ie‚Ä¶ https://t.co/wKoPsM4iNT,neutral,0.03,0.96,0.02,neutral,0.03,0.96,0.02,True,English,"['GweebarraG', 'NipperMads', 'Orsted', 'imelda_hurley', 'cdp', 'coilltenews', 'anbordpleanala', 'corporateknight', 'euronext_ie', 'wKoPsM4iNT', 'GweebarraG', 'NipperMads', 'Orsted', 'imelda_hurley', 'cdp', 'coilltenews', 'anbordpleanala', 'corporateknight', 'euronext_ie', 'wKoPsM4iNT']",2022-04-11,2022-04-11,Unknown
2696,EuroNext,Twitter API,Twitter,Trust Stamp (Nasdaq: IDAI  Euronext Growth: AIID ID)  the Privacy-First Identity Company‚Ñ¢ providing AI-powered trus‚Ä¶ https://t.co/EvqooMcUxo,nan,Trust Stamp (Nasdaq: IDAI  Euronext Growth: AIID ID)  the Privacy-First Identity Company‚Ñ¢ providing AI-powered trus‚Ä¶ https://t.co/EvqooMcUxo,neutral,0.03,0.96,0.01,neutral,0.03,0.96,0.01,True,English,"['Privacy-First Identity Company‚Ñ¢', 'Trust Stamp', 'Euronext Growth', 'AIID ID', 'AI-powered trus', 'Nasdaq', 'IDAI', 'EvqooMcUxo', 'Privacy-First Identity Company‚Ñ¢', 'Trust Stamp', 'Euronext Growth', 'AIID ID', 'AI-powered trus', 'Nasdaq', 'IDAI', 'EvqooMcUxo']",2022-04-11,2022-04-11,Unknown
